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Abstract 
The use of Adeno-associated viral (AAV) vectors for gene therapy has been most promising 
because of their safety profile; however, current production methods limit desirable amounts 
of AAV vectors. Significant efforts have been made to improve AAV production systems, 
including the optimisation of vector expression cassettes and the regulation of producer cell 
factors. In this study, we endeavoured to alter the host cell gene expression using CRISPR/Cas9 
technology to improve AAV production. We generated knockouts of Y-Box protein (YB)1 in 
293T, and the putatively identified homologue Spodoptera frugiperda Y-Box protein (SfYB) in 
Sf9 cells. We present the first example in which CRISPR/Cas9 genome editing can be utilised to 
regulate cell-intrinsic factors that may be implicated in AAV vector production; although, the 
disruption of YB1 or SfYB did not generate enhanced AAV vector producer cell lines. YB1 
knockout cells presented with heightened sensitivity to chloroquine and limited its use for AAV 
vector production. The protective function of YB1 to chloroquine-induced cytotoxicity was 
demonstrated, and analysis of YB1 mutants suggested that its cold shock domain was the 
principle mediator of this resistance. We also identified YB1 associations with AAV serotype 2 
(AAV2) inverted terminal repeat (ITR) in vitro, and a rather distinct colocalisation between YB1 
mutant – encompassing YB1’s C-terminal domain (CTD) and AAV2 intact particle and AAV2 
capsid to the nucleolar compartment. Therefore, there may be associations between YB1 and 
its CTD in AAV2 vector production. We also present the advantages of using a repertoire of 
assays to characterise CRISPR/Cas9-edited cell lines. This included the advantage of 
establishing clonal populations that were homozygous for their knockout mutation(s), and 
utilising target-specific antibodies for screening knockouts. Regardless, CRISPR/Cas9 has 
become a mainstream technology allowing for specific and efficient genome editing, and is 
revolutionising human gene therapy with the potential of giving rise to an entirely new class of 
therapeutics. 
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Chapter 1: Introduction 
 
1.1.0 Gene Therapy 
1.1.1 Definition of gene therapy 
Gene therapy is defined as the directed and targeted delivery of exogenous genetic material to 
correct a negative phenotype or disease. The goal of gene therapy is to cure the clinical status 
of patients, whom suffer from certain heritable or acquired genetic diseases. In this way the 
recipient of gene therapy is corrected of their genetic defect either by mediating the repair of 
patients’ genetic information (Urnov et al., 2005; Wu et al., 2015), or inserting the functioning 
gene into the target tissue(s) (Anderson, 1984).   
 
1.1.2 Conception of gene therapy 
The core principles behind gene therapy derived from initial studies that propagated within 
the last century with work performed on bacteria. Frederick Griffith examined the then 
unknown phenomenon of transformation (Griffith, 1928) by mixing live, non-virulent R form of 
Type I pneumococcus with heat-inactivated virulent S strain. Subsequent infection of this 
mixture in mice developed active infection, pneumonia, and death. Additionally, viable isolates 
of S form of Type II pneumococcus were cultivated from infected mice. Thus Griffith concluded 
the R form had converted to the more virulent micro-organism. Studies that followed, shortly 
thereafter, showed that the key factor that permitted such transformation was mediated by 
the transfer of deoxyribonucleic acid (DNA) (Avery et al., 1944).  
 
Additional gene transfer mechanisms were shortly discovered, and perhaps an important 
mediator of horizontal transfer of genetic material was via bacteriophages, in a process 
dubbed ‘transduction’ (Zinder and Lederberg, 1952). These particulates invade and inject their 
genetic material into target bacterial cells, which then facilitates their replication and 
consequently induces cell lysis. Or a dormant infection establishes with integration of 
bateriphage genetic material into the target genome. Upon particle assembly, bacteriophages 
are capable of acquiring the target’s genetic information.  Subsequent infection facilitates the 
exchange of genetic material between bacteria (Zinder and Lederberg, 1952; Wilson et al., 
1979). This process contributes to the rapid acquisition of antibiotic resistance in certain 
bacteria (Colomer-Lluch et al., 2011). The process exemplifies the extent at which 
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bacteriophages are capable of functioning as transforming mediators.  
 
Further to this, work performed by Waclaw Szybalski demonstrated the potential for rescuing 
genetic defects by the acquisition of functional exogenous DNA (Szybalska and Szybalski, 
1962). Cells require the synthesis of nucleic acids for growth and survival. This synthesis is 
programmed in the form of dihydrofolate reductase (DHFR), and when inhibited, an 
alternative pathway is utilised in the form of hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT). Taking advantage of this, Szybalska generated HGPRT+ and HGPRT- clones 
from the human bone marrow cell line, D98S. Inhibition of DHFR by aminopterin 
(supplemented as hypoxanthine, aminopterin, and thymidine [HAT] medium) promoted the 
survival of HGPRT+ derivatives only because the alternative HGPRT-mediated synthesis of 
nucleic acid compensated for the lack of DHFR activity. Subsequent isolation of genomic DNA 
from the HGPRT+ cells and transformation of HGPRT- cells with said isolated DNA resulted in 
the complete rescue of HGPRT- cells when grown in HAT medium. Furthemore, daughter cells 
of transformed cells also showed a similar phenotype to the HGPRT+ derivative, indicating 
stable transfer of the rescued gene (Szybalska and Szybalski, 1962). This represented one of 
the earliest indicators that the physical transfer of genetic information could be a means to 
produce a desired phenotype. 
 
The phenomena of transduction, genetic transfer, and the concept of rescuing genetic defects 
fuelled research innovation with extension to eukaryotic viruses. One driver of this potential 
application was the observation that pseudovirions were an additional product of 
polyomavirus (Winocour, 1968) or simian virus 40 (SV40) (Trilling and Axelrod, 1970) infections 
in vitro. Pseudovirions refer to progeny particles that harbour packaged fragments of host 
DNA instead of virus-specific genome. Observations made by Osterman et al. (1970) showed 
that pseudovirions were capable of intracellular uncoating and, therefore, exogenously-
acquired DNA could be shuttled safely into infected cells. Although, no indication of the fate of 
the shuttled host DNA fragments could be deduced from initial studies, the aforementioned 
work provided the initial premise that genetic information could be delivered safely in vivo. It 
quickly became apparent that the mammalian SV40 virus could be manipulated to function as 
a transfer vector of genetic information into eukaryotic cells, and propagate recombinant 
vectors from cultured mammalian cells (Ganem et al., 1976; Goff and Berg, 1976; Nussbaum et 
al., 1976). Replacing SV40 genome sequences, namely the sequences encoding the SV40 large 
T antigen and/or sequences encoding the structural proteins Vp1-3, with a desired transgene 
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permitted in vitro production of replication-defective recombinant SV40 vectors in COS-7 cells 
(Strayer, 1996). Vector production was permissive because COS-7 cells provided the large T 
antigen in trans (Strayer, 1996). The therapeutic potential of recombinant SV40 vectors has 
been demonstrated in animal models of select human diseases (Goldstein et al., 2002; Duan et 
al., 2004; Vera et al., 2007). However, a considerable limitation of recombinant SV40 vector 
technology and its use in clinical studies included the accumulation of replication-competent 
SV40 vectors during production processes (Vera et al., 2004). This was likely as a result of 
recombination between recombinant SV40 DNA (for vector production) in COS-7 cells that 
were originally immortalised by the introduction of origin of replication-mutant SV40 viral DNA 
(Gluzman, 1981). 
 
1.1.3 Gene therapy strategies 
It became essential to identify more appropriate viral vectors for the delivery of exogenous 
genetic material into target cells, especially those that could stably transduce target cells for 
therapeutic purposes. Additional studies revealed the capacity for gene transfer by means of 
alternative viral vectors, including: lentivirus, Adenovirus and Adeno-associated viruses (AAVs) 
(Volpers and Kochanek, 2004; Kotterman and Schaffer, 2014). Therefore, the principles of 
gene therapy involved introducing nucleic acid to be administered directly to humans with the 
aim of genetic engineering of target cells. This would allow substitution or replacement of 
defective gene sequences, and potentially provide long-term curative benefit to those patients 
who suffer from acquired or genetic disease. 
 
The predicted collective of monogenic diseases affect a great number of people worldwide. A 
list of approximately 10,000 monogenic diseases is available in the Online Mendelian 
Inheritance in man (OMIM) database. The prospect of alleviating these conditions by a single-
administration, curative strategy is highly attractive. And with enhanced next-generation 
sequencing technologies, the precise genes or genetic defects responsible for a great many 
genetic disorders (approximately 50%) have been identified in good confidence (Boycott et al., 
2013). With enhanced molecular understanding of genetic diseases, the targeting efficiency of 
these identified gene defects can be improved substantially with greater overall clinical 
success. 
 
To tackle this viral vector-based gene therapy platforms have been actively developed. Their 
applications have been widely extended from the original concept of reintroducing the correct 
 4 
 
gene to target cells or tissue. Such includes direct correction of the defective genes using 
genome editing technologies (this will be briefly discussed in section 1.6.4). However, it is 
worth mentioning that alternatives to viral vector based gene therapies are actively being 
researched and have even undergone clinical trials. The intention is to expand gene therapy 
platforms to overcome limitations of viral vector and/or rAAV vector strategies for gene 
therapy. Such includes non-viral delivery methods that involve the gene transfer of 
therapeutic cDNA-encoding gene, plasmid, or RNA. Non-viral vector gene transfer methods 
involving electroporation (Neumann et al., 1982) of desired nucleic acids have shown some 
clinical translation potential, either in vivo and/or ex vivo (Brown et al., 2009). However, given 
the nature of the gene transfer technique, the use of electric fields and impulses can incur 
localised cell death and damage, which is more apparent that physical gene transfer methods 
such as viral vector strategies (Lefesvre et al., 2002; Kubota et al., 2005). 
 
Additional non-viral vector strategies can also involve introducing nucleic acids complexed to 
liposomes (for example pGM169/GL67A), polymers, or gold nanoparticles for gene therapy 
applications (Alton et al., 2015; Lee et al., 2017b; Sun et al., 2017). The use of a viral vector to 
shuttle the desired nucleic acid is omitted. Many advantages are proposed for using non-viral 
gene delivery methods over viral delivery methods. This includes the increased safety from the 
naked DNA randomly integrating into the host genome and potentially encouraging insertional 
mutagenesis. The cDNA/RNA used in non-viral delivery methods is largely non-integrating into 
host genomes, and are unlikely to affect the genomics of proto-oncogenes or tumour 
suppressor genes. Additionally, non-viral methods are associated with low immunotoxicity 
given the absence of viral proteins, which reduces the chance for adverse immunological 
responses to the gene delivery as compared to using viral vector methods (Chen et al., 2010; 
Kelley et al., 2018). This is largely because recombinant viral vectos are typically derived from 
naturally occurring viruses, from which a subset of the human population may be experienced 
against and already have an immunological memory component ready to mount exaggerated 
immune responses against cells targeted by viral vectors (Veron et al., 2012). Finally, viral 
vectors often come with a packaging limit for the desired therapeutic gene as is seen with 
rAAV vectors (up to 4.5kbp). The restricition in cDNA size is in theory lifted using non-viral 
methods as packaging capacities do not need to be considered. Having said this, gene 
delievery efficiencies are compromised with significantly large cDNAs regardless of complexing 
with liposomes, polymers, or gold particles (Ribeiro et al., 2012).      
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1.1.4 Advantages of AAV vectors in gene therapy 
To facilitate the above, vector-based gene therapy has become an extremely attractive 
approach. AAV vectors show considerable promise as a system to deliver recombinant nucleic 
acid into target cells. The great wealth of information available on AAVs and its biology has 
permitted its easy manipulation. Knowledge in AAV capsid structure and design has enabled 
commercial applications for research and translational benefit. Wildtype AAVs have shown, 
until more recently (and briefly discussed in Section 1.1.5), no known association with active 
human disease or cytopathogenicity, and thus potentiates the viral system as safe (Nathwani 
et al., 2007; van Gestel et al., 2014). Moreover, AAV transduces a broad range of cells 
including non-dividing cells. This poses a complication and limitation when concerning other 
vector-based strategies, which have a marked preference for transducing actively dividing cells 
only. However, given AAV’s tractable infectivity towards either cell states (dividing or non-
dividing), vectors derived from this system are able to circumvent this limitation, and broaden 
cell targeting capabilities. By extension, the prospect of targeting a greater repertoire of 
genetic diseases is thus more permissible.  
 
It should be appreciated, that unlike SV40-based gene transfer, use of recombinant (r)AAV 
vectors is associated with long-term and stable transgene expression (Kaspar et al., 2005) – a 
prerequisite for successful gene therapy. Recombinant AAV has therefore been used in gene 
therapy clinical trials for a number of diseases, such as: Duchenne muscular dystrophy (Bowles 
et al., 2012), haemophilia B (Nathwani et al., 2011; Nathwani et al., 2014; French et al., 2018; 
Miesbach et al., 2018), and cystic fibrosis (Moss et al., 2004). More promising is the fact that 
the first EU-licensed gene therapy product, Glybera, and the even more recent US-approved 
Luxturna, are both rAAV-based gene therapy products for the treatment of hereditary 
lipoprotein lipase deficiency (Carpentier et al., 2012) and Leber’s congenital amaurosis 
(Bennett et al., 2016), respectively. Collectively, these examples demonstrate that rAAV-based 
gene therapies are a promising advancement as a modern healthcare and medicine. 
 
1.1.5 Disadvantages of AAV vectors in gene therapy 
Despite the advantages of using rAAV vectors for gene therapy applications (as briefly outlined 
above and in further detail in the rest of the literature review), the vector system is not 
without some drawbacks that limit its extended use as a gene therapy platform. Firstly, the 
packaging capacity of rAAV vectors is very limiting, where wildtype AAV genomes are 
approximately 4.7kb in length (Srivastava et al., 1983). Therefore, after removal of the rep and 
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cap encoding sequences, little cargo space is left for the desired therapeutic transgene. An 
attempt to overload rAAV vectors is met with challenges in packaging intact vector genomes – 
vector genomes are found truncated at the 5’-end and/or showed impaired transduction 
efficiencies in vitro (Wu et al., 2010). Next, rAAV vector genomes chiefly persists episomally in 
the nucleus of transduced cells (Penaud-Budloo et al., 2008), and rarely integrates randomly 
into the host genome (Inagaki et al., 2008). Therefore, depending on the target cell type, 
episomal rAAV vector genomes can be simply diluted out by cell division, leading to a transient 
state of gene correction. Additionaly, given that in most instances the capsids of naturally 
occurring AAV serotypes are used to pseudotype rAAV2 vector genomes, of which wildtype 
counterparts naturally infect humans, and consequently contribute to an immune response 
and immune memory to rAAV vectors. Ultimately, the host immunological response to rAAV 
vectors is evident (Veron et al., 2012), and restricts the efficacy of rAAV vectors as a gene 
therapy tool (Janelidze et al., 2014).  
 
Furthermore, the safety profile of using rAAV vectors for gene therapy has become a 
controversial topic despite the number of clinical trials to date that suggest its general safety 
profile. Potential genotoxicty by rAAV vectors was first implied in murine models that 
demonstrated a significant risk in hepatocellular carcinoma development (Donsante et al., 
2001; Donsante et al., 2007). The genotoxicity issue was further raised by Nault et al. (2015), 
of which group identified the integration of wildtype AAV2 genome sequences in 11/193 
human hepatocellular carcinoma samples. The integration occurred in key genes known to be 
cancer drivers and correlated with their overexpression (CCNA2, TERT, CCNE1) (Nault et al., 
2015). Having said this, no long term studies on large animal models thus far have 
demonstrated rAAV-mediated genotoxicity, post-transduction with rAAV vectors in a clinical 
context (Gil-Farina et al., 2016). Nonetheless, this potential revelation that AAV, and by 
extension rAAV, may show some tendancy for insertional mutagenesis and hepatocellular 
carcinoma risk, may warrant long term followup and observation of clinical trial participants 
for tumour formation. This would likely include identifying AAV vector integration sites to 
evalulate the risk of insertional mutagenesis in studies involving rAAV vector transduction. 
 
1.2.0 Biology of AAV 
1.2.1 Taxonomy and classification of AAV 
Human AAV was first identified as contaminants of simian Adenovirus preparations (Atchison 
et al., 1965). AAVs are small (20-25nm), non-enveloped, DNA viruses which have been classed 
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into the Parvoviridae family. Parvoviridae family of viruses are among the smallest viruses 
known, and comprise a wide number of non-enveloped viruses with capsid shells that form an 
icosahedral structure of T=1 symmetry (Xie et al., 2002). AAVs belong to its own genus, 
Dependovirus, originally described due to their tendency to require helper-viral functions to 
propagate. Therefore, AAVs are non-productive alone, and AAVs’ life-cycle is incomplete 
unless aided by the presence of an unrelated DNA virus – namely Adenovirus (Hoggan et al., 
1966) or Herpes Simplex Virus (HSV) (Buller et al., 1981). Upon super-infection these helper 
viruses act to change the intracellular milieu and permit AAV gene expression and replication. 
Adenovirus provides AAV with early Adenoviral proteins: E1A, E1B, E4 and E2A. These helper 
proteins function to promote host-cell entry into S-phase and DNA replication (Samulski and 
Shenk, 1988). It also has been described that AAV replication can be stimulated by cellular 
genotoxic stresses (experimentally simulated by ultra-violet light, chemical carcinogens, or 
inhibitors of DNA replication) in the absence of helper virus, resulting in infectious AAV 
progeny (Yalkinoglu et al., 1988). In contrast to this, when helper functions are absent, AAV 
establishes latent infection with site-specific integration into chromosome 19q13.4 (Kotin et 
al., 1990). Thirteen serotypes of AAV (that are capable of infecting humans and primates) have 
been described; with AAV2 being the best characterised serotype. The remainder of this 
literature review will focus on this particular serotype as a prototype for the entire family.  
 
1.2.2 Structure and organisation of AAV genome 
All AAV serotypes package a single-stranded (ss)DNA genome of either polarity (plus or minus 
strands) at equal efficiency during assembly of AAV progeny (Steinbach et al., 1997). AAV DNA 
genome is approximately 4.7kb in length (Srivastava et al., 1983), and at either end (5’ and 3’ 
ends) are specialised T-shaped hairpin secondary structures. These form as a result of 145 
nucleotide (nt) sequences called inverted terminal repeats (ITRs), and flank AAV coding 
regions. 
 
The organisation of AAV genome’s coding sequence can be summarised by the possession of 
two main coding gene cassettes or open reading frames (ORFs) – rep and cap (Fig. 1.1). The 
primary ORFs contain a region in which the rep and cap genes are overlapping by a small  
intron sequence. The rep and cap encode for four non-structural proteins and three structural 
proteins, respectively. Although, an additional non-structural protein involved in AAV 
assembly (assembly-activating protein, AAP) has been identified by Sonntag et al. (2010), and 
is encoded within the cap ORF. More recently, an additional AAV2 gene has been 
 8 
 
characterised (AAV2 X). The AAV2 X gene was found in the more 3’-end of the AAV2 genome, 
which is associated with its own promoter – p81 (Cao et al., 2014). It was found that the 
product of the X gene enhanced autonomous and helper-directed DNA replication six-fold 
(Cao et al., 2014). 
 
A total of three major messenger (m)RNA transcripts are generated from the two ORFs of AAV 
genome’s plus strand (Jay et al., 1979). Transcription initiation of each transcript is controlled 
by individual promoters termed p5, p19 and p40 (defined by their relative location within the 
genome). Both ORFs share a common 3’-end polyadenylation site to dictate transcriptional 
termination. Moreover, through the use of multiple promoters and hijacking of the host cell 
transcriptional machinery a total of eight proteins are easily encoded within the short coding 
sequence of AAV. 
 
Figure 1.1 Genome organisation of AAV2. Representative organisation of AAV2 genome, with rep and 
cap ORFs flanked by ITR sequences. Further dissection of rep and cap ORFs is also shown, with several 
main transcripts encoded by two ORFs – coding for three structural proteins (Vp1-3), and four non-
structural proteins (Rep78, -68, -52 and -40). Black lines within cap represent surface-exposed aa 
residues. AAP alternative reading frame is denoted by the grey arrow. Coloured arrows indicate 
separate hypervariable regions. Figure from Kotterman and Schaffer (2014). 
 
Because of the limited coding capacity of AAV, AAV is restricted in its self-sufficiency. For 
instance, AAV does not encode its own RNA polymerase for transcription. To compensate, AAV 
is dependent on the host cell machinery to engage transcriptional activity and processing. 
Nonetheless, through transcriptional processing of alternate splice variants, the rep ORF 
encodes four non-structural proteins termed Rep78, Rep68, Rep52 and Rep40, which engage 
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in a number of processes – namely replication. Expression of Rep78 and Rep68 are under the 
transcriptional control of p5 promoter, whereas Rep52 and Rep40 are determined by the p19 
promoter. Rep68 and Rep40 are C-terminal truncated splice variants of the Rep78 and Rep52 
major transcripts, respectively. The cap ORF, instead, is under the transcriptional control of 
the p40 promoter and encodes the capsid structural proteins Vp1, Vp2 and Vp3, as well as 
AAP. Vp1-3 makes up the core components of AAV’s protein shell, and also determines the 
AAV serotype. The major transcripts undergo splicing events due to the presence of the small 
intron sequence found within the rep-cap overlapping region (Qiu et al., 2003). The small 
intron possesses relevant splice donor and splice acceptor sites to facilitate splicing of either 
ORF, and therefore contributes to the repertoire of proteins expressed by wildtype AAV 
genome. 
 
1.2.3 AAV ITRs 
The 5’ and 3’ ends are described as the ITRs of AAV genome, where the terminal 145nt form T-
shaped hairpin secondary structures. The initial-most 125nt form imperfect palindromes that 
folds upon itself to adopt the T-shaped hairpins. The ITR is a key requirement for certain 
aspects of AAV biology; for example a key role of the ITR is to facilitate AAV genome 
replication by creating double-stranded (ds)DNA duplex that helps self-prime DNA synthesis. 
In addition to this the ITRs also possess cis-elements such as the Rep-binding elements (RBE 
and RBE’), and terminal resolution site (trs) involved in the nicking of dsDNA after completion 
of DNA replication. These are all necessary for active replication of AAV genome and packaging 
of genomes into preformed AAV capsids, to then form infectious units. Wildtype AAV is known 
to integrate site-specifically into the infected cell’s genome into chromosome 19q13.4, and 
this process is largely dependent on the ITRs. A representative diagram of AAV2 ITR is 
portrayed in Fig. 1.2. 
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Figure 1.2 AAV2 ITR sequence and secondary structures. Secondary structure of the left ITR is depicted, 
with annotations describing relevant features of the AAV2 ITR. AAV ITR is composed of two palindrome 
sequences (B-B’ and C-C’) that make up the arms of the T-hairpin structure, and the longer palindrome 
sequence (A-A’) that makes up the stem of the ITR. The D-sequence on either end of the AAV genome is 
the point where the AAV genome becomes single-stranded. RBE, Rep binding element; RBE’, second 
Rep binding element; trs, terminal resolution site. Figure from Goncalves (2005). 
 
1.2.4 Capsid structure 
As depicted previously the cap ORF encodes the capsid proteins (Vp1-3). Each share C-
terminus residues; however, Vp2 and Vp3 are N-terminus truncated splice variants of Vp1. 
Vp1-3 are 87kDa, 73kDa and 61kDa in size, respectively. The capsid of AAV virions is composed 
of sixty subunits made up of these three core proteins. The triplets of proteins arrange 
themselves in a specific 1:1:10 ratio of Vp1, Vp2 and Vp3, respectively, to form individual 
subunits (Agbandje-McKenna and Kleinschmidt, 2011). Altogether these 60 subunits assemble 
to form an icosahedral structure with T=1 icosahedral symmetry (Fig. 1.3A) as determined by 
X-ray crystallography at 3Ǻ resolution for AAV2 (Xie et al., 2002). The 3D-structure of several 
AAV serotypes has also been determined by X-ray crystallography, including: AAV4 (Padron et 
al., 2005) and AAV5 (Walters et al., 2004). Shared characteristics are evident between AAV 
serotype capsids, and these shared topological features are mainly found at each axis of 
symmetry. For instance, the most prominent features of AAV capsids are protrusions that 
appear at the three-fold symmetry axis, and a cylindrical channel that appears at the five-fold 
symmetry axis (Fig. 1.3B). Fig. 1.3B also depicts prominent depressions at the two-fold 
symmetry axis, which are immediately followed by the protrusions at the three-fold symmetry 
axis (O'Donnell et al., 2009).  
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Figure 1.3 3D-structure of AAV2 capsid. A) 3D representation of AAV2 capsid shell, where the white 
triangle represents one subunit composed of the Vp1-3 at 1:1:10 stoichiometry. These assemble to form 
the icosahedral structure. Topology is coloured to reflect distance from centre of particle – white, 
furthest distance from centre, and red is closest to centre. Figure adapted from Xie et al. (2002). B) 
Cross-sectional of AAV2 capsid with symmetry axes 2, 3, and 5 annotated. Arrows indicate protrusions 
at the 3-fold symmetry axis that flank 2-fold symmetry axis depression. Figure adapted from O'Donnell 
et al. (2009). 
 
1.2.5 AAV serotypes 
Serotypes are defined as an isolated virus that does not cross-react with neutralising 
antibodies or antiserum that is originally specific against other existing forms. AAV2 was the 
first isolated serotype to be cloned into a bacterial plasmid by Samulski et al. (1982). 
Therefore, it became the key serotype used for clinical and research purposes. Consequently, 
AAV2 biology is best characterised and extensively elucidated in comparison to all other 
naturally occurring AAV serotypes.  
 
The initial most AAV serotypes 1-4 and 6 were mainly isolated as contaminants of Adenovirus 
preparations (Atchison et al., 1965), whereas AAV5 was identified from human penile genital 
warts (Bantel-Schaal and zur Hausen, 1984). Several more recent AAV serotypes have also 
been identified, including AAV7-9, as well as well over 100 AAV variants (Gao et al., 2002a; 
Gao et al., 2004; Mori et al., 2004; Schmidt et al., 2006). This novel repertoire of AAV 
serotypes was identified through PCR-based strategies that targeted homologous regions of 
the cap gene in a number of human tissues (Gao et al., 2004). It then became apparent that 
some AAV serotypes showed distinct in vivo transduction properties despite significant 
homology at the DNA-level. For example, isolation of AAV8 showed remarkable transduction 
into murine liver compared to AAV2 (Sands, 2011). The distinct transduction biology between 
serotypes encouraged expansion of AAV as a tool for gene therapy. Where the select tropism 
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displayed by particular serotypes proves advantageous in a clinical setting by avoiding broad, 
non-specific transduction, and thus allowing for more site-specific targeting of cell or tissues. 
 
1.2.6 AAV life-cycles and helper-virus functions 
Upon infection into target host cell, AAV typically undergoes one of two life-cycles – lytic or 
lysogenic. Lytic infection predominates when helper functions and virus are made available. 
Productive AAV results and is characterised by active genome replication, gene expression of 
viral-encoded genes, and the eventual production of AAV virions. Helper virus-mediated lysis 
of host cell results in the release of AAV virus progeny.  
 
The repertoire of Adenovirus genes that mediate the helper functions for AAV production 
were identified as E1a, E1b, E2a, E4orf6 and virus-associated RNAs (VA RNAs) (Samulski and 
Shenk, 1988). The encoded proteins and RNAs permit AAV production by affecting different 
aspects of AAV life-cycle as well as the biology of the infected host cell. To start with, E1a 
encodes E1A protein, which up-regulates cyclin E and cdc25A expression and activity and 
promotes host cell entry into active S-phase of the cell cycle (Spitkovsky et al., 1996). 
Additionally, E1A is directly implicated in the pRb/E2F-1 pathway, by binding to the pRb family 
of proteins to release key transcription factors that are defined as key regulators of S-phase 
entry from the G1 stage of the cell cycle (Nevins, 1990). Ultimately there is gross manipulation 
of the infected cell that prompts cell cycle entry and up-regulation of DNA replication and 
synthesis machineries. E1A additionally functions to regulate virus replication by promoting 
transcriptional up-regulation of the AAV promoters, p5 and p19 (Tratschin et al., 1984). E1A is 
capable of stabilising p53 – the tumour suppressor gene product, to elicit pro-apoptotic 
functions. This is mediated through E1A’s ability to render p53 incapable of proteasomal 
degradation (Lowe and Ruley, 1993; Li et al., 2004). Although, remaining helper functions have 
evolved to prevent E1A-mediated p53-induced apoptosis. Namely, the E1B and E4orf6 helper 
proteins (encoded by E1b and E4orf6, respectively) are able to destabilise p53 by forming a 
complex with associated cellular proteins. This complex harbours an E3 ubiquitin ligase 
function and targets p53 for ubiquitin-mediated proteolysis (Luo et al., 2007; Schwartz et al., 
2008). Furthermore, E1B and E4orf6 possess additional helper functions that promote the 
nuclear export of late viral mRNA to the cytoplasm for downstream processing (Pilder et al., 
1986; Krätzer et al., 2000; Blanchette et al., 2008). Considering AAV or Adenovirus virus-
specific elements are exposed within infected cells, the host cellular anti-viral responses must 
be repressed. The VA RNAs assist in this regard to impressively block anti-viral mechanisms by 
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inhibiting interferon (IFN) signalling that would otherwise activate anti-viral enzyme systems 
such as Dicer and the RNA-induced silencing complex (RISC) (Andersson et al., 2005). Lastly, 
the final helper function required for AAV production is performed by E2A (encoded by E2a), 
which functions to promote AAV DNA replication (Ward et al., 1998). Therefore, the range of 
helper functions work in concert to promote an intracellular milieu permissive for AAV2 
production.   
 
1.2.7 AAV site-specific integration 
On the other hand, in the absence of a helper virus or helper functions, AAV is significantly 
compromised in self-sufficiency and undergoes latency. Here, AAV genome replication is 
limited and gene expression is repressed. Latency is established by the preferred site-specific 
integration of AAV genome into chromosome 19q13.4, dubbed the AAV integration site 1 
(AAVS1) (Kotin et al., 1990; Samulski et al., 1991). Specifically AAV genome integrates into the 
initial exon of the myosin binding subunit 85 (MBS85) gene (Janovitz et al., 2013). This site-
specific integration accounts for roughly 45% of all integrations detected by Janovitz et al. 
(2013).  
 
A direct consequence on the lack of helper virus co-infection is the limited expression of AAV 
Rep78 and Rep68. This results in the repression of AAV-specific gene expression and DNA 
cannot be replicated (Labow and Berns, 1988). Integration into the AAVS1 locus is particularly 
favoured because of the presence of GCTC repeat elements, of which elements appear 
similarly in wildtype AAV ITRs. The presence of these elements permits the N–terminus of 
Rep78 and Rep68 proteins to bind to (Weitzman et al., 1994; Surosky et al., 1997). 
Additionally, the presence of a trs within the AAVS1 site also has been identified, and thought 
to be nicked upon integration of AAV genome (Linden et al., 1996). In particular, supplying the 
rep gene in cis to an ITR-flanked GFP expression cassette demonstrated enhanced integration 
into AAVS1 compared to supplying in trans (Balagúe et al., 1997). Given that the only viral 
components present in these investigations included the rep gene and ITR sequences, this 
essential work showed that the minimum requirements for site-specific integration was the 
presence of Rep and ITRs. 
 
The exact mechanism of AAV integration has been explored, especially to elucidate any 
adverse consequence of AAV integration or latency. Rep78/68 protein are capable of binding 
to both AAV RBE and cellular RBE at the same time (Weitzman et al., 1994), suggesting a 
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possible mechanism of integration involving Rep tethering the ITR containing sequence to the 
AAVS1 site. Henckaerts et al. (2009) investigated site-specific integration using mouse 
embryonic stem cell lines because mice cells harbour an MBS85 orthologue. It was observed 
that integration of AAV genome was associated with duplication of the target integration site. 
Specifically, and given integration can occur with the AAV genome orientated in the 5’-3’ 
transcriptional direction of the Mbs85 gene (Lusby et al., 1981; Rahim et al., 2011), the left ITR 
sequence was found within the Mbs85 gene. Whereas the right ITR was located in the 
promoter region of Mbs85 instead, with the addition of 18nt spare that resembled the reverse 
complement of the Mbs85 sequence from the junction that reads into the left ITR (Henckaerts 
et al., 2009). Therefore, integration was suggested to be mediated by Rep, which nicks at the 
cellular trs in AAVS1 leading to DNA synthesis of the target site with co-recruitment of AAV 
genome via Rep and AAV left ITR RBE sequence. With AAV genome in proximity, strand 
displacement leads to AAV genome being replicated instead and is contiguous with the initial 
replication of the target integration site. Seeing as 18nt (reverse complement) of the Mbs85 
was observed by Henckaerts et al. (2009) at the far right junction at the integration site, this 
suggested that the AAV genome was replicated and the replication fork switches back to the 
Mbs85 sequence (the strand complementary to the displaced strand) as template. The 
proposed model (Fig. 1.4) is extended by ligation of the 3’-hydroxyl group of the nascent 
strand with the 5’-end of the originally displaced cellular DNA by Rep, because Rep has shown 
previous ligase activity (Smith and Kotin, 2000). Although, the importance of cellular ligase IV 
in AAV integration was more recently noted by Daya et al. (2009), where significantly less AAV 
specific integration was observed in cells that expressed less ligase IV. Nonetheless, quiescent 
AAV is readily rescued when latently infected cells are subsequently infected by helper virus. 
The lytic life-cycle of AAV commences with the excision of AAV provirus from the host genome 
(a Rep-dependent process), and the production of infectious progeny in the presence of 
superinfection with Adenovirus (Berns et al., 1975). 
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Figure 1.4 Model for AAV site-specific integration into AAVS1 locus. I) A nick is generated in the trs 
structure in AAVS1, mediated by AAV Rep78/68. II) Strand displacement occurs by DNA synthesis at site 
of nick. III) Strand displacement occurs with AAV genome as template instead. IV) DNA synthesis 
switches back to the Mbs85 DNA sequence (complementary to the displaced strand). V) Ligation 
between synthesised DNA (here annotated as replicated AAV and ‘unknown sequence’) and the 
displaced DNA strand occurs. VI) A nick is generated in the opposite strand by Rep, and DNA synthesis 
completes AAV genome integration. VII) This model of AAV integration into the AAVS1 generates a 
duplication of the Mbs85 sequence. Figure from Henckaerts et al. (2009). 
 
1.2.8 AAV receptor-ligand interaction 
Infection by AAV is a multi-step process that involves virus attachment to relevant cell surface 
receptors. This leads to intracellular signalling that promotes virus uptake by endocytosis. AAV 
is then trafficked towards the nucleus, and its ssDNA genome is translocated into the nucleus 
for replication and gene expression for production of progeny. AAV2 has been shown, by 
single virus tracing studies by Seisenberger et al. (2001), to make multiple contacts with cell 
membranes to decelerate. By virtue of AAV2’s selective binding to its primary attachment 
receptor, heparan sulphate proteoglycan (HSPG) (Summerford and Samulski, 1998; Rabinowitz 
et al., 1999), AAV2 is capable of making the necessary contacts it requires to slow down its 
acceleration and firmly attach to cell surface membranes. This process seems especially reliant 
on Vp3 capsid protein (Rabinowitz et al., 1999). The use of site-directed mutagenesis of the 
cap ORF helped identify critical functional domains within Vp3, which facilitate receptor-ligand 
binding between AAV2 and HSPG (Wu et al., 2000). The corresponding mutations introduced 
by Wu et al. (2000) correlated with two amino acid (aa) clusters in Vp3’s loop IV. The precise 
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aa residues that contribute to the heparin-binding motif was further elucidated by Kern et al. 
(2003) as being R484, R487, K532, R585, and R588. These are located as patches of basic aa 
within loop IV at the three-fold rotation axis of AAV2 capsid. Considering that these key 
residues are not exposed on the capsid surface but rather buried, and that K532A and R585M 
mutants showed only a modest effect in AAV2 infectivity, it seems that AAV2 binding to HSPG 
initiates contact to cell membranes in order to enhance cell-virus interactions for anchorage, 
and is not wholly necessarily for infection.  
 
It was also apparent that a number of co-receptors were necessary to facilitate AAV2 entry. It 
was identified that co-receptors αVβ5 integrin, αVβ1 integrin (Asokan et al., 2006), fibroblast 
growth factor receptor-1 (FGFR1) (Qing et al., 1999), and hepatocyte growth factor receptor, 
c-Met (Kashiwakura et al., 2005) enhanced infectivity with little to no effect on the binding 
properties of the virus particles to target cell. For instance, cells treated with antibodies that 
targeted αVβ5 integrin showed inhibited endocytosis of AAV2, but binding affinity was 
unchanged relative to the use of control anti-mouse immunoglobulin G (IgG) (Sanlioglu et al., 
2000). However, it was noted that initial attachment of virus to cell surface seemed to be 
enhanced by the FGFR1, as the loss of FGFR1 expression alone correlated with the inability for 
AAV2 to bind (Qing et al., 1999).  
 
1.2.9 AAV cell entry 
As a consequence of AAV binding to primary cell surface receptor (HSPG) and secondary co-
receptor(s), downstream signalling pathways are activated to permit virus uptake by clathrin-
mediated endocytosis (Bartlett et al., 2000). The sequestration of virus by αV integrins and 
localisation of AAV2 to clathrin-coated pits facilitates the molecular cue for clathrin-mediated 
endocytosis (Mukherjee et al., 1997; Wang et al., 1998). This paradigm of cell entry is 
conserved between AAV serotypes (Bartlett et al., 2000). Even serotypes that bind to an 
alternative, unrelated primary receptor(s), such as AAV5 (which binds to sialic acid receptor), 
has also been shown to sequester to clathrin-coated pits for receptor-mediated endocytosis 
(Bantel-Schaal et al., 2002). 
 
Downstream signalling events associated with actin cytoskeletal reorganisation and 
endocytosis has been largely supported. AAV2 has been shown to internalise into HeLa cells in 
a Ras-related C3 botulinum toxin substrate 1 (Rac1)-dependent manner (Sanlioglu et al., 
2000). Rac1 is a small signalling GTPase involved in cell cytoskeletal reorganisation, cell 
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motility, adhesion and membrane trafficking (Lamaze et al., 1996; Ridley, 2006; Fujii et al., 
2013). Integrins have been widely known to interact with a number of intracellular signalling 
molecules and function as molecular cues for downstream signalling events. Integrin 
interactions with Rac, Rho and Cdc42 families of GTPases have been described (Nobes and 
Hall, 1995; Van Aelst and D'Souza-Schorey, 1997). With the clustering of integrins to a focal 
point at the cell surface enables proximal activation of phosphatidylinositol-3 kinase (PI3K) 
pathway, followed by Rac1 activation (Li et al., 1998). PI3K is a lipid kinase which 
phosphorylates PtdIns(4,5)P2 (PIP2) to form the active secondary messenger, PIP3. PIP3 then 
acts upon small GTP-binding proteins such as Rac1 and results in actin polymerisation. 
Ultimately, actin filaments propagate directly under the plasma membrane at the focal point. 
Membrane extensions then form and engulf AAV2 particles in the initial process of 
endocytosis. Complete internalisation is deemed dynamin-dependent, where dynamin 
oligomerisation forms a ring structure that is necessary for the formation of clathrin-coated 
vesicles, and the final pinching of coated pits from the cell membrane into the internal 
compartment (Duan et al., 1999). However, inhibition of dynamin showed only a partial block 
in viral endocytosis (Duan et al., 1999), indicating the presence of alternative entry 
mechanisms. It should be noted that a number of the aforementioned investigations assayed 
AAV2 infection in the presence of Adenovirus co-infection for helper function, which may 
affect cell homeostasis and thus confound previous reports on AAV2 internalisation. 
 
On the other hand, Nonnenmacher and Weber (2011) demonstrated that infectious AAV2 
internalisation was predominantly controlled by the clathrin-independent carriers (CLIC)/GPI-
anchored-protein-enriched endosomal compartment (GEEC) pathway, instead. This was 
determined by blocking clathrin-mediated endocytosis through the overexpression of 
truncation mutant of Eps15 (a clathrin-coated vesicle component), or chemical inhibition using 
chlorpromazine. Virus internalisation was unaffected under these conditions indicating AAV2’s 
independence to clathrin-mediated endocytosis. Alternatively, inhibiting effectors of 
CLIC/GEEC, such as Arf1 and Cdc42 GTPase showed reduced transduction of AAV2 into HeLa 
and 293T cells by 70%. AAV2 was evidenced within CLIC/GEEC endosomes, as per co-localised 
markers of CLIC/GEEC endosomes, such as GRAF1 (Nonnenmacher and Weber, 2011). AAV2 
entry was not completely blocked by inhibiting clathrin-mediated endocytosis mentioned 
above, whereas, inhibition of both the CLIC/GEEC- and dynamin-dependent pathways of 
endocytosis were needed to block entry completely. Therefore, both entry pathways are 
simultaneously used by AAV2 (Fig. 1.5), although the dependence of either may vary 
 18 
 
considerably between different host cell types. 
 
Figure 1.5 Proposed mechanisms of AAV vector trafficking to the nucleus. AAV binds to key receptors 
on the surface of target cells, and are internalised by clathrin-mediated endocytosis (CCP) and/or 
CLIC/GEEC. Trafficking of AAV then is transported to the nucleus, likely involving early endosome 
maturation to late endosome or recycling endosomes. AAV is then released to transverse the nuclear 
membrane into the nucleus to continue its life-cycle. Acronyms thereafter include: CAV, caveolar 
endocytosis; Cyt, cytosol; Dyn, dynamin; ER, endoplastic reticulum; EE, early endosome; LE, late 
endosome; LY, lysosome; MP, micropinocytosis; No, nucleolus; NP, nucleoplasm; NPC, nuclear pore 
complex; Nuc, nucleus; PNRE, perinuclear recyclying endosomes; TGN, trans-Golgo network. Figure 
from Nonnenmacher and Weber (2012). 
 
1.2.10 AAV trafficking to the nucleus 
Inarguably, the AAV genome must be trafficked into the nucleus, express relevant viral 
proteins, and replicate progeny in order to establish an infective or latent life-cycle. Successful 
transduction of AAV requires intact particle to migrate to the nucleus, and import at least its 
genome. It remains unclear exactly how AAV is trafficked to the nucleus, especially when 
exactly viral uncoating occurs. To answer these, studies have predominantly utilised rAAV 
vectors and examined the subcellular localisation and trafficking mechanisms employed.  
 
Recombinant AAV vectors are compartmentalised into Rab5+ early endosomes after initial 
uptake by clathrin-mediated endocytosis. These vesicle-bound rAAV are shown to traffic to the 
perinuclear space (Bartlett et al., 2000; Sanlioglu et al., 2000). More recent evidence suggests 
AAV is trafficked to the Golgi apparatus that occupies the perinuclear space (Bantel-Schaal et 
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al., 2002; Xiao and Samulski, 2012; Xiao et al., 2016). Strong evidence suggests that 
compartmentalised AAV utilises the cells’ microtubule network to traffic itself towards the 
nucleus via the perinuclear space, unidirectionally (Xiao and Samulski, 2012). Despite using 
nocodazole treatment to disrupt microtubule formation and inhibit the formation of the 
microtubule organisation centre (MTOC), a small portion of infecting AAV still manage to 
translocate into the nucleus, indicating alternative mechanisms for AAV trafficking and/or 
nuclear translocation (Xiao and Samulski, 2012). 
 
Efficient trafficking and transduction is dependent on early endosome processing to late stage 
endosomes. Reports have shown trafficking of AAV through the Rab7+ late endosomes; 
although trafficking via Rab11A+ recycling endosomes has also been reported (Douar et al., 
2001; Ding et al., 2006; Harbison et al., 2009). Redirecting AAV to traffic via the Rab7+ vesicles, 
using EerI to inhibit endosomal reticulum-associated degradation processing, contributed to 
enhanced transduction efficiencies (Berry and Asokan, 2016). This indicated a benefit for AAV 
particles to commit to a single trafficking pathway. Interestingly, a dose-dependent disparity in 
AAV2’s infection route has been described: high multiplicity of infection (MOI) of 10,000 
genomes/cell correlated with co-localisation of AAV2 particles with Rab11A+ endosomes. 
Rab7A+ late stage endosomes was associated with low MOI of 100 genomes/cell (Ding et al., 
2006). In addition to this, the mechanism utilised by AAV to traverse infected cells likely is cell-
type dependent (Pajusola et al., 2002), as chemical inhibition of micropinocytosis in HeLa, 
HepG2 or Huh7 cell lines showed enhanced transduction rates only in the hepatocellular cell 
lines (Weinberg et al., 2014). Differential trafficking pathways may be a feature of different 
AAV serotypes infecting the same permissive cells. This may be attributed to the fact that 
different AAV serotypes utilise different primary receptors to mediate viral or vector entry into 
target cells, which would likely impact on downstream signalling events (Liu et al., 2013). 
 
Endosomal escape of rAAV typically ensues, and involves the release of rAAV from their 
processed endosome vesicles. Therefore, once trafficked close to the nucleus, endosomal pH 
is modulated to favour AAV escape. Endosome maturation into late endosomes and lysosomes 
is accompanied with acidification of this compartment. The use of chemical inhibition of 
endosomal acidification has outlined the importance of this step. Inhibitors have included 
ammonium chloride, bafilomycin A1, or chloroquine, all of which treatments correlated with 
reduced AAV transduction (Bartlett et al., 2000; Xiao and Samulski, 2012). Eventually, a 
conformational change in the N-terminus of Vp1 of AAV capsid, which houses the 
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phospholipase A2 (PLA2) domain and nuclear localisation signals (Fig. 1.6), is stimulated 
(Venkatakrishnan et al., 2013). Given both the inhibition of late-endosome formation and 
acidification of late endosomes is associated with reduced AAV transduction, it seems late-
endosome acidification is the trigger for this conformation change. Mutations in PLA2 catalytic 
domain correlated with reduced AAV gene expression and translocation into the nucleus, but 
did not affect AAV entry into cells and its localisation to the perinuclear space (Girod et al., 
2002; Stahnke et al., 2011). Moreover, AAV infectivity and transduction were rescued when 
co-infecting Vp1 mutated AAV vectors with specialised AAV vectors, which were composed of 
Vp1 fusion proteins that allowed their capsid surfaces to be exposed, with inherently activated 
PLA2 domains (Grieger et al., 2007). In turn, these data imply that the PLA2 domain is necessary 
for AAV infectivity downstream of AAV entry and trafficking to the perinuclear space. Given 
PLA2 functions to hydrolyse phospholipids, it was reasonably assumed that this activity is 
employed by infectious AAV to hydrolyse the endosome compartment’s membrane and 
escape. 
 
It remains widely accepted that AAV translocates into the nucleus as intact particles (Nicolson 
and Samulski, 2014; Kelich et al., 2015). Despite the growing evidence in support of nuclear 
translocation of intact AAV, the point at which viral uncoating actually occurs remains 
debated. Fewer studies imply viral uncoating of AAV2 as occurring prior to nuclear 
translocation (Lux et al., 2005). In further support of the former is the presence of three basic 
regions (BR1-3) in the unique N-termini of Vp1 and Vp2 (Fig. 1.6). The sequences of which 
closely resemble nuclear localisation signals (NLS) (Grieger et al., 2006). Mutations in BR1-3 
are associated with reduced transduction and the inability for AAV to translocate into the 
nucleus (Johnson et al., 2010). The mechanism in which intact AAV particles physically 
translocate the nuclear membrane has thus been proposed, and seems to operate in a 
different manner to minute virus of mice (MVM) – another parvovirus – that disrupts the 
nuclear lamina in order to access the nucleus (Cohen et al., 2006; Cohen et al., 2011). The 
proposed mechanism has been shown to involve nuclear pore complexes (NPCs) instead for 
AAV2. Labelled AAVs were directly evidenced to move into the nucleus through labelled NPCs 
(Kelich et al., 2015). And the inhibition of NPCs using wheat germ agglutinin prevented nuclear 
entry of infecting Cy5-AAV to a greater extent than vehicle control used in the study (Nicolson 
and Samulski, 2014). Furthermore, rAAV2 was found to co-localise with importin-β (a key 
chaperone involved in directing nuclear entry of NLS containing proteins) after 1h post-
infection, and post-acidification of AAV2 containing endosomes (Nicolson and Samulski, 2014). 
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Figure 1.6 Vp1 and Vp2 contain key signals for AAV life-cycle. Schematic of AAV Vp1-3 proteins, which 
contain PLA2 (HD) domain and basic regions (BR1-3) in the N-terminus of Vp1 and Vp2 proteins 
necessary for AAV infectivity. + regions indicate putative nuclear localisation signals. Figure from 
Johnson et al. (2010). 
 
After entering the nucleus AAV2 localises to nucleoli, but mobilisation into the nucleoplasm 
seems to be required for AAV to uncoat and permit gene expression (Johnson and Samulski, 
2009). The exact means that intact AAV capsids use to traffic to nucleoli is not recognised in 
full, but nucleolar proteins have been shown to directly interact with intact AAV. Namely, 
nucleolin and nucleophosmin have been shown to bind and co-localise with AAV after nuclear 
import (Qiu and Brown, 1999; Bevington et al., 2007). Although, nucleolar accumulation of 
infecting AAV seems to act as a barrier to efficient transduction; specifically short interfering 
(si)RNA knockdown of either nucleolin or nucleophosmin in HeLa cells showed enhanced 
transduction efficiencies (Johnson and Samulski, 2009). Chemical treatment with hydroxyurea 
significantly affected the subcellular distribution of nucleolin, and treatment with hydroxyurea 
correlated with enhanced AAV transduction efficiency, with a diffuse distribution of AAV in the 
nucleoplasm but excluded from the nucleoli (Johnson and Samulski, 2009).  
 
1.2.11 AAV DNA replication 
AAV genome replication predominantly occurs in the presence of Adenovirus or HSV co- or 
super- infection, which provides all the necessary helper functions that permit AAV 
transcription and gene expression. Ultimately, AAV DNA replication occurs by the synthesis of 
dsDNA from the ssDNA AAV genome acting as template. The dsDNA AAV replication product 
serves as replicative intermediates (Straus et al., 1976), from which ssAAV genomes with plus 
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or minus polarities are packaged into AAV capsids (Berns and Rose, 1970). Host cell 
machineries and viral factors require access to naked AAV genome in order to commence DNA 
replication. Although, the disassembly of AAV capsid has not been fully elucidated, work by 
Johnson and Samulski (2009) propose infectious AAV2 vector remain compartmentalised in 
nucleoli, and mobilise to the nucleoplasm in order to instigate AAV genome replication or gene 
expression.  
 
DNA replication is achieved initially from the inherent property of the AAV ITRs. The ITRs 
harbour the viral origin of replication in the forms of the RBE and trs, but also, the initial-most 
125nt of ITRs form imperfect palindromes that folds upon itself. This self-annealing property 
provides a suitable dsDNA template, and importantly provides a base-paired 3’-hydroxyl group 
from which unilateral DNA synthesis can occur. The replication machinery is thought to be 
recruited for unidirectional DNA synthesis from the ITR-derived 3’-hydroxyl group. However, 
the unilateral DNA replication alone does not complete DNA replication of the entire AAV 
genome, due to a lack of a base-paired 3’-hydroxyl group on the opposite strand to replicate 
the remainder of 3’ ITR that served as a replication primer. In this case, AAV Rep68/78 
proteins bind to the dsDNA of the ITR via the RBE (McCarty et al., 1994). Rep also recognises a 
second motif (RBE’) present in the top of one of the ITR’s hairpins (Hickman et al., 2004). Rep 
is thought to function as a helicase to generate ssDNA around the trs, which is necessary to 
allow the trs to form an intermediary hairpin structure. This change in conformation within the 
AAV ITR sequence promotes cleavage of the trs via Rep’s endonuclease function, and provides 
another 3’-hydroxyl group to permit DNA synthesis and single-strand displacement. The 
remainder of the ITR that served as a replication primer is faithfully replicated, resulting in a 
completely replicated AAV genome as a dsDNA intermediate. The DNA ends of which can 
renature to form terminal hairpins from each strand and generate another base-paired, 3’-
hydroxyl group for replication by single-strand displacement. This provides concatemeric AAV 
genomes and the ssAAV genome for packaging (Straus et al., 1976; Hong et al., 1994). An 
overall schematic of replication by single-strand displacement is depicted below in Fig. 1.7. 
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Figure 1.7 Model for AAV genome replication. The 3’ ITR of AAV2 genome forms a T-shaped hairpin 
structure, which provides a base-paired, 3’-hydroxyl group necessary for DNA synthesis. Firstly 
Rep68/78 binds to the 3’ ITR as the origin of replication, and further recruitment of the cell’s replication 
machinery facilitates DNA synthesis of the AAV genome. The trs site at the 3’ of the AAV genome is 
nicked by Rep68/78, and provides another base-paired, 3’-hydroxyl group to permit complete DNA 
replication of the ITR that served as a replication primer. After complete DNA replication, the ITRs can 
renature to serve as replication primers to promote single-strand displacement and elongation of the 
AAV genome. The entire model results in concatameric dsAAV genome. The ssAAV genomes can be 
packaged. Solid lines refer to template strand; dashed lines refer to replicating strands. Figure from 
Goncalves (2005). 
 
1.2.12 AAV assembly 
It is commonly perceived that AAV assembly occurs in two distinct phases, i) assembly of a 
preformed capsid shell, followed by ii) the packaging of ssAAV genome into the preformed 
capsid (Myers and Carter, 1980). The assembly of preformed capsid vectors has been observed 
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in the nucleoli or nucleolar periphery, with encapsidation of AAV genome occurring in the 
nucleoplasm (Wistuba et al., 1997). The expression of Vp1-3 leads to the coordinated 
assembly of AAV capsid with the 1:1:10 stoichiometry of Vp1, Vp2 and Vp3, respectively. This 
process of which requires host factors in order to facilitate capsid assembly (Steinbach et al., 
1997; Wistuba et al., 1997).  
 
Assembly of preformed AAV capsids is promoted by an additional protein, AAP, which is 
encoded by an alternative ORF in the cap gene (Fig. 1.1).  Expression of Vp2/3 and Vp3 only 
capsid proteins can result in successful assembly of empty vectors, albeit, non-infectious 
vectors (Grieger et al., 2007). This is likely due to the loss of the PLA2 domain and BR1-3 
sequences. Nonetheless, vectors derived from solely Vp3 expression was only possible when 
the entire AAV2 cap gene, with mutated initiation codons for Vp1 and Vp2 ORFs, was 
transfected (Sonntag et al., 2010). This indicated the presence of an AAV-encoded factor 
upstream of Vp3 ORF responsible for nucleolar trafficking and capsid assembly of Vp3, and 
was characterised as AAP (Sonntag et al., 2010; Sonntag et al., 2011; Earley et al., 2015). 
Silencing AAP expression prevented the nucleolar trafficking of Vp1-3 proteins and capsid 
formation, which could not be rescued by tagging Vp3 with a nucleolar signalling peptide 
(Sonntag et al., 2010). Therefore, a proposed role for AAP is to function as a scaffolding 
protein by binding to capsid proteins and concentrating the assembly process to the nucleoli 
(Naumer et al., 2012; Earley et al., 2015). The mechanistic role of AAP in promoting capsid 
assembly may be conserved between serotypes given AAV2-derived AAP can promote capsid 
assembly of a diverse range of AAV serotypes (Sonntag et al., 2011; Naumer et al., 2012). 
However, Earley et al. (2015) have shown that AAP is not essential for capsid assembly for 
AAV4, 5, and 11, and for nucleolar localisation of capsid assembly.  
 
Encapsidation of ssAAV genome into preformed capsids is likely to follow after AAV genome is 
replicated, and is thought to occur in the nucleoplasm at later stages of AAV infection 
(Wistuba et al., 1997). Additionally, Rep -40, -52, -68, and -72 proteins were shown to bind 
directly to free capsid proteins or assembled capsids independent of ITR-containing AAV 
vector DNA, by co-immunoprecipitation studies (Dubielzig et al., 1999). Certain bulky 
mutations at AAV2’s pores at their five-fold symmetry axes correlated with reduced Rep-
capsid interactions and genome packaging efficiency (Bleker et al., 2005; Bleker et al., 2006). 
Such protein-protein interaction may generate an intermediate complex with AAV ssDNA, 
given Rep78 covalently associates with AAV 5’-ITR sequence (Prasad and Trempe, 1995).  
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AAV vector genomes have been identified to enter AAV capsids in a polar manner. The 3’-
ssDNA sequence was identified in partially-packaged AAV2 vectors implying the 3’-ssDNA 
sequence is first translocated into preformed capsids (King et al., 2001),  despite the fact that 
the 5’-sequence associates with preformed capsids in context with Rep78 (Prasad and Trempe, 
1995). Especially, the loss of the ITR’s D-sequences, but retention of the hairpin secondary 
structures, in plasmid constructs was defective in their ability to produce ssDNA genomes. 
Therefore, ssDNA progeny genome could not be packaged, and vector genomes were not 
detectable (Wang et al., 1996). Further to this, after associating dsAAV genomes to preformed 
capsid via Rep78, smaller Rep40/52’s DNA helicase activity promoted the unwinding the ds 
AAV genomes, principally at the 3’-end to feed and encapsidate ssAAV genome (King et al., 
2001).  
 
1.3.0 In vitro production of recombinant AAV vectors 
1.3.1 Recombinant AAV vectors 
The development of rAAVs for vector-based gene therapy has progressed significantly and 
continuously over the years. Use of AAV vectors has become a very successful and promising 
therapeutic tool for treatment of monogenetic diseases. However, despite the current 
developments, certain limitations have restricted the full utilisation of AAVs. One main 
limitation is the constrained viral titres produced from current production methods. Interest in 
this field of research is due to the need for high MOI for efficient in vivo transduction by rAAV 
vectors. Generally an MOI of 103-105 infectious particles/cell is predicted to be needed (Ellis et 
al., 2013), or clinical doses of 1012-1013/kg infectious particles needed for human 
administration (Bryant et al., 2013); though these quantities are quite dependent on the 
intended target tissue type. 
 
1.3.2 Components required for rAAV production 
Recombinant AAV production is mediated most commonly by triple transfection of three 
recombinant plasmids that introduce the transgene, cis and trans components of AAVs, as well 
as helper functions. These recombinant plasmids individually encode for the transgene of 
interest flanked by AAV2 ITRs, or the Rep and Cap proteins, or finally the helper functions 
minimally required for rAAV vector production (Matsushita et al., 1998; Xiao et al., 1998). The 
gold standard for the laboratory-scale in vitro production of vectors is the use of the packaging 
cell line, human embryonic kidney (HEK)293T. Therefore, adherent 293T cells are subjected to 
triple transfection by above mentioned plasmids to commence rAAV production. 
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293T cells are a specialised cell line, and have been developed and commercialised for the use 
in rAAV vector production. This immortalised cell line has been specifically modified by the 
addition of human Adenovirus type 5 E1 early region coding DNA, and in turn provides E1A 
and E1B helper function (Graham et al., 1977). Therefore, an advantage of this transformation 
allows for a immortalised cell line as per E1A oncogene function, and the necessary helper 
function provided by E1A’s trans-acting function to up-regulate viral promoters. Another 
advantage of using a 293-AAV specialised cell line is the partial independence from Adenovirus 
or alternative helper virus infection, which improves the safety profile of subsequent rAAV 
vectors – the risk of pathogenic contamination is ablated. The remainder minimal helper 
function is provided by the aforementioned helper plasmid that provides the E2A, E4orf6 
proteins and the VA RNA’s. This is delivered into the packaging cell line simultaneously by 
triple transfection with the AAV-transgene and rep/cap plasmids.  
 
It should be noted that the transgene of interest is cloned into a vector backbone that 
comprises the AAV2 ITRs, and therefore the rep and cap ORFs have been replaced completely. 
With the removal of the rep and cap coding sequences with intended transgene, the coding 
capacity increases significantly. A coding capacity of approximately 5kb in length is generated 
with the replacement of the rep and cap genes. The ITRs are maintained for their cis-acting 
functions in particle assembly (packaging of the recombinant AAV genome into preformed 
empty capsids), and genome replication. Additionally, the discovery of different serotypes of 
AAV (Rutledge et al., 1998) promoted pseudotyping of rAAV vectors. This meant the capsid 
encoding element of the recombinant systems derived from different serotypes, whereas the 
ITRs and rep gene were based on AAV2. This permitted a wide range of serotypically different 
vectors to be produced, and thus expanded the transduction potential of rAAV vectors 
because pseudotyping particles provide a wide collective tropism.   
 
1.3.3 Recombinant AAV vector production 
Scalable systems of rAAV production are currently in development. However, an important 
consideration to take into account is the need to produce sufficient quantities of vector that 
can be used for clinical use. This has been a long-standing limitation in the history of rAAV-
mediated gene therapy, but constant advancements have been developed to procure higher 
and purer yields of rAAV. 
 
Generally speaking 293T cells are grown and expanded in vitro. After which, triple transfection 
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with three plasmids (encoding transgene and cis- or trans- acting factors) is performed on 
adherent 293T cells (Fig. 1.8). A number of means can be utilised to promote the efficient 
transfer of plasmid DNAs into 293T cells, especially the use of Calcium Phosphate precipitation 
(Xiao et al., 1998), and polyethylenimine (PEI) (Drittanti et al., 2001), and cationic lipids (Liu et 
al., 2008). The Calcium Phosphate precipitation method is widely used for large-scale 
production of rAAV, attributable by the reagents cost-effective use in transfection of 293T 
cells, especially with high transfection efficiency documented by Meissner et al. (2001) (up to 
90% transfer of exogenous DNA into cultured cells). It must be noted that for rAAV vector 
production using Calcium Phosphate or even other chemical methods of DNA transfer, the 
process and conditions must be specially optimised. Additionally, consistency between 
productions must be upheld to truly ensure reproducible and comparable AAV titres and 
quality. Additional considerations are the viability and quality of cultured 293T cells and the 
variation in protocols between established laboratories. Consistency in this respect is difficult 
to achieve, with variation in chemical makeup of reagents and technique, culture conditions, 
all of which can impact on rAAV vector production. Despite this, Calcium Phosphate-mediated 
triple transfection has shown to provide vector titres ranging from 103-105 viral genomes/cell 
(Aucoin et al., 2008), therefore showing a range of 100-fold difference in infectious viral 
genomes. This is a considerable difference to have to account for, and one that has proven 
difficult to narrow.  
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Figure 1.8 Schematic of a common AAV vector production method by triple transfection. The triple 
plasmid system to generate rAAV vectors in 293T, or suitable E1A/B-expressing cell line is illustrated. 
The vector genome is encoded by one plasmid, and contains the gene of interest under transcriptional 
control of a suitable promoter and polyA signal, all of which is flanked by AAV2 ITRs. The second plasmid 
(pAAV-RepCap) encodes AAV2 Rep protein, and Cap proteins for the desired AAV serotype. The third 
plasmid (pHelper) contains E2, E4 and VA-RNA – the minimal adenovirus factors required for AAV 
replication. 293T cells are ultimately co-transfected, after which, AAV vectors can be harvested. Figure 
adapted from Ayuso et al. (2010). 
 
Nonetheless, triple transfection results in the production of rAAV and 72h post-transfection, 
cells are harvested and lysed to recover rAAV vectors. Therefore, each cell treated must be 
transfected with each of the three plasmids for vector production to occur. This transfection 
pressure therefore restricts the efficiency of production on a cell-by-cell basis. Subsequent 
purification of infectious rAAV vectors from empty capsids and cellular proteins is then 
performed. For example purification was most initially based on multiple rounds of caesium 
chloride density-gradient ultracentrifugation. Here, caesium chloride salts are able to form 
gradients based on differential buoyancies. This generates differing equilibriums between 
sample compositions when subjected to ultracentrifugation. When viruses are treated with 
caesium chloride salts and centrifuged, viruses are collectively separated from contaminants 
and cellular constituents. In fact, where rAAV production involves Adenovirus helper, caesium 
chloride density-gradient ultracentrifugation is capable of partitioning rAAV from Adenovirus 
contaminants. Main disadvantages of this purification method must be considered; these 
include caesium chloride toxicity, which means downstream clinical use is limited unless 
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viruses are dialysed against a physiological buffer. Further to this, reports have indicated that 
rAAV stocks purified by this method have shown loss in purity and infectivity (Zeltner et al., 
2010; Strobel et al., 2015). 
 
An alternative purification method involves non-ionic iodixanol gradients, and was developed 
by Zolotukhin et al. (1999). The bulk purification step by iodixanol provides a number of 
benefits, including faster turnaround for purifying rAAV, better infectivity of rAAV particles, 
and lower downstream toxicity compared to caesium chloride (Zolotukhin et al., 1999; Potter 
et al., 2002; Zolotukhin et al., 2002). Additionally, aggregation of rAAV particles was not a 
feature associated with iodixanol density-gradient purification, and to non-ionic and non-
viscous characteristic of the iodixanol medium meant that preps could be loaded onto 
chromatographic columns almost directly. Chromatographic steps also resulted in higher 
yields of infectious titres when crude lysates were subjected to iodixanol density gradient 
purification, compared to using caesium chloride gradients by up to 10-fold. An impressive 
70% of rAAV from crude lysates could be recovered (Zolotukhin et al., 1999). Following this 
initial step of purification, rAAVs are subjected to further purification by affinity 
chromatography. This technology exploits AAVs natural ligand for receptor binding. HSPG has 
been shown to facilitate AAV2 entry upon receptor binding (Summerford and Samulski, 1998), 
and shows high sensitivity and affinity of binding. Therefore use of high-performance liquid 
chromatography (HPLC) with heparin columns can purify rAAV vector products. A purity of 
>99% was documented by Zolotukhin et al. (1999). This method of purification is also limited 
by the selectivity of binding – only rAAVs with a tropism for heparin will bind in the above 
setup. Alternative to this, the use of capsid specific antibodies conjugated to heparin columns 
bypasses the purification restriction. In this way a broader class of AAV serotypes can be 
purified for a wider set of downstream uses. 
 
1.3.4 Advancements in rAAV vector production methods 
The traditional production systems involved a double-transfection setup (using plasmids that 
encoded for AAV2 ITRs and transgene, or rep and cap ORFs), with subsequent infection with 
wildtype Adenovirus (Samulski et al., 1987). This method proved undesirable as eliminating 
wildtype Adenovirus post-production was problematic and laborious. The process also raised 
caution with respects to the safety profile of rAAV vectors produced in this manner. 
Subsequent development to this process involved the use of a two-plasmid system (as above); 
however, the helper plasmids included AAV rep/cap and Adenovirus supporting functions. This 
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ensured a helper virus-free system that resulted in an 80-fold increase in vector production 
compared to methods using wildtype Adenovirus. A two-plasmid system also ensured higher 
transfection efficiencies (Collaco et al., 1999). Similarly, the design of a recombinant plasmid 
that separately provided helper functions (in that in the absence of Adenovirus co-infection) 
demonstrated higher levels of vector output than compared to production of AAV in the 
presence of Adenovirus co-infection (Matsushita et al., 1998; Xiao et al., 1998). Despite these 
milestones, investigations to scale-up the amount of rAAV vector from packaging and 
producing systems is on-going.  
 
Developing production systems have now involved looking towards modifying cell lines in 
effort to improve upon the limited scalability of rAAV vectors. A number of modifications have 
been described in the literature, of which fall under one of four themes: i) generation of stable 
producer HeLa or A459 cell lines (Gao et al., 2002b); ii) use of insect cell line Sf9 that is derived 
from ovarian tissue of Spodoptera frugiperda (Vaughn et al., 1977); including an Sf9-based 
partial packaging cell line with stable expression of AAV rep and cap (Smith et al., 2009; 
Mietzsch et al., 2014); iii) use of HSV-1 systems (Kang et al., 2009); and lastly, the most recent 
development, iv) manipulation of human cell lines and endogenous genes to improve vector 
production (Satkunanathan et al., 2014; Satkunanathan et al., 2017). 
 
The relationship between cellular factors and rAAV vector production remains, to date, 
understudied. Whereas, in contrast there is substantial understanding of helper virus function 
on AAV and host cell biology. A number of reports do support a role of host cellular factors in 
AAV biology and production. For instance, it was shown that AAV vectors associated with a 
number of cellular proteins, including nucleophosmin (Dong et al., 2014). Nucleophosmin 
functions mainly in the nucleolus, but studies between AAV2 and nucleophosmin indicated 
that it interacts with AAV Rep proteins (Bevington et al., 2007), and functions to modulate 
particle mobilisation and genome uncoating (Johnson and Samulski, 2009). Therefore, 
Satkunanathan et al. (2014) aimed to decipher the cellular protein makeup that is either co-
produced or co-purified with rAAV vectors in vitro, in further detail. 
 
Using mass spectrometry Satkunanathan et al. (2014) identified several cellular proteins, 
including nucleophosmin, that were associated with rAAV vectors. Mass spectrometry 
identified the Y-Box binding protein (YB)1, which is a highly complex and multifunctional 
protein. It was suggested that YB1 may have an important function in rAAV vector production, 
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seeing as short-haripin (sh)RNA-mediated knockdown of YB1 in 293T cells exhibited an 
enhanced packaging cell line quality. A number of YB1 knockdown effects were documented: 
YB1 had a drastic effect on AAV biology with significant impact on both Rep and AAV2 genome 
turnover (increased vector production forr AAV2 up to 45-fold increase). The effect of YB1 
knockdown was profoundly most evident on rAAV2 serotype than compared to rAAV5 or 
rAAV8. This indicated that YB1 functioned in a serotype-specific manner. Taken together it 
seems that the molecular mechanisms of YB1 directly or indirectly impacted on rAAV vector 
production in a negative manner.  
 
1.3.5 Recombinant baculovirus technology 
Recombinant AAV vector production in Sf9 cell lines was adapted because of the ability for 
recombinant baculoviruses to infect insect cell lines and produce large quantities of 
heterologous proteins in vitro. This was due to the strong insect-specific promoters, such as 
p10 and polyhedrin (polh), used in baculovirus expression vector systems, which drive late 
acting, high level expression of protein (Graber et al., 1992; Miranda et al., 1997; Usami et al., 
2011; Wilde et al., 2014). Additionally, insect cells such as Sf9 are easily grown in suspension 
culture and in serum-free conditions. Post-translational modifications of proteins synthesised 
in insect cells is an additional feature and benefit, as these processes occur (to a limited 
extent) similar as is seen in mammalian cells (Vrljic et al., 2011). Given these main features, 
the production of heterologous protein or rAAV vectors could be produced in a scalable 
manner, especially when mediated by the use of recombinant baculoviruses. 
 
Recombinant baculovirus technology is mainly derived from Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV), an insect-specific virus with a predominant infectivity for the 
larvae of the order Lepidoptera, which includes S. frugiperda and Trichoplusia ni. Towards the 
latter stages of AcMNPV infection, large amounts of polyhedrin gene expression was identified 
due to its promoter (polh) activity (Carstens et al., 1979). However, the non-essential property 
of polyhedrin protein to virus replication in culture (Smith et al., 1983a), drove the exploitation 
and utilisation of AcMNPV for baculovirus expression vector systems. Although, AcMNPV 
contains a very large circular genome (>130kb) (Ayres et al., 1994), which proved difficult to 
manipulate using classical cloning strategies. Instead recombinant baculoviruses were 
generated by homologous recombination (HR) strategies upon co-transfection of insect cell 
lines between a transfer vector (containing gene of interest) and the non-essential polyhedrin 
gene region of AcMNPV circular genomic DNA. The polyhedrin gene acted as target for 
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recombination; however, considerable development to the baculovirus expression vector 
system for generation of recombinant baculovirus was required. The generation of 
recombinant baculovirus by the aforementioned method was a highly inefficient process, as 
only an average of 0.5% of progeny virus were evaluated as recombinant (Smith et al., 1983b). 
This meant that highly time-consuming purification protocols were necessary to isolate 
recombinant baculovirus from wildtype. 
 
The baculovirus expression system was further improved to diminish the inefficiency in 
recombinant baculovirus generation. This improvement mainly originated from attempts to 
make deficient the wildtype progeny. Strategies included linearization of the AcMNPV genomic 
DNA at either the polyhedrin or p10 loci, through careful and targeted insertion of restriction 
enzyme sites (Kitts et al., 1990). In theory, using linearised baculovirus genomic DNA for 
recombination with an appropriate transfer vector would permit only transfection of re-
circularised genomic DNA, and therefore generation of recombinant baculovirus populations 
only. This approach increased the fraction of recombinant baculovirus from wildtype to 
approximately 30% (Kitts et al., 1990), which in itself was a substantial improvement from the 
near impractical 0.5% efficiency.  
 
Soon after, this system was further improved to permit highly efficient recombinant 
baculovirus production with up to 98% efficiency (Kitts and Possee, 1993). Essentially, the 
adapted production process resulted in further hampering the ability for wildtype progeny 
from being produced. This adapted system took advantage of the essential gene, orf1629, 
found just downstream of the polyhedrin locus. The orf1629 was truncated in the engineered 
baculovirus genomic DNA, coupled with the linearisation at the polyhedrin locus. Instead the 
remainder of the orf1629 was found in the transfer vector used to produce recombinant 
baculovirus upon co-transfection. This meant that upon co-transfection, successful 
recombination between linearised baculovius genomic DNA and transfer vector would restore 
essential orf1629 gene function, and permitted only recombinant baculovirus progeny to be 
produced. 
 
Further innovative strategies to produce clonal recombinant baculoviruses in a direct, and 
almost one-step manner were developed soon after. This allowed for quick production of 
recombinant baculovirus, which does not necessarily require purification by sequential plaque 
assays. The technology and production method was developed so that all baculovirus genomic 
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DNA product contained the heterologous gene of interest. Such methods involved production 
of recombinant baculovirus by site-specific transposition events between the genomic DNA of 
baculovirus (engineered into a bacterial artificial chromosome [BAC]), and shuttle vector using 
bacteria systems. Instead, in bacterial cells the process was simplified and proved more 
efficient as the entire baculovirus genomic DNA was recombined into a BAC at the polh locus. 
This allowed the engineered BAC DNA to propagate in E. coli (Luckow et al., 1993; Zhu and Qi, 
1999). Shuttle vectors in this context were referred to as bacmids. An additional advantage of 
this methodology meant that transformation of E. coli harbouring the engineered BAC with 
desired bacmid would allow for site-specific transposition between the Tn7 transposon 
elements present in the baculovirus portion of the BAC and bacmid. Ultimately, the developed 
system allowed for propagation of a single genotype of recombinant baculovirus genomic DNA 
post site-specific transposition. The resultant genome can subsequently be used to transfect 
insect cells for recombinant baculovirus production, in a more than less clonal manner than 
previously described. Resultant recombinant baculoviruses were referred to as (r)baculovirus 
expression vectors (BEVs). 
  
1.3.6 Recombinant baculovirus technology for rAAV vector production 
Virus-like particles (VLPs) have successfully been generated using the baculovirus expression 
system, and includes VLPs derived from parvovirus B19, human pillomavirus, and even AAV 
(Ruffing et al., 1992; Tsao et al., 1996; Aucoin et al., 2008; Abdoli et al., 2013). In the case of 
AAV VLPs, the AAV2 Vp1, Vp2, and Vp3 sequences were individually expressed or co-expressed 
from single recombinant baculoviruses. Upon infection of Sf9 cells, expressed Vp1-3 showed 
competency for VLP formation, in that empty AAV vectors were synthesised. However, the 
formation of AAV2 VLPs was limited to situations where Vp2 expression was present and Vp2 
seemingly promoted capsid assembly in its entirety. Single or combination infection with 
recombinant baculoviruses expressing Vp1 or Vp3 did not yield detectable formation of VLPs 
(Ruffing et al., 1992). Nonetheless, initial proof of principle was obtained that AAV particles 
could be produced in Sf9 cells.    
 
The use of recombinant baculovirus and Sf9 cells for rAAV vector production was further 
exploited by Urabe et al. (2002), and involved the expression of AAV2 rep and cap ORFs and 
AAV2 ITR-containing vector (GFP expressing vector) from three separate recombinant 
baculoviruses. AAV2 Rep78 and Rep52 encoding sequences were split and cloned into a single 
bacmid, and controlled under the truncated immediate-early 1 gene promoter, ΔIE1 (derived 
 34 
 
from Orgyia pseudotsugata [Oc]MNPV), and  p10 respectively. This differential use of 
promoters to drive Rep78 and Rep52 protein expression separately allowed optimal protein 
expression dynamics for rAAV vector production, as it was more previously noted that 
unregulated overexpression of Rep78 and Rep68 inhibited rAAV titres (Li et al., 1997). 
Although, these observations were concluded from studies involving Adenovirus-infected or 
Adenovirus-helper transfected mammalian cells as opposed to in an insect cell line. 
Nonetheless, AAV2 cap ORF was cloned into a separate bacmid under the polh promoter 
control. Additional adjustments were also made to ensure the near expected 1:1:10 
stoichiometry of Vp1-3 expression by mutating the cap ORF start codon (for Vp1) from ATG to 
ACG, and a 9nt sequence element found upstream to Vp2 ACG start codon was added in a 
similar position relative to Vp1 start codon (Urabe et al., 2002). The ITR-containing bacmid, 
harbouring the GFP transgene, was also modified such that the GFP transgene was cloned 
under the control of both CMV and p10 promoters. This permitted the resultant baculovirus 
(BEV-GFP or BEV-vector) to permit expression in both insect cell lines and mammalian cell 
lines. Ultimately, the ITR-containing bacmid contained the necessary cis-acting elements 
required for AAV genome replication and packaging. The resultant system meant that Sf9 
producer cells were co-infected with three separate baculoviruses in order to instigate rAAV2 
vector production (Fig. 1.9).  
 
Though the system of using three recombinant baculoviruses to produce rAAV vectors from 
Sf9 cells by Urabe et al. (2002) showed promising, some drawbacks of the adapted technology 
proved it limiting. For instance, having to use three different recombinant baculovirus to infect 
Sf9 cells for rAAV vector production relied on each baculovirus to infect a single Sf9 cell for 
vector production. This was in part offset by the productive infection by recombinant 
baculovirus – in that baculovirus infection of insect cell lines results in the generation of 
progeny recombinant baculovirus harbouring the heterologous gene. These are able to bud 
out of the initial infected cell and superinfect the same cell or neighbouring cells (Xu et al., 
2013). Although, it is noted that high MOI’s are required to infect insect cells for AAV vector 
production, meaning high titre stocks of rBEVs are usually required. Another drawback was 
found to be genetic instability of the rBEVs. Scale-up of rBEVs is an advantageous feature of 
using the technology for heterologous protein expression in insect cell lines. However, it has 
been repeatedly observed that genetic instability of recombinant baculovirus was a feature 
from vectors derived from the bacmid system. In fact, serial passage of the recombinant 
baculovirus in insect cell culture resulted in eventual loss of the transgene or even substantial 
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losses in the baculovirus genomic DNA (Pijlman et al., 2003; Kohlbrenner et al., 2005; Negrete 
et al., 2007). Concerning the recombinant baculovirus encoding the rep78 and rep52, the 
sequence that encodes Rep52 was also present in the sequence that encodes Rep78. A high 
degree of homology is shared between the two transgenes. Furthermore, given the 
orientation in which these transgenes were cloned a perfect palindrome of the homologous 
sequences within the same baculovirus vector DNA was present. The sequences within this 
particular vector were inclined to show genetic instability and HR, which led to the loss of the 
transgenes upon serial passage. 
 
To circumvent the loss of the rep transgenes, the AAV2 rep ORF was modified to permit the 
expression of Rep78 and Rep52 from a single mRNA transcript (Smith et al., 2009). This was 
achieved by exploiting the insect cell line’s ribosome scanning mechanism. The rep ORF (under 
the promoter control of polh) was modified, predominantly at the rep78 initiation codon, from 
AUG to CTG, to allow suboptimal initiation of translation. On the other hand, the ribosome 
scanning property allowed optimal expression of Rep52 due the presence of a suitable AUG 
initiation codon by leaky scanning mechanisms. Additionally, in order to simplify the rAAV 
vector production system, the cap ORF (driven by p10 promoter) was cloned into the same 
bacmid vector in the opposite transcriptional orientation. This allowed production of only two 
different recombinant baculoviruses for rAAV vector production in Sf9: i) the ITR-containing 
transfer vector (BEV-vector), and ii) the dual rep and cap encoding vector (BEV-RepCap), which 
determined the serotype. The end result was a simplified system to produce rAAV vector from 
Sf9 cells using two rBEVs (Fig. 1.9), as well as, the genetic stability of the rBEV-RepCap showed 
significant improvement (Smith et al., 2009). 
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Figure 1.9 Recombinant AAV vector production using recombinant baculovirus technology. Insect 
cells, typically Sf9 cells, are used to generate rAAV vectors. In particular, production in insect cells does 
not require adenoviral-derived helper functions, as these are provided by the baculovirus infection and 
use of insect-specific promoters. Ultimately, two main production systems for rAAV vector in Sf9 cells 
are described – the three-vector and two-vector systems. The former three-vector system involves 
three separate BEVs (BEV-Rep, BEV-Cap, and BEV-vector) to infect Sf9 cells and produce rAAV vector of 
a desired serotype. The two-vector system includes two separate BEVs - BEV-Rep/Cap, which includes 
both cap and rep ORFs, and BEV-vector, which supplies the AAV genome and transgene. Figure adapted 
from Ayuso et al. (2010). 
  
It is important to note that unlike production systems using mammalian cell lines, Adenovirus-
derived helper functions supplied in trans are entirely unnecessary for rAAV vector production 
using insect cell lines and baculovirus technology. This is because the natural promoters used 
to drive expression of rep ORF (p5) and cap ORF (p40) were replaced with the aforementioned 
insect-specific promoters, which would be activated and upregulated upon infection of Sf9 cell 
line with the relevant baculoviruses (Smith et al., 2009). In essence, the infection of Sf9 cells by 
the recombinant baculovirus provides the sole helper function required to drive p10, polh, or 
ΔIE1 promoter activities, and in turn expression of AAV Rep and Cap proteins for rAAV vector 
assembly and vector genome amplification. 
 
1.3.7 Identification of human YB1 as a putative AAV restriction factor 
Little direct association between human YB1 and AAV biology has been identified, except by 
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Nash et al. (2009) who found that human YB1 co-immunoprecipitated with AAV2’s non-
structural protien Rep78, and by Satkunanathan et al. (2014) using shRNA-mediated 
knockdown of YB1 in 293T cells. YB1 co-immunoprecipitation of Rep78, including additional 
others explored by the study. It was implied, given YB1’s charcaterised functions, that the 
expression of AAV proteins under Rep78 and p5, p19, p40 promoter may be affected by YB1 
binding () (Nash et al., 2009). The effect of this binding on AAV biology, however, was not 
further explored. However, LC-MS/MS identified YB1 associated with wildtype AAV (Nash et 
al., 2009) and rAAV vectors (Satkunanathan et al., 2014), which prompted further 
characterisation of YB1’s impact on rAAV vector biology and output. In fact, performing YB1 
knockdown studies correlated with enhanced rAAV2 and rAAV8 vector titres in vitro. 
Therefore, YB1 potentially functions negatively with respect to AAV in a serotype-specific 
manner. Importantly, YB1 knockdown was associated with enhanced AAV Rep protein 
expression, vector genome copies, and improved full:empty particle ratios after triple 
transfection for rAAV vector production (Satkunanathan et al., 2014).  Therefore, an enhanced 
AAV vector producer cell line was established, which showed an impressive up to 1.5 log 
increase in rAAV2 or 8 vector titres, and it was suggested that YB1 seemed to possess antiviral 
properties that limit AAV virus production and replication (Satkunanathan et al., 2014). We 
next explore the functions and properties of human YB1 in section 1.4.0, below.  
 
1.4.0 Cellular protein YB1 
1.4.1 Introduction to YB1 and its structure 
Bacteria have evolved the ability to respond to a number of environmental stresses, including 
a rapid decrease in temperature – ‘cold shock’. Bacteria respond to a ‘cold shock’ by shutting 
down molecular and cellular machineries, including reducing the efficiencies in transcription 
and translation (Nakaminami et al., 2006). A means to overcome this environmental stress and 
prevent stress-induced death is mediated by cold shock proteins, which function to permit 
bacteria to adapt and survive these extreme environmental changes. 
 
Y-Box proteins encompass a highly evolutionary conserved family of nucleic-acid binding 
proteins between prokaryotes and eukaryotes (Karlson and Imai, 2003; Nakaminami et al., 
2006). Y-Box proteins harbour the cold shock domain (CSD), which is homologous to cold 
shock proteins (Mani et al., 2012; Kljashtorny et al., 2015), and represents the most 
conserved, defining feature of Y-Box proteins. Human YB1 protein is better described as a 
highly complex protein with great number of functions within the cell. Not only does YB1 
 38 
 
possess DNA/RNA-binding functions, YB1 is also capable of binding to proteins, making the 
protein highly unconstrained in function. YB1 was first recognised as a component of 
cytoplasmic messenger ribonucleoprotein (mRNP) in the 1970’s (Kumar and Pederson, 1975). 
However, it was so aptly named for its then preferential binding to a DNA nucleotide sequence 
called the Y/CCAAT box (Y-box) – 5’-CTGGATTGG C/T C/T AA-3’ (Didier et al., 1988).  
 
YB1’s functions are dictated by its ability to form homo-complexes, complexes with other 
unrelated proteins, and its interactions with nucleic acids. YB1 is also widely expressed 
throughout development, and that YB1 deficiency has been predicted to be incompatible for 
cell survival based on transgenic mice models (Lu et al., 2005; Uchiumi et al., 2006). Transgenic 
mice models were developed for YB1 knockout, but YB1-/- showed embryonic lethality. Some 
embryos did manage to develop relatively normally at early stage development, but during 
late development YB1 was deemed more essential and non-redundant in function (Lu et al., 
2005).  
 
Human YB1 is encoded by the YBX1 gene, found on chromosome 1 (Ch1p34.2), and the gene 
itself is composed of 8 exons that span across approximately 19kbp. YB1 protein is a 324aa 
long, 36kDa protein and is composed of three structural domains. The N-terminal domain is 
the alanine/proline-rich (A/P) domain (1-50aa). Next is the highly evolutionary conserved CSD 
which covers 51-129aa. Lastly, the C-terminal domain (CTD) encompasses the rest of YB1, and 
is formed of alternating clusters of positively and negatively charged residues. A diagrammatic 
representation of YB1 and its domains is depicted in Fig. 1.10.  
 
Figure 1.10 Organisation of YB1 protein. YB1 protein is composed of three structural domains: A/P 
domain (1-50), CSD (51-129), and CTD (130-324). The A/P domain is so called because of its richness in 
alanine and proline residues. The CTD domain contains alternating clusters and positively (+; regions 
coloured red) and negatively (-; white coloured regions) charged residues. Both A/P and CTD domains 
are considered highly disordered. A NLS is found at position 186-205, and a CRS is found at position 267-
293. A 20S proteasome cleavage site at position 219 is also annotated. Figure from Lyabin et al. (2014). 
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The A/P and the CTD domains do not appear to form definitive or regular secondary 
structures. Instead they are predicted as intrinsically disordered because these domains have 
yet to be solved for their structure in solution (Guryanov et al., 2012). The presence of type II 
polyproline helical structures dictates intermolecular interactions between YB1 and other 
proteins (Guryanov et al., 2013). The CTD is responsible for most protein-protein interactions, 
of which alternative basic and acidic aa residues can potentially bind to RNP complexes, and 
therefore shuttles them between the nucleus and cytoplasm (Raffetseder et al., 2003). This 
shuttling property is facilitated by the presence of a NLS and cytoplasmic retention signals 
(CRS), which are mainly found in the CTD (Fig. 1.10).  
 
On the other hand, the solution structure of YB1’s CSD has been determined and modelled 
(Kloks et al., 2002), and its tertiary structures resembles that of bacterial cold shock proteins 
(Wang et al., 2000b; Kljashtorny et al., 2015). The CSD is a highly conserved domain, which 
adopts a five-stranded β-barrel tertiary structure. The β-strands are arranged in an anti-
parallel manner and connected by loops. The second and third strand of the β-barrel follows a 
consensus sequence of K/N-G-F/Y-G-F-I/V and V-F-V-H-F (Landsman, 1992), otherwise known 
as the RNP-I and II motifs, respectively (Kloks et al., 2002). YB1’s ability to bind to DNA and 
RNA is mediated by these consensus motifs, but binding to dsDNA, ssDNA and RNA species 
(Izumi et al., 2001; Zasedateleva et al., 2002; Kljashtorny et al., 2015) is relatively non-specific; 
or rather, not confined to the Y-box. In fact, YB1 showed preferential binding to ss GGGG 
motifs and G-rich RNA, and by comparison binds with less affinity to Y-Box motifs as it was 
originally named for (Zasedateleva et al., 2002; Kljashtorny et al., 2015).  
 
1.4.2 YB1’s role in transcriptional and translational regulation 
YB1’s function in transcriptional regulation was initially proposed due to YB1’s ability to bind 
to DNA Y-Box sequence in promoter regions of the major histocompatibility complex II gene, 
HLA-DRα (Didier et al., 1988). Its role as a potential transcription factor was supported further 
by studies which showed its preferential binding to ssDNA sequences compared to dsDNA 
(Izumi et al., 2001), and that it possesses the abilities to melt or anneal nucleic acids (Skabkin 
et al., 2001). It is now better established that YB1 is not limited to binding to just the Y-Box 
motif. This flexibility allows YB1 to upregulate or downregulate a number of gene targets, 
including those involved in cell proliferation and division, cell cycle arrest, apoptosis, and 
multiple drug resistance, and its role in these cellular processes will be outlined in brief in 
following sections. For example, in response to IFNγ, YB1 has been found to associate with an 
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IFNγ-response element (that is present in COL1A2 gene promoter sequence). In response to 
IFNγ treatment YB1 repressed the transcription of the COL1A2 gene. Interestingly, a Y-Box 
sequence is also present in COL1A2’s gene promoter, but transcriptional regulation via YB1 
was predominantly mediated via the IFNγ-response element (Higashi et al., 2003). The IFNγ-
response element coincides with binding sites for transactivators Sp1 and Sp3, and therefore, 
it is possible that the sequence region is under competitive control between YB1 and relevant 
transactivators to regulate COLA2 gene transcription. 
 
Transcriptional regulation by YB1 is not limited to transactivation or repression of genes. It has 
been shown to be involved in regulating pre-mRNA splicing and alternative splicing events, as 
well. It is a component of the splicesome (Hartmuth et al., 2002; Deckert et al., 2006), which 
functions to mediate splicing events to generate mRNA fit for translation into protein. 
Although the exact function of YB1 in pre-mRNA splicing has been challenging to elucidate, 
few studies have shown its direct involvement as a splicing activator when concerning 
exons/introns that harbour A/C-rich exon enhancer (ACE) elements (Stickeler et al., 2001). YB1 
was associated with increased activation of exon inclusion of the CD44 exon v4, and this was 
dependent on the presence of ACEs (Stickeler et al., 2001); the binding of which promoted 
inclusion of exon v4 into the CD44 mRNA product. The alternative splicing of CD44 exon v4 is 
further regulated by YB1’s association with the PP2Cγ protein (a Ser/Thr phosphatase); of 
which involvement in splicing is relatively unknown but at the very least promotes the 
assembly of the splicesome. However, its phosphorylation enables its binding with YB1, and 
knockdown of PP2Cγ compromises splicing of CD44 pre-mRNA in context with exon v4 
(Allemand et al., 2007). Direct interaction of YB1 with the repressor of 3’ splice site utilisation, 
SRp30c, was also demonstrated. This interaction skewed the preferential splicing pattern of 
the Adenovirus E1A mini-gene (Chansky et al., 2001; Raffetseder et al., 2003). More recently, 
YB1 facilitated the activation of alternative splicing and exon inclusion by binding the CAUC 
and CACC motifs in target exon and upstream intron, to recruit U2AF65 splicing factor and in 
turn mediate the exon inclusion of CD44 exon v5 (Wei et al., 2012).  
 
YB1 was identified in eukaryotic cells as a major protein factor that helps to make up 
polyribosomal mRNPs, and predominantly helps make up inactive, non-polyribosome-bound 
mRNPs (Kumar and Pederson, 1975; Minich et al., 1993). The exact mechanism in which YB1 
functions to regulate translation seems complex, but the protein generally exhibits properties 
that inhibit translation or help stabilise mRNA. YB1 was shown to negatively affect the 
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assembly of 48S pre-initiation complex to β-globin mRNA using an in vitro, cell-free translation 
system (Pisarev et al., 2002). Low levels of cytoplasmic YB1 relative to mRNA correlates with 
active translation and protein synthesis. However, with high levels of YB1 relative to mRNA, 
translation initiation is repressed (Davydova et al., 1997; Pisarev et al., 2002). With a low 
YB1/mRNA ratio, YB1 binds to mRNA as monomer units along the length of mRNA using its 
CSD and CTD, but homo-oligomeric YB1 complexes associate with mRNA instead when 
YB1/mRNA ratio is high. Multimerisation occurs through YB1’s CTD, and the CSD facilitates 
binding to mRNA. The transition may promote free mRNP formation, and prevent translation 
factors associating with the mRNP because excess YB1 packages mRNA so that its termini are 
thought to be buried inside its complex, preventing the key components of translation from 
assembling (Skabkin et al., 2004).  
 
YB1’s CSD was found to be the main functional domain that facilitated mRNA stability in a 5’-
GTP or m7GTP cap-dependent manner. In this way it protects mRNA from degradation 
(Evdokimova et al., 2001). The 5’-cap structure is well known in permitting mRNA stability and 
allowing mature mRNA to undergo translation efficiently (Gillian-Daniel et al., 1998). 
Therefore, uncapped mRNAs would be susceptible to degradation. Evdokimova et al. (2001) 
found that YB1 sequesters to 5’cap to improve mRNA stability and regulate translation, 
predominantly by YB1’s CSD. Its CTD was reportedly responsible for the inhibition of 
translation initiation by interfering with eIF4G binding to mRNA, and preventing the initiation 
of translation (Nekrasov et al., 2003). This could be a complementary effect to promote mRNA 
protection, especially in context with mRNAs and mRNPs that are not bound to ribosomes and 
are translationally inactive. Therefore, during active translation, YB1 levels are ‘optimal’ to 
permit accessibility of translation initiation factors to bind to mRNA. Displacement of initiation 
factors by YB1 from the length of the mRNA promotes the accumulation of relevant initiation 
factors at the 5’-cap end, which in turn allows the assembly of functional translational 
machineries. 
 
1.4.3 YB1’s function in cell proliferation and the cell cycle 
YB1 has been frequently linked to tumour malignancy, and its upregulation is commonly seen 
in a number of solid tumours, including: breast, lung, prostate cancers (Gimenez-Bonafe et al., 
2004; Fujita et al., 2005; Kashihara et al., 2009) and melanoma (Sinnberg et al., 2012). YB1 has 
been argued to have significant prognostic value. As a prognostic marker, aberrant YB1 
expression in certain tumours has been associated with worse prognosis (Dahl et al., 2009; 
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Fujiwara-Okada et al., 2013). YB1’s role in cell proliferation was initially postulated due to 
phenotypic changes that resulted from targeted disruption of the Chicken-YB1 gene in DT-40 
cells (Swamynathan et al., 2002). Deletion of the 5’ end of one of the Chicken-YB1 alleles led 
to cell cycle defects, with slowed cell proliferation, and increased apoptosis rates. Additionally, 
silencing YB1 in SH-SY5Y neuroblastoma cell line using shRNA resulted in G0/G1 arrest with 
suppressed cell growth rates and an increased susceptibility to apoptosis (Wang et al., 2015b). 
A benefit of the study by Wang et al. (2015b) was the in vivo examination of YB1’s role in cell 
proliferation using xenograft tumour models. Silencing YB1 expression in SH-SY5Y cells and 
inoculating these subcutaneously in nude mice resulted in slower growing tumours, while 
intra-tumour injection of SH-SY5Y-derived tumours with shRNA plasmid targeting YB1 was 
associated with reduced tumour sizes. 
 
YB1, therefore, exerts a positive effect on cell proliferation and the cell cycle, and currently, 
this seems to be partly due to a relationship between YB1 and cyclins (a family of protein 
involved in the regulation of cell cycle progression). YB1 was shown to stimulate CCND1 gene 
expression by binding to its promoter and upregulating its expression, whereas when YB1 was 
silenced, CCDN1 gene expression was repressed, resulting in a stall in cell cycle progression 
and proliferation (Fujiwara-Okada et al., 2013; Wang et al., 2015b). However, it was 
appreciated that most studies that explore the role of YB1 in relation to cell proliferation and 
cell cycle progression, chiefly make use of cancer or immortalised cell lines and not primary 
cell lines to postulate the role of YB1. Work on human and mouse primary cell lines provided 
evidence that YB1 directly regulates the expression of the tumour suppressor gene, p16, at the 
INK4 locus (Kotake et al., 2013). Protein p16 is a cyclin-dependent kinase inhibitor and 
negatively regulates cell cycle progression by inhibiting progression into S-phase. Upregulated 
expression of YB1 correlated with reduced p16 gene expression, and as a result primary cells 
were not as easily succumbing to cellular senescence. 
 
1.4.4 YB1’s function in DNA repair 
YB1’s suggested role in DNA repair was postulated based on YB1’s increased binding affinity 
for apurinic DNA (Hasegawa et al., 1991). This was supplemented by the fact that YB1 
harbours 3’-5’ exonuclease and endonuclease activities (Izumi et al., 2001; Gaudreault et al., 
2004). Additionally, use of heterozygous mouse embryonic stem cells (YB1+/-) implied YB1’s 
involvement in repair of DNA damage or adducts induced by DNA crosslinking agents, 
including: mitomycin C and cisplatin. Treatment of YB1+/- mouse embryonic stem cells with 
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these agents showed increased sensitivity and cytotoxicity, especially when compared to the 
wildtype YB1+/+ control (Shibahara et al., 2004). Furthermore, YB1 was successfully co-
immunoprecipitated with Mre11 and Rad50 proteins, which comprise the DNA repair 
complex, MRN (Mre11-Rad50-Nbs) complex. This co-immunoprecipitation was only evident 
from NIH3T3 cell lysates that had been treated with etoposide or doxorubicin, and absent 
from lysates derived from non-treated NIH3T3 cells, both transiently expressing a truncated 
YB1 (Kim et al., 2013). There was no indication that exogenously expressed YB1 (full length) 
could co-immunoprecipitate the same proteins. Association with additional protein factors of 
DNA repair pathways had been evidenced more previously by Gaudreault et al. (2004). Here, 
instead, GST-YB1 fusion protein was immobilised and 293 cell extract was loaded to 
demonstrate that full length YB1, albeit without DNA damaging stimuli, could bind additional 
proteins involved in DNA repair; namely, MSH2, DNA polymerase δ, Ku80 and WRN proteins. 
Collectively, these studies imply that YB1 may have functions in base-excision and mismatch 
repair pathways in vitro. 
 
The above studies do not in its entirety directly show YB1 has a direct function in DNA repair 
pathways. The evidences simply imply a role for YB1 based on correlative association and/or 
binding with DNA repair proteins in vitro, and does not illustrate the exact significance of the 
associations. However, Das et al. (2007) firstly identified YB1’s physical association with Nei-
like-2 (NEIL2), and its functional complex with DNA polymerase β and ligase IIIα; but 
additionally provided evidence that the YB1 interaction with NEIL2 resulted in enhanced 
enzymatic activity after oxidative stress in vitro (Das et al., 2007). NEIL2 is a key player in base-
excision repair of DNA by functioning as a DNA glycosylase and initiating the DNA repair 
pathway. Therefore, YB1’s involvement in base-excision repair was partly elucidated in vitro, 
such that the presence of YB1 enhances the enzymatic activity of NEIL2. Interestingly, YB1’s 
role in DNA repair is not limited to reparation of chromosomal DNA, but also seems to be 
involved in maintaining the integrity of mitochondrial DNA. YB1 was identified as capable of 
binding to mismatched DNA, and to DNA mismatch repair proteins present in the 
mitochondria (de Souza-Pinto et al., 2009). Using MMR assays (M13 assays involving circular 
substrate with a mismatch in the β-galactosidase encoding complementary [c]DNA) with 
mitochondrial extracts from control and YB1 depleted cell lines, a significantly reduced degree 
of repair activity was observed when YB1 was deficient (de Souza-Pinto et al., 2009). 
Therefore, YB1 has been consistently observed to be associated with nuclear and now 
mitochondrial DNA repair pathways, and the deficit leads to inefficient DNA repair in vitro.   
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1.4.5 YB1’s function in cellular stress 
YB1 predominantly exists in the cytoplasm, and in response to cell stress cytoplasmic YB1 
functions to repress translation initiation to promote cell survival. Translation initiation is put 
on pause by phosphorylation of translation initiation factor eIF2α upon the detection of 
certain cell stresses including hypoxia, oxidative stress, heat shock, to name a few (Pavitt et al., 
1998). As a result, stalled translation preinitiation complexes organise themselves in the 
cytoplasm and form stress granules. These are composed of non-ribosome-bound mRNAs, 
translation initiation factors, and YB1, and represent a form of mRNA protection and storage 
that are translationally inhibited during the duration of adverse cell conditions (Yang and 
Bloch, 2007).  
 
Despite the close association of YB1 with stress granules, the exact function of YB1 in stress 
granule formation or in stalling mRNA translation remains to be fully characterised. Studies 
exploring YB1’s role demonstrate that YB1 regulates the post-transcriptional expression of 
G3BP1 mRNA; the product of which is a nucleating factor required for stress granule formation 
(Somasekharan et al., 2015). It was identified in U2OS cells that YB1 binds directly to G3BP1 
mRNA, presumably within its 5’-untranslated region (UTR) sequence to instigate the 
translation of the G3BP1 mRNA, and allow the formation of stress granules under the stress 
conditions tested. In contrast to this, the downregulation of YB1 was associated with reduced 
G3BP1 mRNA translation, and compromised stress granule formation. However, YB1 knockout 
cell lines generated from U2OS cells by Lyons et al. (2016) were also defunct in stress granule 
formation. But this was unrelated to G3BP1 expression. Despite the knockout of YB1, G3BP1 
expression remained unchanged, thus implying that stress granule formation is regulated by 
YB1 in a more stress-specific manner.  
 
Alternatively, tRNA cleavage products, 5’-tiRNAAla and 5’-tiRNACys, occur as a result of 
angiogenin RNase activation in response to cell stress (Li and Hu, 2012). These tiRNAs are able 
to induce the formation of stress granules and inhibit translation initiation in a phospho-eIF2α-
independent manner. Additionally, tiRNAs have been shown to bind to YB1 via its CSD (Ivanov 
et al., 2011; Ivanov et al., 2014). These tiRNAs function by displacing the eIF4F from m7GTP-
capped mRNA and prevents translation initiation. This process seemingly requires YB1 to 
efficiently mediate this process as determined by YB1 knockdown studies (Ivanov et al., 2011). 
However, cell free translation systems using YB1 knockout U2OS cell lysates showed that 
tiRNAs were able to maintain their ability to repress translation initiation independent of YB1 
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(Lyons et al., 2016).   
 
Tumour progression can present with multidrug-resistance to chemotherapies. Typical 
chemotherapies are cytotoxic agents that aim to destroy cancerous cells; however, the 
eventual development of multidrug-resistance circumvents this. Multidrug-resistance is 
associated with the overexpression of P-glycoprotein, encoded by the multidrug-resistance 1 
(MDR1) gene (Trock et al., 1997). P-glycoprotein functions as an efflux pump that actively 
pumps out various substrates, including anticancer drugs, from cells (Trock et al., 1997). This 
poses a significant issue when treating certain cancers. MDR1 gene expression seems to be 
controlled by YB1, because YB1 was found to bind to a previously identified Y-Box sequence 
present on the MDR1 promoter (Goldsmith et al., 1993). Transcriptional activation of the 
MDR1 gene correlated with YB1 levels and/or nuclear translocation only in cells treated by 
certain stresses, including UV irradiation or genotoxic agents (Ohga et al., 1998; Shibahara et 
al., 2004). Although, YB1 modulation of MDR1 expression and chemoresistance is not a 
feature of all solid tumours; for example: PC-3, LNCaP and 22Rv1 cell lines derived from 
prostate cancer have shown that YB1 overexpression had no effect on MDR1 expression when 
treated with chemotherapeutic agent docetaxel (Saupe et al., 2015).  
 
1.4.6 YB1’s function in apoptosis 
We have examined YB1’s function in cell proliferation (Section 1.4.3) and in response to cell 
stress (Section 1.4.5). It comes to no real surprise that YB1 is also implicated in functioning in 
or regulating apoptosis. Transcriptional targets of YB1 include genes that are associated with 
cell death, including the Fas-receptor, FAS (Lasham et al., 2000). This initiates pro-apoptotic 
signalling upon its binding to its cognate ligand. A number of studies also implicate YB1 and 
the tumour-suppressor, p53, which shows direct interactions (Okamoto et al., 2000). YB1 was 
found to repress the TP53 gene promoter, which was associated with the downregulation of 
TP53 gene expression (Lasham et al., 2003). Moreover, inducing TP53 expression and 
activating p53 in C/ERp53/7 cells resulted in the translocation of YB1 into the nucleus and cell 
cycle arrest. YB1 is a dominant negative regulator of p53, and functions by binding to active 
p53 to inhibit its binding to promoter regions and transactivate genes BAX, NOVA (Homer et 
al., 2005), and APAF-1 (Zhang et al., 2003). BAX and NOVA, which encode pro-apoptotic 
factors Bax and Nova, respectively, are therefore not upregulated to contribute to cellular 
apoptosis when YB1 is in functional interplay with activated p53. 
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1.4.7 YB1 and viral biology 
YB1 has been reported important to select viral life-cycles. Human immunodeficiency virus 
(HIV)1 genomic and transcribed RNA species are prone to the host cells’ RNA quality systems. 
RNA viruses have evolved measures to permit its longevity within infected cells. One way this 
is achieved is by protecting its RNA from both degradation and recognition by host RNA quality 
systems. HIV1 is capable of hijacking YB1 to stabilise viral RNA. As a result this led to enhanced 
HIV1 gene expression and virus production (Mu et al., 2013). This was mainly identified by co-
transfecting 293T cells with a plasmid expressing YB1 as well as HIV1 constructs, and measured 
luciferase activity was increased in YB1 overexpressing producer cells. Downregulation of 
endogenous YB1 by siRNA correlated with reduced luciferase activity in producer cell lines and 
reduced viral-vector titres (Mu et al., 2013). RNA decay was significantly more stable in co-
transfected 293T cells overexpressing YB1 (Mu et al., 2013). This contradicts conclusions made 
by Ansari et al. (1999), who demonstrated that interaction of YB1 with HIV1 TAR RNA 
sequence and Tat protein correlated with increased Tat-induced and basal transcriptional 
activity as opposed to RNA stability. An enhanced transcriptional profile was not observed by 
Mu et al. (2013); however, increased RNA could be attributed by either more stable RNA forms 
or enhanced transcriptional activity. Nonetheless, YB1 is utilised by HIV1 in order to increase 
RNA levels to promote production. Similar was reported by Li et al. (2012) with respects to 
murine leukaemia virus (MLV) – MLV genomic RNA was stabilised by YB1 binding to the repeat 
region of MLV genomic RNA. This allowed for more available genomic RNA to be packaged for 
higher titres of recombinant MLV.   
 
The mouse mammary tumour virus (MMTV) is a murine β-retrovirus, which instead seems to 
co-opt YB1 via Gag in an RNA-dependent manner. YB1 associates with genomic MMTV RNA 
during the formation of immature capsids in cytoplasmic granules. It was suggested that YB1 
sequesters viral RNA away from translation machineries, and helps localise Gag to viral RNP 
(vRNP) cytoplasmic foci, which ultimately promotes virion assembly (Bann et al., 2014). 
Influenza A virus also has shown to be regulated by YB1 (Kawaguchi et al., 2012). Evidence 
suggests that YB1 is hijacked by Influenza A virus, relocates to the nucleus, and associates with 
promyelocytic leukaemia (PML) nuclear bodies in infected cells. Here YB1 complexes with 
Influenza A virus vRNPs in the PML nuclear bodies in order to facilitate their export from the 
nucleus, for further downstream trafficking via microtubules (Kawaguchi et al., 2012; 
Kawaguchi et al., 2015a). YB1-overexpressing cells correlated with higher virus titres, despite 
no significant change in the expression of viral proteins or viral RNA levels (Kawaguchi et al., 
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2012). This increase in titres was only valid in context of Rab11a GTPase protein and its 
association with positive recycling endosome pathway along microtubules (Grimsey et al., 
2016), which functions to transport vRNPs to the plasma membrane to stimulate production 
of viral progeny (Stone et al., 2016). 
  
The above examples demonstrate YB1’s role in promoting virus infectivity and production 
dynamics. Alternatively, YB1 has been reported to regulate viruses in a negative manner. 
Paranjape and Harris (2007) identified YB1 binding to Dengue Virus (DV) RNA, especially to the 
regulatory region of DV RNA 3’-UTR structure called the 3’-stem loop that plays a role in viral 
replication. Furthermore, Paranjape and Harris (2007) generated YB1+/+ and YB1-/- mouse 
embryonic fibroblasts (MEF) from transgenic mice models, and infected these with DV strain 
16681. YB1-/- cells produced higher quantities of DV progeny compared to YB1+/+ cells. Further 
functional analyses indicated that YB1 played an antiviral role to DV infection in a complex 
manner involving, in part, binding of YB1 to 3’-UTR, repressing translation of viral proteins 
and/or repressing DV RNA replication.  
 
Adenovirus relies on the expression of viral proteins encoded by E1 and E2 genes for 
replication. YB1’s involvement in pre-mRNA splicing was first recorded by Chansky et al. 
(2001), and the splicing of pre-mRNA to mRNA, encoding E1A Adenovirus helper protein, was 
positively regulated by YB1 (Chansky et al., 2001). The overexpression of YB1 in NIH3T3 cell 
lines promoted the alternative splice variants of E1A; namely influencing selection of E1A pre-
mRNA splice sites for the 13S and 12S isoforms. Although, the above study did not look into 
the pre-mRNA splicing effect by YB1 in the context of Adenovirus infection, replication and/or 
production. However, a more direct involvement of YB1 with Adenovirus was demonstrated 
by studies using Adenovirus vectors and immunofluorescence by Holm et al. (2002). 
Adenoviral E1B was found to be co-targeted with YB1 to the nuclear compartment by Holm et 
al. (2002), and co-localised to nuclear bodies thought to be key sites for viral transcription and 
replication. Additionally, YB1 was shown to positively regulate gene expression, at least in 
part, from the late E2 promoter (Holm et al., 2002). Overall, having reviewed YB1’s role in the 
context of viral biology using specific examples, and outlining the relevance of YB1 in rAAV 
vector biology in section 1.3.7, YB1 seems to function in a virus specific-manner – YB1 is either 
hijacked by viruses which exploit YB1’s DNA, RNA or protein binding functions to facilitate 
important steps in the virus life-cycle. Alternatively, YB1 seems to possess antiviral properties 
that limit certain virus’ production and replication. 
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1.5.0 CRISPR and genome editing 
1.5.1 CRISPR-Cas9 system – evidence of a prokaryotic adaptive immune system 
The stress of dynamic, ever-changing microbiological communities has ensured the evolution 
of very effective coping mechanisms. These have ensured that dominant bacteria and archaea 
are able to host a number of natural habitats, even when these are often associated with 
challenging pressures. Pressures include naturally occurring biotic stresses that affect the 
survivability of a given bacterial/archaeal micro-organism. Biotic stresses, such as 
transmissible genetic elements (cosmids, plasmids) and predatory viruses, exert a constant 
pressure and pose a considerable threat. In addition, the exerted pressures are further 
complicated by the enhanced mutation rates that viruses easily succumb to (Lauring et al., 
2013). Micro-organisms, therefore, require co-evolving inherent defence mechanisms to 
respond to the variability of predatory viruses and transmissible genetic elements, to ensure 
their survival. 
 
A regulatory system inherent in a number of bacterial and archaeal species termed the 
clustered regulatory interspaced short palindromic repeats (CRISPR)-CRISPR-associated 
protein (Cas), is one such mechanism. The CRISPR-Cas system(s) describes an adaptive 
immune system that responds to the surveillance of foreign genetic elements that invade host 
micro-organisms (Labrie et al., 2010). As a consequence, the process leads to successful 
immunisation against subsequent invasion by exogenic species. This is achieved by uptake of 
and loci-specific integration of foreign DNA into CRISPR loci. These loci comprise of short, 
alternating, interspaced, near-palindromic DNA repeats (varying between 23-55bp). 
Interspacing sequences (21-72bp) show hyper-variability. Given the near palindromic nature of 
these repeat sequences, post-transcriptionally these elements have great potential to form 
complex secondary structures in the form of RNA hairpins.  
 
Figure 1.11 Generic architecture of a CRISPR locus. A CRISPR locus is composed of the CRISPR array that 
is made up of short repeat sequences (between 23-55bp in length), separated by unique spacer 
sequences (between 21-72bp in length). The CRISPR locus is further characterised by an AT-rich leader 
sequence (L) that precedes the CRISPR array. The CRISPR array is usually flanked by cas genes encoding 
Cas proteins – the functional effectors of CRISPR-Cas. The cas1 and cas2 genes are universally present 
within CRISPR systems, and signature cas genes define the type of CRISPR/Cas system – cas3 for type I, 
cas9 for type II, and cas10 for type III. Figure from Barrangou (2015). 
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These loci were found to be accompanied by flanking cas genes (Fig. 1.11), which encode 
effector proteins that employ protective functions against invasive genetic elements (Jansen et 
al., 2002). CRISPR loci were first identified in Escherichia coli K12 strain upstream to its alkaline 
phosphatase (iap) gene (Ishino et al., 1987). Later more bacterial and archaeal species 
demonstrated frequent abundance of CRISPR loci – approximately half of bacterial genomes 
and approximately 83% of archaeal species (Grissa et al., 2007). It is commonly recognised that 
most prokaryotic genomes possess a single locus, however, Methanolocococcus harbour 
multiple loci dispersed within its genomes (Grissa et al., 2007). It has been more recently 
identified that CRISPR-like systems are also inherent to some larger giant viruses, which 
possess the genomic content to support CRISPR-Cas systems. A prototype example is 
mimivirus, of which lineage A type displays genomic content that resembles Zamilon (a unique 
virophage) as interspersed within an operon (Levasseur et al., 2016). The presence of which 
locus correlated with resistance to the virophage (Levasseur et al., 2016). Therefore, the 
associated system resembles a CRISPR-like system dubbed ‘mimivirus virophage resistance 
element’ (MIMIVIRE). 
 
It was not until 2005 that the variable spacer sequences within CRISPR loci were identified as 
homologous to exogenous genetic sequences, originally derived from plasmids and viruses 
(Bolotin et al., 2005; Pourcel et al., 2005). Pourcel et al. (2005) dissected the spacer sequences 
of Yersina pestis strains and determined that a number of spacer sequences were homologous 
to sequences derived from prophages (Pourcel et al., 2005). Most instances revealed sequence 
homology specific to phage (Shmakov et al., 2017). This mechanism of adaptation to foreign 
phage invaders was first observed in S. thermophiles (Barrangou et al., 2007). Infection of S. 
thermophilus with phage resulted in the acquisition of phage-specific DNA in phage-resistant 
or surviving mutants. Consequently, the sensitivity of tested prokaryotic species to phage 
inversely correlates with the number of phage-homologous spacer elements (Bolotin et al., 
2005).  
 
The ability to acquire, integrate, or expel exogenic material in a loci-specific manner provides a 
means to respond to highly mutable and evolving viruses (Jansen et al., 2002; Makarova et al., 
2002). The system can be described as a highly dynamic immune system that maintains 
evolutionary sustenance against competing microorganisms. Similar is observed between 
eukaryotic organisms and the interactions these have with prokaryotic pathogens assumed 
under the Red Queen hypothesis (Van Valen, 1973). 
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The context in which CRISPR-Cas systems operate is governed by the upstream cas genes, 
which encode effector proteins necessary for CRISPR-Cas-mediated immunity. Originally it was 
suggested that these proteins functioned in a previously uncharacterised DNA repair system 
(Makarova et al., 2002). Next, it was postulated that the CRISPR-Cas system functioned as a 
novel adaptive immune system inherent to prokaryotic micro-organisms, because of its 
resemblance to eukaryotic RNA inference (RNAi) system. The RNAi system promotes an 
additional level in eukaryotic gene regulation; it represents a post-transcriptional process, 
where the generation of dsRNA leads to gene silencing (Sijen et al., 2001). Long dsRNA is 
recognised by Dicer, a nuclease of the RNase III family (Bernstein et al., 2001; Doi et al., 2003; 
Myers et al., 2003). Dicer then processes the long dsRNA into smaller dsRNA molecules called 
siRNA (Zamore et al., 2000; Elbashir et al., 2001). These are able to bind to a number of RNase-
activity containing proteins and form a complex called the RNA-induced silencing complex 
(RISC). RISC functions to help siRNA to target RNA in a sequence-specific manner for 
degradation (Hammond et al., 2000; Martinez et al., 2002). MicroRNAs (miRNAs) are another 
form of short non-coding (nc)RNA that also function post-transcriptionally to silence gene 
expression by inhibiting protein synthesis, similarly to that of siRNAs (Zeng et al., 2003). Dicer-
mediated maturation of miRNA allows it to bind to 3’-UTRs of mRNAs, followed by RISC 
recruitment for nuclease-mediated degradation (Chendrimada et al., 2007). Some analogy 
between CRISPR-Cas and eukaryotic RNAi systems was inferred. Common featurs include the 
use of small ncRNAs that function in tandem with RNPs to facilitate sequence-specific 
cleavage. Despite the fact that CRISPR-Cas-mediated interference can target RNA, it is more 
commonly associated with targeting dsDNA (Jiang et al., 2015). 
 
1.5.2 Classifications of CRISPR systems in prokaryotes 
Despite the genetic diversity of the cas genes (Jansen et al., 2002; Makarova et al., 2002), 
analyses of these genes suggested inclusive domains that are characteristic to endo- and exo- 
nucleases, helicases, RNA- and/or DNA- binding proteins (Jansen et al., 2002; Makarova et al., 
2002). Originally, only four cas genes (cas1-4) were found in prokaryotes that harbour CRISPR 
loci. However, approximately 65 distinct Cas orthologs have been identified since, and work 
presented by Haft et al. (2005) has helped classify these into a collection of 45 families.  
 
Generally, cas1 and cas2 genes are universally present within all CRISPR systems (Makarova et 
al., 2011a). Identification of signature cas genes and genomic organisation has helped classify 
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CRISPR systems. In fact CRISPR systems have been classified into three main types (types I-III), 
which are distinguished by their unique cas gene content. Types I-III CRISPR-Cas systems are 
defined by the presence of cas3, cas9, and cas10, respectively (Makarova et al., 2011b; 
Gasiunas et al., 2012; Makarova et al., 2015). Given the engineering and utilisation of type II 
CRISPR systems and Cas9 nuclease for genome editing, the type II system will be the principal 
focus for this review.  
 
Type II CRISPR systems contain the repeat-spacer array as described above, but only contain 
three to four cas genes. cas1, cas2 are required for the acquisition of spacer elements within 
the CRISPR locus. This is mediated, in part, by the required protospacer adjacent motif (PAM) 
sequences that are located downstream of the protospacers. PAM is required for target 
recognition, cleavage and then the acquisition of incoming DNA elements. The cas9 gene 
predominantly classifies the CRISPR system as type II, and exact function will be detailed in a 
section 1.5.7; however, a unique feature that contributes to this CRISPR-type classification is 
the fact that Cas9 endonuclease is sufficient to mediate the effector functions of targeting and 
endonucleolytic cleaving foreign DNA, alone (Gasiunas et al., 2012). This is unlike other CRISPR 
types I and III, which require recruitment of multiple proteins to form a functional Cas protein-
CRISPR (cr)RNA complex – (cr)RNP (Brouns et al., 2008). It is also noteworthy that the type II 
CRISPR system is further subtyped as type IIA, IIB and IIC, based on phylogenetic data 
(Makarova et al., 2011a). Another distinguishing feature between the CRISPR types is also 
dictated by the biogenesis of crRNAs. The reliance on endogenous RNase III is required to 
process pre-crRNA transcripts into the separate crRNA functional units in type II systems 
(Deltcheva et al., 2011).  
 
In principle, all CRISPR-Cas system’s main molecular mode of immunity is conserved – in that 
RNA guided nucleases elicit the effector functions for adaptation and interference towards 
foreign and invading genetic elements. Specifically, the crRNP complex assembled in type I 
systems is called the CRISPR-associated complex for antiviral defence (Cascade) (Brouns et al., 
2008). In type II systems, the entire interference is mediated by RNA-guided Cas9 protein – a 
singular Cas protein instead of a multiprotein composition as seen with Cascade (Wei et al., 
2015a). Type III systems are further standalone in their classification, and instead type III 
systems encode Csm or Cmr Cas proteins for subtypes III –A or –B, respectively (Rouillon et al., 
2013; Staals et al., 2013). 
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1.5.3 PAM sequence dependency and self-non-self discrimination 
The recognition of foreign material does show some CRISPR-type-dependent differences. 
Although, a constant feature of distinguishing self from non-self involves recognition of 
sequence motifs in the form of PAMs. PAM sequences are not only utilised for interference by 
CRISPR systems, but also for self and non-self discrimination for target acquisition. The 
unregulated acquisition of self instead of non-self could prove detrimental to the prokaryote, 
and would reflect a scenario analogous to autoimmunity observed in higher eukaryotes, 
except that self DNA is recognised by the host organism’s CRISPR-Cas system.  
 
‘Self’ acquisition has been defined in prokaryotic systems – Stern et al. (2010) dissected the 
underlying properties of self-acquisition into CRISPR loci and surmised that the acquisition of 
self into CRISPR loci occurred in 0.4% of total spacers examined. Furthermore, self-acquisition 
was not an evolutionary conserved phenomenon amongst the repertoire of CRISPR-encoding 
organisms tested, and was unlikely to contribute to a regulatory system of endogenous gene 
expression (Stern et al., 2010). Given the partial or full inactivation of the CRISPR loci 
associated with self-acquisition, it was suggested that in such scenarios self-acquisition was 
considered deleterious to the organism. Since, additional studies have been performed and 
demonstrate the contrary – CRISPR-Cas systems is utilised as a form of endogenous gene 
regulation (Sampson and Weiss, 2013). 
 
Further checkpoints are proposed in CRISPR-Cas containing organisms, which explain, in part, 
the preference for foreign DNA over self DNA. Work by Levy et al. (2015) has shown that in E. 
coli the selection of protospacers, and therefore their acquisition, was replication-dependent. 
Genomic loci which correspond to predicted stalled replication forks and DSBs in foreign DNA 
were preferred for selection. These breaks would be repaired by endogenous 
helicase/exonuclease RecBCD complex, which functions to degrade broken DNA ends. This 
degradation occurs until the RecBCD meets a Chi site. Chi sites are profoundly more rich and 
frequent in the chromosomal DNA, and far less evident in the invading, foreign DNA (Dabert et 
al., 1992; Halpern et al., 2007). Chi sites are short stretches of sequence that functions to 
change the enzymatic action of RecBCD complex from exonuclease to helicase. In turn, this 
promotes HR mediated by RecA instead as a DSB repair mechanism in prokaryotes (Dabert et 
al., 1992). If no Chi sites are met, as is the case for RecBCD complexes in context with foreign 
DNA, it is thought that RecBCD generates candidate protospacer sequences that can then be 
processed further for spacer acquisition by its exonuclease function (Levy et al., 2015). 
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However, the products of RecBCD exonuclease activity are variable ssDNA fragments and 
protospacer selection requires a short, 33bp dsDNA fragment (at least in the Type I CRISPR-Cas 
systems). 
 
1.5.4 Mechanism of CRISPR-mediated adaptive immunity 
A key defining feature of CRISPR-Cas systems is cas genes that are associated with a given loci. 
The proteins in which they encode are extremely diverse, and are the main effector molecules 
that carry out the core functions of the adaptive immune system for the given prokaryote. The 
CRISPR-Cas system carries out its function in three well-defined steps, and is summarised by: i) 
adaptation involving the acquisition of foreign genetic material and its integration into CRISPR 
loci in a PAM-dependent manner; ii) crRNA biogenesis, whereby the adapted CRISPR loci is 
capable of transcribing the repeat elements and spacer DNA, and its processing into functional 
guide (g)RNAs, and iii) targeting of foreign nucleic acids and its interference (Fig. 1.12). 
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Figure 1.12 Three stages of CRISPR-mediated immunity in prokaryotes. CRISPR-mediated immunity in 
prokaryotes is instigated by acquisition of new spacer sequences from invading, foreign genetic 
material. Acquisition involves CRISPR-Cas-mediated integration of new spacer sequences into the 
CRISPR array, effectively immunising the CRISPR-containing organism against the invading species. Once 
integrated, the spacer sequence can be transcribed from the CRISPR array, with eventual processing 
results in crRNA biogenesis. The mature crRNA facilitates targeting of invading genetic elements, by 
binding to Cas effector protein(s), that recognises target sequence with suitable protospacer adjacent 
motifs (PAM) and that is complementary to crRNA. The end result is the degradation of the target DNA. 
Figure from Barrangou and Marraffini (2014). 
 
1.5.5 Mechanism of spacer acquisition into CRIPSR loci 
Establishing a record of a previous infection of phage or plasmid by the CRISPR-Cas system is 
dictated by the adaptation and spacer acquisition machinery. This effectively immunises the 
CRISPR-containing organism to subsequent infections. Alternatively, in the context where a 
pre-existing immunity is held and subsequent infection involves a variant strain, then 
acquisition is described as priming (Datsenko et al., 2012).  
 
Spacer acquisition has been experimentally observed in various CRISPR types, and as a result 
the minimum prerequisites for the adaptation process have been identified. Some variations 
between CRISPR-Cas subtypes have been noted. The adaptation and spacer acquisition 
process can be generally described to involve a multistage procedure that first identifies 
foreign genetic material, followed by the insertion of DNA into the CRISPR loci as a new 
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spacer. The discrimination of acquisition of self from non-self is made possible by the presence 
of recognisable PAM sequences and dependency on DNA absent of Chi sites. Spacer 
acquisition generally occurs at the leader sequence end of the CRISPR locus with duplication of 
repeat sequence to maintain the repeat-spacer-repeat configuration, necessary for 
downstream crRNA biosynthesis (Wei et al., 2015a). 
 
Studies on spacer acquisition have been performed across the CRISPR types I-III, but the most 
comprehension on spacer acquisition has been demonstrated from studies involving type IE 
and type IIA systems. Recognition of new protospacer sequences is mediated predominantly 
by Cas1-Cas2 complex via interactions with PAM sequences. In fact, close conservation of the 
cas1 and cas2 genes is observed between CRISPR systems, indicating that a common 
mechanism is likely used. Currently it is understood that Cas1 of the complex is the main 
functioning component. Cas1 is a metal dependent nuclease-helicase (Wiedenheft et al., 
2009), and Cas2 seems to possess a structural role, instead to bridge and bind Cas1 proteins 
and act as a scaffold for the substrate DNA duplex (Wang et al., 2015c). Cas2’s metal-
dependent nuclease activity showed no significant contribution to the adaptation phase. 
Mutations within Cas1’s active site correlated with abolished integration of new spacers into 
CRISPR loci, whereas the catalytic activity of Cas2 was non-essential (Nunez et al., 2014). 
When present, however, enhanced acquisition activity was observed (Nunez et al., 2014).  
 
E. coli’s type IE CRISPR system involves Cas1 and Cas2 forming a stable heterohexameric 
complex (Wang et al., 2015c), which is composed of two Cas1 dimers that are bound to either 
side of a Cas2 dimer. This heterohexameric complex has been shown to function in both 
acquisition of the protospacer and its integration into the CRISPR locus. Firstly, Cas1-Cas2 
complex recognises the PAM sequence as 5’-AAG-3’ and the PAM-complementary sequence 
(Wang et al., 2015c). Substrate selection is further discriminated by the requirement for a 
23bp duplex DNA with 3’-overhangs. Complete binding encourages a conformational change in 
the Cas1-Cas2 complex (Wang et al., 2015c). Cas1-mediated cleavage of the protospacer’s 3’-
overhangs generates 5nt long overhangs with free 3’-hydroxyl groups. These are required for 
integration into the leader end of CRISPR locus (Nunez et al., 2015). The proximal repeat is 
recognised by the Cas1-Cas2-protospacer complex and staggered cuts are proposed to be 
generated, the cuts of which are highly regulated by the presence of molecular rulers encoded 
in the repeat element (Goren et al., 2016; Wang et al., 2016b). Therefore, with the 3’-hydroxyl 
groups, nucleophilic attacks occur on the plus and minus strand of the repeat sequence at 
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either junction ends, creating two half-site intermediates. The flanking repeat sequences are 
DNA repaired by as yet uncharacterised DNA polymerase and ligase (Yosef et al., 2012; Nunez 
et al., 2015; Rollie et al., 2015; Wang et al., 2016b). The orientation of the protospacer 
acquisition process allows for the 3’-cytosine derived from the PAM-complementary sequence 
to attack the phosphate group of the distal repeat junction, to generate a spacer with a 5’-
guanine as the first nucleotide in the complementary sequence (Nunez et al., 2015). 
 
Type I systems rely on protospacer acquisition and integration by Cas1-Cas2 complex. 
However, CRISPR-Cas type IIA systems rely additionally on trans-acting CRISPR (tracr)RNA, and 
Cas9, Cas1, Cas2, Csn2 Cas proteins. It is further noted that despite Cas1-Cas2 share 
conservation between CRISPR-Cas types, Cas9 in CRISPR-Cas type IIA predominantly performs 
the role of PAM recognition for protospacer selection (Heler et al., 2015; Wei et al., 2015b). 
The importance of this function is reflected by mutations in Cas9’s PAM recognition domain. 
Mutations result in the acquisition of non-PAM containing spacer sequences (Heler et al., 
2015). Nonetheless, Cas9-dependency likely encourages the recruitment of the remainder Cas 
proteins to facilitate integration in a similar manner as type IE systems, thereafter (Wei et al., 
2015b). 
 
1.5.6 Mechanism of crRNA biosynthesis 
Completely mature crRNA is required for efficient targeting of foreign DNA. The transcription 
and processing of the CRISPR loci follows a general theme between CRISPR-Cas types – 
transcription is driven by an internal promoter located within the leader sequence (Pul et al., 
2010). This results in the generation of a long pre-crRNA transcript, which is processed by Cas 
endoribonucleasases to cleave the pre-crRNA at specific sites within the repeat regions (Li et 
al., 2013; Wakefield et al., 2015). This forms the required downstream gRNAs for crRNP 
formation and target DNA recognition. Similarities in pre-crRNA processing have been 
observed between CRISPR-Cas types, especially between types I and III. For instance, almost all 
type I and III CRISPR systems utilise Cas6 protein (or a closely related orthologue) for pre-
crRNA processing (Li et al., 2013; Wakefield et al., 2015). Therefore crRNAs that are formed 
are composed of the central spacer RNA sequence which is complementary to the target DNA 
sequence flanked by some repeat sequences (Carte et al., 2008; Li et al., 2013). 
 
Type II processing of crRNA shows some differences from that observed in type I and III 
systems, where the coordinated action of the trans-acting tracrRNA, endogenous RNase III and 
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Cas9 protein function together to process pre-crRNA into functional gRNAs. Specifically, the 
tracrRNA was identified by differential RNA sequencing by Deltcheva et al. (2011) on a type II 
CRISPR-Cas locus in Streptococcus pyogenes. The small RNA is encoded upstream to cas genes 
on the opposite strand within the leader sequence of type II CRISPR loci (Deltcheva et al., 
2011). Most strikingly, this study identified primary long tracrRNA species, which showed 
some sequence complementarity to the repeat sequences present within pre-crRNA 
sequence, potentiating base-pairing with pre-crRNA transcripts. Differential RNA sequencing 
of co-processed tracrRNA and pre-crRNA also exhibited short 3’-overhangs, which were 
indicative of endoribonuclease cleavage by RNase III (Deltcheva et al., 2011). In fact, crRNA 
biogenesis was highly dependent on the activity of endogenous RNase III, as mutations in the 
RNase III-encoding rnc gene or in the repeat complementary sequences resulted in the 
inability to process tracrRNA and pre-crRNA into intermediate or mature species.    
 
Following stabilisation of tracrRNA:pre-crRNA interactions by Cas9 (Karvelis et al., 2013), 
RNase III is recruited and cleaves within the repeat sequences to form individual crRNA units, 
(Deltcheva et al., 2011). The 5’-end of the crRNA unit is further trimmed down (Deltcheva et 
al., 2011), with the loss of some spacer sequence. The remainder of the spacer sequence is 
complementary to the target DNA, and is sufficient to successfully target invader DNA for 
degradation in a Cas9-dependent manner. Type IIC systems, such as that seen in N. 
meningitides (Zhang et al., 2013), the individual crRNA units are instead generated separately 
due to the presence of separate promoters within or around the repeat sequences that drives 
transcription of these single pre-crRNA units. Though RNase III-mediated processing can occur 
for these individual pre-crRNA units, RNase III was shown to be relatively unnecessary. RNase 
III-deficient E. coli (rnc-) was capable of processing of CRISPR array that included only a single 
spacer (Karvelis et al., 2013). Type IIC CRISPR-Cas from N. meningitidis possesses separate 
promoters between each spacer for individual crRNA expression, and does not require 
additional processing (Zhang et al., 2013). In these instances, tracrRNA and RNase III was 
required for 3’-end formation, but RNase III was considered dispensable in this type IIC 
CRISPR-Cas system (Zhang et al., 2013). This perhaps illustrates an interesting form of 
evolution of the CRISPR-Cas system, where type IIC-containing bacteria have evolved means to 
target specific phage infections that would otherwise inhibit endogenous RNase activity. In 
fact, the giant phage фKZ encodes RNase inhibitor gp37/Dip, which has been shown to inhibit 
RNA degradasome formation in Pseudomonas aeruginosa (Van den Bossche et al., 2016). 
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1.5.7 Mechanism of CRISPR interference 
Therefore, with the biosynthesis of functional guide crRNAs specific to target invading DNA 
molecules, the CRISPR systems are capable of providing robust and adaptive immunity in the 
form of interference. The process of interference involves the crRNA elements to guide the 
recognition and precise cutting of target DNA by effector Cas nucleases. This is made possible 
by complex of the Cas nuclease(s) to crRNA to form a crRNP molecule. The crRNA-
‘programmed’ Cas nuclease is specifically guided to and recognises target DNA by way of PAM 
sequences, which in turn instructs Cas proteins to perform their function to degrade target 
DNA.  
 
Type I interference has been modelled principally by E. coli type IE system, and the mechanism 
of interference involves the formation of the crRNA-guided Cascade complex to perform 
foreign DNA surveillance and interference (Jore et al., 2011). Cascade assembly is initially 
comprised of five different Cas proteins in various subunit stoichiometry: (Cse1)1, (Cse2)2, 
(Cas5)1, (Cas7)6, and (Cas6)1 (Brouns et al., 2008; Jore et al., 2011). This complex of Cas 
proteins assemble upon the 61nt long crRNA. Final structural analysis gave the Cascade crRNP 
a structure that was divided into parts – the head, belly and tail, with an overall resemblance 
to a seahorse. Maturation of the 61nt long crRNA, by Cas6-mediated endoribonuclease 
cleavage within the repeat sequence of the pre-crRNA transcript (Li et al., 2013; Wakefield et 
al., 2015), generates a final crRNA product which is composed of a central 32nt spacer 
sequence, a 21nt long 3’-hairpin structure and 8nt 5’-end (Jore et al., 2011). Cas6 remains 
bound to the 3’-hairpin structure of the mature crRNA (Jackson et al., 2014), forming the head 
of the assembled structure. This is followed by the rest of Cascade assembly by recruitment of 
Cas5 to the 5’-end and association with the large subunit (Cse1) to form the tail of the Cascade 
complex (Jackson et al., 2014). The six units of Cas7 bind to the spacer sequence and form a 
helical backbone, effectively bridging the head and tail (Jore et al., 2011). The small Cascade 
subunit (a dimer of Cse2) is also recruited and forms the belly, and functions to stabilise both 
target DNA and crRNA (Jackson et al., 2014). 
 
In order to carry the final step of interference, Cascade first recognises the PAM sequence that 
is present in target DNA. This is mediated by interactions between the target DNA and Cse1 
(Tay et al., 2015; Xue et al., 2017). Target duplex is then unwound and crRNA binds to 
complementary, target DNA sequence (van Erp et al., 2015). Conformational change of 
Cascade and the formation of a DNA R-loop in the target, foreign DNA ensue,  which permits 
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the recruitment of Cas3 helicase-endonuclease (Mulepati et al., 2014). Cas3 is the main 
effector enzyme that nicks foreign ssDNA, resulting in a 200-300nt gap adjacent to the crRNA-
complementary sequence (Redding et al., 2015). Cas3 continues to translocate the bound DNA 
in the 3’>5’ direction to processively unwind and degrade it (Gong et al., 2014; Redding et al., 
2015). 
 
Unlike the type I system which requires a multi-subunit complex to elicit its effector functions, 
type II systems requires only a single protein (Cas9) to function in cohort with crRNA (Gasiunas 
et al., 2012). However the addition of tracrRNA bound to Cas9 is essential to perform target 
DNA recognition and degradation (Deltcheva et al., 2011; Chylinski et al., 2013). Crystal 
structures of type II crRNP belonging to S. pyogenes has been examined (Jinek et al., 2014; 
Nishimasu et al., 2014), and provided insight of overall mechanism of action. S. pyogenes 
(Sp)Cas9 was found to be approximately 100-190kDa, with ultrastructural analysis revealing a 
bi-lobed protein composed of a variable α-helical lobe for binding to nucleic acids, a nuclease 
lobe that harbours the catalytic RuvC and HNH nuclease domains, and a C-terminal 
topoisomerase homology domain (Jinek et al., 2014; Nishimasu et al., 2014). In order to target 
foreign DNA, Cas9 nucleic acid binding region associates with the gRNA (dual crRNA:tracrRNA). 
Cas9 binds to the guide portion of the crRNA in a sequence-independent manner, and also to 
the duplex region of the gRNA in a sequence-specific manner (Jinek et al., 2012). Additionally, 
Cas9 binding with gRNA or single-gRNA (sgRNA) is required to activate the scanning 
capabilities of Cas9 for PAM recognition (Jinek et al., 2012; Jinek et al., 2014). Local melting of 
target DNA ensues and complementary base-pairing occurs between crRNA and target DNA 
(Anders et al., 2014; Mekler et al., 2017). Target DNA is cleaved on both strands by the 
nuclease lobe of Cas9 – HNH nuclease domain cleaves the strand complementary to the 
crRNA, while the RuvC nuclease domain cleaves the non-complementary DNA strand, 
generating a DSB, precisely 3nt upstream from the PAM sequence (Fig. 1.13) (Gasiunas et al., 
2012). 
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Figure 1.13 Cas9 mechanism of CRISPR interference of target DNA. The dual-RNA (gRNA) is composed 
of the crRNA and tracrRNA, and in its mature state is able to complex with Cas9 endonuclease. Cas9 is 
able to scan target DNA for the PAM, after which local melting of the DNA duplex occurs. This allows the 
crRNA sequence to bind to protospacer sequence by complementary base-pairing. Cas9 is then able to 
cut the target DNA and cause a DSB, by nicking the complementary and non-complementary DNA 
stands, 3nt upstream of the PAM. Figure from Jinek et al. (2012). 
 
1.6.0 From adaptive immunity to targeted genome editing in vitro and in vivo 
1.6.1 Definition of targeted genome editing 
Genome editing describes a process involving the targeting of genomic DNA sequence, and 
incorporating a desired change(s). The use of targeted gene modifications has a number of 
advantages in biomedical, biotechnology, and basic biological research. Techniques and 
technologies that allow for precise and targeted deletions, insertions or modifications can 
allow complete characterisation of specific genes and their function.  
 
Gene targeting was perhaps initially explored by research introducing transgenes into the 
genome in a targeted manner. This required HR to facilitate such process  (Folger et al., 1982); 
however, the main facilitator of gene targeting was found to be DSBs at/or around the desired 
loci. This helped drive endogenous HR-mediated DNA incorporation when a donor DNA 
template was present. The importance of induced DSBs was first impacted by model 
experiments done in yeast (Rudin et al., 1989), and mammalian cell lines (Rouet et al., 1994; 
Choulika et al., 1995). These studies showed that inducing DSBs with highly specific 
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endonucleases facilitated the repair of the DSB by recombinogenic mechanisms. These 
induced DSBs instigated the gene targeting of an exogenous, homologous gene sequence to 
function in the repair of the DSBs. Desired genome alterations was made possible in a targeted 
fashion, albeit inefficiently. The frequency of the desired recombination was very poor – 1 in 
106-109 cells (Capecchi, 1989). Alternatively, when an exogenous, homologous gene sequence 
was absent, then these induced DSBs would instead incorporate insertions and/or deletions 
(indels) due to the non-homologous end joing (NHEJ) pathway of DNA repair (Bibikova et al., 
2002).  
 
1.6.2 Features of type II CRISPR-Cas system utilised for genome editing 
In more recent years, programmable nuclease-based technologies were established as the 
more prominent and efficient methodology for targeted genome editing. The CRISPR/Cas9 
system, in particular, has been most rapidly developing and applied for manipulation of 
mammalian and non-mammalian genomes.  
 
As a genome editing tool, CRISPR-Cas9 type II system has been mostly adopted given the Cas9 
nuclease ability to function alone with no need for other Cas proteins (Gasiunas et al., 2012). 
Cas3 from the type I system, in contrast to Cas9, degrades target DNA processively. This was 
less useful for precise genome editing, especially when processive degradation of the target 
DNA could not be fully controlled for the intention of exact genome editing. Additionally, the 
type I system requires a machinery of different Cas proteins as a minimum requirement to 
target a specific DNA sequences. On the other hand, Cas9 generates a single DSB at the target 
sequence, which is an important requirement of genome editing systems to date. This results 
in a simple and programmable genome targeting system for desired genome editing.  
 
Work performed by Jinek et al. (2012) on the type II CRISPR-Cas system identified that Cas9 
recognised target foreign DNA for cleavage via a combined dual-RNA structure composed of 
the crRNA and tracrRNA. The crRNA contains a sequence that is complementary for a portion 
of the tracrRNA, forming a region of duplex (Jinek et al., 2012). The crRNA alone in the 
presence of purified Cas9 was unable to cleave plasmid DNA harbouring the crRNA-
complementary sequence with the necessary PAM. When tracrRNA was also present Cas9 was 
active and capable of cleaving the plasmid DNA at the intended site. This led to the 
understanding that the crRNA:tracrRNA dual-RNA structure was necessary for Cas9-mediated 
targeting. Additionally, the minimum tracrRNA sequence was dissected, which still encourages 
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Cas9 functionality, and in turn paved way for the development and utilisation into a 
programmable genome editing tool (Deltcheva et al., 2011; Jinek et al., 2012). Jinek and 
colleagues designed chimeric RNA that encoded both the 5’-crRNA and 3’-tracrRNA (Jinek et 
al., 2012). The chimeric RNA (otherwise known as sgRNA) was permissible for Cas9-mediated 
DNA cleavage of target DNA that contained the crRNA complementary target sequence. These 
redefined sgRNAs further simplified the use of the CRISPR/Cas9 system for DNA cleavage and 
genome editing.   
 
Another attractive feature of using SpCas9 for targeted genome editing is the simple PAM 
requirement of 5’-NGG-3’ adjacent to the target sequence on the 3’ end (Anders et al., 2014). 
This is in contrast to other Cas9 homologues such as those derived from Staphylococcus 
aureus (SaCas9), Streptococcus thermophilus (St -1 or -3 Cas9), which have PAM requirements 
of 5’-NNGRRT-3’ (Nishimasu et al., 2015), 5’-NNAGAAW-3’, and 5’-NGGNG-3’ (Karvelis et al., 
2015), respectively. The shorter PAM sequence requirement demonstrated by SpCas9 
significantly increases the number of potential genomic targets, as longer PAM sequences with 
relatively strict sequence motif limitations are less likely to occur naturally in target genomes.  
 
Therefore, altogether, the CRISPR/Cas9 system for genome editing requires only the Cas9 
endonuclease, the sgRNA with specificity to the intended target site, and/or a donor template. 
The CRISPR/Cas9 system operates similar to the aforementioned interference mechanism that 
is native for type II CRISPR systems - a DSB is generated precisely 3nt upstream of the 5’-NGG-
3’ PAM sequence (Fig. 1.14A). Principally, it is the host cells’ own DSB repair mechanism that 
performs the genome editing – NHEJ promotes the formation of indels, but HR is required if a 
desired mutation (site directed mutagenesis) or DNA sequence (knock-in) is to be incorporated 
(Fig. 1.14B). 
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Figure 1.14 CRISPR/Cas9 genome editing of target DNA. A) Genomic loci can be targeted using 
CRISPR/Cas9 system, involving the association of sgRNA with Cas9. Cas9 is guided to target genomic 
locus due to presence of PAM and complementary binding between crRNA sequence and DNA target 
sequence. As a result, Cas9 is able to generate a DSB precisely 3nt upstream of the PAM sequence (see 
red arrows). B) After Cas9 generates a DSB, the host cell DNA repair machineries perform genome 
editing. NHEJ occurs when no donor DNA template is present. NHEJ repairs DSBs in an error-prone 
manner, leading to generation of indels and frameshift mutations. HR occurs when donor DNA template 
is present, and recombination between the DSB and donor DNA template allows the incorporation of 
desired mutations, for precise genome editing. Figures from Ran et al. (2013b). 
 
1.6.3 The development of CRISPR/Cas9 system for genome editing and gene 
manipulation 
The CRISPR/Cas system for genome editing has developed considerably since the 
characterisation of CRISPR systems in prokaryotes (Ishino et al., 1987), and the demonstration 
that the CRISPR/Cas9 system can be engineered to target specific sequences in eukaryotic cell 
lines (Cong et al., 2013; Mali et al., 2013b). The initial adaptation of CRISPR/Cas9 technology 
for genome editing involved cloning codon optimised SpCas9 (with NLS) and the chimeric 
crRNA and tracrRNA sequences into plasmids for transfection into mammalian cell lines. Since 
then, a public depository called Addgene (https://www.addgene.org/crispr/), and now 
biotechnology development companies, including, but not limited to, Thermo Fisher Scientific 
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(https://www.thermofisher.com/uk/en/home/life-science/genome-editing/geneart-
crispr.html) and Sigma-Aldrich 
(https://www.sigmaaldrich.com/catalog/product/sigma/crispr?lang=en&region=GB) have 
made available CRISPR/Cas9 vectors, to provide the genome editing tool to virtually all 
research institutions. 
 
A large concern of CRISPR/Cas9 genome editing was off-target activity by Cas9 – in that sgRNA 
designs used to edit a desired gene could redirect Cas9 to an off-target sequence. Off-target 
DSBs could be followed by unintended mutations. Experimentally, the fidelity of Cas9 was 
analysed and minimum off-target sites were identified for the given targeted genomic 
sequences in mammalian cell lines (Kim et al., 2015; O'Geen et al., 2015; Tsai et al., 2015). This 
is due to the flexibility Cas9 has for gRNA:DNA complementarity; as few as three mismatches 
can be tolerated (Mali et al., 2013a). Therefore, the propensity for off-target influences is 
possible when using Cas9, meaning improving the genome editing system was essential. Initial 
attempts to improve its fidelity included Cas9 modifications, namely the D10A or H840A 
substitutions in the RuvC and HNH nuclease domains, respectively, creating Cas9 nickase 
(Cas9n) variants (Ran et al., 2013a). These Cas9 mutants functioned by generating a single nt 
nick only on the PAM-containing or PAM-complementary DNA target sequence, respectively. 
Therefore, a second sgRNA that was specific to another PAM sequence on the opposite strand 
was required to generate a staggered DSB (Ran et al., 2013a). In theory Cas9n would reduce 
off-target effects, because off-target sites were unlikely to share complementary DNA 
sequences for both sgRNAs in close proximity and on opposite strands to each other. 
Additionally, single nt nicks are easily repaired with high fidelity by base-excision repair 
compared to DSBs and NHEJ (Shen et al., 2014). When Cas9 possessed both the D10A and 
H840A mutations, this generated a nuclease-deficient, dead Cas9 (dCas9), which retained the 
DNA targeting function. Improved targeting efficiencies have also been observed when dCas9 
was fused to Fokl nuclease at its N-terminus (Guilinger et al., 2014; Wyvekens et al., 2015). 
Fokl nuclease requires dimerization in order to become catalytically active and cleave DNA. 
Therefore, a pair of Fokl-dCas9:sgRNA is required to complex at the target sequence in order 
for Fokl nuclease activation and subsequent mutagenesis.  
 
Additional developments included modifications in the sgRNA, either in the tracrRNA-scaffold 
or target complementary sequences. Truncating the 5’-end of complementary sequence of the 
gRNA from 20nt to 17/18nt demonstrated reduced or undetectable off-target mutagenesis (Fu 
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et al., 2014). Extending the tracrRNA sequence to generate a longer crRNA:tracrRNA duplex 
region or utilising full length tracrRNA sequence, generated optimised sgRNA structures, and 
correlated with enhanced on-target activity and specificity (Dang et al., 2015; Xu et al., 2017).  
 
A large research focus has also been invested in development of Cas9 itself other than the 
aforementioned Cas9n and dCas9 variants. This includes expanding the delivery mechanism of 
Cas9 nuclease with gRNAs. For instance, CRISPR/Cas9 genome editing is not limited to 
transfection or electroporation of plasmids into target cells, but delivery vehicles also include 
lentiviral (Doench et al., 2014; Sanjana et al., 2014) or AAV (Ran et al., 2015) vectors. In the 
case of AAV vectors, the limited packaging capacity restricts the CRISPR/Cas9 system to SaCas9 
(approximately 3.2kbp) (Ran et al., 2015). Although, SpCas9 (approximately 4.2kbp) can 
technically fit, but this leaves very little room for sgRNAs and control elements to be encoded. 
Additionally, recombinant Cas9 protein is available to transfect or electroporate into target 
cell lines with either synthetic or in vitro transcribed sgRNAs (Liang et al., 2015). The purpose 
of which is to create a genome editing platform based on CRISPR/Cas9 that is significantly 
more transient than the transfection of plasmids, which otherwise runs the risk of integrating 
into the genome.  
 
SpCas9 requires the presence of the 5’-NGG-3’ PAM sequence on the 3’ of the target 
sequence. Although a simple PAM sequence, and likely found frequently throughout the target 
genome, SpCas9 remains 5’-NGG-3’-restricted. Sequences that do not possess 5’-NGG-3’ PAM 
sequences are thus restricted, and include AT-rich regions. Granted there are additional Cas9 
orthologues: SaCas9 or StCas9s with different PAM requirements. These help increase the 
range of target sequences for genome editing. However, their PAM requirements are stricter, 
and can still limit potential targets for genome editing. Given, also, that SpCas9 is the most 
commonly used Cas9 for research and genome editing, keeping to a single Cas9 orthologue for 
all CRISPR/Cas9 research and translational needs would enable far easier standardisation of 
the genome editing tool. The PAM sequence is recognised by a PAM interaction domain found 
in the C-terminal topoisomerase homology domain of Cas9 (Jinek et al., 2014; Nishimasu et al., 
2014). Two arginine residues (R1333 and R1335) facilitate the interaction with atoms of the 
guanine nucleobases that make up the 5’-NGG-3’ PAM (Anders et al., 2014). However, simply 
introducing substitution mutations in SpCas9 gene sequence (corresponding to R1333Q and 
R1335Q) did not generate functional SpCas9 nucleases that cleaved at target sites with 5’-
NAA-3’ PAM (Anders et al., 2014). Alternatively, engineered SpCas9 was generated by directed 
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evolution (Kleinstiver et al., 2015). This resulted in the identification of select aa substitutions: 
D1135V, R1335Q, T1337R or D1135E, R1335Q, T1137R, and were required to generate two 
novel SpCas9 variants that were capable of recognising the altered 5’-NGA-3’ PAM sequence in 
vitro (Kleinstiver et al., 2015). 
 
Alternatively, manipulation of gene expression has also been researched using modified Cas9 
nucleases. Initially, dCas9 was found capable of repressing gene expression when targeted to 
gene promoter sequences (Qi et al., 2013). This CRISPR-mediated interference (CRISPRi) was 
further adapted with dCas9-fusion proteins; for example dCas9 was fused with transcriptional 
repressors and chromatin modifiers, such as Krüppel associated box (KRAB), which resulted in 
substantial gene silencing of targeted endogenous genes when compared to dCas9 alone 
(Gilbert et al., 2013). In contrast, upregulation of endogenous genes resulted from fusion of 
dCas9 with transcriptional activators such as VP64, creating the CRISPR-mediated activation 
(CRISPRa) system. However, earlier studies showed that multiple sgRNAs are encouraged per 
target to see markedly enhanced upregulation of target gene expression (Maeder et al., 2013; 
Perez-Pinera et al., 2013). 
  
SpCas9 has been further engineered to increase its specificity for on-target sequences and 
reduce non-specific interactions at off-target sequences (Kleinstiver et al., 2016; Slaymaker et 
al., 2016; Lee et al., 2017a). This has been achieved by close analysis of SpCas9 crystal 
structure in complex with gRNA and target DNA. Analysis suggested a positively-charged 
groove made up of 32aa, in which SpCas9 is thought to stabilise the PAM-complementary 
sequence (Slaymaker et al., 2016). Select substitution mutations of this positively-charged 
groove with neutral alanine residues, generated enhanced specificity SpCas9 (eSpCas9) 
variants. As a result, the eSpCas9 variants require only the minimum binding energy between 
gRNA and target DNA to prevent re-hybridisation of target DNA strands. As a result, eSpCas9 
showed improved on-target specificity due to undetectable off-target indels in the known off 
target sites against EMXI and VEGFA gRNAs in 293 (Slaymaker et al., 2016). Alternative to this 
was alanine substitutions in key residues that make contact with the PAM-containing DNA 
strand instead. This generated SpCas9 high fidelity (SpCas9-HF) variants (Kleinstiver et al., 
2016), which demonstrated reduction in nearly all genome-wide off-target sites for gRNAs 
against EMXI, FANCF, RUNXI and ZSCAN2 genes (Kleinstiver et al., 2016). More recently, 
directed evolution of SpCas9 in E. coli has been used to identify SpCas9 variants that 
discriminate against off-targets sites and show preferential binding to on target sites (Lee et 
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al., 2017a). Using positive selection pressure of on-target cleavage of the plasmid encoded 
ccdB lethal gene (harbouring the on-target sequence), and negative selection pressure of off-
target cleavage of E. coli chromosomal DNA (harbouring the off-target sequence), Cas9 variant 
(Sniper-1) was identified and showed improved specificity, even when compared against 
eSpCas9 and SpCas9-HF (Lee et al., 2017a). However, this demonstrates a potential need for 
directed evolution of SpCas9 against any given gene target in competition against a plethora of 
possible off-target sequences in vitro to merit actual development.  
 
Both type I and III CRISPR/Cas systems have been demonstrated as capable of performing 
genome editing. However, repurposing of these CRISPR/Cas systems for genome editing has 
mainly been explored in archaeon species and not mammalian cell lines (Li et al., 2016; Cheng 
et al., 2017a; Liu et al., 2017). A Cas endonuclease (Cpf1) derived from the relatively new type 
V CRISPR-Cas system was identified (Zetsche et al., 2015), and shows unique features that 
promoted its potential for programmable genome editing. First, DNA targeting with Cpf1 only 
required crRNA, unlike Cas9 which requires a dual-RNA composed of crRNA and tracrRNA. 
Second, Cpf1 recognises a T-rich PAM at the 5’-end of the target protospacer, namely 5’-TTTV-
3’ (Kim et al., 2017), unlike SpCas9 which recognises 5’-NGG-3’. Third, Cpf1 generates a DSB 
with cohesive ends, whereas Cas9 generates blunt ends. Lastly, Cpf1 also possesses RNase III 
catalytic activity, required for endogenous pre-crRNA processing (Fonfara et al., 2016), which 
is advantageous in multiplex genome editing from a single CRISPR array. Type II CRISPR-Cas9 
system requires endogenous RNase III to process pre-crRNAs - a function that is not inherent 
to Cas9. Therefore, mature sgRNAs are encoded in CRISPR/Cas9 systems to off-set this 
limitation, but this does prevent multiplex genome editing from a single CRISPR array in vitro. 
Cpf1 orthologues from Lachnospraceae bacterium ND2006 (LbCpf1) and Acidaminococcus sp. 
BV3L6 (AsCpf1) have shown promising and demonstrable potential for genome editing in 
human and mammalian cell lines (Zetsche et al, 2015; Kleinstiver et al, 2016b; Toth et al, 
2016). With the unique features of type V CRISPR-Cas systems, Cpf1 further expands the 
genome editing and manipulation potential where SpCas9 fails or is restricted. 
 
1.6.4 Development of CRISPR/Cas9 system for gene therapy and as a future novel 
medicine 
Regardless of certain shortcomings reviewed above, the development of the CRISPR/Cas9 
system has delivered a potent genome editing tool with remarkable applicability in vivo. We 
have mainly stressed the application of CRISPR/Cas9 and derivatives or variants thereof in 
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vitro; however, CRISPR/Cas9 genome editing is quickly being incorporated ex vivo, in vivo, and 
clinical research as a potentially novel class of medicine. 
 
With high-throughput sequencing technologies, the relationship between genes and a number 
of human diseases has become clearer. Moreover, animal disease and cancer models are well 
established, and have permitted in vivo testing models to examine the viability of the 
CRISPR/Cas9 genome editing tool as a gene therapy. Interestingly, the CRISPR/Cas9 system has 
become a more reliable and robust tool to generate transgenic animal models, and outclassing 
conventional methodologies (Wang et al., 2013; Huang et al., 2017). Initial evidence that 
suggested that the CRISPR/Cas9 system could be exploited as a gene therapy was perhaps 
demonstrated with studies targeting HIV1 in vitro. CRISPR/Cas9 showed encouraging inhibition 
of the HIV1 expression machinery in HIV1 provirus-integrated human cell lines, by targeting 
the long terminal repeat (LTR) promoter sequences, specifically the TAR and U3 regions (Ebina 
et al., 2013). This was found to be, in part, due to the power of the CRISPR/Cas9 to excise the 
latent form of HIV1 pro-viral DNA from the host genome (Ebina et al., 2013; Hu et al., 2014) 
(Kaminski et al., 2016), and significantly impacted on the replicative and reactivating potential 
of HIV1 infection in vitro (Liao et al., 2015; Zhu et al., 2015). Furthermore, Liao et al. (2015) 
conceptualised that stable HIV1-targeting CRISPR/Cas9 conferred significant resistance to 
subsequent HIV1 infection, especially in more physiologically and clinically relevant human 
primary CD4+ T cells and haematopoietic lineages, which function as latent HIV1 reservoirs.  
 
Careful consideration in CRISPR/Cas9 target has been recently warranted – the emergence of 
HIV viral escape mutants has been reported after targeting using CRISPR/Cas9 (Wang et al., 
2016a; Wang et al., 2016d; Lebbink et al., 2017). In such cases, indels introduced by the 
CRISPR/Cas9 system were either deleterious to HIV1 or the virus emerged as mutated escape 
strains, which were refractory to CRISPR/Cas9 and the gRNA originally used (Wang et al., 
2016a; Wang et al., 2016d; Lebbink et al., 2017). This revelation warrants caution when 
targeting HIV1’s latent pro-viral DNA in vivo. Although, a study performed by Kaminski et al. 
(2016) were incapable of identifying escape mutants in vivo in transgenic mice and rat models 
that carry a transgene derived from a replication-deficient HIV1 genome after targeting using 
CRISPR/Cas9. 
 
An alternative strategy explored genome editing of induced pluripotent stem cells (iPSCs) 
using CRISPR/Cas9 and piggyBac technology to generate homozygous CCR5Δ32 mutation in 
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the C-C chemokine receptor type 5 gene (CCR5)  (Ye et al., 2014). The CCR5 protein is utilised 
by HIV1 as a co-receptor to infect T-cells, macrophages and monocytes (Choe et al., 1996). 
However, CCR5Δ32 mutation was originally found in individuals who showed resistance to 
primary macrophage-tropic HIV1 (Liu et al., 1996). Therefore, CCR5 potentiated as a promising 
target for conferring HIV1 resistance in vivo and prevent the rebound of HIV load after 
discontinuation of anti-retroviral therapy (Hutter et al., 2009). A curative, allogenic stem-cell 
transplant strategy was devised, albeit, represented by only a single treated individual. 
Introducing homozygous CCR5Δ32 mutation in the CCR5 gene using CRISPR/Cas9 resulted in 
HIV1 resistant cell lines, such that HIV1 p24 glycoprotein concentrations were undetectable in 
the genome edited iPSCs, post-differentiation into macrophages and monocytes (Ye et al., 
2014; Kang et al., 2015). Perhaps the only caveat of this approach was the relatively low 
efficiency of generating and identifying iPSCs with homozygous CCR5Δ32 mutation (33-41%); 
although, CRISPR/Cas9 performed significantly better compared to alternative nucleases such 
as TALENs (14%) (Ye et al., 2014; Kang et al., 2015). In turn, an autologous, ex vivo gene editing 
pipeline to generate differentiated cells that are resistant to HIV1 infection provides a 
promising strategy to combat HIV1 infection into remission, analogous to observations by 
Hutter et al. (2009). The antiviral therapeutic capacity of CRISPR/Cas9 is becoming more 
relevant for targeting other clinically relevant viruses. This includes, but not limited to: 
Hepatitis B Virus (Lin et al., 2014; Seeger and Sohn, 2014; Li et al., 2017), Epstein Barr Virus 
(Wang and Quake, 2014; Yuen et al., 2015; van Diemen et al., 2016), and HSV (van Diemen et 
al., 2016).  
 
Exploring CRISPR/Cas9’s antiviral therapeutic potential has been limited mainly to in vitro and 
even fewer in vivo studies. The adaptation of CRISPR/Cas9 as a novel class of antiviral medicine 
requires much further exploration and optimisation before human clinical trials can be 
considered. That being said, early phase human clinical trials have been completed or are 
currently active, which are exploring the capacity for zinc-finger nucleases to vaccinate against 
HIV1 (Table 1.1). These studies perpetuate the potential for human clinical trials that could 
explore the feasibility of CRISPR/Cas9 genome editing as a novel, anti-viral strategy. Of 
particular note is clinical trial research data presented by Tebas et al. (2014), whose team 
engrafted twelve patients with autologous CD4+ T-cells that had been edited at CCR5 using 
zinc-finger nucleases ex vivo to confer disruption of CCR5 expression. Engraftment of these 
edited CD4+ T-cells persisted, and as defined by the parameters of the study, the application of 
gene edited CD4+ T-cells in human subjects was concluded as safe (Tebas et al., 2014). 
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Table 1.1. List of human clinical trials harnessing zinc-finger nuclease to target HIV1 infection 
Identifier Title of study Phase Status Reference 
NCT00842634 
Autologous T-Cells Genetically Modified at the CCR5 
Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-
Finger) 
1 Completed (Tebas et al., 2014) 
NCT02388594 
A Phase 1 Study of T-Cells Genetically Modified at the 
CCR5 Gene by Zinc-Finger Nucleases SB-728mR in HIV-
Infected Patients 
1 Active n/a 
NCT01044654 
Phase 1 Dose Escalation Study of Autologous T-cells 
Genetically Modified at the CCR5 Gene by Zinc Finger 
Nucleases in HIV-Infected Patients 
1 Completed n/a 
NCT02500849 
Safety Study of Zinc Finger Nuclease CCR5-modified 
Hematopoietic Stem/Progenitor Cells in HIV1 Infected 
Patients 
1 Recruiting  n/a 
NCT02225665 
Repeat Doses of SB-728mR-T After Cyclophosphamide 
Conditioning in HIV-Infected Subjects on HAART 
1/2 Active n/a 
n/a, not applicable 
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Substantial progresses in proof-of-concept studies have been made, which demonstrate the 
advantage of utilising the CRISPR/Cas9 as a gene therapy. Mouse disease models that centre 
on a single culprit gene mutation have been particularly useful in demonstrating that 
CRISPR/Cas9 can correct and rescue disease phenotypes. Initial in vivo studies examined the 
effect of delivering CRISPR/Cas9 directly into the animal germline to target a defined 
mutation; as was exemplified by the mutated Crygc gene in mice (Wu et al., 2013). The 1bp 
deletion in exon 3 of Crygc produces a truncated protein product that confers a dominant 
cataract disorder. Repair of mutant Crygc by NHEJ or HR with exogenous DNA encoding the 
wildtype sequence at the zygote level resulted in rescue from the diseased phenotype in a 
modest proportion of the P1 generation (approximately 30%) (Wu et al., 2013). Additionally, 
the repaired Crygc gene was transmitted to the next generation (Wu et al., 2013). However, 
due to ethical concerns of germline manipulation in humans and human embryos, the 
approach explored by Wu and colleagues (2013) presents limited translatability as a curative 
human gene therapy. This is even in despite of the fact that between 10-25% cases of 
congenital cataracts are a result of genetic mutations, which includes the human homologue 
of the Crygc gene – CRYGC (Zhong et al., 2017).  
 
Instead, somatic gene editing using CRISPR/Cas9 holds more potential translation as a novel 
medicine. The application of somatic gene editing presents with fewer ethical considerations. 
Recent research has successfully shown clinical benefit and gene correction for a number of 
monogenetic diseases based on animal models. Haemophilia B is an X-linked genetic bleeding 
disorder attributed by a deficiency in the blood coagulator factor IX, and caused by mutations 
in the human factor IX (FIX) gene (Rallapalli et al., 2013). Reconstituting a small proportion of 
factor IX levels in the plasma resulted in significant restoration to the clotting activity (Wang et 
al., 2000a; Nathwani et al., 2014). Perhaps one of the initial-most proof-of-concept, in vivo 
studies to explore the curative potential of CRISPR/Cas9 for haemophilia B was performed by 
Guan et al. (2016). Here, CRISPR/Cas9 and donor template were delivered as naked DNA via 
the tail veins of haemophilia B mice model, which successfully corrected the factor IX mutation 
in situ. Coagulation activity in the haemophilia B mice was restored and survival rates 
increased after tail-clip challenges to nearly 90% from 38% of the control group (Guan et al., 
2016). The corrected mouse FIX gene occurred in approximately 0.56% of endogenous alleles 
by HR (Guan et al., 2016). This was sufficient to ameliorate the clotting deficiency phenotype. 
Similar results were reported by additional studies using CRISPR/Cas9 in situ to correct 
haemophilia B mouse models (Huai et al., 2017; Ohmori et al., 2017). However, the use of 
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mouse FIX knockout haemophilia B models function well to recapitulate the severe 
haemophilia B phenotype in animals, a number of human cases of haemophilia B are a result 
of dysfunctional factor IX protein being expressed due to single, missense point mutation. This 
results in the deficiency in functional factor IX expression overall, and not necessarily a 
complete knockout phenotype per se (Rallapalli et al., 2013; Guan et al., 2016; Yuen et al., 
2017). Therefore, the impact dysfunctional factor IX has and the interplay this has with 
corrected factor IX in haemostasis cannot be taken into consideration when applying 
CRISPR/Cas9 to mouse FIX knockout models. Perhaps in situ gene therapy of more directly 
comparable mouse models of human haemophilia B, of which analogous FIX mutations are 
represented, would provide more confident translation potential. More recently, the 
autologous, ex vivo expansion of haemophilia B patient-derived iPSCs was subjected to gene 
correction by CRISPR/Cas9 genome editing to restore native sequence or factor IX cDNA 
knock-in into exon 1 of the endogenous FIX gene (Ramaswamy et al., 2018). In vitro 
differentiation of corrected iPSC lines into hepatocyte-like cells was followed by 
transplantation into immune-deficient FIX knockout mice. These transplantations correlated 
with detectable factor IX expression, increased clotting efficiency (rescued to approximately 
25% clotting activity of wildtype), and grafts were well sustained (Ramaswamy et al., 2018).  
 
Duchenne muscular dystrophy is characterised by progressive muscle weakening and 
degeneration, due mutations in the dystrophin gene (DMD) and absence of the dystrophin 
protein (Mital et al., 1998). Restoration of a functional dystrophin protein product was 
successfully achieved using CRISPR/Cas9 (AAV-CRISPR) to excise the mutated exon from post-
natal mdx mouse model of Duchenne muscular dystrophy in vivo. This resulted in the 
expression of a truncated form of dystrophin that retained partial wildtype functionality (Long 
et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016). The modified dystrophin was 
successfully found expressed in cardiac and skeletal muscles, and provided partial recovery of 
muscle function (Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016). Alternatively, 
Zhu et al. (2017) achieved ex vivo culture and expansion of muscle stem cells derived from 
mdx mice for HR-mediated genome editing to repair of the mutated Dmd gene by Cas9 
endonuclease via an Adenovirus vector. Following the transplantation of the gene-corrected 
muscle stem cells into mdx mice, an appreciable level of dystrophin was detectable in skeletal 
muscle. However, the study fails to inform us on whether or not a clinical benefit was 
measurable in the mdx mice using gene-corrected muscle stem cells. This methodology was in 
some contrast to the previously proposed in vivo approaches that relied on Cas9 endonuclease 
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function to excise the mutated Dmd exon and NHEJ to repair the break and facilitate encoding 
an in-frame dystrophin protein by exon skipping. The benefit of genome editing muscle stem 
cells is the capacity for stem cells and replicating cells to mediate HR, which was a presumably 
lost feature of terminally differentiated cells such as myocardiocytes (Saleh-Gohari and 
Helleday, 2004). This has recently been contested – non-dividing cardiomyocytes were found 
to utilise HR, and were capable of being genome edited using CRISPR/Cas9 (Ishizu et al., 2017).  
 
As a result of the promising capacity of CRISPR/Cas9 genome editing in animal models, a boom 
in several, early phase human clinical trials examining the safety profile of ex vivo CRISPR/Cas9 
genome edited cell lines are to be conducted (Table 1.2). In this regard, the function of 
CRISPR/Cas9 genome editing is being exploited to enhance the cellular therapy product, rather 
than directly apply it as a gene therapy, gene correcting tool. As is represented by Table 1.2, a 
number of human clinical trials will involve the application of CRISPR/Cas9 to disrupt 
endogenous T-cell receptor (TCR) and/or programmed cell death protein (PD)1 expression 
from autologous T-cells. The goal is to generate T cells expressing tumour specific TCRs to 
differentially recognise and target cancer cells in vivo (chiefly by clinical trial NCT03399448). 
PD-1 disruption was warranted due to studies implicating PD-1 expression and its constitutive 
stimulation of tumour-specific T-cells with impaired T-cell function (Blank et al., 2006; Wei et 
al., 2013; Wu et al., 2014). This was due to, in part, the PD-1 ligation to the PD-L1 ligand that 
was expressed by tumour cells in order to coax peripheral immune tolerance and favour its 
survival (Blank et al., 2006; Wei et al., 2013; Wu et al., 2014). Therefore, the disruption of PD-1 
expression from T-cells aims to augment the capacity of tumour-specific T-cells to mediate 
killing of PD-L1+ tumours by eliminating this check-point inhibitory stimulation (Su et al., 
2016a; Rupp et al., 2017). Additionally, the existing endogenous TCR effectively competes with 
the tumour specific TCR for surface expression, and is capable of forming mixed dimers. This 
may compromise tumour-specificity (van Loenen et al., 2010; Bunse et al., 2014). Elimination 
of endogenous TCR is thought to generate more efficacious T cell therapy product.  
 
Assessment of the safety profile of using CRISPR/Cas9 genome editing to produce gene and 
cellular therapy products for human clinical trials is a promising step in the direction of 
generating a novel class of medicine. The concept of harnessing the genome editing tool to 
improve or enhance a gene and/or cellular therapy product is a rather novel field of research. 
It remains, however, to objectively interpret the data from the aforementioned human clinical 
trials when completed before further progress can be recommended. 
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Table 1.2. List of human clinical trials utilising CRISPR/Cas9 genome editing 
Identifier Title of study targeted condition Phase Status 
NCT03057912 
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of 
HPV-related Cervical Intraepithelial Neoplasia 
HPV-related malignant 
neoplasm 
1 
Not yet 
recruiting 
NCT03164135 
Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-
infected Subjects With Haematological Malignancies 
HIV1 infection 
Not 
determined 
Recruiting  
NCT03399448 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Multiple cancers 1 Recruiting  
NCT03081715 PD-1 Knockout Engineered T Cells for Advanced Oesophageal Cancer Oesophageal cancer 2 Recruiting  
NCT02863913 PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer 
Invasive bladder 
cancer stage IV 
1 
Not yet 
recruiting 
NCT02867345 PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer 
Hormone refractory 
prostate cancer 
1 
Not yet 
recruiting 
NCT02867332 PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. 
Metastatic renal cell 
carcinoma 
1 
Not yet 
recruiting 
NCT02793856 PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer 
Metastatic non-small 
cell lung cancer 
1 Recruiting  
NCT03044743 
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) 
Associated Malignancies 
Multiple cancers 1/2 Recruiting  
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1.7.0 Aims and objectives  
The study and application of gene therapy products are intensely growing fields of research. 
Successful gene therapy has been especially exemplified by the successful introduction of 
AAV-based gene therapy products – Glybera and Luxturna – as the world’s first gene therapy 
products to be clinically available for the treatment of monogenetic diseases. Therefore, there 
is considerable promise in gene therapy, especially when mediated by rAAV vector technology, 
as a means to treat and cure select human diseases. However, the clinical efficacy of using 
rAAV vectors is restricted by limitations pertaining to our limited understanding of the roles 
host cellular factors have towards AAV assembly and processing. Such limitations also include 
a pre-existing immunity towards current AAV serotypes (Kotterman et al., 2015), and the 
insufficient production of rAAV vector titres to meet the demands of clinical studies. 
 
Advancements in rAAV vector production and technology includes the development of 
partially stable cell lines for rep and/or cap expression (Gao et al., 2002b; Mietzsch et al., 
2014), or exhibit improved transduction profiles or have enhanced target specificities (Aslanidi 
et al., 2013; Buning et al., 2015; Ling et al., 2016), and the adaptation of the baculovirus 
expression system to generate rAAV vectors from insect cells (Urabe et al., 2002; Smith et al., 
2009). However, given our limited understanding of the roles host cellular factors have 
towards AAV assembly and processing, there is a need to exploit this avenue of research for 
the enhancement of rAAV vector production and rAAV vector-based gene therapy products.  
 
Previously, it has been identified that the endogenous human cell factor, YB1, was 
incorporated into rAAV vectors, and that gene manipulation of YB1 protein expression by 
shRNA-mediated knockdown in 293T cells correlated with enhanced rAAV2 and rAAV8 vector 
titres (Satkunanathan et al., 2014). Therefore, it was postulated that YB1 may have an 
important role in rAAV vector production and processing. However, a transient rAAV titre 
enhancement was observed by shRNA-mediated targeting of YB1 protein expression. With 
these in mind, the aims of this thesis were to i) utilise the CRISPR/Cas9 genome editing system 
to target the YB1-encoding gene (YBX1) in 293T cells to generate a novel YB1 knockout cell line 
for rAAV vector production; ii) extensively characterise the novel YB1 knockout cell lines at the 
molecular and phenotypical levels as conducive for rAAV vector production, and establish a 
well-controlled rAAV production model for effective comparisons; iii) examine the role of 
wildtype YB1, YB1 truncation mutants and YB1 knockout in rAAV biology and vector 
production; and lastly, iv) identify the YB1 orthologue and orthologous gene in S. frugiperda, 
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for genome manipulation using CRISPR/Cas9 and subsequent analysis on rAAV vector 
production. The overall purpose of this project was to examine the utility of CRISPR/Cas9 
genome editing in generating a novel rAAV vector production system from both 293T and Sf9 
cell lines, and in doing so, examine the impact YB1 and YB1 knockout (or its orthologue in the 
Sf9 cell) has on rAAV vector production. 
 
It is important to acknowledge and appreciate that the use of CRISPR/Cas9 genome editing has 
been largely been researched for its direct application in genome editing as a potentially novel 
method for gene therapy i.e. gene editing to correct genetic defects associated with a disease 
phenotype. Little research has been performed using CRISPR/Cas9 genome editing to enhance 
a gene therapy product such as viral vector production platforms (Satkunanathan et al., 2014; 
Satkunanathan et al., 2017). Core research, instead, focuses on modifying AAV capids, 
transgenes and/or expression cassettes, with little attention on the AAV vector producer 
factory i.e. the cell line itself, to address the restricted vector titres achieved by current 
platforms. Instead, more focus is centred on delivering CRISPR/Cas9 for somatic genome 
editing to correct defective genes and clinical phenotype (Bengtsson et al., 2017; Pingjuan et 
al., 2018). Perhaps the closest examples of modifications of the actual cellular or gene therapy 
products using CRISPR/Cas9 in the current literature is the generation of engineered T cells 
with endogenous PD-1 (Su et al., 2016a; Rupp et al., 2017) or TCR (Osborn et al., 2016; Ren et 
al., 2017) disruption by CRISPR/Cas9 genome editing, ex vivo. Here, the cellular therapy 
product is being modified for improved performance in tumour cell killing rather than using 
CRISPR/Cas9 for somatic genome editing in vivo. Such edited cells are to be utilised in a 
number of early phase human clinical trials (Table 1.2). Given this encouraging spur in the use 
of CRISPR/Cas9 genome editing to develop enhanced cellular therapy products, the utilisation 
of the genome editing technology to potentially produce enhanced rAAV vector production 
systems is certainly warranted. However, little exploration in endogenous gene manipulation 
has been performed on producer cells for enhanced rAAV vector titres or production; of which 
this thesis will be first to represent.  
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Chapter 2: Materials and Methods 
 
2.1.0 Materials 
2.1.1 General laboratory reagents 
Common reagents are listed below in Table 2.1, with more protocol-specific reagents 
described in their relevant sections. 
 
Table 2.1 General reagents used   
Reagent Supplier 
β-Mercaptoethanol Sigma-Aldrich 
Acetic acid VWR 
Agarose Sigma-Aldrich 
Ammonium persulphate (APS) Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
Calcium Chloride (CaCl2) Sigma-Aldrich 
Coomassie® Brilliant Blue R-250 Sigma-Aldrich 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Dipotassium phosphate (K2HPO4) Sigma-Aldrich 
Disodium phosphate (Na2HPO4) Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Ethanol France Alcools 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Formaldehyde solution (37-41%) Fisher Scientific 
Glycerol Sigma-Aldrich 
Glycine Fisher Scientific 
HEPES Sigma-Aldrich 
Hydrochloric acid (HCl) VWR 
Isopropanol Sigma-Aldrich 
Magnesium Chloride (MgCl2) Sigma-Aldrich 
Methanol VWR 
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N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Sodium dodecyl-sulphate (SDS) Sigma-Aldrich 
Sodium hydroxide (NaOH) VWR 
Triton™ X-100 Sigma-Aldrich 
Trizma base (Tris-base) Sigma-Aldrich 
Tween™ 20 Sigma-Aldrich 
 
2.1.2 Oligonucleotides (oligos) 
All polymerase chain reactions (PCR), cloning and sequencing oligos are listed in Table 2.2. 
Oligos that correspond to gRNA DNA designs for CRISPR/Cas9 genome editing of 293T cells are 
listed in Table 2.3. Oligos that correspond to gRNA DNA designs for CRISPR/Cas9 genome 
editing of Sf9 cells are listed in Tables 2.4 and 2.5. Oligos used to generate or function as 
desthiobitotin- or biotin- labelled DNA capture probes are listed in Table 2.6. Most oligos were 
synthesised by Sigma-Aldrich, whereas 5’-desthiobiotin or 5’-biotin labelled oligos were 
synthesised by Integrated DNA Technologies (IDT). All oligos were prepared as 100μM stock 
solutions in nuclease-free water (H2O) unless stated otherwise, and further diluted to 10μM 
working stocks in nuclease-free H2O. All oligos were stored at -20°C. Where relevant, the 
applications in which oligos are used and annealing temperatures (Ta) for PCR are also 
described.  
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Table 2.2 List of cloning and sequencing oligos 
oligo name 5'>3' sequence Application Ta (°C) 
U6.F(orward) GGA CTA TCA TAT GCT TAC CG Sequencing n/a 
Surv-gRNA1.F(orward) GTC GCT CGT AGG GCT TAT CC Sequencing, PCR 
(Surveyor® assay) 
58* 
Surv-gRNA1.R(everse) CTA ACG GTT CCG CTG CTG 
Surv-gRNA2.F(orward) GTC ATT TCT GTG CAC CCC TG Sequencing, PCR 
(Surveyor® assay) 
58 
Surv-gRNA2.R(everse) CTC CAT CAC TTC TCC CTG CA 
Surv-gRNA3.F(orward) ACT CTT GGA TTT ATC TGG T Sequencing, PCR 
(Surveyor® assay  
and HRM template) 
50 
Surv-gRNA3.R(everse) TTA TCT TAC CTG TTC AAG GA 
Surv-gRNA4.F(orward) TTA CAC AAA TTG CCT ACA GA 
PCR  50 
Surv-gRNA4.R(everse) ATA AAT GGA TGG CCA TCC AA 
Surv-sgRNAsf1.F(orward) ACT CTA ACC TGA CTT CAC AG Sequencing, PCR 
(Surveyor® assay) 
56 
Surv-sgRNAsf1.R(everse) ACA CAC GAT CAA TAA CGC CG 
HRM-KOC.F(orward) TGA GGC AGA ATA TGT ATC GG 
HRM 58 
HRM-KOC.R(everse) CTA ACA CGG GTT TGA GGA AA  
HRM-5'KOC.F(orward) CCC AGT AGG CTT AAT TTC CA  
HRM 58 
HRM-5'KOC.R(everse) CCG ATA CAT ATT CTG CCT CA  
HRM-3'KOC.F(orward) TTT CCT CAA ACC CGT GTT AG 
HRM 58 
HRM-3'KOC.R(everse) TCA CCT CTT AGG CAT CTG AT  
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SfYB-inf.F(orward) AAT CAA AGG AGA TAT ACC ATG GCA CA PCR (In-Fusion® 
cloning)  
58 
SfYB-inf.R(everse) ATG GTG ATG ATG GTG GTG TTA AGC CTG 
pIEx1-ie1prom.F(orward) CAA GAT CGT GAA CAA CCA AG Colony PCR 55 
pIEx1-ie1term.R(everse) ACT TAG TGC TCG AGA TCC TC Colony PCR 55 
eGFP.colPCR.R(everse) TTA CTT GTA CAG CTC GTC CA Colony PCR 55 
T7.F(orward) TAA TAC GAC TCA CTA TAG G  Sequencing n/a 
YBF1 GCT AGG ATC CGC CAC CAT GAG CAG CGA GGC CGA G 
High-fidelity PCR 
58°C for YBF1 and YB1R2, YBF1 
and YBR2, YBF1 and YBR3, and 
YBF1 and YBR4 oligo pairs, or 
54°C for YBF2 and YBR3, YBF3 and 
YBR1, and YBF2 and YBR1 oligo 
pairs 
YBF2 GCT AGG ATC CGC CAT GAA GAA GGT CAT CGC AAC G 
YBF3 GCT AGG ATC CGC CAC CAT GGT TCC AGT TCA AGG CAG T 
YBR1 GC AGC GGC CGC TTA CTC AGC CCC GCC CTG 
YBR2 GCT AGC GGC CGC TTA TCT AGG CTG TCT TTG GCG 
YBR3 GCT AGC GGC CGC TTA CAC TTC TCC CTG CAC AGG 
YBR4 GCT AGC GGC CGC CGC TTA ACC AGG ACC TGT AAC ATT TG 
SFFV.F(orward) CCC AAG GAC CTG AAA TGA CC TGC Sequencing n/a 
WPRE.R(everse) GCA GCG TAT CCA CAT AGC G Sequencing n/a 
CMV.F(orward) TTC CTA CTT GGC AGT ACA TCT ACG 
qPCR 60 CMV.R(everse) GTC AAT GGG GTG GAG ACT TGG 
CMV.hyd_probe [6FAM]TGA GTC AAA CCG CTA TCC ACG CCC A[TAM] 
*, 98°C denaturation during PCR thermocycling was required. Underlined nucleotides refer homology arms for cloning by In-Fusion®. HRM, high-
resolution melting; PCR, polymerase chain reaction; qPCR, quantitative PCR; Ta, annealing temperature. 
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Table 2.3 YBX1-specific gRNA designs to target YBX1 gene 
  
name YBX1-specific gRNA sequence (5' > 3') 
YBX1-specific gRNA sequence (5' > 3') + 3' 
overhang 
YBX1 intron/exon 
target 
YBX1sgRNA1.F(orward) ATC GGC GGC GCC TGC CGG CG ATC GGC GGC GCC TGC CGG CGG TTT T  
exon 1 
YBX1sgRNA1.R(everse) CGC CGG CAG GCG CCG CCG AT  CGC CGG CAG GCG CCG CCG ATC GGT G  
YBX1sgRNA2.F(orward) GTA ATG GCT TTT GTA GGG TG GTA ATG GCT TTT GTA GGG TGG TTT T  
exon 5 
YBX1sgRNA2.R(everse) CAC CCT ACA AAA GCC ATT AC CAC CCT ACA AAA GCC ATT ACC GGT G  
YBX1sgRNA3.F(orward) GGA CCA TAC CTG CGG AAT CG GGA CCA TAC CTG CGG AAT CGG TTT T  
intron 6 
YBX1sgRNA3.R(everse) CGA TTC CGC AGG TAT GGT CC CGA TTC CGC AGG TAT GGT CCC GGT G  
YBX1sgRNA4.F(orward) CAA AGA CAG CCT AGA GAG GA CAA AGA CAG CCT AGA GAG GAG TTT T  
exon 7 
YBX1sgRNA4.R(everse) TCC TCT CTA GGC TGT CTT TG TCC TCT CTA GGC TGT CTT TGC GGT G  
The gRNA oligo specific to PAM-containing target sequence required 5'-GTTTT-3' overhang (red sequences). The complementary oligo 
required 5'-CGGTG-3' overhang (green sequences), to facilitate cloning into linearised GeneArt™ CRISPR nuclease vector. 
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Table 2.4 SFYB-specific gRNA designs to target SFYB gene   
name 
SFYB-specific gRNA sequence 
(5' > 3') 
YBX1-specific gRNA sequence (5' > 3') 
+ 3'-overhang 
potential SFYB 
intron/exon target 
SFYBsgRNA1.F(orward) CAC CAT GGC TGA TAC CGA AA CAC CAT GGC TGA TAC CGA AAG TTT T 
exon 1 
SFYBsgRNA1.R(everse) TTT CGG TAT CAG CCA TGG TG  TTT CGG TAT CAG CCA TGG TGC GGT G  
SFYBsgRNA2.F(orward) GTG GAT ATG GTT TCA TCA AC  GTG GAT ATG GTT TCA TCA ACG TTT T  
exon 2 
SFYBsgRNA2.R(everse) GTT GAT GAA ACC ATA TCC AC  GTT GAT GAA ACC ATA TCC ACC GGT G  
SFYBsgRNA3.F(orward) GTG GAG TTT GCC GTG GTT GC  GTG GAG TTT GCC GTG GTT GCG TTT T  
exon 3 
SFYBsgRNA3.R(everse) GCAACCACGGCAAACTCCAC  GCA ACC ACG GCA AAC TCC ACC GGT G  
The gRNA oligos specific to PAM-containing target sequence required 5'-GTTTT-3' overhang (red sequences) on the 3’-end. The 
complementary oligo required 5'-CGGTG-3' overhang (blue sequences) on the 3’-end, to facilitate cloning into linearised 
GeneArt™ CRISPR nuclease vector. 
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Table 2.5 SFYB-specific gRNA designs to target SFYB gene 
    
name 
SFYB-specific gRNA sequence 
(5' > 3') 
SFYB-specific gRNA sequence (5' > 3') + T7 or crRNA 
sequences 
potential SFYB 
intron/exon target 
IVTSFYBsgRNA1.F(orward) CAC CAT GGC TGA TAC CGA AA 
TAA TAC GAC TCA CTA TAG CAC CAT GGC TGA TAC 
CGA 
exon 1 
IVTSFYBsgRNA1.R(everse) TTT CGG TAT CAG CCA TGG TG  
TTC TAG CTC TAA AAC TTT CGG TAT CAG CCA TGG 
TG 
IVTSFYBsgRNA2.F(orward) GTG GAT ATG GTT TCA TCA AC  
TAA TAC GAC TCA CTA TAG GTG GAT ATG GTT TCA 
TCA  exon 2 
  
IVTSFYBsgRNA2.R(everse) GTT GAT GAA ACC ATA TCC AC  
TTC TAG CTC TAA AAC GTT GAT GAA ACC ATA TCC 
AC 
IVTSFYBsgRNA3.F(orward) GTG GAG TTT GCC GTG GTT GC  
TAA TAC GAC TCA CTA TAG GTG GAG TTT GCC GTG 
GTT exon 3 
  
IVTSFYBsgRNA3.R(everse) GCA ACC ACG GCA AAC TCC AC  
TTC TAG CTC TAA AAC GCA ACC ACG GCA AAC TCC 
AC 
To generate the gRNA DNA templates for IVT of sgRNAs, gRNA designs specific for the PAM containing target sequence strand required oligos 
with T7 sequences on 5'-end. The complementary oligo required crRNA sequence on 5'-end. Underlined G refers to initial G nt where 
transcription is initiated from T7 promoter. IVT, in vitro transcription. 
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Table 2.6 List of oligos for DNA-affinity YB1 pulldown 
oligo name modification 5'>3' sequence Application Ta (°C) 
ITR_YB1.F(orward) n/a TGG TAG AGA CGG GGT TTC AC  
PCR 58 
ITR_YB1.R(everse) 5’-desthiobiotin GGG AAG AAA GCG AAA GGA GC  
rep_YB1.F(orward)  5’-desthiobiotin CTT CCG GCT CGT ATG TTG TG  
PCR 58 
rep_YB1.R(everse) n/a CGT GCA TGT GGA AGT AGC TC  
E2A_YB1.F(orward) n/a TCT TGT GAC GAG TCT TCT TCG  
PCR 58 
E2A_YB1.R(everse) 5’-desthiobiotin TAG GTA GTC GCC ATG CCT TT  
L-ITR_YB1.F(orward)  5’-desthiobiotin CCC ACC AGC CTT GTC CTA AT  
PCR 58 
L-ITR_YB1.R(everse) n/a CAG AAG GAC AGG GAA GGG AG  
R-ITR_YB1.F(orward) n/a GCC TGA TGC GGT ATT TTC TCC  
PCR 58 
R-ITR_YB1.R(everse) 5’-desthiobiotin GGG TTG AGT GTT GTT CCA GT 
GCcomp.F(orward) 3’-biotin GGC GGG GGC GGG GGC GGG GGC GGG TTT TT Capture probe n/a 
GCcomp.F(orward) n/a GGC GGG GGC GGG GGC GGG GGC GGG  Capture probe n/a 
GCcomp.R(everse) n/a CCC GCC CCC GCC CCC GCC CCC GCC Capture probe n/a 
Luciferase.F(orward) 3’-biotin GCA TAG AAC TGC CTG CGT CAG ATT CTC TTT TT Capture probe n/a 
Luciferase.R(everse) n/a GAG AAT CTG ACG CAG GCA GTT CTA TGC Capture probe n/a 
ITR(-)sense.F(orward) n/a GCA GGA ACC CCT AGT GAT GGA GTT GGC Capture probe n/a 
ITR(-)sense..R(everse) 3’-biotin GCC AAC TCC ATC ACT AGG GGT TCC TGC TTT TT Capture probe n/a 
E2A(-)sense.F(orward) n/a CGA GAA GGA GGA CAG CCT AAC CGC CCC Capture probe n/a 
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E2A(-)sense.R(everse) 3’-biotin GGG GCG GTT AGG CT GTC CTC CTT CTC GTT TTT Capture probe n/a 
rep(+)sense.F(orward) 3’-biotin GCG CAG CCG CCA TGC CGG GGT TTT ACG TTT TT Capture probe n/a 
rep(+)sense.R(everse) n/a CGT AAA ACC CCG GCA TGG CGG CTG CGC Capture probe n/a 
Underlined nucleotides refer to YB1 binding motifs (GGGGTT or CCTCCT). n/a, not applicable; PCR, polymerase chain reaction; Ta, 
annealing temperature. 
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2.1.3 Chemically competent bacteria – strains 
α-Select Silver Efficiency Chemically Competent Cells, E. coli (Bioline); genotype: F- deoR endA1 
recA1 relA1 gyrA96 hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA argF)U169 ф80lacZΔM15λ- 
 
MAX Efficiency™ DH10Bac™ Competent Cells, E. coli (Gibco); genotype: F-mcrA Δ(mrr-hsdRMS-
mcrBC) ф80lacZΔM15 ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ-rpsL 
nupG/pMON14272/pMON7124 
 
One Shot™ TOP10™, Chemically Competent, E. coli (Invitrogen); genotype: F- mcrA Δ(mmr-
hsdRMS-mcrBC) ф80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu) 7697 galU rpsL (StrR) endA1 
nupGλ- 
 
2.1.4 Antibodies 
Primary antibodies are listed in Table 2.7. Secondary antibodies are listed in Table 2.8. The 
applications in which antibodies were used and the corresponding dilution factors are also 
described. 
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Table 2.7 List of primary antibodies 
primary 
antibody 
listed 
name 
antigen immunogen raised in clonality manufacturer application (dilultion) 
A20 A20 
AAV2 intact 
capsid 
unspecified Ms mAb Progen ICC (1:20) 
αCRISPR-
Cas9 
7A9-3A3 Cas9 unspecified Ms mAb Abcam WB (5μg/mL) 
αGAPDH CB1001 GAPDH unspecified Ms mAb Calbiochem WB (1:1250) 
αYB1 ab114999 YB1 
synthetic peptide corresponding to 
224-274aa of human YB1 (NP_004550) 
Rb pAb Abcam 
WB (1:2000) 
ICC (1:500) 
αYB1 ab76149 YB1 unspecified Rb pAb Abcam 
WB (1:10,000) 
ICC (1:500) 
αYB1 
PA5-
19453 
YB1 
synthetic peptide corresponding to 1-
100aa of human YB1 (NP_004550) 
Rb pAb 
Thermo Fisher 
Scientific 
WB (1.4μg/mL) 
ICC (1:500) 
αSOX13 ab96776 SOX13 
synthetic peptide corresponding to 
75-490aa of human SOX13 
(NP_005677) 
Rb pAb Abcam WB (1:1000) 
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αPANK4  ab137243 PANK4 
synthetic peptide corresponding to 
50-100aa of human pank4 
(NP_060686.1) 
Rb pAb Abcam WB (1:2000) 
αSDF4 ab113413 SDF4 
synthetic peptide corresponding to 
161-175aa of human SDF4 
(NP_057631.1; NP_057260.2) 
Gt pAb Abcam WB (0.5μg/mL) 
αSfYB n/a rSfYB(His)10 
whole protein, 10xHis-tagged 
recombinant SfYB 
Rb pAb Covalab 
Dot blot (as indicated) 
WB (1:32,000) 
ICC (1:32,000) 
αRep 
10R-
A140A 
AAV2 Rep 
171aa N-terminally truncated AAV2 
Rep78 
Ms mAb Fitzgerald 
WB (1:50) 
ICC (1:50) 
αCap B1 AAV2 Vp1-3 unspecified Ms mAb Progen ICC (1:100) 
αCap VP51 AAV2 Vp1-3 unspecified Rb pAb Progen WB (1:200) 
α6His-
HRP 
ab1187 Hexa-His tag 
synthetic peptide corresponding to six 
histadine  
Rb pAb Abcam 
Dot blot (as indicated) 
WB (1:5000) 
FC (1:500) 
FC, flow cytometry; Gt, Goat; ICC, immunocytochemistry; mAb, monoclonal; Ms, mouse; n/a, not applicable; pAb, polyclonal; Rb, rabbit; WB, western 
blotting.
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Table 2.8 List of secondary antibodies    
secondary 
antibody 
conjugate raised in manufacturer 
Application 
(dilution) 
αMouse IgG (H+L) HRP Sh Sigma-Aldrich WB (1:2000) 
αRabbit IgG (H+L) HRP Gt Sigma-Aldrich WB (1:2000) 
αGoat IgG (H+L) HRP Rb Dako WB (1:2000) 
αRabbit IgG (H+L) Alexa Fluor 647 Gt Thermo Fisher Scientific FC (1:500) 
αMouse IgG (H+L) DyLight 633 Gt Thermo Fisher Scientific ICC (1:500) 
αRabbit IgG (H+L) Alexa Fluor 547 Gt Thermo Fisher Scientific ICC (1:500) 
αRabbit IgG (H+L) Alexa Fluor 488 Gt Thermo Fisher Scientific 
ICC (1:500) 
FC (1:500) 
FC, flow cytometry; Gt, goat; HRP, horse radish peroxidase; ICC, immunocytochemistry; Rb, 
rabbit; Sh, sheep; WB, western blotting. 
 
2.1.5 Eukaryotic cell lines 
Mammalian and insect cell lines used are detailed in Table 2.9. 
 
 Table 2.9 List and details of cell lines. 
cell line 
organism 
(origin) 
organ 
origin 
characteristics Supplier 
293T H. sapiens kidney 
Derived from 293 cells that were 
transformed by introducing sheared 
Adenovirus 5 DNA containing the E1 
gene (Graham et al., 1977), and further 
transformed by transfection of 293 cells 
with plasmid encoding temperature-
sensitive mutant of SV40 large T antigen 
and neomycin resistance (DuBridge et al., 
1987). 
Stratagene 
Ao38 T. ni ovaries 
Derived from single cell cloning by serial 
dilution in 96-well plates of primary 
culture of ovarian tissue harvested from 
T. ni (Hashimoto et al., 2010; Hashimoto 
et al., 2012). 
A kind gift 
from Prof. 
Ian Jones, 
University 
of Reading 
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Sf9 
S. 
frugiperda 
ovaries 
Sf9 cell line was cloned from the parent 
line, IPLB-SF21-AE (Sf21), which was 
derived from pupal ovarian tissue of S. 
frugiperda by Vaughn et al. (1977). 
Invitrogen 
Sf-9ET 
S. 
frugiperda 
ovaries 
 Derived from Sf9 cell line, transfected 
with plasmid encoding EGFP gene under 
promoter control of polh, and neomycin 
resistance gene for selection (Hopkins 
and Esposito, 2009). 
A kind gift 
from Prof. 
Ian Jones, 
University 
of Reading 
Sf9-
disrupted 
S. 
frugiperda 
ovaries 
Derived from Sf9 cells, genome 
engineered for targeted knockout of SfYB 
protein expression. 
This study 
YB1 
knockout 
H. sapiens kidney 
Derived from 293T cells, genome 
engineered for targeted knockout of YB1 
protein expression. 
This study 
 
2.2.0 Methods 
2.2.1 Molecular cloning 
2.2.1.1 Designing single guide (sg)RNAs for CRISPR/Cas9 
CRISPR/Cas9 sgRNA designs against human YBX1 were designed using the online CHOPCHOP 
tool (http://chopchop.cbu.uib.no/) (Montague et al., 2014), and four separate sgRNAs 
targeting exon 1, 5, 7, and intron 6 were selected. CRISPR/Cas9 sgRNA designs specific against 
exons 1-3 of the putatively identified Spodoptera frugiperda Y-Box protein homologue gene, 
after construction of its gene structure (see section 2.2.2.8), were designed manually, instead. 
Generally, sgRNA designs were 20nt in length and directly upstream of the 5’-NGG-3’ PAM 
sequence on the target DNA strand, to facilitate Cas9 recognition and endonuclease activity 
3nt upstream of the PAM (Anders et al., 2014). The CHOPCHOP online tool additionally 
provides efficiency scores of sgRNA designs that are normalised between 0-1, of which 
algorithm takes into factor potential off-target sites as a result of 1, 2, or 3 mismatches, and 
the identification of a guanine residue at sgRNA position 20, just upstream of the PAM 
(Doench et al., 2014; Xu et al., 2015; Doench et al., 2016). The sgRNAs were ordered as ssDNA 
oligos corresponsdoing to that target, PAM-containing sequence (forward oligo) and the 
complementary sequence (reverse oligo), with the appropriate 5’-overhangs for direct cloning 
into the GeneArt™ linearised, all-in-one CRISPR nuclease vector (forward oligo: 5’-GTTTT-3’, 
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and reverse oligo: 5’-CGGTG-3’), or for assembly PCR and in vitro transcription (IVT) (forward 
oligo: 5’-T7 promoter sequence, and reverse oligo: 5’-crRNA sequence). See Tables 2.3-5 for 
sgRNA designs. 
 
2.2.1.2 Standard polymerase chain reaction (PCR) 
Standard PCRs were used to amplify DNA sequences of interest. Therefore, in order to 
perform PCRs, forward (corresponding to the sequence in the sense strand) and reverse 
(corresponding to the sequence in the anti-sense strand) oligos were designed and ordered). 
In the case of PCR amplification of sequences intended for cloning, forward and reverse oligos 
would additionally contain the appropriate sequences required for restriction enzyme 
digestion plus buffer DNA bases on their 5’-ends. 
 
PCRs were generally performed as 50μL reactions, and comprised of the following at their final 
concentrations: 1X Master Mix (Promega) constituting 25U/mL Taq polymerase, 200μM of 
each dNTP (dATP, dGTP, dCTP, and dTTP), and 1.5mM MgCl2., forward and reverse oligos at 
0.5μM each, and 50ng of genomic DNA or 10ng of plasmid DNA as template, made to 50μL 
with nuclease-free H2O. Non-template control PCR reactions were prepared in parallel with 
template DNA substituted for nuclease-free H2O. PCRs were performed on a Biorad PTC-200 
DNA Engine Thermal Cycler with the programmed thermocycling conditions: 95°C initial 
denaturation for 2mins, followed by 34 cycles of denaturing at 95°C (unless stated otherwise) 
for 1min, annealing at a suitable temperature (dependent on the oligo pairs) for 30secs, with 
an extension step at 72°C for 1min/kb of DNA to be amplified. A final extension step at 72°C 
for 5mins followed, and reactions were stored at 4°C. 
 
2.2.1.3 Colony PCR 
Colony PCR was performed to screen transformed bacteria for correct cloning of inserts using 
REDTaq® ReadyMix PCR Reaction Mix (Sigma-Aldrich). Colony PCRs were set up as 25μL 
reactions, comprising of the following at their final concentrations: 1X REDTaq® ReadyMix PCR 
Reaction Mix, constituting 30U/mL Taq polymerase, 200μM of each dNTP (dATP, dGTP, dCTP, 
and dTTP), 10mM Tris-HCl, 50mM KCl, 3mM MgCl2, 0.001% gelatin, stabilisers, forward and 
reverse oligos at 0.4μM each, mixed with a picked transformed bacteria colony (using sterile 
pipette tip), made to 25μL with nuclease-free H2O. Non-template control reactions were also 
run in parallel, and involved the aforementioned setup without adding transformed bacteria 
colony. PCR reactions were performed on a Biorad PTC-200 DNA Engine Thermal Cycler, with 
programmed thermocycling conditions: 94°C initial denaturation for 2mins, followed by 34 
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cycles of denaturation at 94°C for 1min, annealing of oligos at 55°C for 2mins, and extension at 
72°C for 3mins. Final extension at 72°C for 5mins followed, after which, reactions were held or 
stored at 4°C. 
 
2.2.1.4 High-fidelity PCR 
High-fidelity PCR was utilised to PCR amplify target sequences with high fidelity and accuracy 
for cloning. High-fidelity PCR was performed using Q5® Hot Start High-Fidelity 2X Master Mix 
(NEB). Reactions were set up by mixing 10ng of plasmid template with Q5® Hot Start High-
Fidelity 2X Master Mix made to a final 1X concentration, constituting 200μM of each dNTP 
(dATP, dGTP, dCTP, and dTTP), 2mM MgCl2, and final concentration of 0.5μM of each forward 
and reverse oligo, made to 50μL using nuclease-free H2O. Thermocycling conditions were 
programmed on a Biorad PTC-200 DNA Engine Thermal Cycler: initial denaturation at 98°C for 
10mins; followed by 34 cycles of denaturation at 98°C for 1min, annealing step for 1min at the 
optimal annealing temperature (depending on the oligo pairs), extension at 72°C for 1min; and 
a final extension step at 72°C for 2mins. Reactions were then stored at 4°C. 
 
2.2.1.5 Assembly PCR 
Assembly PCR was utilised to produce the gRNA DNA template for in vitro transcription (IVT). 
Assembly PCR functioned to assemble the target-specific forward and reverse assembly 
oligonucleotides (see Table 2.5 for IVT oligo pairs) with Tracr fragment plus universal T7 primer 
mix as per GeneArt™ Precision gRNA Synthesis Kit (Invitrogen). IVT-designated forward and 
reverse oligos included the required 5’-T7 or crRNA sequences, respectively, as per 
manufacturer’s guidelines (Invitrogen). Firstly, 0.3μM oligo mix working solution was prepared 
by taking 3μL of each 10μM oligo stock for each oligo pair, and diluting in 94μL of nuclease-
free H2O. This was then briefly vortexed and spun down. 1μL of this 0.3μM mix was used to set 
up PCR reactions constituting Phusion™ High-Fidelity PCR Master Mix (final 1X concentration), 
1μL of Tracr Fragment+T7 Primer Mix, made to 25μL using nuclease-free H2O. Non-template 
control reaction was included, which included the exclusion of the Tracr Fragment+T7 Primer 
Mix template, with nuclease-free H2O substituted instead. PCR thermocycling conditions 
followed manufacturer’s guidelines, and was programmed using a Biorad PTC-200 DNA Engine 
Thermal Cycler: initial denaturation at 98°C for 10secs; followed by 32 cycles of denaturation 
at 98°C for 5secs, annealing at 55°C for 15secs; and a final extension at 72°C for 1min. 
Reactions were held at 4°C and 5μL samples mixed with 6X DNA Loading Dye (Thermo Fisher 
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Scientific) for subsequent 2% TBE agarose gel electrophoresis to determine PCR assembly 
reactions.  
 
2.2.1.6 In vitro transcription (IVT) 
Assembly PCR products were then subjected to IVT as per GeneArt™ Precision gRNA Synthesis 
Kit (Invitrogen) to generate the sgRNA for CRISPR/Cas9 genome editing applications. 6μL of 
the gRNA DNA template (generated by assembly PCR) was mixed with 2μL of TranscriptAid™ 
Enzyme Mix and NTP mix (ATP, CTP, GTP, and UTP) for a final 40mM concentration, 5X 
TranscriptAid™ Reaction Buffer made to 1X, to a final volume of 20μL. The IVT reaction was 
incubated at 37°C for 3h. This was followed by the addition of 1U DNase I (Invitrogen) and 
incubated at 37°C for 15mins to degrade the DNA template. The sgRNA was then purified by 
adjusting the volumes of IVT reactions to 200μL in nuclease-free H2O, followed by the addition 
of 100μL of IVT Binding Buffer (composition – propriety information) and 300μL of 100% 
ethanol. Mixtures were mixed by pipetting and then transferred to GenJET™ RNA Purification 
Micro Columns and centrifuged at 13,000rpm for 1min. The flow-through was discarded and 
the column washed with 700μL of Wash Buffer 1 (composition – proprietary information; 
diluted with 13mL 100% ethanol prior to use) and centrifuged at 13,000rpm for 1min. The 
flow-through was discarded and the column washed twice with 700μL of Wash Buffer 2 
(composition – propriety information; diluted with 30mL 100% ethanol prior to use) and 
centrifuged at 13,000rpm for 1min. The flow-through was discarded and the column 
centrifuged at 13,000rpm for 1min to remove the residual Wash Buffer 2. The column was 
then transferred to a clean 1.5mL Collection Tube, and 20μL of nuclease-free H2O was added 
to the centre of the column. This was followed by centrifugation at 13,000rpm for 1min to 
elute the sgRNA. The sgRNA was quantified by Qubit™ 3.0 Fluorometer (Thermo Fisher 
Scientific) and Qubit™ RNA BR Assay Kit (Invitrogen) and stored at -20°C. IVT prep quality was 
determined by mixing 0.5μL of IVT reaction or purified product in 10μL of DEPC-treated H2O 
(Sigma-Aldrich), and mixed with 6X DNA Loading Dye. Samples were heated at 70°C for 
10mins, and then chilled on ice prior to 2% TBE agarose gel electrophoresis. 
 
2.2.1.7 Restriction enzyme digests 
For analytical restriction enzyme digestions, 1μg of plasmid was digested with 5U of enzyme/s 
as 20μL or 50μL reactions for NEB- or Promega- based reactions, respectively. Digestions were 
performed in final 1X concentration of suitable buffer that was supplied by the manufacturer, 
and made to the corresponding volumes in ultra-pure H2O. For the purpose of generating 
cloning fragments, 30U of restriction enzyme(s) was used to digest 8μg of plasmid DNA. 
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Reactions were performed as 100μL reactions in the appropriate buffer supplied by the 
manufacturer, made to 1X using ultra-pure H2O. For reactions with two restriction enzymes, a 
compatible buffer shared by both enzymes (as indicated by the manufacturer) was used. 
Where appropriate, undigested plasmid control(s) were included and involved omission of the 
restriction enzyme(s) to reaction mixes, with ultra-pure H2O substituted instead. Restriction 
enzyme digestions were performed at the indicated temperature (as indicated by the 
manufacturer) for the given restriction enzyme(s) used – typically 37°C for 1h (3h for cloning 
fragments). Restriction enzyme digests were then heat-inactivated at the required 
temperature and incubation time as indicated by the manufacturer. After which, digestion 
reactions intended for the isolation of DNA fragments were subjected to dephosphorylation of 
DNA ends (where indicated), and/or 1% TAE agarose gel electrophoresis for gel extraction.  
 
2.2.1.8 Annealing complementary pairs of oligos 
Annealing of complementary pairs of oligos was performed by mixing 50μL of complementary 
pairs of oligos (100μM stock) together. The mixture was then heated to 95°C for 5mins to 
denature oligos. Following which, the oligo mix was allowed to cool down slowly to room 
temperature (RT) for approximately 2h. However, DNA oligo pairs that corresponded to gRNA 
designs (listed in Tables 2.3 and 2.4) were annealed following the GeneAart® CRISPR Nuclease 
Vector Kit (Invitrogen) instructions. 200μM oligo stock solutions were prepared using 
nuclease-free H2O. 5μL of each 200μM oligo pair were mixed together in a final 1X 
Oligonucleotide Annealing Buffer (10X: 100mM Tris-HCl [pH 8.0], 10mM EDTA [pH 8.0], 1M 
NaCl), made up to 20μL with nuclease-free H2O. The mixture was briefly spun down and 5μL 
was transferred to a clean Eppendorf tube, followed by incubation at 95°C for 4mins. 
Denatured oligos were cooled to RT for 10mins, and then briefly spun down. Annealed oligos 
was then diluted 1:100 in nuclease-free H2O to 500nM stock solution, which was briefly 
vortexed and spun down. 5nM working solution was then prepared by diluting 500nM stock 
solution 1:100 in a final 1X Oligonucleotide Annealing Buffer, made to 100μL with nuclease-
free H2O. The working stock was briefly vortexed and then spun down. 5nM stock was 
immediately used to ligate into GeneArt™ linearised, all-in-one, CRISPR nuclease vector 
(Invitrogen).  
 
Alternatively, 3’-biotin labelled DNA capture probes were annealed by mixing 5μL of each 
10μM oligo pairs (Table 2.6) to a final volume of 100μL in Binding Buffer A (25mM HEPES [pH 
7.5], 100mM KCl, 12.5mM MgCl2, 1mM DTT, 0.1% IGEPAL-CA630 [v/v], 20% glycerol [v/v], 3% 
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BSA). The cold competitor DNA probe was prepared separately for each intended ratio of 
hot:cold DNA capture probe ratio, by scaling up or down the volume of 10μM oligo pairs made 
to a final volume of 100μL of Binding Buffer A. Mixtures were then subjected to 55°C for 
10mins, followed by cooling to RT for approximately 10mins, and then kept on ice. 
 
2.2.1.9 Dephosphorylating 5’-ends of DNA 
To prevent re-linearisation of single restriction enzyme digested plasmids and improve cloning 
efficiencies, dephosphorylation of 5’-ends of restriction enzyme digested DNA was performed 
where indicated. Therefore, recombinant Shrimp Alkaline Phosphatase (rSAP; NEB) was added 
after heat-inactivation of restriction enzyme(s) at 1U/pmol of DNA ends. Dephosporylation 
reactions were performed at 37°C for 1h, followed by heat-inactivation at 65°C for 10mins. 
Restriction enzyme digested and dephosphorylated DNA was then subjected to 1% TAE 
agarose gel electrophoresis for gel extraction. 
 
2.2.1.10 Blunting DNA ends by Klenow Fragment 
DNA ends were blunted using Klenow Fragment (NEB), which removes 3’-overhangs or fill in 
5’-overhangs. Approximately 1μg of restriction enzyme-digested DNA was mixed in Cutsmart 
buffer (NEB) to a final 1X concentration, 1U of Klenow Fragment, and supplemented with final 
concentration of 33μM dNTP mix (Promega) to a final volume of 50μL using nuclease-free H2O. 
This was followed by incubation at RT for 15mins. The Klenow Fragment was then inactivated 
by the addition of 500mM EDTA (pH 8.0) solution to a final 10mM concentration, and heat-
inactivated at 75°C for 20mins. Blunted DNA fragments were stored at -20°C. 
 
2.2.1.11 Phosphorylating DNA ends 
Phosphorylation of DNA 5’-ends was performed using T4 PNK (NEB) for subsequent ligation 
reactions. 300pmol of 5’-ends was calculated for DNA plasmid required for phosphorylation. 
This was mixed into T4 DNA Ligase Buffer (NEB) to a final 1X (10X: 500mM Tris-HCl, 100mM 
MgCl2, 10mM ATP, 100mM DTT, pH 7.5) and 10U of T4 PNK. Phosphorylation reactions were 
incubated at 37°C for 30mins, and then heat-inactivated at 65°C for 20mins. Phosphorylated 
DNA fragments were stored at -20°C. 
 
2.2.1.12 Agarose gel electrophoresis 
DNA PCR products and fragments or RNA products were subjected to agarose gel 
electrophoresis to separate DNA or RNA molecules relative to their size. Agarose powder 
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(Sigma-Aldrich) was dissolved in 1X TAE (50X: 2M Tris-base, 0.95M acetic acid, 50mM EDTA; 
diluted 1:50 in ultra-pure H2O), or 1X TBE Buffer (10X: 0.9M Tris, 0.9M boric acid, 25mM EDTA; 
diluted 1:10 in ultra-pure H2O), to make final 1% or 2% concentration of agarose, where 
indicated. 1% agarose gels were generally used for the separation of DNA fragments required 
for cloning and screening. 2% agarose gels were prepared for small DNA or RNA products. The 
agarose mixture was dissolved by boiling using a microwave. The mixture was briefly cooled to 
allow addition of the SYBR™ Safe DNA Gel Stain (Invitrogen) at 1:10,000 dilution and mixed by 
swirling. The mixture was then poured into a gel tray with a gel comb to generate the gel’s 
sample wells. The gel was then allowed to set at RT, and then transferred to an 
electrophoresis tank (Bio-rad) and completely immersed in 1X TAE or 1X TBE Buffer for the 
corresponding gels. Nucleic acid samples were mixed with 6X DNA Loading and loaded into 
submerged wells with a pre-stained DNA ladder(s) in parallel. Pre-stained DNA ladders 
included 100bp DNA Ladder (NEB) or GeneRuler 1kb DNA Ladder (Thermo Fisher Scientific), 
and functioned as reference markers for DNA resolution through an agarose gel for 
approximate DNA sizing. Gels were run at 80-120V for a suitable length of time (typically up to 
1h) to allow for the required separation. DNA fragments required for cloning, however, were 
run for 3h using a large electrophoresis apparatus. Resolved DNA/RNA molecules designated 
for screening were visualised and imaged using a UV trans-illuminator (BioDoc-It™ Imaging 
System; UVP), whereas, DNA fragments required for cloning were excised from gels visualised 
by a Safe Imager™ 2.0 Blue Light Trans-illuminator (Thermo Fisher Scientific). 
 
2.2.1.13 Gel extraction and purification of DNA fragments 
DNA fragments were extracted and purified by first resolving DNA fragments by 1% TAE 
agarose gel electrophoresis. Excised DNA within agarose gel slices were purified using either 
MinElute Gel Extraction Kit (Qiagen) or QIAquick Gel Extraction Kit (Qiagen). Mainly, the 
QIAquick Gel Extraction Kit was used for gel purification of DNA unless otherwise stated. 
Excised DNA fragment in gel slice was incubated in three volumes of Buffer QG (solubilisation 
buffer, composition – proprietary information) to one volume of gel, at 50°C until gel slice had 
completely solubilised, with intermittent vortexing. Following which, one gel volume of RT 
isopropanol was added and mixed. Mixtures were then transferred to a QIAquick column or 
MinElute column, for QIAquick Gel Extraction Kit and MinElute Gel Extraction Kit, respectively. 
Samples were then centrifuged for 1min at 13,000rpm. The flow-through was discarded, and 
columns were washed by the addition of 750μL of Buffer PE (10mM Tris-HCl pH 7.5, 80% 
ethanol), and centrifuged for 1min at 13,000rpm. The flow-through was discarded and column 
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centrifuged again at 13,000rpm for 1min to remove residual ethanol. The column was then 
placed in a clean Eppendorf tube and 10μL or 50μL of nuclease-free H2O (for QIAquick Gel 
Extraction Kit and MinElute Gel Extraction Kit, respectively) was added to the column 
membrane, and left to stand at RT for 1min. DNA was eluted by centrifuging columns for 1min 
at 13,000rpm. Extracted DNA fragments were stored at -20°C. 
 
2.2.1.14 Purification of DNA fragments 
PCR purification of DNA products using QIAquick PCR Purification Kit (Qiagen) was performed 
where gel purification was not recommended. This involved adding five times volume of Buffer 
PB (composition – proprietary information) followed by the addition of 10μL of 3M Sodium 
acetate (pH 5.0) to the PCR sample. The DNA sample was then loaded into a QIAquick column 
to bind DNA to the resin by centrifuging columns for 1min at 13,000rpm, with flow-through 
discarded. The column was then washed with 750μL of PE Buffer and centrifuged for 1min at 
13,000rpm, and flow-through discarded. Residual PE Buffer was removed by an additional spin 
at 13,000rpm for 1min, and flow-through discarded. The column was then transferred to a 
clean Eppendorf tube and 50μL of nuclease-free H2O was applied to the membrane and left to 
stand for 1min, RT. The DNA was finally eluted by centrifuging columns for 1min at 13,000rpm. 
Purified DNA was stored at -20°C. 
 
2.2.1.15 DNA ligations 
DNA ligations were prepared as 20μL reactions, and were performed using T4 DNA Ligase (NEB 
or Invitrogen, where indicated). Purified vector DNA and restriction enzyme digested DNA 
fragments were mixed at 3:1 molar ratio of insert to vector. Reaction volumes were made to 
20μL with nuclease-free H2O and a final 1X concentration of T4 DNA Ligase Buffer (NEB) and 
1U of T4 DNA Ligase (NEB). Reactions were performed at 4°C overnight. Ligations between 2μL 
of annealed gRNA DNA (5nM) and 2μL of pre-linearised GeneArt™ CRISPR nuclease vector was 
performed using 1U of T4 DNA Ligase (Invitrogen), with final concentration of 1X Ligation 
Buffer (5X: 250mM Tris-HCl [pH7.6], 50mM MgCl2, 5mM ATP, 5mM DTT, 25% w/v 
polyethylene glycon-8000), made to 20μL with nuclease-free H2O. Reactions were performed 
at RT for 10mins. 
 
2.2.1.16 Cloning by In-Fusion® 
Cloning by In-Fusion® was performed using the In-Fusion® HD Cloning Kit (Clontech). This 
involved the directional cloning of a PCR amplicon into the desired vector backbone using the 
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In-Fusion® enzyme that catalyses the recombination between homology arms that are present 
at both ends of cloning insert and linearised vector backbone. The desired cloning insert was 
PCR amplified using In-Fusion® designated oligos (Table 2.2), followed by gel purification. The 
resultant PCR amplicon contained the homology arms (denoted in Table 2.2 for the relevant 
primers) complementary to homology arms present in intended, pre-linearised cloning vector. 
100ng of purified cloning insert was mixed with 100ng of linearised cloning vector in a final 1X 
In-Fusion® HD Enzyme Premix (5X: composition – propriety information), made to 10μL using 
nuclease-free H2O. The In-Fusion® reaction was incubated at 50°C for 15mins, and then placed 
on ice to terminate the reaction. 
 
2.2.1.17 Culture and maintenance of bacteria stocks 
Cultivation of transformed bacteria requires positive selection screening using antibiotics, 
given plasmids typically harbour an antibiotic resistance gene(s). Therefore, ampicillin (1000X) 
stocks were prepared by dissolving ampicillin sodium salt (Sigma-Aldrich) in ultra-pure H2O for 
100mg/mL concentration. Kanamycin (1000X) was prepared by dissolving kanamycin sulphate 
(Sigma-Aldrich) into ultra-pure H20 to make 50mg/mL. Tetracycline (1000X) was prepared by 
dissolving tetracycline hydrochloride (Sigma-Aldrich) in 100% ethanol to make 10mg/mL. 
Lastly, gentamicin was provided as a 50mg/mL solution (Gibco). Ampicillin, kanamycin and 
tetracycline stock solutions were all filtered using 0.22μm filters, and stored at -20°C as 1mL 
aliquots. 
 
Transformed bacteria were cultivated to amplify plasmid DNA, and performed as liquid 
cultures using Luria Broth (LB) composed of 1% tryptone (Oxoid), 0.5% yeast extract (Oxoid), 
0.8% NaCl, pH 7.0. LB agar plates were used for solid phase growth, and involved preparing LB 
medium as above with the addition of agar powder (Sigma-Aldrich) for a final 1.5% 
concentration (w/v). Both LB and LB agar mixtures were autoclaved at 122°C. Appropriate 
antibiotic(s) was added to LB medium for 50μg/mL concentration of ampicillin (1:2000 
dilution). However, transformed DH10Bac™ cells were cultivated in LB medium supplemented 
with kanamycin (final 50μg/mL; 1:1000 dilution), gentamicin (final 7μg/mL; 1:7142 dilution), 
and tetracycline (final 10μg/mL; 1:1000 dilution). To prepare LB agar plates, solid LB agar was 
melted and allowed to cool to approximately 55°C to add antibiotic(s) to the appropriate 
concentration - 100μg/mL ampicillin, or 50μg/mL kanamycin, 7μg/mL gentamicin, and 
10μg/mL tetracycline. After which, liquid LB agar with antibiotics was then poured into 
Sterilin™ 10cm petri-dishes until solidified. 
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Stocks of transformed bacteria were stored as glycerol stocks, which involved cultivating 
transformed bacteria as liquid cultures overnight at 37°C, 200rpm. Glycerol stocks were then 
prepared by mixing bacteria culture with autoclaved 50% glycerol (v/v), to make 20% glycerol 
stocks. Bacteria glycerol stocks were then immediately stored as 1mL aliquots at -80°C. 
 
2.2.1.18 Transformations 
Transformation of chemically competent E. coli cells with plasmid DNA was performed to 
generate bacteria that could cultivate plasmid DNA for amplification. Generally, plasmids or 
ligation reactions were transformed into α-Select Chemically Competent Cells (Bioline). The α-
Select Chemically Competent Cells were removed from -80°C storage and thawed slowly on 
ice, after which, cells were transferred to pre-chilled tubes as 50μL aliquots. 5μL of ligation 
reaction or approximately 100ng of plasmid DNA was transformed into 50μL of α-Select 
Chemically Competent Cells, followed by flicking to mix and 30mins incubation on ice. Cells 
were then subjected to heat-shock at 42°C for 45secs. Tubes were returned to ice for 2mins, 
followed by dilution of the transformation reaction with 950μL of S.O.C. Medium (Invitrogen). 
OneShot™ TOP10™ Chemically Competent E. coli (Invitrogen) was used for transformation of 
GeneArt™ CRISPR nuclease ligation reactions. Transfomation of TOP10™ E. coli was performed 
similarly as described for α-Select Chemically Competent Cells, except 3μL of GeneArt™ CRISPR 
nuclease ligation reaction was used. In both cases, diluted transformation reactions were 
incubated for 1h at 37°C, 200rpm, after which, 100μL transformation reaction was spread on 
LB agar plates, supplemented with 100μg/mL ampicillin. Plates were incubated overnight at 
37°C for the growth of bacterial colonies and positive transformants.    
 
MAX Efficiency™ DH10Bac™ Competent Cells were used to transform pFastBac constructs.  
DH10Bac™ Competent Cells were removed from -80°C storage and thawed on ice. Cells were 
then transferred into pre-chilled 15mL falcon tubes, and 1ng of pFastBac plasmid was added 
and mixed by pipetting up and down. Mixtures were then incubated on ice for 30mins, 
followed by heat-shock at 42°C for 45secs. Transformation reactions were then returned to ice 
for 2mins, followed by the addition of 900μL S.O.C. Medium. Transformations were incubated 
at 37°C at 225rpm for 4h. Serial dilutions of transformation reactions were then prepared at 
10-1, 10-2 and 10-3 using S.O.C. Medium. LB agar plates containing 50μg/mL kanamycin, 7μg/mL 
gentamicin, 10μg/mL tetracycline were pre-warmed at 37°C, followed by the addition of 40μL 
of Blue-White Select™ Screening Reagent to LB agar plates and spread evenly. Plates and Blue-
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White Select™ Screening Reagent were allowed dry for 15mins at RT prior to the addition of 
100μL DH10Bac™ transformed cells. Plates were incubated for 48h at 37°C until white colonies 
formed. White colonies were re-streaked onto LB agar plates containing 50μg/mL kanamycin, 
7μg/mL gentamicin, 10μg/mL tetracycline, with 40μL of Blue-White Select™ Screening 
Reagent, and incubated for a further 24h at 37°C to isolate single white colonies with more 
confidence.  
 
2.2.1.19 Plasmid amplification and isolation – mini-preps 
5mL LB media (with appropriate antibiotic) was inoculated with approximately 10μL bacteria 
glycerol stock or a single colony of transformed bacteria. Inoculations were grown overnight at 
37°C, 200rpm. The following day, 5mL cultures were transferred to Eppendorf tubes by 
pelleting cells at 4000rpm for 1min. Plasmid DNA was then extracted using QIAprep Spin Mini-
prep Kit (Qiagen). Pelleted bacteria cells were resuspended in 250μL P1 Buffer (50mM Tris-HCl 
[pH 8.0], 10mM EDTA, 100μg/mL RNase A), followed by the addition of 250μL P2 Lysis Buffer 
(200mM NaOH, 1% SDS [w/v], including LyseBlue reagent – 1:1000 dilution), which was mixed 
by inversion six-times and incubated for up to 5mins. Lysis reactions were neutralised by the 
addition of 350μL N3 Buffer (4.2M Gu-HCl, 0.9M potassium acetate, pH 4.8) and mixed by 
inversion six-times. Samples were then centrifuged for 10mins at 13,000rpm and 
approximately 800μL plasmid DNA containing supernatant was transferred to QIAprep 2.0 spin 
columns to bind plasmid DNA. The supernatant was spun down for 1min at 13,000rpm and 
flow-through discarded. Columns were washed by the addition of 750μL Buffer PE and 
centrifuging for 1min at 13,000rpm. The flow-through was discarded, and residual wash buffer 
was removed by an additional centrifugation step. Columns were transferred to clean 
Eppendorf tubes, and DNA eluted by adding 50μL nuclease-free H2O. Columns were left to 
stand for 1min at RT, followed by centrifuging columns for 1min at 13,000rpm. Plasmid DNA 
was stored at -20°C. 
 
2.2.1.20 Plasmid amplification and isolation – maxi- and giga- preps 
5mL LB media (with appropriate antibiotic) was inoculated with approximately 10μL bacteria 
glycerol stock or a single colony of transformed bacteria. Inoculations were grown for 
approximately 8h at 37°C, 200rpm to generate a starter culture. Starter culture was then used 
to inoculate 200mL LB media (with appropriate antibiotic) and grown overnight at 37°C, 
200rpm. Plasmid DNA was then extracted using QIAfilter Plasmid Maxi Kit (Qiagen). Cultured 
bacteria cells were pelleted down by ultracentrifugation at 8000rpm for 15mins at 4°C. 
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Pelleted cells were resuspended in 10mL P1 Buffer, followed by the addition of 10mL P2 
Buffer, with vigorous inversions six-times. Lysis reactions were performed at RT for 5mins, and 
then neutralised by the addition of 10mL pre-chilled P3 Buffer (3M potassium acetate, pH 5.5) 
with vigorous inversions six-times. Neutralised reactions were immediately transferred to the 
barrel of the QIAfilter Cartridge, and incubated up-right for 10mins at RT. The QIAGEN-tip 500 
was then equilibrated using 10mL Buffer QBT (750mM NaCl, 50mM MOPS, pH 7.0, 15% 
isopropanol [v/v], 0.15% Triton™ X-100 [v/v]) until the solution flowed through completely. 
The cell lysate was filtered into the equilibrated QIAGEN-tip 500. The lysate was allowed to 
enter the resin to bind plasmid DNA by gravity flow, and the flow-through was discarded. The 
QIAGEN-tip 500 was washed twice with 30mL Buffer QC (750mM NaCl, 50mM MOPS, pH 7.0, 
15% isopropanol), and flow-through discarded. Plasmid DNA was eluted using 15mL Buffer QF 
(1.25M NaCl, 50mM Tris-HCl, pH 8.5, 15% isopropanol [v/v]) and collected in a clean tube. 
Plasmid DNA was then precipitated by mixing in 10.5mL RT isopropanol and centrifuged 
immediately at 12,000rpm for 30mins, 4°C. The supernatant was decanted and DNA pellet 
washed with 5mL RT 70% ethanol. The washed pellet was further centrifuged at 12,000rpm for 
10mins and supernatant decanted. The pellet was air-dried at RT for approximately 5mins, and 
DNA pellet finally dissolved in 500μL nuclease-free H2O. Alternatively, for larger quantities of 
plasmid the QIAfilter Plasmid Giga Kit (Qiagen) was used, and was performed similarly to 
QIAfilter Plasmid Maxi Kit. However, starter cultures and overnight bacteria cultures were 
scaled-up five-fold; bacteria pellet was resuspended and lysed in 125mL of P1, P2, and P3 
Buffers. Lysates were then transferred to a QIAfilter Mega-Giga Cartridge and left to incubate 
for 10mins, RT. This was followed by vacuum-filtering the lysate until most of the liquid had 
been pulled through. 50mL of Buffer FWB2 (1M potassium acetate, pH 5.0) was added to the 
remaining lysate and gently mixed, and then completely vacuum filtered. The QIAGEN-tip 1000 
was equilibriated with 75mL QBT Buffer, and after filtered lysate had completely run through 
the QIAGEN-tip 10000, the QIAGEN-tip was washed with a total of 600mL of Buffer QC. 
Plasmid DNA was eluted with 100mL of Buffer QF into a clean tube, followed by the addition 
of 70mL RT isopropanol to precipitate the DNA. The mixture was then centrifuged immediately 
at 12,000rpm for 30mins, 4°C. The supernatant was carefully decanted and DNA pellet was 
washed with 10mL of 70% ethanol, followed by centrifugation at 12,000rpm for 10mins, 4°C. 
The supernatant was carefully decanted and the DNA pellet air-dried for approximately 
10mins. The DNA pellet was then dissolved in 1mL of nuclease-free H2O, and stored at -20°C. 
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Harvesting bacmid DNA, however, involved the use of the Qiagen Plasmid Maxi Kit. 
Transformed DH10Bac™ colony or glycerol stock was inoculated in 4mL LB medium containing 
50μg/mL kanamycin, 7μg/mL gentamicin, and 10μg/mL tetracycline, and grown overnight at 
37°C, 250rpm to generate a starter culture. The overnight culture was then used to inoculate 
200mL of LB medium with appropriate antibiotics, and incubated overnight at 37°C, 250rpm. 
Bacmid was then harvested similarly as described for QIAfilter Plasmid Maxi Kit, however, 
neutralised lysis reactions were incubated on ice for 20mins. Lysates were not filtered, and use 
of the QIAGEN-tip 500 was omitted because the size of recombinant bacmid DNA is too large 
to bond efficiently to the QIAGEN-tip 500. Instead, the lysate was pelleted down at 16,000rpm 
for 15mins. The clarified supernatant was then mixed with 10.5mL RT isopropanol and bacmid 
DNA eluted as described QIAfilter Plasmid Maxi Kit. 
 
2.2.1.21 Measuring DNA concentrations 
DNA concentration of DNA fragments and plasmids were quantified using a Nanodrop™ 1000 
spectrophotometer (Thermo Fisher Scientific) after blank measurement with 1μL of the 
corresponding dissolvent. Next, 1μL of undiluted plasmid or eluted DNA fragment was applied 
to the lower measurement pedestal and the sampling arm was then brought down to bring 
the upper measurement pedestal in contact with the loaded sample. Spectral measurement 
was then initiated to estimate DNA concentration. This was achieved by measuring the 
sample’s absorbance at 260nm (A260), and assuming that 1 A260 unit corresponds to 
50μg/mL of dsDNA. DNA purity was assessed by the A260/A280 ratio, where a ratio of 
approximately 1.8-2.0 was considered pure DNA, in that the sample was relatively free from 
protein and RNA contaminants. 
 
2.2.1.22 Measuring RNA concentrations 
RNA concentrations were measured using a Qubit™ 3.0 Fluorometer (Thermo Fisher Scientific) 
and Qubit™ RNA BR Assay Kit (Invitrogen). RNA-specific fluorescent dyes bind to RNA species 
within a given sample, and the fluorescence emitted can be quantified, and made relative to 
calibrated samples of known concentration. RNA sample was first diluted 1:100 in nuclease-
free H2O. The Qubit™ RNA BR Reagent (composition – propriety information) was diluted 
1:200 in Qubit™ RNA BR Buffer (composition – propriety information) to make Qubit™ 
Working Solution. Sample preparation was then made in 0.5mL Qubit™ Assay Tubes 
(Invitrogen). 1μL of diluted RNA was mixed in 199μL of Working Solution and 10μL of standard 
was mixed in 190μL of Working Solution, each. Standards and samples were briefly vortexed 
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for 3secs, and incubated at RT for 2mins. Standards were then read by the Qubit™ 3.0 
Fluorometer to calibrate measurements, and concentrations of RNA samples were quantified. 
Final concentrations of RNA were adjusted to take into account the 1:100 dilution factor.  
 
2.2.1.23 Sanger sequencing 
Sanger sequencing was performed by Source Bioscience to confirm cloning and characterise 
genomic sequences of CRISPR/Cas9-genome edited cell lines. The following were prepared: 
plasmid DNA was provided at 100ng/μL concentration, PCR product was provided as 10ng (per 
100bp)/μL concentration, and, sequencing-designated oligos (Table 2.2) were provided at 
3.2pmol/μL concentration. All samples and primers were submitted to Source Bioscience in 
tube format (5μL of sample DNA or primer per sequencing reaction) using SpeedREAD™ 
service. Sequencing results were received online and analysed using BioEdit Sequence 
Alignment editor. 
 
2.2.1.24 Plasmid constructs 
Plasmid constructs that were generated by cloning and used in this thesis are presented 
below. The cloning strategy employed for the construction of particular plasmids is also 
described.  
 
CRISPR constructs 
CRISPR constructs includes the GeneArt™ linearised, all-in-one CRISPR nuclease vector 
(Invitrogen), pCRISPR-YBX1sgRNA1-4, and pCRISPR-SFYBsgRNAsf1-3 constructs. The pCRISPR 
constructs were generated by direct cloning of 5nM sgRNA DNA designs (see section 2.2.1.1 
for details on sgRNA designs) after annealing oligo pairs listed in Tables 2.3 and 2.4 together, 
as per section 2.2.1.7. This allowed for 3’-overhangs to be established (forward oligo: 5’-
GTTTT-3’, and reverse oligo: 5’-CGGTG-3’), which are compatible with the 3’-overhangs 
present in the GeneArt™ linearised, all-in-one CRISPR nuclease vector, and resulted in gRNA 
expression under U6 promoter control. CRISPR constructs also harboured the CMV-promoter 
driven SpCas9-2A-OFP expression cassette. CRISPR constructs were verified by sequencing 
using the U6.F(orward) oligo (Table 2.2). 
 
AAV plasmids 
Plasmids utilised for rAAV2 vector production in mammalian cell lines included pAAV2-hrGFP 
(Stratagene), pAAV2/2-RC (Stratagene), pHelper (Stratagene), pAAV2-MCS (Stratagene), and 
pAAV2-FLuc. Plasmid pAAV2-hrGFP transfer vector includes the hrGFP transgene under CMV 
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promoter control, and a β-globin intron, flanked by AAV2 ITRs. Plasmid pAAV2/2-RC harbours 
the AAV2 rep and cap genes required for rAAV2 vector genome replication and packaging. 
Plamsid pHelper harbours the Advenovirus type 5 helper functions required in trans for rAAV 
vector production: E2A, VA RNAs, and E4orf6. Plasmid pAAV2-MCS is a expression vector, of 
which multiple cloning site is under CMV promoter control and β-globin intron, and flanked by 
AAV2 ITRs. Plasmid pAAV2-FLuc was generated by sub-cloning of the Firefly luciferase coding 
sequence (FLuc) from pJET1.2-FLuc (a kind gift from Kam Zaki, Univesirty College of London) as 
a BamHI-HindIII fragment. Firstly, pJET1.2-FLuc was double restriction enzyme digested with 
BamHI (NEB) and NotI (NEB) followed by gel purification. Next a NotI-HindIII adapter molecule 
was generated by annealing 5’-GCTGCGGCCGCAGTCGACCTGCAGAAGCTTGCCT-3’ and 5’-
AGGCAAGCTTCTGCAGGTCGACTGCGGCCGCAGC-3’ oligos together, and double restricition 
enzyme digested with NotI and HindIII (NEB), followed by PCR purification. The adapter 
molecule and purified BamHI-NotI FLuc fragment were then ligated using T4 DNA Ligase and 
then PCR purified. Finally the pAAV2-MCS expression vector was double digested with BamHI 
(Promega) and HindIII (Promega), followed by dephosphorylation of DNA ends using rSAP and 
gel purified. The BamHI-HindIII vector backbone and BamHI-HindIII FLuc fragment were ligated 
together with T4 DNA Ligase. Positive cloning was verified by analytical restriction enzyme 
digestion of pAAV2-FLuc with BamHI and HindIII. 
 
Lentiviral vector plasmids 
Plasmids used to transfect 293T cells for lentiviral vector production included 
pRRLSIN.cPPT.PKG-GFP.WPRE (a gift from Didier Trono; Addgene plasmid# 12252), pRSV-REV 
(a gift from Didier Trono; Addgene plasmid# 12253), pMDLG/pRRE (a gift from Didier Trono; 
Addgene plasmid# 12251), pMD2.G (a gift from Didier Trono; Addgene plasmid# 12259). The 
pRRLSIN.cPPT.PKG-GFP.WPRE is a third generation lentiviral transfer vector encoding EGFP 
under hPGK promoter control and WPRE terminator flanked by HIV1 5’-LTR (truncated) and 
self-inactivating 3’-LTR (ΔU3). Plasmid pRSV-REV is a third generation lentiviral packaging 
plasmid encoding rev under RSV promoter control, where Rev is required for efficient export 
of lentiviral transcripts to the cytoplasm. Plasmid pMDLG/pRRE is another third generation 
packaging plasmid encoding gag and pol under CMV promoter control and β-globin intron, 
and code for the structural proteins and viral enzymes, respectively, required for functionally 
transducing lentiviral vectors. Plasmid pMD2.G is the VGV-G envelope expressing plasmid 
required for lentiviral vector infectivity. Finally, pDUAL.mIL6-puro (a kind gift from Illaria Nisoli, 
University College London) is a third generation lentiviral transfer vector that encodes mouse 
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IL6 (mIL6) under SFFV promoter control and WPRE terminator, and puromycin resistance gene 
under ubiquitin promoter control, all flanked by HIV1 5’-LTR and self-inactivating 3’-LTR (ΔU3) 
from HIV1.  
 
YB1 expressing construct and YB1Δ1-6 lentiviral transfer vectors 
Exogenous YB1 (myc-tagged) expression was mediated by transfection of mammalian cell lines 
using pDESTmycYBX1 plasmid (a kind gift from gift from Thomas Tuschl; Addgene plasmid# 
19878). Lentiviral vector constructs encoding YB1 full length and YB1Δ1-Δ6 truncation mutants 
were generated: pDUAL.YBX1-puro, pDUAL.YBX1Δ1-puro, pDUAL.YBX1Δ2-puro, 
pDUAL.YBX1Δ3-puro, pDUAL.YBX1Δ4-puro, pDUAL.YBX1Δ5-puro, and pDUAL.YBX1Δ6-puro, 
respectively; and were derived from pDUAL.mIL6-puro backbone. These constructs were 
generated by High-Fidelity PCR amplification of the YB1 full length coding sequence and 
YBX1Δ1-Δ6 mutants using pDESTmycYBX1 plasmid as template. Amplification of full length 
YBX1 coding sequence used YBF1 and YBR1; amplification of YB1Δ1 used YBF1 and YBR2; 
amplification of YB1Δ2 used YBF1 and YBR3; amplification of YB1Δ3 used YBF1 and YBR4; 
amplification of YB1Δ4 used YBF2 and YBR3; amplification of YB1Δ5 used YBF3 and YBR1; 
amplification of YB1Δ6 used YBF2 and YBR1 (see Table 2.2). PCR amplicons included 5’-NotI 
and 3’-BamHI restriction enzyme sites, Kozak sequence, and stop codon where appropriate. 
Following which, gel purified PCR products were double restriction enzyme digested with NotI 
(NEB) and BamHI (NEB) to generate NotI-BamHI fragments. These were cloned into gel 
purified pDUAL.mIL6-puro backbone (after NotI and BamHI double enzyme restriction enzyme 
digestion and dephosphorylation of DNA ends), using T4 DNA Ligase. Positive transformants 
were verified by double restriction enzyme digestion with BamHI and NotI, and by sequencing 
using SFFV.F(orward) and WPRE.R(everse) oligos (Table 2.2). 
 
His-SfYBco encoding constructs for Sf9 transfections   
Plasmids for transfection of insect cell lines included: pIEx™-1 expression vector (Novagen), 
pIEx™-1.eGFP, pIEx™-1.His-SfYBco, pre-linearised pTriEx™1.1 (a kind gift from Prof. Ian Jones, 
University of Reading), of which pTriEx™-1.His-SFYBco was derived from. The pIEx™-1 plasmid 
is an insect cell line-transfection compatible expression vector, which drives desired 
recombinant protein expression under the control of hr5 enhancer and the IE1 promoter, and 
IE1 terminator. Cloning into pIEx™-1 multiple cloning site provided an in-frame Histidine-tag 
(deca-His-tag) encoded sequence for expression of His-tagged recombinant protein where 
intended. The pTriEx™-1.1 vector enables the expression of desired recombinant protein 
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under the control of CMV or baculovirus-derived p10 promoters, and also provides an in-
frame deca-His-tag encoded sequence for His-tagged recombinant protein expression after 
cloning. The pTriEx™-1.1 also harbours flanking Tn7 right and left transposon elements for 
directional transposition. 
 
The pIEx-1.eGFP construct was generated by digesting pIEx™-1 with NcoI (NEB) restriction 
enzyme, and then sub-cloning of the EGFP coding sequence from pFBGR as an NcoI fragment. 
Firstly, the pFBGR was double restriction enzyme digested with HindIII (NEB) and AgeI (NEB) to 
remove a third, undesirable NcoI(3) restriction site. After gel purification, cohesive ends were 
blunted using Klenow Fragment and DNA ends phosphorylated. Blunted pFBGR was then PCR 
purified for self-ligation using T4 DNA ligase. The resultant plasmid (pFBGRΔNcoI(3)) was then 
restriction enzyme digested with NcoI for EGFP fragment dropout and isolated by gel 
purification. The pIEx™-1 plasmid was also restriction enzyme digested with NcoI and gel 
purified to isolate the vector backbone. After PCR purification the EGFP fragment was ligated 
into the gel purified pIEx™-1 vector backbone using T4 DNA Ligase to generate pIEx-1.eGFP 
plasmid. Positive transformants were screened by colony PCR using pIEx1-ie1prom.F(orward) 
and eGFP.colPCR.R(everse) oligos (Table 2.2).  
 
Plasmid pIEx-1.His-SFYBco vector construct was generated by cloning of codon optimised SFYB 
(SFYBco) gene-string for S. frugiperda expression. SFYBco gene-string also included 5’-BamHI 
and 3’-HindIII restricition sites, and was synthesised by Thermo Fisher Scientific, GeneArt 
(Table 2.10). Codon optimisation involved substituting wildtype SFYB cDNA sequences for 
improved codon usage for S. frugiperda expression, as well as improved codon quality 
distribution and optimised GC content compared to wildtype SFYB cDNA sequence (Table 
2.10), and multiple sequence alignment (MSA) using NCBI global align tool with wildtype SFYB 
as reference (‘Sbjct’) coSFYB as ‘Query’ (Fig. 2.1). Therefore, 200ng of SFYBco gene string was 
double restriction enzyme digested with BamHI and HindIII and gel purified. Next, the pIEx™-1 
expression vector was double restriction enzyme digested with BamHI and HindIII, and DNA 
ends subjected to dephosphorylation. This was followed by gel purification to isolate the 
vector backbone. The BamHI-HindIII SFYBco fragment was cloned into the vector backbone 
using T4 DNA Ligase. This allowed for the SFYBco fragment to clone into the pIEx™-1 vector 
backbone in-frame of the vector’s start codon and immediate deca-His-tag encoded sequence. 
Positive transformants were screened by colony PCR using pIEx1-ie1prom.F(orward) and 
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pIEx1-ie1term.R(everse) oligos (Table 2.2), and plasmids by analytical restriction enzyme 
digestion using BamHI and HindIII. 
 
Finally, pTriEx™-1.His-SFYBco was generated by PCR amplification of the SFYBco sequence 
using Promega 2X Master Mix, SFYB-inf.F(orward) and SFYB-inf.R(everse) oligos (Table 2.2), 
and pIEx™-1.His-SFYBco template. The PCR product was then gel purified and cloned by In-
Fusion® (Clontech) into the pre-linearised pTriE™x-1.1 cloning vector. Positive transformants 
were verified by analytical restriction enzyme digestions using EcoRI and NcoI, and Sanger 
sequencing using the T7.F(orward) oligo (Table 2.2). 
 
Table 2.10 wildtype SFYB and SFYBco gene string sequence 
cDNA 5’>3’ sequence 
wildtype 
SFYB 
ATGGCTGATACCGAAAAGGCGCCGCAGCCGCAGCCCCAACAGCAGCAGCAACAAGAG
CAACAACCCCCACAGCAACCGCAACAAGCTAAAGCGGCTAAACAAAAGCAGGTCATTG
CTGAGAAAGTTTCGGGAACCGTCAAATGGTTTAATGTCAAGAGTGGATATGGTTTCAT
CAACAGGAATGACACCAAGGAGGATGTGTTTGTGCATCAAACTGCAATCGCCCGGAAC
AACCCTCGCAAGGCTGTGCGCTCGGTCGGCGACGGGGAGGCGGTGGAGTTTGCCGTG
GTTGCCGGGGAGAAAGGCTATGAAGCAGCCGGAGTAACTGGTCCCGGTGGTGAGCCG
GTAAAGGGCTCGCCCTATGCAGCTGACAAACGCCGCGGCTTCCATCGCCAATATTACCC
CCGTCAAGGTGGCGGACGTGGCGGGGAAGGCGCTCCACGTAGAGGTGGAATGGGAC
GTCGTGGGCCCCCGACCAACCAGGGGGGTGCACAGGGGGATGAAGGTCAGGAGGGA
GGCGGAGCACCACCACAGCGCAGCTACTTCCGCCGCAACTTCCGTGGTGGACGCCGTG
GTGGCGGTCCAGGGCCCATGAATCGCGGAGGATACCGTCGCGCTCGTCCACGCAACTT
CCAACCGGGCCAAGGACAGGGCCAGCCCCAAGCTGGTGGTCAGCCTAACCAAGCACCA
CGTCAAAATGGTCAGGAGGCAGAGGCCCCAGCCACCGCTGCGTCGCCAACGCAACAGC
AACAGGCCAAGCCGAAATCTACCACCAAGCCTGCTGGTACTACCATTGAGACCACTACC
AATGAGAG CCAGGCCTAA 
 
SFYBco 
GCGCGGATCCCGCTGACACTGAAAAGGCTCCTCAGCCTCAGCCACAGCAGCAACAACA
GCAAGAGCAGCAGCCTCCTCAGCAGCCCCAACAAGCTAAGGCTGCTAAGCAAAAGCAA
GTGATCGCTGAGAAGGTGTCCGGCACCGTGAAGTGGTTCAACGTGAAGTCCGGTTACG
GTTTCATCAACCGCAACGACACCAAAGAAGATGTGTTCGTCCACCAGACCGCTATCGCT
CGTAACAACCCTCGCAAGGCTGTGCGTTCTGTCGGAGATGGCGAGGCTGTGGAATTCG
CTGTGGTGGCTGGCGAGAAGGGTTACGAAGCTGCTGGTGTTACTGGTCCCGGTGGCGA
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ACCTGTGAAGGGTTCTCCTTACGCTGCTGACAAGCGTCGTGGTTTCCACCGTCAGTACT
ACCCTCGTCAAGGTGGTGGTCGTGGTGGCGAAGGTGCTCCTAGAAGAGGTGGAATGG
GTCGTCGTGGTCCTCCTACCAATCAAGGTGGCGCTCAAGGCGACGAGGGTCAAGAAGG
TGGCGGCGCTCCTCCACAGAGGTCTTACTTCCGTCGTAACTTCCGCGGTGGTCGTAGAG
GTGGTGGACCCGGTCCTATGAACCGTGGTGGTTATCGTCGTGCTCGTCCCCGTAATTTC
CAGCCTGGTCAAGGACAGGGACAGCCCCAAGCTGGTGGACAGCCTAATCAGGCTCCTC
GTCAGAACGGTCAAGAGGCCGAAGCTCCTGCTACCGCTGCTTCTCCTACTCAGCAGCAG
CAGGCTAAGCCCAAGTCCACCACTAAGCCCGCTGGCACCACCATCGAGACTACCACCAA
CGAGTCCCAGGCTTAAGCTTGCGC 
Bold underlined sequence, BamHI restriction site; blue bold sequence, wildtype SFYB or 
SFYBco coding sequences; double underlined sequence, HindIII restriction site. 
 
Figure 2.1 BLAST/MSA analysis of wildtype vs codon optimised SFYB cDNA sequences. Wildtype 
(‘Sbjct’) and codon optimised SFYB (‘Query’) cDNA sequences were inputted into NCBI Global align tool, 
and cDNA sequence similarity assessed by MSA. BLAST analysis indicated that codon optimisation of 
SFYB by GeneArt™ introduced some nucleotide substitutions, resulting in 79% sequence identity to 
wildtype SFYB.  
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pFastBac plasmids  
pFastBac plasmids used to transform DH10Bac™ E. coli included pFBGR (a kind gift from 
Robert Kotin; Addgene plasmid# 65422), pSR657 (a kind gift from Robert Kotin; Addgene 
plasmid# 65214), and pSR660 (a kind gift from Robert Kotin; Addgene plasmid# 65216). The 
pFBGR functioned as the shuttle vector for the EGFP transgene under the control of CMV 
enhancer and promoter or p10 promoter, flanked by AAV2 ITRs. Plasmid pSR657 functioned as 
the shuttle vector harbouring AAV2 rep and cap ORFs, under promoter control of polh and 
p10, respectively. Finally, pSR660 functioned as a shuttle vector encoding AAV2 rep and AAV8 
cap ORFs, under promoter control of polh and p10, respectively. All pFastBac plasmids 
harboured the Tn7L and Tn7R transposon elements required for transposition of desired rAAV-
specific sequences into bacmid DNA to generate recombinant bacmid DNA. Positive 
transposition was verified by growing transformed DH10Bac™ cells on LB agar containing Blue-
White Select™ Reagent. 
 
2.2.2 In silico methods 
2.2.2.1 Predictive alternative splice site activation and alternative splicing motifs 
Alternative splice site activation was assessed using Human Splicing Finder (HSF) v3.0 
(http://www.umd.be/HSF3/HSF.html; Desmet et al., 2009), and simulating the mutations that 
were detected by sequencing. Alternative splicing predictions were calculated against wildtype 
YBX1 splicing patterns and motifs (ENST00000321358) as reference and using the HSF 
Matrices prediction algorithm (Desmet et al., 2009). Potential alternative transcripts identified 
by HSF were input into protein translator tool (https://web.expasy.org/translate/) to 
conceptually translate and determine encoded amino acid (aa) sequence, and compared to 
wildtype YB1 aa sequence (NP_004550.2) as reference. Multiple sequence analysis was also 
performed in which the extrapolated aa sequence for each potential alternative transcript was 
input into NCBI global align tool (as ‘Query’), against wildtype aa sequence (NP_004550.2) as 
reference (‘Sbjct’). 
 
2.2.2.2 CRISPR/Cas9 off-target screening 
In order to identify potential off-target sites for potential CRISPR/Cas9-mediated disruption 
with the sgRNA designs used, the sgRNA DNA designs were separately input into NCBI BLAST 
online tool using the Reference Genomic Sequences (refseq_genomic) database (Altschul et 
al., 1997), and restricting organism selection to H. sapiens (taxid: 9606). The top five off-target 
sites for each gRNA DNA design were selected for further analysis.  
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2.2.2.3 Putative identification of Y-Box protein homologues 
The selected cDNA sequences were acquired from the NCBI database 
(https://www.ncbi.nlm.nih.gov/). BLAST assessments were carried out using NCBI’s 
Transcriptome Shotgun Assembly (TSA) database (Zhang et al., 2000) with organism 
refinement limited to Spodoptera (taxid: 7106) or Trichoplusia ni (taxid: 7111). Selected 
candidate cDNA sequences were then input into a protein translator tool 
(https://web.expasy.org/translate/) to conceptually translate candidate cDNA(s) in all forward 
and reverse reading frames. Candidate frame readouts from start methionine to stop codon 
was then input into NCBI’s Global Alignment tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM=blastp&PAGE_TYPE=Blast
Search&BLAST_SPEC=GlobalAln&BLAST_PROGRAMS=blastn), which uses the Needleman-
Wunsch alignment method (Needleman and Wunsch, 1970).  Candidate sequences were 
assigned as subject (Sbjct), against human YB1 (NP_004550.2) or BYB (NP_001036897.1) 
sequences as references (Query), to reverse BLAST and verify aa sequence homology.  
 
2.2.2.4 Multiple sequence alignments (MSA) and phylogeny 
Selected aa sequences were conceptually translated and then inputted into the PRALINE MSA 
programme (http://www.ibi.vu.nl/programs/pralinewww/help.php) (Simossis et al., 2005) to 
construct and analyse MSA. The evolutionary history was inferred by phylogeny using the 
bootstrapped (Felsenstein, 1985) UMGMA method (Sneath and Sokal, 1973) of MSA data. 
Phylogenetic analysis of aligned proteins was conducted by MEGA X (Kumar et al., 2018). The 
evolutionary distances were computed using the Poisson correction method (Zuckerkandl and 
Pauling, 1965) and are in the units of the number of aa substitutions per site. All positions 
containing gaps and missing data were eliminated.  
 
2.2.2.5 Predictive intrinsic disorder 
Intrinsic disorder was predicted by inputting aa sequences into DISOclust 
(http://www.reading.ac.uk/bioinf/IntFOLD/). Prediction of disordered residues was calculated 
based on probability scoring from comparing multiple models on a per-residue basis, and thus 
scores of <0.5 was considered structured and ≥0.5 was considered disordered (McGuffin, 
2008). Additionally, intrinsic disorder was also predicted using PSIPRED and DISOPRED 
(http://bioinf.cs.ucl.ac.uk/psipred/) after inputting of selected aa sequences. PSIPRED and 
DISOPRED predicts intrinsic disorder, secondary structures, and/or protein binding sites by 
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examining patterns of sequence conservation on intrinsically disordered regions (Jones and 
Cozzetto, 2015). 
 
2.2.2.6 Predictive hydrophobicity 
Amino acid sequences were inputted into ExPASy ProtScale programme 
(https://web.expasy.org/protscale/) for hydrophobicity scales using the Kyte and Doolittle 
classifications and scoring criteria (Kyte and Doolittle, 1982), and a window size of 9. Residues 
were considered hydrophobic with scores >0. 
 
2.2.2.7 Comparative 3D-structure protein modelling 
3D-models were generated using IntFOLD server (http://www.reading.ac.uk/bioinf/IntFOLD/), 
by inputting selected aa sequences and running template-based 3D-modelling with model 
quality assesments (McGuffin et al., 2015). Of the resultant structures modelled, the top 
scoring model’s .pdb file were then exported and rendered in the Jmol: an open-source Java 
viewer for chemical structures in 3D (http://www.jmol.org/) for interactive visualization. This 
was followed by use of TM-align (https://zhanglab.ccmb.med.umich.edu/TM-align/) to 
compare and computationally assesses 3D-model structure similarities along superimposed 
structures (Zhang and Skolnick, 2005), using the template modelling (TM)-score between 
template structes provided by IntFOLD server and between Y-Box protein homologues. The 
TM-score was scored between 0-1, with 1 implying a perfect match, and TM-score of 0.5<1 
indicated that the modelled proteins are in about the same fold.  
 
2.2.2.8 Annotating and mapping SFYB gene sequence  
S. frugiperda putative SFYB cDNA sequence (GCTM01011706.1) was inputted into the NCBI 
BLAST tool with organism refinement set to Spodoptera (taxid: 7106) using the Whole-genome 
Shotgun Contigs database to identify the assembled contig encoding the SFYB gene. The BYB 
(YB1 orthologue) gene was identified using NCBI’s Genome Data Viewer 
(https://www.ncbi.nlm.nih.gov/genome/gdv/), and exons and introns were mapped using the 
genomic scaffold (NW_004582015.1) and available transcriptomics (GCF_000151625.1). S. 
litura Y-Box protein homologue gene was mapped using NCBI’s Genome Data Viewer 
(NC_036217.1) and available transcriptomics (LOC111360813). Using both Y-Box protein 
homologue gene annotations as genomic scaffolds for SFYB’s gene, its exons and introns were 
mapped for the assembled contig accession OEOA01010394.1 based on sequence homology. 
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2.2.3 Cell culture, transfections and infections of mammalian and insect cell lines 
2.2.3.1 Cell culturing conditions 
293T and cell-derivatives were cultured in complete Dulbecco’s Modified Eagle Medium 
(DMEM; Sigma-Aldrich) supplemented with 10% heat-inactivated foetal calf serum (FCS), 2mM 
L-glutamine (Sigma-Aldrich), and 50U/mL penicillin and 50µg/mL streptomycin (Sigma-Aldrich). 
Cells were cultured at 37°C and 5% CO2. Passaging cells involved washing monolayer cells with 
sterile 1X phosphate buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM 
KH2PO4, pH 7.4; sterilised by autoclaving), followed by brief treatment with Trypsin-EDTA 
solution (Sigma-Aldrich) diluted 1:10 in sterile 1X PBS. Cells were allowed to detach from the 
plate with gentle rocking. Trypsin-EDTA was inactivated by the addition of equal volume of 
complete DMEM. Cell clumps were dissociated by pipetting cells up-and-down. Sf9, Sf-9ET, 
and Ao38 cells were cultured in Sf-900™ II serum-free media (Sf-900™ II SFM; Gibco), and 
50U/mL penicillin and 50µg/mL streptomycin (complete Sf-900™ II SFM), supplemented with 
2% heat-inactivated FCS for Ao38 and Sf-9ET cells. Insect cells were cultured either as 
adherent cells or in suspension. Adherent monolayers were grown using suitable sandwich 
boxes with hydration supplied by facial tissue dampened with sterile H2O, which was 
frequently replaced. Sandwich boxes were first washed with 70% ethanol and every three days 
for extended static cell culturing. Cells were incubated at 27°C using a refrigerated incubator. 
Suspension cells were instead maintained at 27°C at a constant 135rpm rotation. Adherent Sf9 
cells would be passaged by disrupting the adherent monolayer in flasks by forcefully hitting 
the base of the flask against a hard surface. Cells were then well resuspended by pipetting to 
dissociate cell clumps. 
 
With respects to seeding plates or flasks for a controlled density, well resuspended cells were 
first counted by haemocytometer. The number of cells within each central 5x5 grid was 
counted, and an average count was calculated. In the case of insect cell lines, cells were first 
mixed with an equal volume of Trypan Blue Solution, 0.4% (Gibco). Cells were then transferred 
to haemocytometer chambers. The average number of cells counted (N) corresponded to N 
x104 cells/mL. The cell density calculated for insect cell lines were multiplied by two to account 
for the dilution factor. The % of viable insect cells was determined by 1 – (number of stained 
cells/number of total cells) x100. Sf9, Sf-9ET and Ao38 cells were passaged and used as log-
phase growing cells exhibiting >95% viability. Ultimately, a known number of cells were 
transferred to new flasks or plates as indicated, in a suitable volume of their corresponding 
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complete media. This was followed by gentle rocking to distribute the cells homogenously 
across the surface of plate or flasks.  
 
2.2.3.2 Freezing and thawing cells 
Mammalian cell lines were trypsinised with Tryspin-EDTA solution and cell density/mL counted 
as described in section 2.2.3.1. Cell suspension was then transferred to a falcon tube and cells 
pelleted down at 1000rpm for 5mins. Supernatant was removed and the cell pellet was 
resuspended in freezing solution (composed of 90% FCS and 10% DMSO). 1mL suspensions 
corresponding to approximately 3-5x106 cells were aliquoted into freezing vials. 
Cryopreservation of insect cell lines, however, involved counting cells as described in section 
2.2.3.1, followed by pelleting cells for 5mins at 1500rpm. After which the conditioned media 
was aspirated and mixed into equal volume of fresh Sf-900™ II SFM, and then mixed with 
DMSO to constitute 7.5% of the final volume. Cells were transferred as 1.5mL aliquots, 
corresponding to 1.5-2x107 cells, into freezing vials. Vials were slowly frozen at -80°C 
overnight, and then transferred into liquid nitrogen vapour phase tanks for indefinite storage 
at -150°C. 
 
Thawing either cells involved removing frozen cells from liquid nitrogen storage, and thawing 
cells briefly at 37°C. This was followed by resuspending thawed cells in their corresponding 
complete media (pre-warmed). Mammalian cells were then pelleted for 5mins, 1000rpm to 
remove DMSO. The supernatant was removed, and replaced with suitable volume of pre-
warmed complete media. Well resuspended cells were then transferred to suitable flasks or 
plates, and then rocked gently to homogenously distribute cells.   
 
2.2.3.3 Single-cell cloning by limiting dilution 
Mammalian or insect cell lines were harvested and resuspended well in their corresponding 
complete culture media. The cell density was quantitated by haemocytometer and with 
Trypan Blue exclusion where indicated. The cell suspension was serially diluted in their 
corresponding culture media with or without particular supplements (as indicated), to achieve 
the required cell densities. 100μL of diluted cell suspension was then aliquoted into 96-well 
plates. An additional 50μL of the corresponding culture media was finally added to each well 
to increase the final volume to 150μL/well. Cells were then cultured at 37°C and 5% CO2 or 
27°C (for mammalian and insect cell lines, respectively) until clonal cell populations were 
identified. Clonal cell populations were then grown to confluency for expansion. 
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2.2.3.4 Measuring cell growth 
Log phase-growing cells were collected and cell densities calculated by haemocytometer with 
Trypan Blue exclusion. Cells were then passaged into 125mL Erlenmeyer flasks at a seeding 
density of 3x105 cells/mL per flask, in a total 30mL complete Sf-900™ II SFM. Cells were 
cultured at 27°C, 135rpm. Cell densities and viable cell counts were then counted by 
haemocytometer and Trypan Blue exclusion for up to 14 days, with live cell densities/mL and 
% of viable cells recorded at approximately 24h intervals. 
 
2.2.3.5 Lentiviral vector production 
293T (5x106) cells were seeded into 15cm dishes in 25mL complete DMEM per plate, and 
cultured at 37°C and 5% CO2 to achieve approximately 70% confluency the next day. Cells 
were then transfected using the Calcium Phosphate precipitation method. On the day of 
transfection, on a per plate basis, 5μg pMD.2G, 5μg pRSV.REV, 10μg pMDLg/pRRE, and 20μg of 
transfer vector was mixed to 0.9mL final volume in sterile ultra-pure H2O. This was followed by 
the addition of 100μL of 2.5M CaCl2 (0.45μm sterile filtered) and 1mL of 2X HBS (1.5M NaHPO4, 
50mM HEPES, 280mM NaCl, pH 7.05, 0.22μm sterile filtered) dropwise. Mixes were incubated 
at RT for 5mins, then the precipitation was inactivated by the addition of 2mL pre-warmed 
complete DMEM (37°C). 293T cells were then treated with chloroquine (25mM stock; 
prepared by diluting chloroquine diphosphate [Sigma-Aldrich] in ultra-pure H2O and 0.22μm 
filter sterilised) at 25μM final concentration. Cells were transfected with 4mL of transfection 
mix added dropwise with swirling to mix. Transfections were returned to culture at 37°C and 
5% CO2. 72h post-transfection, culture media was harvested and centrifuged at 4000rpm for 
10mins. The supernatant was then filtered through a 0.45μm filter, and transferred to ultra-
clear Beckman ultracentrifuge tubes (ultracentrifuge tubes were initially rinsed with 70% 
ethanol and washed with sterile 1X PBS, followed by air-drying). Tubes were balanced with the 
addition of sterile 1X PBS for ultracentrifugation of lentiviral vectors for 90mins, 28,000rpm at 
4°C using a Beckman Coulter Optima XL ultracentrifuge and SW32 Ti rotor. After which, the 
supernatant was carefully decanted and excess liquid drained by inverting tubes onto tissue. 
Lentiviral vector pellets were then soaked in 350μL opti-MEM™ (approximately 100-fold 
concentration), and pellet resuspended by pipetting up-and-down sixty-times. Resuspended 
pellets were incubated on ice for 1h, after which, the resuspended pellet was pipetted up-and-
down again sixty-times. Lentiviral vector suspension was then transferred to screw-capped 
Eppendorf tubes and stored at -80°C. 
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2.2.3.6 Lentiviral vector titration 
293T cells were seeded in 500μL at 6x104 cells/well, in complete DMEM into 24-well plates. 
Cells were then cultured overnight at 37°C and 5% CO2. On the day of infection, three wells of 
293T cells were trypsinised and counted by haemocytometer to establish the approximate 
number of cells at the time of infection. Next, lentiviral vector stock was then serially diluted in 
pre-warmed (37°C) opti-MEM™ with polybrene (Sigma-Aldrich) at 8μg/mL final concentration 
to achieve 1:5, 1:25, 1:100, 1:500, 1:2500, and 1:5000 dilutions. Complete DMEM was then 
aspirated from 293T cells, and 200μL of titrated lentiGFP was added carefully in triplicate for 
each titration. 200μL of opti-MEM™ with polybrene was added to 293T cells in three separate 
wells to function as negative infection control. Plates were returned to incubate at 37˚C and 
5% CO2 for 6h. The media was then replaced with 500μL of complete DMEM. 72h post-
infection, cells were harvested and fixed in final 1% formaldehyde, and then analysed by flow 
cytometry using negative infection control cells to gate against GFP-positive populations. 
Samples expressing 1-30% GFP were considered for calculating lentiGFP vector titres. Titres 
were calculated as transducing units (TU)/mL by TU/mL = (F x Cn) / (Vol x DF). F corresponds to 
the frequency of GFP-positive cells determined by flow cytometry (between 1-30%), Cn 
corresponds to the number of cells on the day of infection, Vol corresponds to the inoculum 
volume of lentiviral vector, and DF refers to the dilution factor. Final TU/mL was calculated as 
the overall average.  
 
2.2.3.7 Lentiviral vector transduction 
Mammalian cells were seeded into 24-well plates in 500μL at 1x105 cells/well of complete 
DMEM, or into 6-well plates at 3.5x105 cells/well in 2mL of complete DMEM, and cultured 
overnight at 37°C and 5% CO2 for approximately 70% confluency the next day. On day of 
infections, for single well infections, 50μL, 60μL or 300μL of lentiviral vector, or volumes 
corresponding to the desired MOI were diluted into pre-warmed (37°C) opti-MEM™ with 
polybrene (final 8μg/mL) to a final volume of 200μL or 1mL, for 24-well plates and 6-well 
plates, respectively. Complete DMEM was aspirated and diluted lentiviral vector was added to 
cells. Cells were incubated at 37°C and 5% CO2 for approximately 6h, after which the inoculum 
was replaced with 500μL or 2mL of complete DMEM for 24-well plates and 6-well plates, 
respectively. Cells were then further incubated at 37°C and 5% CO2 for 72h and then 
expanded. Transduced cells were then selected with puromycin (Invivogen) by replacing 
cultured media with complete DMEM supplemented with puromycin (final 3μg/mL 
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concentration). Transduced cell lines were maintained in complete DMEM supplemented with 
puromycin for several passages, and then maintained in complete DMEM. 
 
2.2.3.8 Transient plasmid transfection of mammalian cell lines – Lipofectamine™ 2000 
Cells were seeded into 6-well plates at 3.5x105 cells/well in 2mL complete DMEM, and 
cultured overnight at 37°C and 5% CO2 for approximately 70-80% confluency the next day. 
Transfections were performed following manufacturer’s instructions for Lipofectamine™ 2000 
Reagent (Invitrogen). On a per well basis, transfection mixes were prepared by diluting 
plasmid DNA of the required quantities into opti-MEM™ for a final volume of 150μL. 6μL of 
Lipofectamine™ 2000 Reagent was separately diluted in opti-MEM™ to a final volume of 
150μL. The dilutions were mixed together and incubated at RT for 5mins, and 300μL of 
transfection mix was then added dropwise to cultured cells. Cells were cultured at 37°C and 
5% CO2 for 72h or as indicated.  
 
2.2.3.9 Transient plasmid transfection of mammalian cell lines – FuGENE® HD 
Cells were seeded into 6-well plates at 3.5x105 cells/well in 2mL complete DMEM, 
respectively, and cultured overnight at 37°C and 5% CO2 for approximately 70-80% confluency 
the next day. Transfections were performed following the manufacturer’s instructions for 
FuGENE® HD Reagent (Promega). Firstly, on a per well basis, plasmid DNA at the required 
quantities was diluted to 300μL with pre-warmed opti-MEM™ (37°C) and briefly vortexed for 
5secs. A 3:1 FuGENE® HD Transfection Reagent:DNA ratio was used, and added to the diluted 
plasmid with a brief vortex of 10secs to mix. The transfection mix was then incubated for 
15mins at RT, and approximately 300μL of transfection mix was added dropwise to cultured 
cells. Transfections of cells in 24-well plates were scaled down accordingly. Transfected cells 
were cultured for 72h, or as indicated, at 37°C and 5% CO2. 
 
2.2.3.10 Transient plasmid transfection of mammalian cell lines – rAAV2 vector production 
Cells were seeded into 15cm dishes at 5x106 cells/plate in 25mL complete DMEM or in triple 
flasks at 2x107 cells/flask in approximately 80mL complete DMEM. Cells were cultured 
overnight at 37°C and 5% CO2 for approximately 70-80% confluency on day of transfection. 
Transfection for rAAV vector production was performed using Calcium Phosphate precipitation 
method with chloroquine (Sigma-Aldrich) or PEImax (Polysciences). On a per plate basis 
transfections using Calcium Phosphate precipitation were prepared by diluting plasmid DNA 
(7.5μg pAAV2-hrGFP, 7.5μg pHelper, and 22.5μg pAAV2/2-RC) in sterile H2O to make a final 
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volume of 0.9mL. 100μL of sterile 2.5M CaCl2 was added, followed by 1mL of 2X HBS dropwise. 
Mixes were incubated at RT for 5mins, then the precipitation was inactivated by the addition 
of 2mL pre-warmed complete DMEM (37°C). At which point chloroquine was added to 
cultured cells for a final concentration of 25μM. 4mL of the Calcium Phosphate transfection 
mix was then added to the cultured cells dropwise with swirling to mix. Cells were incubated 
for 72h (or as indicated) at 37°C and 5% CO2. Cells transfected for rAAV vector production or 
with AAV plasmids using Lipofectamine™ 2000 or FuGENE® HD Reagents were performed 
using scaled-down plasmid quantities described for Calcium Phosphate precipitation. 
Additionally, transfection mixes followed the corresponding protocols described in sections 
2.2.3.8 and 2.2.3.9, respectively.  
 
Cells transfected for rAAV vector production using PEImax per triple-flasks was performed by 
diluting plasmids (13.8μg pAAV2-hrGFP, 13.8μg pAAV2/2-RC, and 41.4μg of pHelper) to a final 
volume of 5mL in pre-warmed opti-MEM™ (37°C). PEImax (1mg/mL stock prepared in ultra-
pure H2O, pH 7.0 and 0.22μm sterile filtered) was warmed to RT and vortexed for 20secs prior 
to use. Following which, 241.5μL of PEImax (3.5:1 PEImax to plasmid DNA ratio) was diluted to 
5mL final volume of pre-warmed opti-MEM™ (37°C). Diluted parts were mixed together and 
vortexed for 20secs, followed by 20mins RT incubation. Approximately 10mL of transfection 
mix was added to 80mL fresh complete DMEM, and used to replace the culture media per 
triple-flask. Transfection of cells in 15cm dishes using PEImax were scaled-down accordingly, 
and added dropwise to cultured cells with swirling to mix, instead. Cells were incubated for 
72h at 37°C and 5% CO2. 
 
2.2.3.11 Transient plasmid transfections of Sf9 cell line 
Sf9 cells were transfected as per Cellfectin™ II (Invitrogen) or Lipofectamine™ CRISPRmax™ 
Cas9 Transfection Reagent (Invitrogen) manufacturer’s instructions. For Cellfectin™ II, log-
phase growing Sf9 cells were seeded into 6-well plates in 2mL complete Sf-900™ II SFM at 
8.5x105 cells/well. Cells were allowed to adhere as a monolayer for 1h at RT. After which, the 
media was replaced with 2.5mL Plating Medium (Grace’s Insect Medium [Gibco] 
supplemented with 1.5% FCS, 7.5U/mL penicillin, and 7.5μg/mL streptomycin). On a per well 
basis transfection mixes were prepared by diluting plasmid DNA at the required quantity in 
100μL Grace’s Insect Medium and diluting 8μL Cellfectin™ II reagent in 100μL Grace’s Insect 
Medium. Dilutions were then mixed both together by pipetting and incubated at RT for 
30mins. The transfection mix (approximately 210μL) was then added dropwise to cells in 
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Plating Medium and transfected for 5h at 27°C. The media was then replaced with 2mL 
complete Sf-900™ II SFM, and transfected cells were returned to 27°C for 72h. Transfection of 
Sf9 cells using Cellfectin™ II Reagent in 24-well plates was scaled down accordingly. 
Alternatively, transfections of suspension Sf9 cells using Cellfectin™ II reagent, log-phase 
growing Sf9 cells were seeded at 1x107 cells in 8mL complete Sf-900™ II SFM in Erlenmeyer 
flasks. Transfection mixes using Cellfectin™ II was prepared by scaling up transfection mixes 
according to cell number from 6-well format and optimum input plasmid quantity. Transfected 
cells were returned to 27°C at 125rpm culture for 72h. 
 
Whereas, log-phase growing Sf9 cells transfected using Lipofectamine™ CRISPRmax™ Cas9 
Transfection Reagent were seeded into 24-well plates in 500μL complete Sf-900™ II SFM at 
2x105 cells/well, and allowed to adhere for 1h at RT. On a per well basis, plasmid DNA at the 
desired quantity and 1μL of Lipofectamine™ Cas9 Plus™ Reagent were then diluted in 25μL 
opti-MEM™, Sf-900™ II SFM, or Grace’s Insect Medium. 1.5μL of CRISPRmax™ Reagent was 
separately diluted in 25μL of the corresponding SFM. The respective diluted mixes were then 
mixed together and vortexed for 10secs and incubated at RT for 15mins. Approximately 50μL 
of transfection mix was then added dropwise and cells incubated at 27°C for 72h. 
Transfections of Sf9 cell lines for recombinant baculovirus (P0) stocks is described in section 
2.2.3.13. 
 
2.2.3.12 Transfection of Sf9 cells with recombinant Cas9 and sgRNA 
Log-phase growing Sf9 cells were seeded into 96-well plate in 100μL of complete Sf-900™ II 
SFM at 3x104 cells/well. Cells were allowed to adhere as monolayer cells for 1h at RT. 
Transfection mixes were prepared as per GeneArt™ Platinum™ Cas9 Nuclease (Invitrogen) 
instructions, with some modifications. On a per well basis, 50ng of recombinant Cas9 with 
0.1μL of Lipofectamine™ Cas9 Plus™ Reagent, and 12.5ng of sgRNA was diluted in 4μL of 
Grace’s Insect Medium. 0.15μL of CRISPRmax™ Reagent was separately diluted in 4μL of 
Grace’s Insect Medium. Both dilutions were mixed together and vortexed for 10secs, followed 
by incubation at RT for 15mins. For 10:1 input sgRNA plus recombinant Cas9 to CRISPRmax™ 
Transfection Reagent ratio, the input quantities of sgRNA, recombinant Cas9 and 
Lipofectamine™ Cas9 Plus™ Reagent was scaled up 10-fold. Transfection mixes were then 
added to Sf9 cells and cells incubated at 27°C for 72h. Non-transfected Sf9 cells was prepared 
in parallel as negative controls.  
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2.2.3.13 Recombinant baculovirus production 
Recombinant baculoviruses were generated using either the Bac-to-Bac® (Invitrogen) or 
flashBAC™ (OET) Baculovirus Expression Systems. For flashBAC™ Baculovirus Expression 
System, log-phase growing Sf9 cells were seeded into 6-well plates in 1mL complete Sf-900™ II 
SFM at a cell density of 2x106  cells/well. Sf9 cells were allowed to adhere as monolayer cells 
for 1h at RT to achieve approximately 80% confluency. This was followed by preparation of the 
co-transfection mix: 500ng of appropriate plasmid (harbouring Tn7 transposon elements) was 
mixed with 100ng of flashBAC™ DNA (OET) and 1.2μL baculoFECTIN Reagent (OET), prepared 
in Sf-900™ II SFM and incubated for 15mins at RT. Cells were then co-transfected with 
flashBAC™ DNA:plasmid mix overnight at 27°C. The next day, 1mL of complete Sf-900™ II SFM 
was added, and cells incubated at 27°C for a further 4 days. The medium containing 
baculovirus (P0 stock) was then collected, and used to propagate to P1 and P2 stocks.  
 
Alternatively, for Bac-to-Bac® Baculovirus Expression System, log-phase growing Sf9 cells were 
seeded into 6-well plates in 1mL complete Sf-900™ II SFM at a density of 8.5x105 cells/well, , 
and allowed to adhere for 1h at RT. After which, the media was replaced with 2.5mL Plating 
Medium. Transfections were performed as described in section 2.2.3.11 using 500ng of 
bacmid DNA and 8μL of Cellfectin™ II Reagent. However, transfected cells were incubated at 
27°C for 5 days. Recombinant baculovirus (P0 stock) was harvested from the cultured media, 
and transferred to clean falcon tubes with FCS added to approximately 2% of harvested media 
volume. Baculovirus stocks were stored at +4°C. 
 
2.2.3.14 Amplification of baculovirus stocks 
An accelerated P1 baculovirus stock was amplified by seeding a T75 flask of Sf9 cells (4.5x106 
log-phase growing cells) in 10mL complete Sf-900™ II SFM and allowing cells to adhere for 1h 
at RT. Following which, the harvested P0 baculovirus stock generated using the flashBAC™ 
Baculovirus Expression System was added directly to cultured Sf9 cells and infected for 3-5 
days for P1 baculovirus stock expansion. After which the culture media was harvested. 
Otherwise, general amplification of the P0 recombinant baculovirus to P1/P2 involved seeding 
log-phase growing Sf9 cells into Erlenmeyer flasks in 30mL complete Sf-900™ II SFM at 2x106 
cell/mL density. Cells were then infected with recombinant baculovirus (P0 or P1 stock to 
generate P1 and P2 stocks, respectively) at MOI of 0.05 prepared in complete Sf-900™ II SFM, 
made to 10% volume of the culture volume. Infected cells were incubated at 27°C at 135rpm 
for 7 days, after which the culture media was harvested. Harvested cells were pelleted at 
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1500rpm for 5mins. The recombinant baculovirus-containing supernatant was transferred to 
new falcon tubes with FCS added to approximately 2% of the harvest volume. P1 and P2 stocks 
were stored at +4°C. 
 
2.2.3.15 Plaque assays 
Recombinant baculovirus stocks were quantified by plaque assays on monolayer Sf9 cells. Log-
phase growing Sf9 cells were seeded into 6-well plates in 2mL complete Sf-900™ II SFM at 
1x106 cells/well, and allowed to adhere for 1h at RT. Baculovirus stock was then serially diluted 
10-fold in complete Sf-900™ II SFM to 10-8 dilution. After cell attachment the media was 
replaced with 1mL inoculums of 10-fold serially diluted baculovirus (10-4 to 10-8 dilutions), in 
triplicate per dilution factor, for 1h at RT. The inoculum was then removed and cells overlaid 
with Plaquing Media (final 1% low melting temperature agarose [Lonza] in Sf-900™ II SFM 
[1.3X, Gibco], warmed to 40°C). The Plaquing Media was allowed to briefly set and then cells 
were incubated for 10 days at 27°C. After which, plates were stained with 0.5mL of Neutral 
Red Solution (Sigma-Aldrich), prepared as 1mg/mL solution in ultra-pure H2O, for 2h at RT. The 
Neutral Red Solution was then drained away by inverting plates on tissue, to allow the 
enumeration of plaques. Plates that exhibited between 2-40 plaques were considered only. 
Approximate recombinant baculovirus titres were calculated by: average number of plaques x 
corresponding dilution factor, and then multiplying by 1/inoculum volume (1mL). Final average 
plaque forming units (pfu)/mL was then calculated. 
 
2.2.3.16 Titration of recombinant baculovirus by endpoint dilution 
Log-phase growing Sf-9ET cells were seeded into 96-well plates at 7.5x104 cells/well in 100μL 
complete Sf-900™ II SFM plus 5% FCS (100μL per well), and allowed to adhere for 1h at RT. 
Baculovirus stocks were then serially diluted in complete Sf-900™ II SFM with 5% FCS from 10-1 
to 10-8, and cells were inoculated with 20μL of diluted baculovirus/well in replicates of eight 
for each dilution factor. Non-infected controls included inoculating Sf-9ET cells with 20μL of Sf-
900™ II SFM plus 5% FCS only, in triplicate. Infected cells were cultured at 27°C for 72h, after 
which the number of wells exhibiting foci of infection (positive foci of infection were defined 
as a cluster of Sf-9ET cells that exhibited green fluorescence by fluorescent microscopy) 
(Hopkins and Esposito, 2009). Virus titres were determined by calculating the median tissue 
culture infectious dose (TCID50) following the Reed-Müench method (Reed and Muench, 
1938). Here, the proportionate distance (PD) was calculated by PD = (fraction of wells next 
above 50% infection rate) - 50% / (fraction of wells next above 50% infection rate) – (fraction 
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of wells next below 50% infection rate). TCID50 was then calculated by subtracting PD from the 
negative logarithm of the dilution next above 50% infection rate. TCID50/mL was calculated by 
multiplying TCID50 by inoculum volume (mL). Finally, final titres were calculated by multiplying 
TCID50/mL by 0.69 for approximate recombinant baculovirus titres as pfu/mL. 
 
2.2.3.17 Infection of insect cells with recombinant baculovirus 
Log-phase growing Sf9 or Ao38 cells were seeded in 6-well plates at 2x106 cells/well in final 
2mL of complete Sf-900™ II SFM (supplemented with 5% FCS for Ao38 cells), and allowed to 
adhere for 1h at RT for approximately 80% confluent monolayers. Where appropriate, the 
seeding density and culture volume was scaled-down for smaller tissue culture plates. 
Alternatively, log-phase growing Sf9 cells were seeded at 2x106 cells/mL density into 
Erlenmeyer flasks. Recombinant bacuovirus(es) (corresponding to MOI of 3) was diluted in 
complete Sf-900™ II SFM to a final inoculum volume corresponding to 10% of the culture 
volume. For rAAV vector production, BacITRGFP and BacAAV2.2 or BacAAV2.8 were co-
infected at MOI 3 each. Diluted recombinant baculovirus(es) was then added dropwise to 
seeded Sf9 or Ao38 cells and infected for the indicated time, and cultured at 27°C (and 135rpm 
for infected Sf9 in suspension culture).   
 
2.2.3.18 Crude AAV vector harvest 
Transfected mammalian cells or infected insect cells for rAAV vector production were 
harvested into their culture media. Cells in 15cm dishes were scraped off into the culture 
media and cells in triple flasks were trypsinised and pooled. Cells were then pelleted down at 
1500rpm for 15mins. Cells were thrice washed with sterile 1X PBS. The final PBS wash was 
then completely aspirated carefully, and cells resuspended in 1mL TD Buffer (140mM NaCl, 
5mM KCl, 0.71mM K2HPO4, 25Mm Tris-HCl [pH 6.8], 6.4mM MgCl2, 0.22μm filter sterilised). 
The volume of TD Buffer used to resuspend transfected mammalian cells lines was scaled-up 
accordingly for transfections performed in triple-flasks. Alternatively 5mL of TD Buffer was 
used to resuspend insect cells infected for rAAV vector production. Resuspended cells were 
immediately placed on dry-ice and subjected to five lots of freeze-thaws in dry ice and 37°C 
water bath until cells were completely frozen or thawed, respectively. Cell debris was then 
pelleted at 4500rpm for 20mins and supernatant collected and transferred to clean Eppendorf 
tubes and -20°C, or subjected to purification by an iodixanol gradient.   
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2.2.3.19 Purification of rAAV vectors 
Different iodixanol gradients were prepared (15%, 25%, 40%, and 60% concentrations) using 
OptiPrep™ Gradient Medium (Sigma-Aldrich). OptiPrep™ was diluted to 15% using ultra-pure 
H2O with NaCl to a final 1M concentration; and to 25% in final 1X TD Buffer (5X: 250Mm Tris-
HCl [Ph 8.5], 750mM NaCl) and 0.00125% Phenol Red Solution (Sigma-Aldrich) using ultra-pure 
H2O; and to 40% using in final 1X TD Buffer using ultra-pure H2O. Finally, the 60% gradient was 
prepared by mixing in Phenol Red Solution to a final 0.00125%. The gradient was assembled 
slowly and stepwise by adding 1.55mL of the 60% gradient, followed by 1.55mL of the 40% 
gradient, then 1.88mL of the 25% gradient, and finally 2.8mL of 15% gradient to Beckman 
ultracentrifuge tubes. 5mL of crude rAAV vector lysate was then treated with 2000U of 
Benzonase® Nuclease (Sigma-Aldrich) for 1h at 37°C. 3mL of crude rAAV vector lysate was then 
slowly added per tube, and tubes balanced. The rAAV vector was then separated from empty 
capsids and recombinant baculovirus by ultracentrifugation for 3h at 40,000rpm and 18°C 
using a Beckman Coulter Optima XL ultracentrifuge and SW40 Ti rotor. Therefore, rAAV vector 
was collected from between the 40-60% layers using a 5mL syringe and 20-gauge needle. The 
collected fraction was pooled for corresponding rAAV vector samples, and concentrated using 
100kDa cut-off Vivaspin 6 Concentrator (Sartorious). This involved the buffer exchange of the 
OptiPrep™ with 1X PBS. Therefore, the pooled rAAV vector sample was mixed with 6mL of 1X 
PBS and applied to the Vivaspin 6 Concentrator, and centrifuged at 1000rpm for 5mins 
intervals. Between each centrifugation interval the diluted rAAV vector sample was mixed by 
pipetting to homogenise the rAAV vector. When approximately 0.5-1mL of sample was left, 
the flow-through was discarded and the Vivaspin 6 Concentrator was topped up with 1X PBS 
to 6mL. Centrifugation at 5mins intervals, 1000rpm and intermittent homogenising the rAAV 
vector and buffer exchange repeated for a total of three buffer exchanges with 1X PBS. Finally, 
approximately 300μL of concentrated rAAV vector was collected, and volumes normalised 
between corresponding batches to 300μL using 1X PBS. Purified rAAV vector was stored at -
20°C.  
 
2.2.3.20 Gene transfer assays 
293T cells were seeded into 24-well plates at 1x105 cells/well in 500μL complete DMEM, and 
cultured overnight at 37°C, 5% CO2. Crude rAAV vector samples were harvested by five-time 
freeze-thaws as described in 2.2.3.18. Collected crude rAAV was then diluted in pre-warmed 
opti-MEM™ (37°C) at 1/5, 1/25, and 1/100 dilutions, and then treated at 60°C for 20mins to 
heat-inactivate baculovirus(es). Crude lysate (neat) derived from five-time freeze-thaws of 
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BacITRGFP+BacMers-M-infected Sf9 cells was also heat-inactivated for 20mins at 60°C as a 
control for complete baculovirus heat-inactivation. Crude lysates derived from five-time 
freeze-thaw of BacMers-M-infected Sf9 cells functioned as mock infection control of 293T 
cells. Therefore, 293T cells were infected with 50μL crude lysates at the indicated dilutions. 
293T cells were also infected with 50μL non-heat-inactivated crude lysate derived from Sf9 
infected with BacITRGFP+BacMers-M control to help establish the efficiency of baculovirus 
heat-inactivation. Infections were carried out for 48h at 37°C and 5% CO2. Cells were then 
harvested and analysed by flow cytometry against mock infected control for negative gating of 
GFP-positive populations. 
 
2.2.3.21 Lactate dehydrogenase (LDH) cytotoxicity assays 
Mammalian cells were seeded in 15cm dishes at 5x106 cells in 25mL complete DMEM per dish 
or 6-well plates at 3.5x105 cells/well in 2mL complete DMEM. Alternatively, Sf9 cells were 
seeded into 6-well plates at 2x106 cells/well in 2mL complete Sf-900™ II SFM and allowed to 
form a monolayer for 1h at RT. Cells were transfected with AAV-plasmids for rAAV vector 
production as indicated (described in sections 2.2.3.8-10), or infected with baculoviruses for 
rAAV vector production (described in section 2.2.3.17). Alternatively, cells were treated with 
the intended reagents – including transfection mixes with the omission of plasmids, or 
chloroquine only, or non-treated. Final input volumes of each treatment were all normalised 
by each cell line’s respective complete media or opti-MEM™. In all cases complete media (with 
5% FCS where appropriate) was added to separate 6-well plates alone and cultured in parallel 
for consideration of LDH activity attributable by FCS and for normalisation of LDH cytotoxicity 
activities.   
 
LDH activities were measured using the Pierce™ LDH Cytotoxicity Assay (Thermo Fisher 
Scientific). At the indicated time points 150μL of culture media was collected and transferred 
to 96-well plates in triplicate for each condition tested and each replicate. Cells from baseline 
reference controls (non-treated or treatments with transfection mixes with the omission of 
plasmids, where indicated) were then harvested in their culture media. Control cells were then 
pipetted up-and-down to dissociate cell clumps. 150μL of these resuspended cells were 
transferred to 96-well plates in triplicate for each replicate. 150μL of FCS-containing (where 
relevant) media was also transferred to 96-well plates in triplicate for background LDH activity 
assessment and normalisation. Plates were then centrifuged at 2000rpm for 3mins. 15μL of 
10X Lysis Buffer (composition – proprietary information) was added to wells containing 
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harvested cells, and functioned as maximum LDH activity controls (100% lysis). Plates were 
gently tapped to mix and then incubated at 37°C and 5% CO2 for 45mins. 50μL of each sample 
was transferred to new 96-well plates, and mixed with 50μL of Reaction Mixture, which was 
composed of lyophilized Substrate Mix (composition – proprietary information) dissolved in 
11.4mL ultra-pure H2O and mixed with 0.6mL of Assay Buffer (composition – proprietary 
information). Plates were incubated for 30mins at RT, and protected from light in order for 
LDH to catalyse the conversion of lactate to pyruvate via the reduction of NAD+ to NADH. A 
colorimetric reaction ensued that utilises the NADH to reduce a tetrazolium salt to a red 
formazan product. Reactions were terminated by the addition of 50μL LDH Stop Solution 
(composition – proprietary information). Bubbles were disrupted by centrifugation at 
2000rpm for 3mins, and plates read by spectrophotometer at 490nm and 680nm. LDH activity 
was calculated by subtracting 680nm absorbance readings from 490nm for each sample, to 
eliminate background absorbance. Following which, the LDH cytotoxicity was calculated as a % 
of max lysis by: %cytotoxicity = (LDH activity – LDH activity present in the complete media) / 
(maximum LDH activity – LDH activity present in the complete media) x100. Average 
%cytotoxicity was then calculated.  
 
2.2.4 Harvesting genomic DNA and protein 
2.2.4.1 Genomic DNA extraction 
Genomic DNA was harvested using the Wizard® Genomic DNA Purification Kit (Promega). Cells 
were routinely harvested, and approximately 3-5x106 cells were centrifuged at 13,000rpm for 
10secs. Supernatant was then removed and washed in 200μL PBS. Cells were pelleted at 
13,000rpm for 10secs and supernatant removed. 600μL of Nuclei Lysis Solution (composition – 
proprietary information) was added and cell pellet resuspended until no cell clumps remained. 
17.5μL of 20mg/mL Proteinase K (Qiagen) was added, and mixtures incubated at 55°C for 3h 
with intermittent vortexing. Mixtures were allowed to cool to RT for 5mins, and 3μL of RNase 
A Solution (4mg/mL RNase A in DNA Rehydration Solution: 10mM Tris-HCl [pH 7.4], 1mM 
EDTA [pH 8.0]) was then added to lysates and incubated for 30mins at 37°C. Lysates were 
cooled to RT for 5mins, after which 200μL of Protein Precipitation Solution (composition – 
proprietary information) was added and immediately vortexed for 20secs. Samples were 
incubated on ice for 5mins, and preciptate then centrifuged for 4mins at 13,000rpm. The 
supernatant containing genomic DNA was transferred to clean Eppendorf tubes, and 
centrifuged at 13,000rpm for 4mins. The clarified supernatant was transferred to new 
Eppendorf tubes and 600μL of RT isopropanol was added. Mixtures were mixed by inversions 
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until white, thread-like strands of genomic DNA formed. The precipitated genomic DNA was 
centrifuged at 13,000rpm at RT for 1min, and supernatant decanted. The pelleted genomic 
DNA was washed with RT 70% ethanol by gentle inversions, and then centrifuged at 
13,000rpm for 1min. The ethanol was completely aspirated and genomic DNA pellet left to air-
dry for 5mins. Following which, 100μL of DNA Rehydration Solution was added to rehydrate 
and dissolve the genomic DNA for 1h at 65°C. Genomic DNA was finally stored at -20°C. 
 
2.2.4.2 Whole cell protein extraction 
Cells were either lysed in RIPA Lysis Buffer (150mM NaCl, 1% Triton™ X-100 [v/v], 0.5% sodium 
deoxycholate, 0.1% SDS [w/v], 50mM Tris-HCl [pH 8.0]) or Lysis Buffer A (25mM HEPES 
[pH7.5], 100Mm KCl, 12.5mM MgCl2, 1mM DTT, 0.1% IGEPAL-CA630 [v/v], 10% glycerol [v/v]), 
supplemented with HALT™ EDTA-free Protease Inhibitor Cocktail (Thermo Fisher Scientific) 
diluted 1:100. Cells were first washed with ice-cold 1X PBS twice, and then scrapped into a 
suitable volume (200μL for a single well of a 6-well plate or 2mL for 15cm dishes) of pre-chilled 
RIPA Lysis Buffer or Lysis Buffer A, and kept on ice for approximately 15mins. Cell debris was 
then pelleted by centrifugation at 13,000rpm for 10mins, 4°C to collect the supernatant 
(lysate) into clean Eppendorf tubes. Lysates were stored at -20°C. 
 
Additionally, where indicated Sf9 cells were harvested 72h post-transfection and pelleted at 
1500rpm for 5mins. Cells were then lysed in 1mL of 0.1% Triton™ X-100 in PBS with 
cOmplete™ Protease Inhibitor Cocktail, EDTA-free (Roche), and homogenised with ten-strokes 
using a Dounce homogeniser on ice. Lysis reactions were then incubated on ice for 20mins 
followed by a brief vortex. Cell debris was pelleted at 13,000rpm for 15mins and supernatant 
transferred to clean Eppendorf tubes and kept on ice for subsequent pulldown using 
Dynabeads™ His-Tag Isolation and Pulldown (see section 2.2.5.2). Alternatively, 96h post-
infection of Sf9 cells with recombinant baculovirus, approximately 2L of cells were harvested 
by centrifugation at 4500rpm for 15mins, 4°C. Cells were then resuspended in 20mL of 0.1% 
Triton™ X-100 in PBS, with cOmplete™ Protease Inhibitor Cocktail, EDTA-free, and then 
sonicated for 10mins, at 20secs on/20secs off pulse-rate, on ice. This was followed by 
centrifugation at 15,000rpm, 30mins at 4°C. The clarified supernatant was collected into a 
clean tube and kept on ice for subsequent purification by affinity chromatography (see section 
2.2.5.5).  
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2.2.4.3 Cytoplasmic and membrane fractionation 
Non-infected and baculovrius-infected Sf9 cells were harvested 96h post-infection, and cell 
densities counted by haemocytometer. 4x106 cells were pelleted down at 1500rpm for 5mins, 
4°C, and resuspended in 300μL ice cold 0.1% Triton™ X-100 in PBS. Cells were lysed for 30mins 
on ice with intermittent vortexing every 5mins. Cell debris (membrane fraction) was pelleted 
down at 13,000rpm for 20mins, 4°C to collect the supernatant (cytoplasmic fraction). 
Following which, the cell debris was washed twice with 0.1% Triton™ X-100 in PBS and spun 
down at 13,000rpm, 4°C for 1min per wash. The supernatant was completely aspirated and 
the pellets were each resuspended in 60μl 5X Laemlli Buffer (250mM Tris-HCl [pH 6.8], 10% 
SDS [w/v], 25% glycerol [v/v], 0.02% Bromophenol Blue, 5% β-mercaptoethanol). Therefore, 
normalised loads were ensured for each fraction between samples. The membrane fraction 
was immediately boiled at 95°C for 10mins, and both fractions stored at -20°C. The 
cytoplasmic fraction was examined for nuclei/DNA contamination by mixing lysates with 6X 
DNA Loading Dye and subjecting samples to 1% TAE agarose gel electrophoresis. 
 
2.2.5 Quantification and detection of proteins 
2.2.5.1 Quantification of protein concentration 
Protein concentrations were generally measured following the Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific) instructions. BSA standards were prepared in the corresponding lysis 
buffer used to lyse cultured cells, and involved diluting the BSA stock (2mg/mL) to achieve 2, 
1.5, 1, 0.75, 0.5, 0.25, 0.125, and 0.025mg/mL standards. 25μL of standard and cell lysate 
sample was transferred to 96-well plates in duplicate, including 25μL of the corresponding lysis 
buffer to function as a blank standard. 200μL of BCA Working Reagent was added per well. 
Plates were mixed by gentle tapping, and protected from light and incubated at 37°C for 
30mins. Plates were allowed to cool to RT and absorbance at 562nm was measured using a 
spectrophotometer. After blank correction, standards were used to generate a standard curve, 
from which the concentration of protein in cell lysate samples was determined. Alternatively, 
purified His-tagged recombinant protein concentration was measured by preparing known 
quantities of BSA standards (200, 400, 600, and 800ng), and loading 2, 4, 6, and 8μL of purified 
recombinant protein onto a 10% Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) gel. After SDS-PAGE, the gel was stained in Coomassie® Blue Solution then 
destained using Destain Solution (see section 2.2.5.6). Destained gels were then imaged and 
exported as .TIFF files, and analysed as 8-bit images by densitometry using ImageJ. A standard 
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curve was generated from the known quantities of BSA standards, from which the 
concentration of recombinant protein was calculated. 
 
2.2.5.2 Recombinant His-tagged protein pulldown 
Transfected or baculovirus-infected Sf9 cell lysates for recombinant His-tagged protein 
expression was purified by Dynabeads™ His-Tag Isolation and Pulldown (Invitrogen). 10μL of 
Dynabeads™ was first washed by resuspending beads in 1mL of 0.1% Triton™ X-100 in PBS 
with cOmplete™ Protease Inhibitor Cocktail, EDTA-free, followed by aspiration of the 
supernatant using a DynaMag™-2 Magnet for 2mins (magnetic rack; Thermo Fisher Scientific). 
Dynabeads™ were then mixed with 1mL of lysate for 30mins on ice. Beads were then washed 
thrice with 0.1% Triton™ X-100 in PBS with cOmplete™ Protease Inhibitor Cocktail, EDTA-free, 
and a magnetic rack for 2mins. His-tagged recombinant protein was then eluted in 100μL high 
Imidazole Elution Buffer (500mM Imidazole, 20mM NaHPO4, 500mM NaCl) for 5mins, on ice, 
and supernatant transferred to clean Eppendorf tubes and stored at -20°C. 
 
2.2.5.3 SDS-PAGE 
Generally, 20μg of protein from whole cell lysates in RIPA Lysis Buffer or Lysis Buffer A was 
used. Whereas, 20μL of either cytoplasmic or nuclear fractions (corresponding to 2.6x105 cells) 
was run; or the indicated volumes of protein samples was used, for subsequent SDS-PAGE. 5X 
Laemmli Buffer was added to 1X final concentration in sample lysates and mixed. Protein 
samples were denatured by boiling at 95°C for 10mins, and subsequently resolved on 10% 
SDS-PAGE mini-gels or pre-cast 4-12% NuPAGE™ Bis-Tris gels (Thermo Fisher Scientific). 10% 
SDS-PAGE mini-gels were prepared by adjusting the volume of 30% acrylamide 
(acrylamide:bis-acrylamide 29:1 solution; Bio-rad) in a solution made to final concentrations of 
0.375M Tris-HCl (pH 8.8), 2.5μL/mL 10% SDS, 3.3μL/mL 10% APS, and 1.7μL/mL TEMED, in 
ultra-pure H2O. Stacking gels were prepared by adjusting 30% acrylamide to 4% in a solution 
made to final concentrations of 0.125M Tris-HCl (pH 6.8), 1.7μL/mL 10% SDS, 3.3μL/mL 10% 
APS, and 1.7μL/mL TEMED, in ultra-pure H2O. 10% SDS-PAGE mini-gels were set up in a Mini-
PROTEAN® Tetra Cell System (Bio-rad), and immersed in 1X SDS-PAGE Running Buffer (10X: 
30.3g Trizma-base, 144.1g glycine, 1% SDS, made to 1L ultra-pure H2O). Pre-cast NuPAGE™ 
Bis-Tris gels were set up in XCell SureLock™ Mini-Cell (Invitrogen) electrophoresis system, and 
gels immersed with 1X MES SDS Running Buffer (20X: 1M MES, 1M Tris-HCl [pH 7.3], 2% SDS, 
20mM EDTA). Boiled protein samples and 4μL of pre-stained protein marker as indicated – 
were loaded onto immersed 10% SDS-PAGE gels and run at 80V initially until sample and 
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Bromophenol Blue dye-front reached the separating gel, after which the voltage was increased 
to 150V until sample and Bromophenol Blue dye-front reached the bottom. 4-12% NuPAGE™ 
Bis-Tris gels were electrophoresed at constant 200V until the Bromophenol Blue dye-front 
reached the bottom. 
 
2.2.5.4 Western blotting 
Proteins were resolved by SDS-PAGE as described in section 2.2.5.3, after which proteins were 
transferred from SDS-PAGE gels to a Hybond® ECL™ nitrocellulose membrane (0.45μm pore 
size) using a Bio-Rad Mini Trans-Blot® Cell transfer system in pre-chilled 1X Transfer Buffer 
(10X: 30.3g Trizma-base, 144.1g glycine, made to 1L in ultra-pure H2O) with 20% methanol 
(v/v). Protein transfer was performed at 100mA/blot for 3h on ice. Membranes were then 
blocked for 1h at RT with gentle agitation (70rpm) using 5% skimmed-dried milk (w/v) in PBS-T 
(0.1% Tween™ 20 [v/v] in 1X PBS). Primary antibodies were prepared in PBS-T with 5% 
skimmed-dried milk (w/v) at the required dilutions overnight at 4°C using a roller shaker. The 
following day, membranes were washed with PBS-T for 10mins, thrice with agitation (70rpm). 
This was followed by incubation in secondary HRP-conjugated αMouse (Sigma-Aldrich), 
αRabbit (Sigma-Aldrich), or αGoat (Dako) antibodies at the required dilution in PBS-T with 5% 
skimmed-dried milk (w/v) for 2h at RT, with agitation at 70rpm. Membranes were washed in 
PBS-T for 10mins thrice with agitation (70rpm). Blotted proteins were then detected by 
chemiluminescence with ECL™ Western Blotting Detection Reagent (Amersham), which was 
prepared according to the manufacturer’s instructions by mixing ECL reagents 1 and 2 (1:1), 
and applying 1mL per blot. After 1min incubation with the ECL™ Western Blotting Detection 
Reagent mix, membranes were exposed on X-ray Hyperfilms (Amersham) for visualisation of 
proteins using an automated X-ray film processor.  
 
2.2.5.5 Dot Blot 
The indicated protein samples were blotted onto 1cm2 squares of Hybond® ECL™ 
nitrocellulose membranes (0.45μm pore size) at the indicated quantities, and blots dried for 
15mins at RT. Blots were blocked in PBS-T plus 5% skimmed-dried milk (w/v) for 1h at RT, with 
gentle agitation (70rpm). Blots were incubated with primary antibody (α6His-HRP; 1:5000) or 
antiserum at the indicated dilution, diluted in PBS-T plus 5% skimmed dried milk (w/v), for 1h 
at RT, 70rpm. This was followed by washes with PBS-T for 10mins, thrice with agitation 
(70rpm), followed by incubation in secondary HRP-conjugated αRabbit antibody at 1:2000 
dilution in PBS-T with 5% skimmed-dried milk (w/v) for 2h at RT, with agitation at 70rpm. 
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Membranes were finally washed in PBS-T for 10mins, thrice with agitation (70rpm). Blotted 
proteins were then detected by chemiluminescence with ECL™ Western Blotting Detection 
Reagent, which was prepared according to the manufacturer’s instructions by mixing ECL 
reagents 1 and 2 (1:1), and applying 100μL per square of blotted membrane. After 1min 
incubation with the ECL™ Western Blotting Detection Reagent mix, membranes were exposed 
on X-ray Hyperfilms for visualisation of proteins using an automated X-ray film processor. 
 
2.2.5.6 Coomassie® Blue staining 
10% SDS-PAGE gels were prepared and loaded with protein samples boiled at 95°C for 10mins. 
Protein samples were then resolved until the run-off the Laemlli loading dye-front. Following 
which, the 10% SDS-PAGE gel was stained in Coomassie® Blue Solution (0.2% Coomassie® 
Brilliant Blue R250 [w/v], 60% methanol [v/v], 8% acetic acid [v/v]) for 2h with gentle agitation. 
This was followed by destaining gels of background Coomassie® Blue stain using Destain 
Solution (25% ethanol [v/v], 8% acetic acid [v/v]) until background gel staining disappeared 
and protein bands were visible. 
 
2.2.5.7 Silver staining 
Silver gel staining of SDS-PAGE gels were performed following Peirce™ Silver Stain Kit (Thermo 
Fisher Scientific) instructions. After protein samples were subjected to SDS-PAGE, the gel was 
submerged and washed with ultra-pure H2O (>18 megohm/cm resistance) for 5mins, twice. 
Gels were then fixed in 30% ethanol:10% acetic acid solution (prepared using ultra-pure H2O) 
for 15mins, twice. This was followed by washing fixed gels in 10% ethanol solution (prepared 
with ultra-pure H2O) for 5mins, twice. The gel was then incubated in Sensitizer Working 
Solution for 1min, followed by two washes at 1min each with ultra-pure H2O. The Sensitizer 
Working Solution was initially prepared by mixing 1 part Silver Stain Sensitizer (composition – 
propriety information) with 500 parts ultra-pure H2O. The washed gel was then incubated in 
Stain Working Solution, prepared by mixing 1 part Silver Stain Enhancer (composition – 
propriety information) with 50 parts Silver Stain (composition – propriety information) for 
30mins. The gel was then washed in ultra-pure H2O, twice, for 20secs each wash. The 
Developer Working Solution, prepared by mixing 1 part Silver Stain Enhancer with 50 parts 
Silver Stain Developer (composition – propriety information), was added and gels incubated 
until silver stained bands appeared. After which, the Developer Working Solution was quickly 
removed and replaced with Stop Solution (5% acetic acid [v/v] prepared in ultra-pure H2O). 
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Gels were washed in Stop Solution for 1min, after which the Stop Solution was replaced and 
incubated for a further 10mins, and imaged.  
 
2.2.5.8 Affinity chromatography 
Clarified supernatant containing recombinant His-tagged protein was filtered through a 2μm 
glass fibre AP20 filter (Merck), and then subjected to immobilised metal affinity 
chromatography using a BioLogic LP System (Bio-rad) and a 5mL HisTrap HP column (GE 
Healthcare). Clarified and filtered supernatant containing recombinant His-tagged protein was 
then applied to a HisTrap HP 5mL column at 1mL/min flow rate in low Imidazole Binding Buffer 
(20mM Imidazole, 20mM NaHPO4, 500mM NaCl) to allow the His-tagged recombinant protein 
to bind to the immobilised resin of Nickel Sepharose. This was followed by elution of the His-
tagged purified recombinant protein from the immobilised Nickel Sepharose resin using high 
Imidazole Elution Buffer at 2.5mL/min flow rate. An in-run spectrophotometer was used to 
analyse the flow-through of total proteins and the elution of target His-tagged recombinant 
protein in 5mL elution fractions. 
 
2.2.5.9 Flow cytometry 
Mammalian or insect cell lines that were infected or transfected with GFP expressing vector or 
stained for intracellular protein were harvested (trypsinised for mammalian cell lines) and 
pelleted down at 1500rpm for 5mins. Following which, cells were washed in 1X PBS, and 
resuspended in 1% formaldehyde solution. Non and/or mock -transfected or -infected cell 
lines were prepared and fixed in parallel as negative controls for fluorescence, and used to 
gate fluorescence-positive cell populations. Fluorescence sorting was performed on a BD 
FACSCanto II flow cytometer (BD Sciences), and in-run data was acquired by FACSDiva 
Software (BD Sciences). Flow cytometry data was analysed on FlowJo 10.2 Software (FlowJo 
LLC). 
 
2.2.5.10 Fluorescent microscopy  
Cells were examined by phase contrast and fluorescence microscopy (using the FITC or Cy3 
fluorescence cubes where appropriate) using an IX51 Inverted Microscope (Olympus) with a 
10X objective lens. Images were captured with an XM10 Monochrome Camera (Olympus) 
attached to the inverted microscope and cellSens Imaging Software (Olympus). 
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2.2.5.11 Laser scanning confocal microscopy  
Cells were seeded into plates containing circular, glass coverslips, thickness 1.5, 0.13mm at the 
required density. At the indicated points cells adhered to coverslips were washed with 1X PBS 
once, then fixed in 4% formaldehyde solution for 30mins at RT. Cells were then permeabilised 
with 0.1% Triton™ X-100 in 1X PBS for 10mins at RT, and washed again three times. Fixed cells 
were blocked in Blocking Buffer (5% FCS [v/v], 5mg/mL BSA [w/v], in 1X PBS) for 1h at RT. Cells 
were then incubated with primary antibodies at the indicated dilutions (table 2.7) in Blocking 
Buffer for 1h at RT, with gentle agitation at 70rpm, or overnight at 4°C. After primary antibody 
incubation, cells were washed with Blocking Buffer five times, followed by incubation with 
Alexa-Fluor- or DyLight- conjugated secondary antibodies at the required dilutions (Table 2.8) 
for 1h at RT and gentle agitation at 70rpm. Staining controls included cells treated with only 
primary or secondary antibody. Cells were finally washed with Blocking Buffer six-times, and 
coverslips were mounted onto glass slides with DAPI mounting medium with Fluoroshield™ 
(Sigma-Aldrich). Images were taken on a Leica SPX upright laser scanning confocal microscope 
with a 63X objective lens, and images analysed by Leica Application Suite X software and 
ImageJ. 
 
2.2.5.12 Orthogonal cross-sections 
To rule out z-plane discrepancy of stained cells for fluorescent signals detected by confocal 
laser scanning microscopy, orthogonal cross-sections of merged z-stacks was acquired using 
Leica Application Suite X software. Orthogonal cross-sections images included the x-, y- and z- 
planes and were exported at .TIFF images. 
 
2.2.5.13 Line-profiling 
Merged confocal images were analysed by Leica Application Suite X software by drawing 
separate lines (ROI) through three individual cells, and included the nucleolar compartment. 
The nucleolar compartment was distinguished by high resolution DAPI-staining. Grey 
intensities were measured along the length of each ROI (μm) for target protein fluorescence 
and DAPI staining, and plotted against the position along the ROI. 
 
2.2.5.14 Quantification of corrected total cell fluorescence (CTCF) 
Confocal images were exported as .TIFF files and converted to 8-bit images. Using ImageJ, the 
total cell fluorescent intensities were calculated by drawing ROIs around individual cells (20 
ROIs per cell line, except of 5 ROIs for negative staining control – secondary antibody staining 
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only) and recording individual grey intensities. Background grey intensity was measured by 
taking the average of 5 ROIs from areas outside of the cell. Therefore, individual cell grey 
intensities were background corrected per measured cell line, and a final average grey 
intensity, corresponding to the CTCF, was then calculated. 
 
2.2.5.15 Quantification of nuclear:cytoplasmic ratios (N/C) 
Confocal images were exported as .TFF files and converted to 8-bit images. Mean fluorescent 
grey intensities in the nuclear and cytoplasmic regions were quantified from 30-40 individual 
cells per cell line, by drawing circular region(s) of interest (ROI) within the respective 
compartments using ImageJ. DAPI fluorescence distinguished the nuclear compartment of 
stained cells.  Background grey intensity was measured by taking the average of 5 ROIs outside 
of the cells. Therefore, background-corrected mean grey intensities for the nuclear and 
cytoplasmic compartments were calculated for background corrected N/C ratios per cell and 
log transformed. Finally, average N/C ratios were determined per cell line. 
 
2.2.6 Specific detection of DNA 
2.2.6.1 Surveyor® mutation screening 
To assess the genotypes of CRISPR/Cas9 genome edited cells, Surveyor® mutation screenings 
were performed. This involved PCR amplification of CRISPR/Cas9-targeted sequences using 2X 
PCR Master Mix, Surveyor® assay-designated oligo pairs (Table 2.2), and 50ng genomic DNA as 
template. Additionally, genomic template between parental cells (293T or Sf9 as indicated) 
was mixed with selected CRISPR/Cas9 genome edited cell line at the indicated ratios of 50ng 
total genomic DNA template, and PCR amplified. PCR of target sequences from parental 
genomic DNA served as reference control for subsequent mutation screenings. Therefore, 
Surv_sgRNA1.F(orward) and R(everse), Surv_sgRNA2.F(orward) and R(everse), 
Surv_sgRNA3.F(orward) and R(everse), and Surv_sgRNA4.F(orward) and R(everse) oligo pairs 
targeted the YBX1sgRNA1-4-specific sequences, respectively, in selected mammalian cell lines. 
Alternatively, the SFYBsgRNAsf1-targeted sequence in Sf9-based cell line was amplified using 
Surv-sgRNAsf1.F(orward) and R(everse) oligos. After confirmation of approximate sized PCR 
amplicon(s) by 2% TBE agarose gel electrophoresis and visualisation and imaging using a UV 
trans-illuminator, 20μL of sample was subjected to hybridisation, to facilitate heteroduplex 
formation between wildtype sequences and CRISPR/Cas9-mutated sequences. Heteroduplex 
formation was performed on a Biorad PTC-200 DNA Engine Thermal Cycler, and the 
programmed thermocycling conditions set up: 95°C for 10mins; -2.0°C/sec ramp down from 
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95°C-85°C, 85°C for 1min; -0.3°C/sec ramp down from 85°C-75°C, 75°C for 1min; -0.3°C/sec 
ramp down from 75°C-65°C, 65°C for 1min; -0.3°C/sec ramp down from 65°C-55°C, 55°C for 
1min; -0.3°C/sec ramp down from 55°C-45°C, 45°C for 1min; -0.3°C/sec ramp down from 45°C-
35°C, 35°C for 1min; -0.3°C/sec ramp down from 35°C-25°C, 25°C for 1min; and hold at 4°C. 
Mutation screening was then performed following the Surveyor® Mutation Detection Kit (IDT) 
instructions by taking 10μL of hybridised DNA and adding 0.1μL of 0.15M MgCl2, 2μL 
Surveyor® Enhancer S (composition – propriety information), and 1μL of Surveyor® Nuclease S. 
Reactions were gently spun down briefly, and then incubated at 42°C for 1h to catalyse 
nuclease S-mediated digestion of mismatched DNA, which would be present only in 
heteroduplex DNA. Finally, 3μL of Surveyor® Stop Solution (composition – propriety 
information) was then added to terminate the digestion reaction. Samples were immediately 
mixed with 6X DNA Loading Dye and subjected to 2% TBE agarose gel electrophoresis, to 
identify digestion bands and determine genotypes. 
 
2.2.6.2 High resolution melting (HRM) curve analyses 
To further confirm the genotype of CRISPR/Cas9-edited cells CRISPR/Cas9-targeted sequences 
were were subjected to HRM, as a sensitive measure to discriminate against wildtype 
sequences in a cloned cell population. Therefore, PCR amplified using 2X PCR Mastermix, 
Surveyor® assay-designated oligo pairs as described in 2.2.6.1. PCR amplicons were gel 
purified using the MinElute Gel Extraction Kit (Qiagen) after 1% TAE agarose gel 
electrophoresis, and DNA concentration quantified by Nanodrop™ 1000. Parental 293T 
genomic DNA served as reference control for subsequent HRM curve reactions and analysis. 
HRM reactions were prepared using SensiFAST™ HRM Kit (Bioline) and comprised of the 
following at their final concentrations: 1X SensiFAST™ HRM Mix constituting DNA polymerase, 
dNTPs (dATP, dGTP, dCTP, and dTTP), EvaGreen® dye, and 3mM MgCl2, HRM designated 
forward and reverse oligo pairs at 0.4μM each, and 2μL template DNA, made to 20μL with 
nuclease-free H2O. Non-template control reactions were prepared in parallel, with the 
substitution of template DNA with nuclease-free H2O. HRM-PCR reactions were performed 
using a Rotor-Gene 6000 platform (Qiagen) and Rotor-Gene Q Series Software (Qiagen). 
Thermocycling conditions were set up as follows: 95°C for 3mins; followed by 45 cycles of 95°C 
for 5secs, 58°C for 10secs, and 72°C for 10secs with acquisition. HRM followed at 0.1°C/step 
ramp up from 70°C-95°C with 90secs wait of pre-melt conditioning on the first step, and 1sec 
wait for all other steps, with acquisition. Dissociation curves derived from parental 293T 
template were assigned as homozygous control for genotype analyses. Dissociation peaks 
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were annotated and their associated dissociation temperatures set with the limit of ±0.5°C. 
HRM curve analyses were set to the 90% confidence threshold.  HRM-PCR reactions were also 
subjected to 2% TBE agarose electrophoresis to confirm PCR amplification or target DNA. 
 
2.2.6.3 Quantitative (q)PCR 
5μL of crude rAAV vector or purified rAAV vector was first treated with 50U of Benzonase® 
Nuclease for 1h at 37°C. This was followed by treatment of samples with 50U of DNase I 
(Invitrogen) in DNase I Buffer made to a final 1X (5X: 100mM Tris-HCl [pH 6.8], 10mM MgCl2, 
250mM KCl) in 50μL reaction volume. Samples were treated with DNase I overnight at 37°C, 
following which samples were briefly spun down and nucleases were heat-inactivated at 75˚C 
for 20mins. Samples were briefly spun down and then placed on ice. 1μL of 20mg/mL 
Proteinase K (Roche) was then added, and reactions incubated at 50°C for 2h for Proteinase K 
to degrade rAAV capsid proteins and liberate rAAV vector genomes. Proteinase K was then 
heat-inactivated at 95°C for 20mins, and samples briefly spun down. 5μL of sample was then 
used to measure physical rAAV2 vector genome titres by qPCR in duplicate, using oligos and 
Taqman probes specific for the CMV promoter – CMV.F(orward), CMV.R(everse), and 
CMV.hyd_probe (Table 2.2). Non-template control reactions for qPCR assays were also 
included and involved the addition of H2O instead of rAAV2 sample, in duplicate. Plasmid 
pAAV2-hrGFP was used to generate a standard curve by ten-fold serial dilution that ranged 
from 108-101 copies (5μL each in duplicate) using nuclease-free H2O. PCR reactions were 
performed using LightCycler® 480 Probes Master (Roche), and composed of the following at 
their final concentrations: 1X reaction buffer with FastStart Taq DNA polymerase, dNTP mix, 
3.2mM MgCl2, and 5μL of testing sample, made to 20μL using nuclease-free H2O. Reactions 
were assembled in white LightCycler® 480 Multiwell Plate 96. The LightCycler® 480 instrument 
II platform (Roche) was used for qPCR and thermocycling conditions were set as follows: 
10mins, 95˚C initial denaturation; followed by 45 cycles: 15secs denaturation at 95˚C, 30secs 
annealing at 60˚C, and 5secs extension at 72˚C, with acquisition. Absolute quantitation of 
vector genome titres was performed using the LightCycler® 480 instrument II with automated 
thresholding and its pre-programmed fit-points algorithm. Recombinant AAV titres were 
calculated as vector genomes/mL from the standard curves. 
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2.2.7 Pulldown and protein binding assays 
2.2.7.1 Double-stranded DNA-affinity YB1 pulldown 
5’-desthiobiotin modified capture probes were PCR amplified using Promega 2X Master Mix 
(see Table 2.6 for list of oligos for PCR). Using pAAV2-MCS as template the ITR capture probe 
was amplified with ITR_YB1.F(orward) and R(everse) oligos. Control capture probes also used 
pAAV2-MCS and L- or R- ITR_YB1.F(orward) and R(everse) oligo pairs, for left- and right- ITR 
flanking sequences, respectively. Using pHelper as template the rep capture probe was 
amplified with rep_YB1.F(orward) and R(everse). Using pAAV2/2-RC as template the E2A 
capture probe was amplified with E2A_YB1.F(orward) and E2A_YB1.R(everse). All PCR 
amplicons were purified by 1% TAE agarose gel electrophoresis and gel extraction. Otherwise, 
short dsDNA 3’-biotin labelled capture probes were generated by annealing ITR(-
)sense.F(orward) and R(everse), E2A(-)sense.F(orward) and R(everse), rep(+)sense.F(orward) 
and R(everse), GCcomp.F(orward) and R(everse), and Luciferase.F(orward) and R(everse) oligo 
pairs, together. 
 
Dynabeads® M-270 Streptavidin Beads (Invitrogen) were initially vortexed for 30secs for 
complete resuspension of beads. Streptavidin beads were transferred to clean Eppendorf 
tubes, and thrice washed in bulk with 500μL of 0.5X SSC (20X: 3M NaCl, 0.3M sodium citrate) 
and magnetic rack for 2mins each. Streptavidin beads were then washed thrice with 500μL 
Binding Buffer A (25mM HEPES [pH 7.5], 100mM KCl, 12.5mM MgCl2, 1mM DTT, 0.1% IGEPAL-
CA630 [v/v], 20% glycerol [v/v], 3% BSA) and 2mins on magnetic rack, followed by incubation 
in 500μL of Binding Buffer A for 30mins at RT. The Binding Buffer A was aspirated after 
exposure to a magnetic rack for 2mins, and beads were resuspended in their original volume 
using Binding Buffer A. Where indicated, 1mg (100μL) or 0.2mg (20μL) of streptavidin beads 
was used per pulldown.  
 
10μg of 5’-desthiobiotin-labelled DNA capture probes was then added to 1mg beads and 
mixed to a final volume of 500μL of Binding Buffer A. As a negative control for protein 
pulldown, streptavidin beads were incubated with Binding Buffer A only. Capture probes were 
immobilised for 30mins at RT with rotation. Coated beads were then isolated by magnetic rack 
for 2mins and free capture probe aspirated from the supernatant. Beads were washed thrice 
with 500μL of Binding Buffer A and magnetic rack for 2mins. After final aspiration of 
supernatant, 200-500μg (as indicated) of cell lysate (lysed in Lysis Buffer A) and 5μg poly(dI-
dC) (Sigma-Aldrich) was mixed and volumes normalised to 500μL in ice-cold Lysis Buffer A. 
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Protein binding was facilitated overnight at 4°C with rotation. Alternatively, 2μg 
(approximately 100pmol) of 3’-biotin labelled dsDNA capture probe (corresponding to 100μL 
of annealed oligo pairs; see section 2.2.1.7) was added to 0.2mg of beads, and final volume 
adjusted to 500μL with Binding Buffer A. 3’-biotin labelled capture probes were immobilised 
for 30mins at RT with rotation, followed by three washes using Binding Buffer A and magnetic 
rack for 2mins. This was followed by the addition of 100μL of cold competitor DNA probe (see 
section 2.2.1.7) to DNA capture probe-bound beads at the required ratio. Negative controls 
included the omission of the cold competitor dsDNA probe, and volume was substituted by 
Binding Buffer A. 200μg of cell lysate (lysed in Lysis Buffer A) was also added per pulldown, 
and final volumes adjusted to 500μL of Binding Buffer A. Reactions were incubated at 4°C for 
1h with rotation. In both cases the streptavidin beads were washed five-times with ice-cold 
500μL of Binding Buffer A and twice with ice-cold 1X PBS, via magnetic rack for 2mins each. 
Beads were then mixed with 50μL 5X Laemlli Buffer and boiled for 10mins at 95°C to dissociate 
capture probe-protein from streptavidin beads. A final pulldown of beads was performed 
using a magnetic rack for 2mins, and supernatant transferred to a new Eppendorf tube. 
Samples were boiled again for 5mins at 95°C before loading 20μL of sample onto a 10% SDS-
PAGE gel and subjected to Western blotting for YB1 pulldown. 
 
2.2.7.2 Single-stranded DNA-affinity YB1 pulldown 
50pmol of 3’-biotin labelled ssDNA capture probe (Table 2.6) was diluted to 500μL of Binding 
Buffer A and added to 0.2mg of streptavidin beads. Capture probes were immobilised for 
30mins at RT with rotation. This was followed by thrice washing the beads using Binding Buffer 
A and magnetic rack for 2mins. The 100μL of cold competitor ssDNA probe –
GCcomp.F(orward) was then added, and corresponded to the required ratio of cold 
competitor by scaling-up the volume of 10μM cold competitor ssDNA probe. Controls included 
no addition of cold competitor ssDNA probe (1:0 ratio of ssDNA capture probe:cold ssDNA 
competitor); the volume of which was substituted by Binding Buffer A. 200μg of cell lysate 
(lysed in Lysis Buffer A) was added per pulldown, and final volumes adjusted to 500μL of 
Binding Buffer A. Reactions were incubated at 4°C for 1h with rotation. Beads were then 
washed with 500μL Binding Buffer A five times and 500μL 1X PBS twice, using a magnetic rack 
for 2mins. Upon the final wash beads were pelleted down at 13,000rpm for 5mins and then 
exposed to magnetic rack for 2mins for the complete aspiration of the final wash volume. 
Beads were resuspended in 50μL of 5X Laemlli Buffer and boiled for 10mins at 95°C to 
dissociate capture probe-protein from streptavidin beads. Beads were finally pelleted down 
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for 1min at 13,000rpm and then supernatant harvested after using a magnetic rack. The 
supernatant was transferred to a new Eppendorf tube, then boiled again for 5mins at 95°C 
before loading 20μL of sample onto a 10% SDS-PAGE gel and subjected to Western blotting for 
YB1 pulldown. 
 
2.2.7.3 Electrophoretic mobility shift assays (EMSA) 
Selected plasmids (200ng) or dsDNA capture probes (50ng) were incubated with purified 
rSfYB(His)10 protein at various quantities (as indicated), and were prepared by mixing each 
component in Cutsmart Buffer (NEB) made to a final 1X concentration in volume of 30μL in 
nuclease-free H2O. As a negative control, each plasmid or dsDNA capture probe was prepared 
in Cutsmart Buffer without the addition of rSfYB(His)10 protein. The volume of which was 
substituted with 1X Cutsmart buffer. Binding reactions were subjected to 37°C incubation for 
30mins and then cooled on ice immediately. Samples were then mixed with 6X DNA Loading 
Dye and then subjected to agarose gel electrophoresis, and gels visualised and imaged. 
 
2.2.8 Statistics 
Graphs and statistical analyses were performed with GraphPad Prism 6 Software. Student’s T-
test was used to assess for statistical significance. Growth curves and LDH cytotoxicity assays 
were analysed using two-way ANOVA with Sidak test for multiple comparisons. Data is 
presented as mean ±standard deviation (±SD), with P < 0.05 as the upper cut-off for statistical 
significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 or P < 0.0001 (as indicated). 
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Chapter 3: Establishment of YB1 Knockout Cell 
Lines for Recombinant AAV Vector Production 
Using CRISPR/Cas9 Genome Editing 
 
3.1.0 Introduction 
Recombinant Adeno-associated viral (rAAV) vectors have become a highly attractive and 
successful vector tool for gene therapy applications. This is due to a number of inherent 
properties associated with AAV that make this the vector of choice for targeting genetic 
diseases. Advantages include the fact that AAV can mediate long-term transgene expression in 
vivo (Xiao et al., 1996), and rAAV vectors have shown clinical efficacy in a number of clinical 
trials (Nathwani et al., 2011; Nathwani et al., 2014; French et al., 2018; Miesbach et al., 2018). 
More promising is the fact that the first EU-licensed gene therapy product, Glybera, and the 
even more recently US-approved Luxturna, are both rAAV-based gene therapy products for 
the treatment of hereditary lipoprotein lipase deficiency (Carpentier et al., 2012) and Leber’s 
congenital amaurosis (Bennett et al., 2016), respectively. These collectively demonstrate that 
rAAV-based gene therapies are a promising advancement as a modern healthcare and 
medicine.  
 
However, the clinical efficacy of using rAAV vectors is restricted by certain limitations. The 
prevalence for neutralising antibodies against different AAV serotypes in the human 
population, for example, presents as a significant obstacle towards a completely efficacious 
gene therapy (Kotterman et al., 2015). Additionally, the demand for sufficient rAAV vector 
quantities is constrained by current production systems. There still remains a need for rAAV 
vector quantities that meet the demands of clinical studies; a situation worsened by the 
strategy to circumvent the limitation of pre-existing immunity by administration of high titres 
of rAAV as one of the ways to improve the effectivity of rAAV vector products. Particular 
advancements in rAAV vector designs have been explored, which encourage further 
engineering rAAV vectors. Approaches in this regard include rAAV vectors that elicit reduced, 
or ablate, immune responses (Martino et al., 2013; Wang et al., 2014; Tse et al., 2017), exhibit 
improved transduction profiles or have enhanced target specificities (Aslanidi et al., 2013; 
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Buning et al., 2015; Ling et al., 2016). AAV vector production methods have also been further 
developed from the conventional triple plasmid co-transfection of 293T cells (Xiao et al., 
1998), or co-infection of Sf9 cells with recombinant baculoviruses (Urabe et al., 2002; Smith et 
al., 2009). These developments include the generation of partially stable cell lines for rep 
and/or cap expression, therefore off-setting the limitation of exogenously introducing these 
proteins into the production cycle (Gao et al., 2002b; Mietzsch et al., 2014). However, our 
understanding of the role of host cellular factors towards AAV genome processing and/or AAV 
assembly remains limited. Recently, host cell factors, including human Y-Box protein (YB)1 
protein (encoded by YBX1), have been found associated with rAAV particles; and targeted 
shRNA-mediated knockdown of YB1 protein expression in 293T cells correlated with enhanced 
rAAV vector titres – up to 45-fold more rAAV2 vector genomes were quantified compared to 
scramble controls (Satkunanathan et al., 2014). This approach demonstrated a rather novel 
rAAV production system involving the regulation of endogenous, cell-intrinsic protein 
expression to influence rAAV vector production. 
 
In the present study, host cell gene expression was modified permanently using the RNA-
guided clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 genome 
editing technology. Particularly, host cell genome editing focused on targeting the human 
YBX1 gene, given the targeted knockdown of YB1 protein expression correlated with an 
enhanced rAAV vector producer cell line after transient triple transfection for rAAV2 and 8 
production (Satkunanathan et al., 2014). Additonally, the enhanced rAAV vector producer cell 
line quality was lost over time, presumably due to the progressive loss of YB1 downregulation 
by shRNA (Satkunanathan et al., 2014). Ultimately, CRISPR/Cas9 offers the ability to 
permanently edit the host genome, with minimal changes to its entire architecture and 
composition of the target genome. This is in contrast to alternative methods of gene 
manipulation, such as shRNA technology which requires the incorporation of shRNA and viral 
vector elements randomly into the genome in order to maintain their effect. Additionally, 
shRNA or RNAi mediated gene silencing strategies are often complicated by off-target effects 
including the upregulation of rhodopsin or interferon promoter activities (Masuda et al., 
2016), or transient functionality, with eventual silencing or loss of shRNA expression over time 
(Ahn et al., 2011; Satkunanathan et al., 2014). Therefore, use of CRISPR/Cas9 technology was 
harnessed to offset the transient shRNA-mediated downregulation of YB1 expression 
experienced by Satkunanathan et al. (2014), to potentially develop a permanent high titre 
rAAV vector production platform.  
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The aim of this study was to utilise the CRISPR/Cas9 genome editing system to target the YBX1 
gene and knockout YB1 protein expression in 293T cells. Further aims included an extensive 
characterisation of the YB1 knockout cell lines generated by CRISPR/Cas9 genome editing. 
Additionally, the suitability of the approach to establish stable YB1 knockout cell lines for the 
intended purpose of rAAV vector production was assessed. The data demonstrated that 
targeted knockout of YB1 protein expression was successfully achieved in 293T cells, and 
supported by a range of both phenotypic and genotypic assessments. Although, YB1 knockout 
did not enhance rAAV2 vector titres, specific targeting of YB1 in 293T cells generated an 
undesirable phenotype with regards to transient transfection modalities. In particular, the use 
of chloroquine and Calcium Phosphate precipitation methodology had an adverse effect of 
YB1 knockout, which potentially limits the broader use of these YB1 knockout cell lines. 
 
3.2.0 Results 
3.2.1 Cloning YBX1-specific gRNA designs into GeneArt CRISPR nuclease vector 
A total of four gRNAs were designed that targeted the YBX1 gene at different sequences (see 
Fig. 3.1A for a schematic of gRNA target sequences relative to the entire YBX1 gene structure). 
These were annotated YBX1sgRNA -1, -2, -3, and -4, and were specific targeting exon 1, 5, 
intron 6, and exon 7 of the YBX1 gene, respectively. The gRNA designs were each cloned into a 
pre-linearised GeneArt™ CRISPR nuclease vector from Invitrogen as their complementary 
dsDNA intermediate as per manufacture’s guidelines (Fig. 3.1B). Sequencing data showed that 
each YBX1sgRNA(1-4) DNA sequence had been successfully cloned into the all-in-one vector as 
intended (Figs. 3.1C-F; underlined sequences refer to the intended gRNA target sequences). 
Further to this, sequence reads upstream and downstream of the cloned gRNA sequences 
corresponded to the GeneArt™ CRISPR nuclease vector backbone. Therefore, CRISPR nuclease 
vectors with the required YBX1-target specific sgRNA were successfully constructed with the 
intention of targeting different intron or exon targets of the YBX1 locus in 293T cells. CRISPR 
vectors plasmids were referred to as pCRISPR-YBX1sgRNA1-4 for their respective YBX1sgRNA 
design (gRNA1-4). 
    
 
     
1
4
1
 
Figure 3.1 Cloning of YBX1-specific into GeneArt™ 
linearised, all-in-one, CRISPR nuclease vector for 
CRISPR/Cas9 genome editing. A) Schematic showing 
YBX1-specific gRNA designs and their target sequence 
location relative to the entire YBX1 gene structure. B) 
Cloning strategy to clone YBX1sgRNA(1-4) sequences 
into the GeneArt™ linearised, all-in-one CRISPR 
nuclease vector involving annealing ssDNA pairs with 
appropriate overhangs. Annealed oligos encode the 
YBX1-specific gRNA(1-4). These are individually ligated 
as a dsDNA intermediate into the GeneArt linearised 
vector downstream of a U6 promoter and upstream to 
the tracrRNA encoded sequence. C-D) Sequencing and 
sequencing chromatograms confirmed cloning of 
GeneArt™ CRISPR nuclease vector harbouring (C) 
YBX1sgRNA1 sequence, or (D) YBX1sgRNA2 sequence, 
or (E) YBX1sgRNA3 sequence, or finally (F) 
YBX1sgRNA4 sequence. Underlined sequences 
correspond to the intended gRNA design.  
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3.2.2 Initial screening of transfected 293T cells identified potential YB1 knockout clones  
To establish YB1 knockout cell lines, 293T cells were transfected with pCRISPR-YBX1sgRNA1-4. 
The transfection efficiency of pCRISPR-YBX1sgRNA1-4 plasmids was examined by fluorescent 
microscopy given the co-expression of orange fluorescent protein (OFP) reporter with SpCas9. 
Overall transfection efficiency was empirically determined, and almost all cells were positive 
for OFP expression for each vector construct used (Fig. 3.2A; panels a-b, c-d, e-f, and g-h, for 
pCRISPR-YBX1sgRNA1-4 tranfections, respectively). Non-transfected 293T cells served as a 
negative control for background OFP expression (Fig. 3.2A, panels i-j), and exhibited no OFP 
expression by fluorescence microscopy. However, transfection efficiency and OFP expression 
does not reflect genome editing. In order to establish a cell line that is truly a knockout of YB1, 
transfected 293T cells underwent single cell cloning and five clones of each target was 
subjected to initial screening by Western blot against bulk- and non- transfected 293T control.  
 
The bulk transfected cells for each YBX1-specfic sgRNA indicated that gene editing had been 
achieved using CRISPR/Cas9 genome editing. YB1 signal was reduced for bulk transfected cell 
populations when compared to 293T control cells (Figs. 3.2B-E, see lanes 2 and 3). However, 
this was not a consistent observation for YBX1sgRNA2 between 293T bulk transfected cells in 
duplicate (Fig. 3.2C, compare lanes 2 and 3) relative to control 293T. Bulk set 1, instead, 
demonstrated equivalent YB1 protein levels compared to non-transfected 293T control, 
indicating little to no gene editing was evident in this particular bulk transfected population. 
Analysis of single cell clones (five for each pCRISPR-YBX1 sgRNA1-4 transfection) indicated that 
targeting exon 1 and intron 6 produced the most YB1 knockout clones, contributing to 4/20 
(20%) clones analysed (Figs. 3.2B and D, and lanes 2 and 5-7, respectively). Overall, targeting 
exon 1 using YBX1sgRNA1 demonstrated 20% (1/5 clones) knockout rate (Fig. 3.2B), targeting 
intron 6 using YBX1sgRNA3 produced clones that showed 60% (3/5 clones) knockout rate (Fig. 
3.2D). Targeting exon 5 using YBX1sgRNA2 also yielded mostly marked reduction of YB1 levels 
in single cell clones analysed (Fig. 3.2C, lanes 5-7). Similarly, targeting of exon 7 using 
YBX1sgRNA4 produced one clone with a reduction in YB1 levels post-single cell cloning (Fig. 
3.2F, lane 4). Unusually, a single clone exhibited YB1 overexpression when compared to the 
equal loading of 293T control (Fig. 3.2F, lane 7). No single cell clones exhibited an YB1 
knockout phenotype for clones derived from targeting exon 5 or 7. Clones A2, B2, C5, and D1 
(the prefix A-D refers to YBX1-sgRNA1-4 targeting, respectively) were selected for further 
characterisation. 
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Figure 3.2 Establishing YB1 knockout cell lines. A) Bright field and fluorescent microscopy images (left 
and right panels, respectively) indicated that most cells exhibited OFP expression for pCRISPR-
YBX1sgRNA1-4-transfected 293T cells, 72h post-transfection (panels a-b, c-d, e-f, and g-h, respectively). 
Non-transfected 293T cells served as negative control for transfection (panels i-j). B-E) Western blot 
using αYB1 (ab76149) of non-transfected 293T (baseline control for YB1 expression; lane 1), bulk 
transfected 293T populations (lanes 2 and 3), and five single cell clones (lanes 4-8) were analysed for 
each pCRISPR-YBX1sgRNA1-4 transfections, respectively. Western blot analysis indicated that partial 
knockout and complete knockout cell lines were achieved. GAPDH protein expression was used as 
loading control (bottom panels for each).  
 
3.2.3 Screening YB1 knockout clones for epitope disruption as a result of CRISPR/Cas9 
genome editing of YBX1 
Depending on the gene editing by CRISPR/Cas9, mutations that disrupt the target epitope 
recognised by αYB1 (ab76149) may have interfered with Western blot analysis. Therefore, 
further Western blotting using αYB1 raised against different N- (PA5-19453) and C-terminus 
(ab114999) epitopes was assessed. Overall, Western blot analysis showed comparative 
profiles were observed between the three different antibodies for clones A2, B2 and C5 (Fig. 
3.3A). Although difficult to observe in the blots (Figs. 3.3A and C) a diminished YB1 signal is 
observed for B2 clone for each αYB1 (see black arrows). However, using alternative αYB1 
(ab114999 and PA5-19543), clone D1’s YB1 levels were considered comparable to the 293T 
control. These findings suggest that genome editing in D1 clone may have disrupted the 
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epitope for ab76149 only. Furthermore, the YBX1sgRNA4 design targeted YBX1’s last exon, of 
which subsequent genome editing may have occurred so far into the YBX1 gene sequence that 
the gene may have mostly retained in-frame coding sequences and significant homology to 
wildtype YBX1. Sufficient homology may enable the avoidance of non-sense mediated mRNA 
decay, with the ab76149-specific epitope disrupted only. The N-terminus-specific αYB1 (PA5-
19453) was raised against peptide corresponding to 1-100aa of YB1, and C-terminus-specific 
αYB1 (ab114999) was raised against peptide corresponding to 224-274aa. With the C-terminus 
specific αYB1 (ab76149) epitope target undisclosed by its manufacturer, it becomes difficult to 
further analyse the exact nature of this potential ‘false-positive’ partial knockout. Given the 
ambiguous YB1-expression profile exhibited by clone D1 this clone was excluded from further 
characterisation.  
 
Clones A2, B2, and C5 were then subjected to a second round of single cell cloning. The 
purpose of this was to analyse subclones to reaffirm that the selected clones were not 
heterogeneous for the YB1-expressing phenotype, and that the initial round of single cell 
cloning had been efficient. The second generation of A2 and C5 clones (subclones A2.1-2.3 and 
C5.1-3, respectively) demonstrated similar profiles to their parental YB1 knockout cell lines 
(Fig. 3.3B). This confirmed confidence in single cell cloning technique as producing bona fide 
knockouts. Clone B2 demonstrated a consistent reduction in YB1 when compared to the 293T 
control, as did its subclones (B2.1-3) when using the different αYB1 (Fig. 3.3C). Western 
blotting A2, B2 and C5 subclones with a larger coverage of YB1-specific antibodies provided 
evidence that the lack of YB1 signal observed in A2 and C5 clones, and their subclones, was 
likely due to the complete knockout of the YBX1 gene by CRISPR/Cas9 genome editing rather 
than epitope disruption.  
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Figure 3.3 Western blot analysis for epitope disruption of selected YB1 knockout cell lines. Epitope 
disruption was ruled out for the observed YB1 knockout phenotypes, especially for clones A2, B2 and 
C5. A) Western blot analysis of selected clones: A2, B2, C5 and D1 using three YB1-specific antibodies 
(ab76149, ab114999, and PA5-19453) that bind to different YB1 epitopes. D1 clone demonstrated 
epitope disruption, which resulted of the partial knockout phenotype previously observed. Western blot 
analysis of selected clones (B) A2, C5, and (C) B2, and their corresponding sub-clones (generation 2), 
showing that the knockout and partial knockout phenotypes observed were considered preserved and 
monoclonal. Non-transfected 293T was used as a base-line control. GAPDH expression was used as a 
loading control. Black arrows refer to diminished YB1 signal observed for B2 clone, which were difficult 
to observe. 
 
3.2.4 Phenotyping YB1 knockout cell lines using immunocytochemistry (ICC) 
The YB1 knockout phenotype was further confirmed using immunocytochemistry. The benefit 
here was exploring for YB1 knockout phenotypes in selected clones, using αYB1 to recognise 
whole, intact YB1 molecule, as opposed to SDS-reduced protein lysates as per Western 
blotting. Essentially, the exposure of epitopes is fundamentally different – whole molecule in 
its native state versus linearized polypeptide (Fieser et al., 1987). 293T cells provided the 
positive control for YB1 expression and localisation by ICC; the localisation of which was 
defined as cytoplasmic as no YB1 signal was identified in the nuclear compartment, which was 
differentiated by DAPI-staining (Fig. 3.4A, panel a-c). YB1 was undetectable for selected YB1 
knockout clones A2, B2, and C5, reflecting the YB1 knockout phenotypes observed by Western 
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blotting (Fig. 3.4A, panels d-f, g-i, and j-l, respectively). Clone B2 previously showed a partial 
knockout phenotype by Western blotting, but using ICC, clone B2 displayed profiles similar to 
that of A2 and C5 clones (Fig. 3.4A, panels g-i). Control 293T cells stained with either αYB1 
(PA5-19453) or secondary antibodies only functioned as negative staining controls, and 
demonstrated only background fluorescence (Fig. 3.4A, panels m-o and q-s, respectively). 
 
Orthogonal cross-sections of 293T and selected YB1 knockout cells confirmed the cytoplasmic 
localisation and knockout of YB1 in 293T cells and selected cell clones, respectively (Figs. 3.4B-
E). Taking into account the depth of the cell (z-plane) the localisation of endogenous YB1 was 
further confirmed as cytoplasmic in parental 293T cells (Fig. 3.4B), and undetectable 
throughout YB1 knockout clones A2, B2, and C5 (Figs. 3.4C-E). The degree of fluorescent 
intensity, reflecting YB1 abundance, was quantitatively analysed. Fig. 3.4F represents the 
normalised or corrected total cell fluorescence (CTCF) of 293T, A2, B2 and C5 cell lines against 
negative staining of control (293T secondary Abs). CTCF measurements indicated that A2, B2, 
and C5 clones, especially B2 clone, exhibited similar average CTCF (525.6±148.9, 
1078.53±351.41, and 698.1±136, respectively) to 293T negative staining control (293T 
secondary Abs; 955.86±230.22). The reduced average CTCF measurements were considered 
statistically significant for A2 and C5 (n = 20 individual cells measured; P < 0.001P < 0.01). 
Nonetheless, CTCF in 293T positive control for YB1 staining was markedly measurable 
(7969.49±2621.94), and statistically significant to 293T negative staining control (n = 20 cells 
each, P < 0.001), and by extension the selected YB1 knockout clones (Fig. 3.4F). 
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Figure 3.4 ICC and confocal microscopy analysis for YB1 knockout phenotype. YB1 knockout 
phenotypes were further validated using ICC and quantifying CTCF and compared between 293T, A2, 
B2, C5. A) ICC analysis by confocal laser scanning microscopy demonstrated that YB1 was only 
detectable for 293T positive control (panels a-c). Panels (d-f), (g-i), and (j-l) refer to selected YB1 
knockout clones (A2, B2, and C5, respectively) stained with both primary (PA5-19453) and secondary 
(αRabbit-Alexa Fluor 488) antibodies for YB1 detection. Panels (m-o) and (p-r) refer to 293T cells stained 
with either primary or secondary antibodies only, respectively, and functioned as staining controls for 
background fluorescence. Scale bar = 20μm, and representative of all panels. (B) Orthogonal section 
analysis of 293T stained cells for YB1 expression and localisation, demonstrating that YB1 protein is 
almost exclusively localised to the cytoplasm and absent from the nucleus. Whereas, orthogonal section 
analysis of YB1 knockout clones (C) A2, (D) B2, and (E) C5 demonstrated an absence of YB1 signal 
throughout the cell, considering all planes of view. Figure legend continues next page. 
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Figure 3.4 ICC and confocal microscopy analysis for YB1 knockout phenotype. F) Graph presenting 
CTCF measurements between 293T positive control, A2, B2, and C5, and 293T secondary Abs only 
stained negative control, indicating that YB1 knockout clones exhibited fluorescence signal similar to the 
293T secondary Abs staining control. Error bars reflect ±SD from mean, n = 20 measured cells for each 
cell line, except 293T secondary Abs only stained control, n = 5; **, P < 0.01; ***, P < 0.001 or P < 
0.0001. Abs, antibody; CTCF, corrected total cell fluorescence. 
 
3.2.5 Sequencing YB1 knockout clones demonstrated mutations by CRISPR/Cas9  
The selected YB1 knockout cell clones were also analysed by genomic methods to establish 
their exact genotypes. Genomic DNA was isolated from parental 293T cells, following which 
the equivalent regions targeted by YBX1sgRNA1-4 were PCR amplified as 400-500bp amplicons 
using Surv_gRNA1, 2, 3, and 4, forward and reverse pairs (Figs. 3.5A and B; referred to as 
293A-D). The intended genomic regions from control 293T, reflecting regions targeted 
centrally by YBX1sgRNA1 (expected 407bp, lane 293A), YBX1sgRNA2 (expected 467bp, lane 
293B) amplicons were successfully identified (Fig. 3.5A). Likewise, genomic regions reflecting 
the regions targeted centrally by YBX1sgRNA3 (expected 405bp, lane 293C) and YBX1sgRNA4 
(expected 435bp, lane 293D) were also successfully amplified. The required sequences could 
be PCR amplified in 293T and selected YB1 knockout cell lines for subsequent purification, 
despite non-template control reactions (NTC-A-D) for each PCR amplification showing 
formation of primer dimers only (Figs. 3.5A and B). 
 
Figure 3.5 PCR amplification of target sequences from 293T genomic DNA template yielded expected 
400-500bp PCR products. Sequences reflecting the YBX1sgRNA(1-4)-target specific DNA sequences were 
PCR amplified and run on a 1% TAE agarose gel. Agarose gel electrophoresis showed that (A) the 
expected 407bp and 467bp DNA sequences were successfully amplified, representing 400-500bp 
regions that include the YBX1sgRNA1 (293A lane) and YBX1sgRNA2 (293B lane) -specific sequences. 
Likewise, (B) the expected 405bp and 435bp DNA sequences were successfully amplified, representing 
400-500bp regions that include the YBX1sgRNA3 (lane 293C) and YBX1sgRNA4 (lane 293D) -specific 
sequences were successfully amplified. NTC-A-D reactions for all respective primer pairs showed no 
contamination. M, Generuler 1kb DNA ladder. NTC, non-template control. 
 
Using the reference genome sequence (NC_000001.11) as control, comparative sequencing 
analyses enabled identification of the exact mutations causative of the observed knockout 
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phenotypes. Sequencing results confirmed that successful mutations were introduced by 
CRISPR/Cas9, especially when compared to reference control. Of note, clone A2 displayed a 
clean single bp deletion 104nt upstream of the targeted PAM sequence, and was located 
within exon 1 of the YBX1 gene (Fig. 3.6A, top sequence read). Sequencing of the B2 clone 
indicated a clean 10bp deletion that covers intron 4 and exon 5 junction of the YBX1 gene (Fig. 
3.6B, bottom sequence read). In particular an 8bp deletion was observed at the 3’-end of 
intron 4 and 2bp deleted from the 5’-end of exon 5 of the YBX1 gene. Sequencing of the C5 
clone displayed a more complicated mutation profile suggestive of a heterozygous genotype, 
where a single nucleotide substitution (A>C) (highlighted bold and underlined in Fig. 3.7) 
followed immediately by 8bp deletion; this mutation was localised at the 3’-end of exon 6 (Fig. 
3.7). 
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Figure 3.6 Sanger sequencing of 
YB1 knockout clones A2 and B2 
identifies CRISPR/Cas9-
mediated mutations. A) Top 
sequence read reflects Sanger 
sequencing read and 
chromatogram of A2 clone 
showing a single bp deletion 
(dash line), compared to 
wildtype reference sequence. B) 
Bottom sequence read reflects 
Sanger sequencing read and 
chromatogram for B2 clone, a 
10bp deletion (striked line) 
compared to WT sequence as 
reference. *, target 
complementary sequence 
analysed; PAM, protospacer 
adjacent motif; WT, wildtype. 
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Figure 3.7 Sanger sequencing of YB1 knockout clone C5 identifies CRISPR/Cas9-mediated mutations. 
Sequence read reflects Sanger sequencing read and chromatogram profile for C5 clone, which displays 
an A>C substitution (bold and underlined), followed by 8bp deletion (striked line) when compared to 
wildtype (WT) sequence as reference. *, target complementary sequence analysed; PAM, protospacer 
adjacent motif; WT, wildtype. 
 
Additionally, 293T parental cells and clones A2, B2 and C5 were kept in culture for an extended 
period, to examine the stability of the YB1 knockout phenotype in selected clones  at 1, 3 and 
6 months post-transfection. As a result, sequencing of the equivalent targeted regions from 
293T genomic DNA corresponded to the reference sequence (NC_000001.11) at all harvest 
points (Figs. 3.8A-C, see reference sequence and sequence reads at 1, 3 and 6M). YB1 
knockout clones A2 (Fig. 3.8A), B2 (Fig. 3.8B), and C5 (Fig. 3.8C) showed identical sequence 
profiles as was previously observed (Figs. 3.8A-C, respectively; compare 1M, 3M, and 6M 
sequence reads to mutated reference sequences). However, further indicative of a 
heterozygous genotype, the dominant A>C substitution initially observed directly upstream of 
the 8bp deletion in C5 clone would read either A or C across the timecourse (Fig. 3.8C, see 
boxed). This was likely a result of both A and C (and even G) nucleotides existing at this 
particular location across the copies of mutated YBX1 (Fig. 3.7, refer to C5 sequence 
chromatogram). The dominant 8bp deletion that followed this A>C substitution was consistent 
throughout the extended culture period. To conclude, the mutations instilled by the 
CRISPR/Cas9 genome editing system with the designed gRNAs targeting YBX1 gene, were 
considered stable. 
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Figure 3.8 Sanger sequencing identifies stable CRISPR/Cas9-mediated mutations in clones A2, B2, and 
C5 over a 6 month timecourse. 293T and selected clones A2, B2, C5 were cultured and genomic DNA 
harvested at 1M, 3M and 6M post-transfection for sequencing. A-C) 293T control served as reference, 
and wildtype sequence remained unchanged throughout the 6M period (top reads). The mutations 
characterised by sequencing were consistently observed for (A) A2 – 1bp deletion 104nt upstream of 
targeted PAM, (B) B2 – 10bp deletion, and (C) C5 – A>C substitution and 8bp deletion (bottom sequence 
reads). The exception of A>C substitution was not consistent throughout the entire culture period, with 
the wildtype A detected at 3M (see boxed). In all instances equivalent sequences sequenced from 293T 
control demonstrated sequences that correspond to reference sequence (NC_000001.11). 1M, 1 month; 
3M, 3 month; 6M, 6 month. 
 
3.2.6 Alternative splicing is a predicted consequence of CRISPR/Cas9 genome editing 
identified in YB1 knockout clones 
Initial screening by Western blotting using different αYB1 indicated that the YB1 knockout 
genotypes did not disrupt epitope targets for their respective αYB1. However, certain 
mutations can influence the splicing characteristics of a gene (Lalonde et al., 2017). Therefore, 
we examined whether or not alternate protein products could result from our CRISPR/Cas9-
mediated mutations in selected clones. This was addressed in silico using the HSF v3.0 
programme (Desmet et al., 2009), which simulated the observed mutations from sequencing, 
and in turn calculated the potential for changes in splicing events.  
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A2’s 1bp deletion was modelled into the HSF v3.0 as a single cytosine residue deleted at 
position 40 (Fig. 3.9A). Based on HSF’s predictive algorithms no significant splicing motif 
alterations was reported to be disrupted as a result of the 1bp deletion. The observed 
mutation probably had no impact on splicing characteristics given the mutation was found 
well within exon 1. The resulting transcript was nonetheless conceptually translated, and the 
encoded aa sequence (candidate), given the 1bp deletion, exhibited several premature stop 
codons when compared to the wildtype YB1 aa sequence (Fig. 3.9B, see asterisks highlighted 
pink). Multiple sequence analysis between the candidate and wildtype YB1 sequences 
demonstrated only 20% sequence identity across the length of wildtype YB1 protein (Fig. 
3.9C). However, A2’s initial most stop codon, which resides at residue 63 (Fig. 3.9C, see first 
asterisk at position 63 for Query sequence), confers a significantly truncated protein that 
shares homology comprised of a stretch of 1-15aa to that of wildtype YB1, only. 
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Figure 3.9 Predictive analysis for alternative splice variants as a result of 1bp deletion in YB1 knockout clone (A2) YBX1 gene. In silico analysis using HSF v3.0 of potential 
and predicted alternative splicing events as a result of the observed 1bp deletion having targeted YBX1 with YBX1sgRNA1, by A) modelling the 1bp deletion in YBX1 exon 1 
and compared against wildtype splicing events. No measurable splicing alterations around exon 1 were predicted as a result of the 1bp deletion. Figure legend continues 
next page. 
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Figure 3.9. Predictive analysis for alternative splice variants as a result of 1bp deletion in YB1 
knockout clone (A2) YBX1 gene. Given the 1bp deletion, A2’s mutated YBX1 mRNA was input into 
online protein translator tool, and (B) candidate reading frame compared to wildtype YB1 aa sequence. 
The candidate reading frame was found out of frame of wildtype YB1 reading frame. This is indicated by 
additional stop codons (denoted as *). C) Multiple sequence analysis between candidate aa sequence 
(Query) and wildtype YB1 aa sequence (Sbjct) presents minimal (20%) identity. 
 
Clone B2 demonstrated a 10bp deletion across the intron 4:exon 5 splice junction. The fact 
that Western blot analysis conferred a partial knockout phenotype, despite this significant 
mutation, led us to postulate a complicated expression profile. The observed mutation was 
modelled into HSF v3.0 against wildtype YB1 as reference (Fig. 3.10A). Table 3.1 refers to HSF 
v3.0 consensus value (CV) findings for this modelled deletion compared to wildtype sequence. 
If a wildtype score is above the CV threshold of 65 and the difference between the wildtype 
and mutant score (∆CV) is under -10%, then the wildtype splice site is considered to be 
broken. On the other hand, when wildtype CV score is below the threshold and the ∆CV is 
above +10%, then a new splice site is predicted. Therefore, with the B2’s mutation modelled, 
the ∆CV% for the wildtype splice site is below -10% (∆CV, -49.28%) indicating this splice site is 
presumably disrupted (Table 3.1). On the other hand, alternative splice sites are predicted to 
be activated (Table 3.1, predictions 2 and 3), where wildtype CV score is below the CV 
threshold, and ∆CV% is above +10% (∆CV, +270.48 and +254.36%, respectively for predictions 
2 and 3). Alternative splice site activation as per prediction 2 conceptually translated a 3aa 
truncated protein (Fig. 3.10B), corresponding to residues 119-121 of wildtype YB1. In fact, 
prediction 2 reading frame remains in-frame with wildtype stop codon, which is in contrast to 
prediction 3 (Fig. 3.10B). The truncation was best demonstrated by multiple sequence 
alignment analysis, which successfully recognised the truncated protein (Query) with 
321/324aa (99% identity) conserved (Fig. 3.10C). This too was in contrast to prediction 3, 
which demonstrated 45% sequence identity across the entire length of the two sequences 
(Fig. 3.10D). More importantly, the major aa sequence that is encoded by this alternative 
splicing product potentially confers a 212aa long protein (corresponding to residues 1-212 
before its first stop codon, see first asterisk Fig. 3.10D), of which length showed 64.15% 
homology (136/212aa), but a reduced 41.9% homology (136/324) when calculated against the 
entire length of wildtype YB1. 
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Table 3.1 Predictive assessment for altered splicing motifs after modelling clone B2’s 
mutated sequence into HSF v3.0 
Prediction 
# 
Splice 
site type 
Motif New splice site 
WT 
CV 
Muta
nt CV 
∆CV% Impact 
1 Acceptor tggcttttgtagGG tggctgcggaggCA 81.49 41.33 -49.28 
WT site 
broken 
2 Acceptor atggcttttgtagG atggctgcggagGC 19.95 73.91 +270.48 
New 
site 
3 Acceptor cttttgtagGGTGC ctgcggaggcagCA 21.65 76.72 +254.36 
New 
site 
Splicing patterns of B2 mutated YBX1 sequence was compared to wildtype at exon 5 using HSF 
v3.0. Intron sequences denoted as lower case and exon sequences are denotes as upper case 
characters. CV, consensus value; ΔCV (%), percent difference between WT CV and Mutant CV; 
WT, wildtype. 
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Figure 3.10 Predictive analysis for alternative splice variants as a result of 10bp deletion in YB1 knockout clone (B2) YBX1 gene. Figure and legend continues next page. 
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Figure 3.10 Predictive analysis for alternative splice variants as a result of 10bp deletion in YB1 knockout clone (B2) YBX1 gene. In silico analysis using HSF v3.0 of 
potential and predicted alternative splicing events as a result of the observed 10bp deletion having had targeted YBX1 with YBX1sgRNA2, by A) modelling the 10bp deletion 
in YBX1 intron 4:exon 5 splice junction and compared against splicing events measured in wildtype sequence. This calculated measurable splicing alterations around intron 
4:exon 5 splice junction (see Table 3.1). B) Given the 10bp deletion, B2’s mutated YBX1 mRNAs for prediction 2 and 3 were input into online protein translator tool, and 
reading frames compared to wildtype YB1. Prediction 3 reading frame is out of frame of wildtype YB1 reading frame (stop codons are denoted as *). However, prediction 2 
reading frame suggests its stop codon is in-frame with wildtype stop codon, and confers a 3aa truncated protein. C) Multiple sequence analysis between prediction 2 
sequence (Query) and wildtype YB1 aa sequence (Sbjct). D) Multiple sequence analysis between prediction 3 sequence (Query) and wildtype YB1 aa sequence (Sbjct). 
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YB1 knockout clone C5 has shown a heterozygous genotype, as indicated by sequencing, and 
made calculating potential alternative splicing predictions difficult. This is because the exact 
mutations that conferred the knockout phenotype for each allele of YBX1 could not be easily 
determined by Sanger sequencing. However, sequencing analysis for the C5 clone did show a 
dominant sequence profile (Figs. 3.6 and 3.7C). This sequence was modelled into HSF v3.0 for 
the exon 6:intron 6 splice junction (Fig. 3.11A). Table 3.2 refers to HSF v3.0 CV findings for the 
modelled A>C substitution and 8bp deletion compared to wildtype sequence, and findings 
suggest that the wildtype splice donor site is potentially broken (Table 3.2, prediction 2; 
wildtype CV is above HSF threshold and ∆CV% is below -10%). However, a potential alternative 
splice site is predicted to be activated instead as a result of the mutation (wildtype CV below 
HSF threshold, and ∆CV% is above +10%). Prediction 1 extrapolated transcript was 
conceptually translated and exhibited premature stop codons (Fig. 3.11B, see asterisks), 
especially when compared to wildtype YB1 sequence. When this aa sequence was compared 
to full length YB1 by multiple sequence analysis, we see that across the entire lengths of both 
aa sequences there is shared 79% (259/327aa) homology (Fig. 3.11C). Although, the initial 
most stop codon occurs for the corresponding residue 253 of YB1, which potentiates in an in-
frame reading frame to wildtype YB1 and the expression of a truncated protein with 97.22% 
(245/252aa) homology. Altogether, potential for alternative splicing was recognised as a 
consequence of CRISPR/Cas9 genome editing of YBX1. This was largely dependent on the 
localisation of the mutations relative to intron and exon junctions. 
 
Table 3.2 Predictive assessment for altered splicing motifs after modelling clone C5’s 
mutated sequence into HSF v3.0 
Prediction 
# 
Splice 
site type 
Motif New splice site 
WT 
CV 
Mutant 
CV 
∆CV 
(%) 
Predicted 
impact 
1 Donor CGAttccgc CGCgtatgg 41.73 73.39 +75.87 New site 
2 Donor CAGgtatgg CGTatggtc 89.26 33.45 -62.53 
WT site 
broken 
Splicing patterns of C5 mutated YBX1 sequence was compared to wildtype at exon 6:intron 6 
using HSF v3.0. Intron sequences denoted as lower case and exon sequences are denoted as 
upper case characters. CV, consensus value; ΔCV (%), percent difference between WT CV and 
Mutant CV; WT, wildtype. 
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Figure 3.11 Predictive analysis for alternative splice variants as a result of A>C substitution and 8bp deletion in YB1 knockout clone (C5) YBX1 gene. The A>C substitution 
and 8bp deletion in YBX1 exon 6:intron 6 splice junction was modelled into HSF v3.0, and compared against splicing events measured in wildtype sequence. HSF calculated 
measurable splicing alterations around exon 6:intron 6 splice junction (see Table 3.2). Figure legend continues next page. 
 
    
161 
    
Figure 3.11. Predictive analysis for alternative splice variants as a result of A>C substitution and 8bp 
deletion in YB1 knockout clone (C5) YBX1 gene. B) Given the A>C substitution and 8bp deletion, C5’s 
mutated YBX1.mRNA for prediction 2 was inputedt into an online protein translator tool, and reading 
frame compared to wildtype YB1 aa sequence, demonstrating the prediction 1 reading frame is out of 
frame of wildtype YB1 reading frame (stop codons are denoted as *). C) Multiple sequence analysis 
between prediction 2aa sequence (Query) and wildtype YB1 aa sequence (Sbjct). 
 
3.2.7 Surveyor® mutation screening identifies heterozygous and homozygous genotypes 
for YB1 knockout clones 
Surveyor® mutation detection assay is typically used to estimate a rate of genome editing 
post-transfection or treatment with CRISPR/Cas9 (Qiu et al., 2004). However, single cell clones 
were generated in this study, and the use of the mutation screening technique was adjusted to 
examine the hetero- or homo- zygous genotypes of YB1 knockout clones. Instead, Surveyor® 
mutation detection assay was used to further characterise of YB1 knockout cell lines was made 
possible through Surveyor® mutation detection assays. This used a sensitive endonuclease 
(nuclease S) to cleave mismatches present in duplex DNA (Vouillot et al., 2015). Therefore, 
CRISPR/Cas9-targeted sequences could be PCR amplified, denatured and hybridised randomly 
to form homoduplexes and heteroduplexes (depending on the genotype nature of cloned cell 
populations), and then subjected to nuclease S digestion to digest all possible mismatches 
(including single nucleotide mismatches) and visualisation. 
 
Given that small deletions were observed for clones A2, B2 and C5 by sequencing, little 
difference was expected to be observed in the resolving nature of each PCR product when 
compared to the equivalent, amplified products from 293T control (Figs. 3.12A-C). Specifically, 
approximately 407, 467 and 405bp PCR amplicons expected for the corresponding 
YBX1sgRNA1-3 CRISPR/Cas9-targeted genomic regions (clones A2, B2, and C5, respectively), 
were identified between 293T, A2, and spiked samples (Figs. 3.12A-C). 293T control was 
confirmed as homozygous for each respective CRISPR/Cas9-targeted region of the YBX1 gene; 
because the corresponding targeted regions showed no nuclease S-mediated digestion 
products (Figs. 3.12D-F, see 293T control lanes). Only the expectant PCR products of 
approximately 407, 467, and 405bp, corresponding to the equivalent CRISPR/Cas9 targeted 
regions identified for exon 1, exon 5, and intron 6, respectively, was evident. Therefore, clone 
A2 also exhibited a homozygous genotype for the observed 1bp mutation, because nuclease S 
digestion products were not observed below the approximate 407bp homoduplex band (Fig. 
3.12D, see A2 lane). Expectant fragments of approximately 194 and 183bp occurred post-
nuclease S treatment only with regards to heterozygous simulated reactions (Fig. 3.12D). 
These involved spiking in A2 genomic DNA into 293T genomic DNA as template to simulate a 
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heterozygous genotype after heteroduplex formation. Additionally, this setup exhibited a 
dose-dependent characteristic, where an increasing ratio of A2 genomic DNA spiked into 293T 
control genomic DNA template correlated with more prominent digestion bands, compared to 
reactions involving a lower ratio of A2 genomic DNA spike. Similarly, a similar homozygous 
genotype was also observed for B2 clone (Fig. 3.12E). Expectant digestion products of 
approximately 302 and 165bp were only evident post-nuclease S treatment and concerning 
heterozygous-simulated reactions with B2 genomic DNA spiked into 293T genomic DNA as 
tempplate. In contrast, clone C5 produced expected digestion bands post-nuclease S digestion 
even without spiking in C5 genomic DNA into 293T genomic DNA for PCR template (Fig. 3.12F). 
Expected bands of approximately 280 and 125bp were evident for C5 lane. In all cases, 
prominent digestion bands for A2, B2, and C5 were observed at higher ratios of YB1 knockout 
clone:293T genomic DNA as template to simulate the heterozygous genotype control. Overall, 
Surveyor® mutation screenings suggested that both homozygous and heterozygous genotypes 
were observed after CRISPR/Cas9-mediated genome editing, despite subjecting transfected 
cells for single cell cloning. 
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Figure 3.12 Surveyor® mutation screening identifies homozygous and heterozygous genotypes by 
CRISPR/Cas9-genome editing of YBX1. Mutated sequences previously observed by Sanger sequencing 
in selected clones A2, B2, and C5, and the corresponding regions in 293T control were PCR amplified 
and subjected to Surveyor® mutation screening. In addition to this, PCR were performed to simulate 
heterozygosity control by spiking 293T genomic DNA with YB1 knockout clone (A2, B2, or C5) genomic 
DNA at the indicated ratios (50ng total DNA template). A-C) Expectant PCR amplicons of approximate 
size was evidenced by 2% TBE agarose gel electrophoresis for 293T and corresponding regions in 
selected YB1 knockout clones (407, 467 and 405bp PCR amplicons for A2, B2, and C5 mutated regions, 
respectively), respectively. PCR samples were then subjected to nuclease S-digestion and (D-F) digestion 
fragments identified by 2% TBE agarose gel electrophoresis. Digestion bands were only evident for 
heterozygous-control samples for (D) A2, (E) B2, and (F) C5, with C5 exhibiting a heterozygous genotype 
given digestion bands were evident in C5 only lane, post-nuclease S treatment. M, 100bp DNA ladder; 
NTC, non-template control. 
 
3.2.8 High resolution melting (HRM) curve analysis distinguishes wildtype alleles from 
mutated 
To explore whether wildtype YBX1 alleles were responsible for the heterozygosity profile 
shown for clone C5, more sensitive genotyping was performed in the form of HRM curve 
analyses. This was because the sensitivity of the Surveyor® mutation assays and sequencing 
analysis were unable to absolutely distinguish heterozygosity in the context of the wildtype 
YBX1 allele. Essentially, discrete differences in nucleotide composition can be distinguished by 
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the differences in melting dynamics by HRM curve analysis, when compared to the equivalent 
region from a wildtype reference (Wittwer et al., 2003).  
 
Taking clone C5, the CRISPR/Cas9-targeted DNA region that was amplified (referred to as KOC) 
was assessed in parallel with the corresponding DNA region from 293T control (referred to as 
293C, and functioned as a baseline reference). Dissociation curve analysis (Fig. 3.13A) revealed 
three distinct dissociation peaks (referred to as KOC1-3, black line) separately observed for C5 
mutated region in quadrupllicate compared to 293T control (red line). KOC1-3 dissociation 
peaks showed average dissociation temperatures of 76.65±0.02˚C, 75.56±0.01˚C, and 
74.75±0.01˚C, respectively, and relatively distinct from 293C control (Figs. 3.13A and B). C5’s 
dissociation peaks were all significantly different to 293C’s dissociation peak average of 
77.66±0.14˚C (Fig. 3.13B, annotated peak WT), derived from 293T as control (n = 4; P < 0.01 
and P < 0.001). Therefore dissociation peaks KOC1, KOC2 and KOC3 showed 1.01˚C (P < 0.01), 
2.10˚C (P < 0.001), and 2.91˚C (P < 0.001) difference in dissociation peak temperature 
compared to 293C, respectively (Fig. 3.13B). Expected HRM-PCR amplicons of approximate size 
was identified by 2% TBE agarose gel electrophoresis indicated that the 293C and KOC 
sequences were successfully amplified as 93bp PCR products, and non-template control 
reaction yielded only primer dimers (Fig. 13.3D), that did not deter above analysis.  
 
Melting curves for clone C5’s KOC and 293T’s 293C amplicons suggests that significant changes 
in melt curve properties were present in the mutated region compared to 293C control (Fig. 
3.13E). The KOC melt region (black line) was distinct from 293C wildtype sequence (red line), 
and that the CRISPR/Cas9-mediated genome editing within the targeted region overall 
reduced the melting temperature properties from wildtype sequence. Again, HRM reactions 
run on a 2% agarose gel (Fig. 3.13D) imply that the melt curves are reflective of the expected 
DNA sequence targets (approximately 93bp), and further distinct primer dimers from non-
template control reactions. Furthermore, difference graph analysis of normalised melt curves, 
after applying 293C’s genotype as homozygous, detected variation when compared to KOC 
(Fig. 3.13E). Therefore, normalised melt curve analysis indicated that i) KOC showed variation 
such that the analysed DNA sequence exhibited no homozygosity for mutated YBX1 copies, 
and ii) KOC DNA sequence was distinct from the assigned reference control. Furthermore, 
difference graphs also indicated that 293C HRM profiles were similar between each technical 
replicate, except for one particular replicate, which was detected as showing ‘variation’, but 
with 85.05% confidence value.  
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Figure 3.13 HRM curve analysis of YB1 knockout clone C5 distinguishes a heterozygous genotype, 
without wildtype YBX1 allele. HRM curve analysis demonstrated that the mutated sequences in YB1 
knockout clone C5 were distinct from the wildtype YBX1 sequence, and further gives evidence of a 
heterozygous genotype. A) Dissociation curve analysis displays multiple peak dissociation temperatures 
(indicative of a heterozygous mutation profile) of C5 mutated region (KOC1-3) compared a single peak 
dissociation temperature to the equivalent region in 293T control (293C). Peak dissociation 
temperatures were annotated as WT for 293C (red line), and KOC1-3 for each KOC-derived peak (black 
line). B) Average dissociation temperatures plotted for 293C (solid white bar, 77.66°C) and KOC1-3 (solid 
black bar, 76.65°C; dotted bar, 75.56°C; and vertical lines bar, 74.75°C, respectively). Error bars reflect 
±SD from mean, n = 4; **, P < 0.01; ***, P < 0.001. C) Normalised melt curve profile between 293C (red 
line) and KOC (black line), portraying the impact C5’s A>C substitution and 8bp deletion has on the 
curvature of melt curve from 293T (293C) control. D) 2% TBE agarose gel electrophoresis of HRM 
reactions showing expected PCR products for 239C and KOC (approximately 93bp), with primer dimer 
formation evident in NTC lane. E) Difference graph between 293C (red line) and KOC (black line), and 
autocalled inference of samples’ genotype when compared against 293C as homozygous control. 
Confidence threshold was set to 90%. NTC, non-template control; M, 100bp DNA ladder; WT, wildtype. 
  
In contrast, dissociation peaks and melt curve properties were comparable between 293T and 
clone C5 for either sequences that immediately flank the amplicon harbouring the observed 
mutation (Figs. 3.14 and 3.15, for 5’ and 3’ -flanking controls respectively). These regions 
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functioned as controls for CRISPR/Cas9-mediated mutations, as these flanking sequences were 
no targeted by Cas9:sgRNA, and were observed intact by sequencing analyses. Therefore 5’-
flanking sequences were referred to as 5’293C or 5’KOC, and 3’-flanking sequences were 
referred to as 3’293C or 3’KOC. When examining the 5’-flanking sequences, an average 
dissociation peak temperature of 82.04±0.01˚C and 81.97+0.04˚C was detected for 5’293C (red 
line) and 5’KOC (black line), respectively (Figs. 3.14A and B); and the calculated difference of 
0.07˚C showed no significant difference (n = 4, P > 0.05). The intended HRM-PCR products 
were correctly amplified (approximately 95bp by 2% TBE agarose electrophoresis), and 
suggested that the dissociation peaks correlated with the 5’293C and 5’KOC control 
sequences, and distinct from primer dimers (Fig. 3.14D). Additionally, normalised melt curves 
presented with similar curvatures between 5’293C (red line) and 5’KOC (black line) (Fig. 
3.14C). Further scrutiny between 5’293C and 5’KOC melt curves was made by difference plots 
(Fig. 3.14E), which identify 5’293C as homozygous and similar between its replicates. 
Interestingly, however, 3/4 5’KOC replicates showed variation when compared to the 
homozygous genotype of the 5’293C reference control, albeit with 70-86% confidence below 
the 90% cut-off.   
 
The 3’-flanking sequence was also analysed by dissociation curve analysis, and showed 
average dissociation peaks of 78.53±0.43˚C and 78.51±0.03˚C for 3’293C (red line) and 3’KOC 
(black line) for downstream flanking DNA sequence, respectively. The difference of 0.02˚C in 
dissociation temperature also showed no significant difference (n = 4, P > 0.05) (Figs. 3.15A 
and B). Intended HRM-PCR products (approximately 104bp by 2% TBE agarose gel 
electrophoresis) were identified, suggesting that the dissociation peaks measured correlate 
with the 3’293C and 3’KOC control sequences, and distinct from primer dimers (Fig. 3.15D). 
Melt curve profiles were also comparable between 3’293C (black line) and 3’KOC (red line) 
with regards to curvature of normalised melt curves (Fig. 3.15C). Further to this, difference 
plots were generated with 3’293C set with a homozygous genotype as control (Fig. 3.15E), and 
3’KOC regions were successfully recognised as homozygous in genotype with confidence 
values all exceeding the threshold of 90% for 2/4 replicates. Altogether, HRM analysis 
provided the additional required sensitivity to confidently characterise a heterozygous 
genotype for a particular mutation, and distinguish from wildtype, simultaneously. 
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Figure 3.14 HRM curve analysis of sequences upstream of the mutated YBX1 sequence identifies as 
comparable to 293T control. A) Dissociation curve analysis displays peak dissociation temperatures of 
5’KOC sequence compared to the equivalent region in 293T control (5’293C). Peak dissociation 
temperatures are annotated as WT for both 5’293C (red line), and 5’KOC peaks (black line). B) Average 
dissociation temperatures plotted for 5’293C (solid white bar, 82.04˚C) and 5’KOC (solid black bar, 
81.97˚C), respectively. Error bars reflect ±SD of mean, n = 4. C) Normalised melt curve profile between 
5’293C (red line) and 5’KOC (black line). D) 2% TBE agarose gel electrophoresis of HRM reactions 
showing expected PCR products (approximately 95bp) for 5’239C and 5’KOC, with primer dimer 
formation evident in NTC lane. E) Difference graph between 5’293C (red line) and 5’KOC (black line), and 
autocalled inference of sample genotype, based on difference graph analysis and setting 5’293C as 
homozygous control, with confidence threshold set to 90%. NTC, non-template control; M, 100bp DNA 
ladder; WT, wildtype. 
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Figure 3.15 HRM curve analysis of sequences downstream of the mutated YBX1 sequence identifies 
as comparable to 293T control. A) Dissociation curve analysis displays peak dissociation temperatures 
of 3’KOC sequence compared to the equivalent region in 293T control (3’293C). Peak dissociation 
temperatures are annotated as WT for both 3’293C (red line), and 3’KOC peaks (black line). B) Average 
dissociation temperatures plotted for 3’293C (solid white bar, 78.51˚C) and 3’KOC (solid black bar, 
78.53˚C), respectively. C) Normalised melt curve profile between 3’293C (red line) and 3’KOC (black 
line). D) 2% TBE agarose gel electrophoresis of HRM reactions showing expected PCR products for 
3’239C and 3’KOC, with primer dimer formation evident in NTC lane. E) Difference graph between 
3’293C (red line) and 3’KOC (black line), and autocalled inference of sample genotype, based on 
difference graph analysis and setting 3’293C as homozygous control, with confidence threshold set to 
90%. Error bars reflect ±SD of mean, n = 4. NTC, non-template control; M, 100bp DNA ladder; WT, 
wildtype. 
 
3.2.9 Stable Cas9 expression was not evident in YB1 knockout clones 
YB1 knockout cell lines: A2, B2 and C5, were further screened for stable Cas9 expression over a 
3 or 12 months timecourse, alongside bulk transfected populations (harvested at 72h and at 
passage 2 post-transfection with CRISPR/Cas9-nuclease vectors). Non-transfected, parental 
293T cells served as a negative control for Cas9 expression. The safety profile of the newly 
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generated cell lines was examined in context of stable Cas9 expression – a bacterium derived 
endonuclease. Additionally, the long-term stability of the YB1 knockout phenotype was 
examined to ensure that the novel cell lines maintained the desired phenotype. 
 
Initially, non-transfected 293T cells cultured upto 12 months were harvested and subjected to 
Western blotting to examine the expression profile of YB1 protein long-term (Fig. 3.16A). 
Given that equal loading was determined by GAPDH, YB1 levels were considered comparable 
between lysates derived from non-transfected 293T harvested at 72h, 1month, and 12 months 
in culture (Fig. 3.16A). Therefore, it was considered that long-term culture of 293T cells did not 
affect the expression of endogenous YB1. Non-transfected 293T cells also demonstrated the 
lack of Cas9 protein expression, including in subsequent Western blot analyses (Fig. 3.16B-D), 
as expected for negative transfection controls. Cas9 expression was, however, detectable only 
in bulk transfected 293T cells with pCRISPR-YBX1sgRNA1-3 for YBX1 targeting via exon 1, 5 and 
intron 6, respectively (Figs. 3.16B-D, respectively). Especially, Cas9 expression levels were 
markedly expressed 72h post-transfection in all cases of bulk transfected 293T populations, 
but significantly diminished by passage 2 for each pCRISPR-YBX1sgRNA1-3 (Figs. 3.16B-D, 
respectively). The levels of Cas9 protein expression was found completely undetectable in all 
clonal populations cultured from 1 month onwards up to 12 months for the A2 YB1 knockout 
cell line (Fig. 3.16B). Similar was observed for B2 and C5 clones from passage 5 onwards upto 3 
months in culture (Figs. 3.16C and D). Additionally, given normalised loads as per GAPDH 
control, the YB1 knockout phenotype was maintained and considered stable in A2 and C5 
clones up to 12 months and 3 months in culture, respectively (Figs. 3.16B and D); whereas 
clone B2 maintained a partial knockout phenotype upto 3 months in culture (Fig. 3.16C). 
Otherwise, YB1 levels were only detectable by Western blotting for non-transfected 293T 
control, and transfected 293T cells prior to single cell cloning up to passage 2 post-
transfection. 
 
Therefore, the phenotypes first identified by Western blotting of the selected clones (Fig. 3.4) 
were also considered stable up to 3 or 12 months in culture having had used CRISPR/Cas9 
genome editing to target the YBX1 gene. Additionally, the transient nature of Cas9 expression 
by pCRISPR plasmid transfection is demonstrated by all three pCRISPR-YBX1sgRNA1-3 vectors 
used in the current study. Rather, stable Cas9 expression, upto 12 months in culture in select 
YB1 knockout clones, was not evident by the limits of detection by Western blotting.  
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Figure 3.16 Western blot analyses indicate Cas9 expression is transiently expressed after pCRISPR-
YBX1sgRNA1-3 transfections. Non-transfected and bulk transfected 293T and selected YB1 knockout 
clones were maintained and harvested at the indicated time-points upto 3 or 12 months in culture, and 
lysates subjected to Western blotting to assess stable Cas9 expression (top blots) and YB1 phenotypes 
(middle blots). A) Non-transfected 293T cells served as negative controls for Cas9 expression, but YB1 
expression remained unchanged despite the extended culture period. Western blot analysis suggests 
that Cas9 expression was transient (exhibited only by bulk transfected 293T 72h and passage 2 post-
transfection), and YB1 knockout phenotypes were maintained for (B) A2, (C) B2, and (D) C5 clones, after 
CRISPR/Cas9 targeting of YBX1 using pCRISPR-YBX1sgRNA1-3, respectively. GAPDH (bottom blots) was 
used as a loading control. p2, passage 2 post-transfection; p5, passage 5 post-transfection; 1M, 1 
month; 3M, 3 months; 6M, 6 months; 12M, 12 months. 
 
3.2.10 Off-target effects in YB1 knockout clones by Western Blotting 
Additional safety features were examined in the selected YB1 knockout clones, and involved 
measuring for off-target effects by CRISPR/Cas9-mediated genome editing, principally by 
Western blotting. Genome editing involves permanent alterations in the genome, and target 
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specificity of Cas9 is dependent on homology driven pairing between the gRNA and target 
sequence (Lim et al., 2016). However, Cas9 can direct its endonuclease function off-target due 
to the flexibility allowed in the base-pairing and complementarity between gRNA and target 
DNA sequence (Mali et al., 2013b). We therefore assessed any change in off-target protein 
expression when compared to non-transfected 293T as baseline control. Potential off-target 
sites were identified in silico by BLAST analysis of YBX1sgRNA1-3 designs. The top five hits for 
each are listed below in Tables 3.3, 3.4, and 3.5, respectively.  
 
Despite each designed YBX1sgRNA showed 100% homology against the intended YBX1 gene, in 
silico screening identified potential off-target sites for YBX1sgRNA1 (Table 3.3), which 
included: 5’-side of exotosin-like glycosyltransferase 1 (EXTLI; 75% homology), pantothenate 
kinase 6 (PANK4; 70% homology), 5’-side of SRY-Box 13 (SOX13; 70% homology), serine 
incorporator 2 (SERINC2; 70% homology), and 5’-side of stromal cell derived factor 4 (SDF4; 
65% homology) genes. Potential off-target sites for YBX1sgRNA2 (Table 3.4) instead included: 
5’-side of regulator complex protein (LAMTOR5; 85% homology), cAMP-dependent kinase 
catalytic subunit β isoform (PRKACB, 75% homology), tudor domain-containing protein 10 
isoform B (TDR10; 75% homology), 5’-side of olfactory receptor 2G3 (OR2G3; 75% homology), 
and 5’-side of olfactory receptor 10J3 (OR10J3; 70% homology). Potential off-target sites for 
YBX1sgRNA3 (Table 3.5), however, included: 5’-end of leptin gene-related protein isoform 2 
(LEPROT; 65% homology), collagen α-1(XXIV) chain precursor (COL24A1; 65% homology), 
ubiquitin carboxyl hydrolase isozyme L5 isoform 2 (UCHL5; 65% homology), 5’-side of β-1,3-
galactosyltransferase 2 (B3GALT2; 65% homology), and finally, piggyback transposable 
element derived protein 5 (PGBD5; 65% homology). 
 
It is appreciated that a number of these potential off-target sites were found in the 
untranslated regions or further upstream/downstream to the associated genes’ coding 
sequence. Off-target sites that matched this parameter were annotated with an asterisk to the 
associated gene name (Tables 3.3-5). For example, the off-target site for YBX1sgRNA1 in 
association with EXTL1 was identified 40-55bp downstream of the gene’s stop TAG codon. 
Analyses also involved identifying 5’-NGG PAM sequences associated with these potential off-
target sites; and no 5’NGG PAMs were recognised following the off-target sequences. The only 
exception to this was the off-target site identified downstream of the EXTL1 gene, of which 
off-target sequence was found to precede a 5’-NGG-3’ PAM sequence (Table 3.3).  
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Table 3.3 Potential off-target sites identified for gRNA1 targeting of YBX1 gene 
  
number gRNA1 vs Subject (5’ > 3’) (coverage and sequence) 
Homology 
(%) 
PAM 
sequence 
present? 
Gene 
identified 
Related protein function 
1 
gRNA1: 
Subject: 
6    
6035402 
CGGCGCCTGCCGGCG 
CGGCGCCTGCCGGCG   
20    
26035416 
75 Yes EXTL1* 
Chain polymerisation of heparan sulphate 
and heparin (Kim et al., 2003). 
2 
gRNA1: 
Subject: 
5       
526229 
GCGGCGCCTGCCGG   
GCGGCGCCTGCCGG 
18   
2526242 
70 No PANK4 
Regulatory enzyme for biosynthesis of 
coenzyme A (CoA) (Halvorsen and Skrede, 
1982). 
3 
gRNA1: 
Subject: 
3 
204129200 
CGGCGGCGCCTGCC 
CGGCGGCGCCTGCC 
16  
204129213 
70 No SOX13* 
Transcription factor involved in regulating 
cell fate and embryonic development 
(Baroti et al., 2016). 
4 
gRNA1: 
Subject: 
6    
31413520 
CGGCGCCTGCCGGC 
CGGCGCCTGCCGGC  
19    
31413507 
70 No SERINC2 
Transmembrane protein involved in 
incorporation of serine into 
phosphatidylserine and sphingolipid 
(Inuzuka et al., 2005). 
5 
gRNA1: 
Subject: 
3    
1232222 
CGGCGGCGCCTGC  
CGGCGGCGCCTGC 
15      
1232234 
65 No SDF4* 
Ca2+-binding protein localised to Golgi 
apparatus (Scherer et al., 1996) 
* denotes potential off-target sites that were found in UTR sequences or further upstream/downstream of the associated gene’s coding sequence. 
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Table 3.4 Potential off-target sites identified for gRNA2 targeting of YBX1 gene 
   
number gRNA2 vs Subject (5’ > 3’) (coverage and sequence) 
Homology 
(%) 
PAM 
sequence 
present? 
Gene(s) 
identified 
Related protein function 
1 
gRNA1: 
Subject: 
1 
110418735     
GTAATGGCTTTTGTAGG 
GTAATGGCTTTTGTAGG 
17 
110418751 
85 No LAMTOR5* 
Involved in sensing aa and activation 
of mTORC1 (Bar-Peled et al., 2012). 
2 
gRNA1: 
Subject: 
5 
84223967     
TGGCTTTTGTAGGGT  
TGGCTTTTGTAGGGT   
19 
84223981 
75 No PRKACB 
Catalytic subunit of cAMP-dependent 
protein kinase, to mediate signalling 
for multiple cell processes (Wu et al., 
2002). 
3 
gRNA1: 
Subject: 
5 
154524687     
TGGCTTTTGTAGGGT 
TGGCTTTTGTAGGGT    
19 
154524701 
75 No TDRD10 
Component of cytoplasmic RNA 
granules and regulates post-
transcriptional activities of specific 
mRNAs (inferred from electronic 
annotation). 
4 
gRNA1: 
Subject: 
1 
247613456     
GTAATGGCTTTTGTA 
GTAATGGCTTTTGTA    
15 
247613442 
75 No OR2G3* 
Encodes olfactory receptor (inferred 
from electronic annotation). 
5 
gRNA1: 
Subject: 
5 
159422240     
TGGCTTTTGTAGGG  
TGGCTTTTGTAGGG   
18 
159422253 
70 No OR10J3* 
Encodes olfactory receptor (inferred 
from electronic annotation). 
* denotes potential off-target sites that were found in UTR sequences or further upstream/downstream of the associated gene’s coding sequence. 
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Table 3.5 Potential off-target sites identified for gRNA3 targeting of YBX1 gene 
   
number gRNA3 vs Subject (5’ > 3’) (coverage and sequence) 
Homology 
(%) 
PAM 
sequence 
present? 
Gene 
identified 
Related protein function 
1 
gRNA1: 
Subject: 
3 
65526447     
ACCATACCTGCGG  
ACCATACCTGCGG   
15 
65526435 
65 No LEPROT* 
Negatively regulates leptin receptor 
expression to cell surface (Couturier 
et al., 2007). 
2 
gRNA1: 
Subject: 
1 
86004650     
GGACCATACCTGC  
GGACCATACCTGC   
13 
86004638 
65 No COL24A1 
Potentially helps regulate type I 
collagen fibrillogenesis (Koch et al., 
2003). 
3 
gRNA1: 
Subject: 
1 
193049737     
GGACCATACCTGC  
GGACCATACCTGC   
13 
193049749 
65 No UCHL5 
De-ubiquitinating enzyme (Yao et 
al., 2008). 
4 
gRNA1: 
Subject: 
1 
194271334     
GGACCATACCTGC  
GGACCATACCTGC   
13 
194271322 
65 No B3GALT2* 
Transfers galactose from UDP-
galatose to substrates with βGlcNAc 
residue (Amado et al., 1998). 
5 
gRNA1: 
Subject: 
8 
230359975     
ACCTGCGGAATCG  
ACCTGCGGAATCG   
20 
230359963 
65 No PGBD5 
Transposase related to piggyBac 
family of proteins (Henssen et al., 
2015). 
* denotes potential off-target sites that were found in UTR sequences or further upstream/downstream of the associated gene’s coding sequence. 
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Next, off-target effects was determined experimentally by Western blotting, but was limited 
off-targets identified for YBX1sgRNA1. This was because the A2 clone demonstrated the most 
confident characterised YB1 knockout phenotype by genotypic and phenotypic assays. 
Additionally, off-target screening was limited to three potential off-targets: PANK4, SOX13 and 
SDF4 expressions. Firstly, non-transfected 293T harvested at 72h and 12 months in culture 
served as baseline references for SOX13, PANK4, SDF4 protein expression. The two different 
harvest points served to exemplify any change in the aforementioned protein expression over 
the course of 12 months. Considering equal loading was demonstrated by GAPDH loading 
control, comparable expression patterns of SOX13, PANK4, SDF4 and YB1 levels was detected 
between 293T control lanes (Fig. 3.17). Therefore, it was generally interpreted that the YB1 
knockout clone exhibited comparable levels of SOX13, PANK4 and SDF4 expression throughout 
the timecourse from passage 5 up to 12 months in culture (Fig. 3.17). This was especially 
relative to expression levels exhibited by non-transfected 293T control. Overall, Western blot 
analysis for off-target effects suggested that the CRISPR/Cas9-targeting of YBX1 gene using 
YBX1sgRNA1 was specific, at least to the limits of detection of Western blotting and for the 
off-targets selected. 
 
Figure 3.17 Western blot analysis for off-target effects by CRISPR/Cas9 targeting of YBX1. Whole cell 
lysates from non-transfected 293T control and A2 clone cell line were harvested at the indicated harvest 
points, and samples subjected to Western blotting. Generally, off-target effects were not evident by 
Western blotting, as SOX13 (top blot), PANK4 (second to top blot) and SDF4 (middle blot) levels were 
relatively comparable between non-transfected 293T control and A2 clone lanes across the timecourse. 
This was especially considered after normalised loading by GAPDH loading control (bottom blot). YB1 
levels were also assessed (second to bottom blot), and consistent phenotypes were observed for 293T 
control and YB1 knockout. h, hour; M, month(s); p5, passage 5 post-transfection and single cell cloning 
of the A2 cell line. 
 
3.2.11 Cell cytotoxicity phenotype was a consequence of YB1 knockout 
A key focus of this project was to examine the effect of YB1 knockout on rAAV2 production 
compared to 293T as producer cells. However, initial attempts to triple transfect clones A2, B2, 
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or C5 for rAAV2 production using a traditional Calcium Phosphate precipitation method in the 
presence of chloroquine, was compromised with the observation that YB1 knockout cells 
showed increased cell death and lysis compared to 293T. In order to establish to which 
chemical component YB1 knockout cell lines were sensitive to, LDH cytotoxicity assays were 
performed to quantitatively measure chemical-mediated cell damage in the presence Calcium 
Phosphate transfection reagents, with and without chloroquine. Here, YB1 knockout clone A2 
was used henceforth. The A2 clone was selected to represent the cohort of YB1 knockout cells 
generated because each clone were observed as equally sensitive to triple transfection for 
rAAV2 vector production using Calcium Phosphate precipitation with chloroquine, and the lack 
of CRISPR/Cas9 off target effects for A2 clone was best characterised.  
 
Cytotoxicity in YB1 knockout cells was measured at 24h, 48h, and 72h post-transfection, and 
presented as %cytotoxicity of max lysis (100%) for the corresponding non-treated control. 
Non-treated 293T and YB1 knockout control cells functioned as baseline references, and 
exhibited low and comparable %cytotoxicity – 3-8% throughout the 72h timecourse (Figs. 
3.18A-C). In fact, comparable cytotoxicity profiles were displayed between 293T and knockout 
cells for each treatment condition (no treatment, chloroquine only, Calcium Phosphate mix 
only, and triple transfection with and without chloroquine) 24h post-treatment (Fig. 3.18A). 
This indicated that baseline cell cytotoxicities were detected at the earliest time-point 
measured. However, in the presence of chloroquine, whether standalone or in the context of 
transfection, YB1 knockout cells demonstrated heightened sensitivity at 48h and 72h post-
treatment (Figs. 3.18B and C, respectively). YB1 knockout cells demonstrated average 
67.97±5.17% and 81.46±8.34% cytotoxicity mediated by chloroquine alone, compared to 
averages of 42±6.01% and 48.28±6.05% cytotoxicity in 293T control, 48h and 72h post-
treatment respectively (Figs. 3.18B and C, respectively). Similar average cytotoxicities of 
60.66±8.64% and 79.4±4.3% for YB1 knockout, and 47±6.87% and 61.21±5.57% for 293T 
control were calculated at 48h and 72h post-transfection with chloroquine, respectively (Figs. 
3.18B and C, respectively). The differences in %cytotoxicity between the two cell lines for the 
given treatment conditions was considered statistically significant at 48h (n = 3; P < 0.001 and 
P <0.01 for either conditions, respectively), and 72h (n = 3; P < 0.001 for both conditions). 
However, triple transfection without chloroquine displayed reduced cell cytotoxicities that 
averaged at 11.18±2.18% and 19.23±5.65% for 293T control, and 21.54±0.44% and 31.38±3.3% 
for YB1 knockout, at 48h and 72h post-transfection, respectively. The differences in 
%cytotoxicities between either cell line for each given time-point was also considered 
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statistically signficiant (n = 3; P < 0.05 and P <0.01 for 48h and 72h post-transfection, 
respectively). It was appreciated that treatment with the Calcium Phosphate mix only 
(plasmids and chloroquine were omitted) demonstrated comparable cytotoxicity profiles 
between 293T and YB1 knockout cells only at 48h post-treatment (Fig. 3.18B) with average 
8.1±0.91% and 19.07±1.5%, respectively. 72h post-treatment a statistically significant 
difference in %cytotoxicity is, however, calculated between 293T control – 9.76±0.6%), and 
YB1 knockout cells – 22.02±1.47% (Fig. 3.18C; n = 3, P < 0.05). The calculated %cytotoxicities 
were further appreciated with comparable transfection efficiencies displayed for 293T and YB1 
knockout cells 72h post-transfection using Calcium Phosphate precipitation supplemented 
with chloroquine (Fig. 3.18D; >94% achieved). However, transfections without chloroquine 
resulted in approximately 88% and 59.2% cells expressing GFP for 293T and YB1 knockout 
cells, respectively (Fig. 3.18D).  
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Figure 3.18 LDH cytotoxicity measurements from 293T and YB1 knockout cell lines after transfection 
with Calcium Phosphate methodology. Significant LDH activity, represented as %cytotoxicity, was 
evident in YB1 knockout clones compared to 293T control, after treatment with chloroquine alone or 
transfection using Calcium Phosphate precipitation method. LDH cytotoxicity profiles were calculated 
between 293T (solid white bars) and YB1 knockout clone (solid black bars), after treatment with 
chloroquine (25μM), Calcium Phosphate mix, or triple transfection for rAAV2 vector production with 
and without chloroquine, over a 72h timecourse. LDH activity measured in the cultured media of 
treated cells at (A) 24h, (B) 48h, and (C) 72h, post-transfection or treatment. Error bars reflect ±SD from 
mean, n = 3; *, P < 0.05; **, P < 0.01; ***, P < 0.001 or P < 0.0001. D) Representative flow cytometry 
analysis for transfection efficiencies for the pAAV2-hrGFP reporter plasmid 72h post-treatment for 293T 
and YB1 knockout cell lines, for each condition tested. Negative controls for transfection included 293T 
and YB1 knockout cells non-treated, and treated with chloroquine or Calcium Phosphate mix, only. 
Transfection efficiencies are presented within scatter plots as %. CQ, chloroquine; CaPO4 only, Calcium 
Phosphate mix only (plasmids and chloroquine were omitted); NT, non-treated; YB1ko, YB1 knockout 
cell line. 
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Alternative transfection methods are available for the production of rAAV vectors in vitro, and 
include the use of PEI-based reagents for transfection (Huang et al., 2013). 293T and YB1 
knockout cells were triple transfected or treated using the alternative PEImax transfection 
reagent to produce rAAV2 instead, and cytotoxicity profiles examined. We opted to explore 
whether or not the reported sensitivity to chloroquine and to a lesser extent Calcium 
Phosphate precipitation method of transfection of YB1 knockout cells extended to other 
transfection modalities for rAAV vector production.  
 
Therefore, LDH cytotoxicity assays were performed between the 293T and YB1 knockout cell 
lines with the following conditions: no-treatment, PEImax only, and triple transfection with 
PEImax for rAAV2 production, over a 72h timecourse. 24h post-treatment, all treatment or 
transfection conditions demonstrated low and comparable %cytotoxicity at least between 
293T and YB1 knockout cells for each given condition, ranging between 2-6% (Fig. 3.19A). 
Treatment with PEImax only transfection mix (plasmids omitted), showed comparable 
%cytotoxicities (n = 3, P ≥ 0.05) with average cytotoxicities measured at 6.33±0.28% and 
10.24±0.17% for 293T, and 9.79±0.05% and 16.86±0.34% for YB1 knockout cells, at 48h and 
72h post-treatmeant, respectively (Figs. 3.19B and C, respectively). With respects to the more 
relevant triple transfection with PEImax, average %cytotoxicities became elevated from 
19.31±7.22% and 21.28±2.94% for 293T and YB1 knockout cells (respectively) at 48h post-
transfection (Fig. 3.19B), to 40.18±8.46% and 45.48±5.25% cytotoxicity for 293T and YB1 
knockout cells (respectively) 72h post-transfection (Fig. 3.19C). The differences in 
%cytotoxicities as a result of triple transfection using PEImax between 293T control and YB1 
knockout was considered statistically insignificant for either time-points (n = 3, P ≥ 0.05). The 
calculated %cytotoxicities were further appreciated given that similar transfection efficiencies 
of 98.4% and 95.5% was exhibited by triple transfected 293T and YB1 knockout cells 
(respectively) 72h post-transfection (Fig. 3.19D).  
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Figure 3.19 LDH cytotoxicity measurements from 293T and YB1 knockout cell lines after transfection 
with PEImax reagent. Comparable LDH activity, represented as %cytotoxicity, was evident in YB1 
knockout clones compared to 293T control, after treatment with PEImax alone or for transfection for 
rAAV2 vector production. Results presented indicated that YB1 knockout cells were not significantly 
susceptible to cell damage or cell death compared to 293T control after treatment or transfection using 
PEImax, throughout the 72h timecourse. LDH activity was measured in the cultured media between 
293T control and YB1 knockout cell lines at (A) 24h, (B) 48h, and (C) 72h, post-transfection or 
treatment. Error bars reflect ±SD from mean, n = 3. D) Representative flow cytometry analysis for 
transfection efficiencies for the pAAV2-hrGFP reporter plasmid at 72h post-transfection or -treatment 
for 293T and YB1 knockout cell lines. Non-treated and PEImax only treated cells functioned as negative 
controls for flow cytometry analysis. Transfection efficiencies are presented within scatter plots as %. 
NT, non-treated; YB1ko, YB1 knockout cell line. 
 
Further LDH cytotoxicity assays also were performed using FuGENE® HD and Lipofectamine® 
transfection reagents over a 72h timecoure (Figs. 3.20 and 3.21, respectively). Cytotoxicity 
profiles were measured in context to the following conditions: Lipofectamine® or FuGENE® 
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reagent only (serving as baseline reference control), triple transfection for rAAV2 production, a 
titration of pAAV2-hrGFP reporter plasmid, and lastly pAAV2-RC plus pHelper plasmids 
transfected per well, to examine the effect of input plasmid transfection on YB1 knockout cells 
using alternative transfection modalities. In general, near comparable or no statistically 
significant difference in cytotoxicity profiles were measured between 293T and YB1 knockout 
cells for all testing conditons, throughout the timecourse, for either FuGENE® HD or 
Lipofectamine® transfection modalities (Figs. 3.20A-C and 3.21A-C, respectively; n = 3 each, P > 
0.05). Although, an exception to this was a statistically significant difference (n = 3, P < 0.05) 
between 293T and YB1 knockout cells triple transfected with FuGENE® HD reagent (Fig. 3.20C). 
YB1 knockout cells exhibited an elevated cytotoxicity profile averaging 12.93±2.63% compared 
to 293T (7.34±1.06%), 72h post-transfection. 
 
Generally, Lipofectamine®-based treatments exhibited slightly higher %cytotoxicity compared 
to FuGENE® HD-treatments, 72h post-transfection (ranging approximately between 20-30% 
cytotoxicity compared to approximately 10-18% by FuGENE® HD-mediated transfections). 
Considering the varied range of %cytotoxicity for either cell, especially with regards to 
Lipofectamine®-based treatment conditions, no real statistical difference in %cytotoxicity was 
observed between 293T and YB1 knockout cell lines. The general consensus was that 
%cytotoxicity was comparable between 293T and YB1 knockout cells for most conditions (even 
at higher reporter plasmid concentrations of pAAV2-hrGFP), because no statistical significant 
difference between %cytotoxicity was identified at any time-point and for any treatment 
condition, between 293T and YB1 knockout cells for either Lipofectamine® or FuGENE® HD-
mediated treatments. The cytotoxicity profiles were further appreciated by the comparable 
transfection efficiencies achieved for pAAV2-hrGFP between 293T and YB1 knockout for any 
given pAAV2-hrGFP transfection condition (>94%), 72h post-transfection. This was recorded 
using either FuGENE® HD reagents (Fig. 3.20D) or Lipofectamine® (Fig. 3.21D); however, only 
85.2% of cells were recorded as GFP-positive after 0.1μg input of pAAV2-hrGFP for 293T cells 
compared to 98.6% for YB1 knockout, 72h post-transfection using FuGENE® HD.  
 
 
  
 
 
 
    
182 
    
Figure 3.20 LDH cytotoxicity measurements from 293T and YB1 knockout cell lines after transfection 
with FuGENE® HD reagent. Comparable LDH activity, represented as %cytotoxicity, was evident 
between YB1 knockout clones and 293T control, after treatment with FuGENE® HD alone or transfection 
with pAAV2-hrGFP, pAAV2/2-RC+pHelper, or triple transfection. Generally, results presented here 
indicated that YB1 knockout cells were not susceptible to cell damage or cell death compared to 293T 
control after treatment or transfection using FuGENE® HD, throughout the 72h timecourse. LDH activity 
was measured in the cultured media between 293T control and YB1 knockout cell lines at (A) 24h, (B) 
48h, and (C) 72h, post-transfection or treatment. Error bars reflect ±SD from mean, n = 3; *, P < 0.05. D) 
Representative flow cytometry analysis for transfection efficiencies for the pAAV2-hrGFP reporter 
plasmid at 72h post-transfection or -treatment for 293T and YB1 knockout cell lines. Negative controls 
for flow cytotomery included FuGENE® HD only treated and pAAV2-RC+pHelper transfections. 
Transfection efficiencies are presented within scatter plots as %. YB1ko, YB1 knockout cell line. 
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Figure 3.21 LDH cytotoxicity measurements from 293T and YB1 knockout cell lines after transfection 
with Lipofectamine® 2000 reagent. Comparable LDH activity, represented as %cytotoxicity, was evident 
between YB1 knockout clones and 293T control, after treatment with Lipofectamine® 2000 alone or 
transfection with pAAV2-hrGFP, pAAV2/2-RC+pHelper, or triple transfection. Generally, results 
presented here indicated that YB1 knockout cells were not significantly susceptible to cell damage or 
cell death compared to 293T control after treatment or transfection using Lipofectamine® 2000, 
throughout the 72h timecourse. LDH activity was measured in the cultured media between 293T control 
and YB1 knockout cell lines at (A) 24h, (B) 48h, and (C) 72h, post-transfection or treatment. Error bars 
reflect ±SD from mean, n = 3. D) Representative flow cytometry analysis for transfection efficiencies for 
the pAAV2-hrGFP reporter plasmid 72h post-transfection. Negative controls for flow cytotomery 
included Lipofectamine® 2000 only treated and pAAV2-RC+pHelper transfections. Transfection 
efficiencies are presented within scatter plots as %. Lipo, Lipofectamine® 2000 only; YB1ko, YB1 
knockout cell line. 
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3.2.12 YB1 knockout does not confer an enhanced rAAV2 vector producer cell line 
A rAAV2 production system was identified that demonstrated comparable cytotoxicity post-
triple transfection between 293T and YB1 knockout cell line – namely PEImax-mediated 
transfections. Therefore, genome titres of rAAV2 vectors harvested from control 293T and YB1 
knockout cell lines were quantified by qPCR. However, the YB1 knockout phenotype did not 
demonstrate a significant effect on rAAV2 vector genome titres when compared to YB1+ 293T 
control (Fig. 3.22). An equivalent relative vector genome titre difference was measured for YB1 
knockout cell line – an average of 0.999±0.405 relative to 293T was calculated (Fig. 3.22A; n = 
4 batches each cell line quantitified, P ≥ 0.05). Individual physical genome titres per batch 
were also plotted, and batch-to-batch variation was exemplified when examining individual 
rAAV2 vector genome titres derived from 293T control and YB1 knockout cell line (Fig. 3.22B). 
As much as 4.23x108 vector genomes/mL was quantified for 293T compared to 5.31x108 
vector genomes/mL for YB1 knockout (batch 1), corresponding to 1.3X more. Or as low as 
2.62x108 vector genomes/mL (293T) compared to 1.05x108 vector genomes/mL from YB1 
knockout cells (batch 2), corresponding to 0.4X less rAAV2 measured from YB1 knockout cells.  
 
The comparable vector genome titres produced from control 293T and YB1 knockout cells was 
substantiated by comparable transfection efficiencies (>83% for both cell lines), as 
demonstrated by flow cytometry analysis (Fig. 3.22C). Ultimately, the data presented suggests 
that CRISPR/Cas9 genome editing for YB1 knockout in 293T cells did not confer an enhanced 
rAAV2 vector producer cell line in accordance with previously reported YB1 knockdown 
studies (45-fold enhancement)(Satkunanathan et al., 2014). 
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Figure 3.22 Recombinant AAV2 vector genome titres compared between 293T and YB1 knockout 
producer cell lines by qPCR. Recombinant AAV2 titres between 293T and YB1 knockout cell lines were 
calculated using qPCR, and titres calculated from YB1 knockout cell line was (A) made relative to 293T as 
the baseline control producer cell line. An equivalent titre difference relative to 293T control producer 
cell line was calculated. Error bars reflect ±SD from mean, n = 4. B) Individual rAAV2 vector genome 
titres/mL for each batch were plotted and compared between 293T and YB1ko as producer cell lines. C) 
Representative flow cytometry analysis for transfection efficiencies for the pAAV2-hrGFP reporter 
plasmid at 72h post-transfection of 293T and YB1 knockout cell lines for rAAV2 vector production. 
Transfection effeciencies are presented in parentheses. VG, vector genome; YB1ko, YB1 knockout cell 
line. 
 
3.3.0 Chapter Summary 
We show in the present study the effective utilisation of CRISPR/Cas9 genome editing tool to 
generate precise and targeted knockouts of an endogenous gene of choice in 293T cells. 
Although, given the limitation of 293T’s pseudotriploid nature, we demonstrated the benefit 
of generating single cell clones of pCRISPR-tranfected cells to isolate homozygous mutants of 
the YBX1 gene. Furthermore, we also show that epitope disruptions can result from genome 
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editing, and false-positives can be differentiated using a range of target-specific antibodies. 
However, a main benefit of the present study is the extensive characterisation of CRISPR/Cas9 
genome edited cells based on sequencing data, wherein, HRM curve analysis was shown to be 
a sensitive tool to differentiate wildtype YBX1 gene sequences from mutated in clones 
exhibiting a heterozygous genotype, and predictive analysis of alternative splicing motifs and 
alternative splice site activation was potentially identified. The latter is not a common method 
of practice utilised in research based on CRISPR technology, currently. However, despite 
establishing YB1 knockout cell lines using the CRISPR/Cas9 genome editing system and 
characterising and defining these cell lines at the molecular level as confident YB1 knockouts, 
the adverse effect of chloroquine on this cell line was unprecedented. This was mainly because 
chloroquine is commonly used to supplement the Calcium Phosphate precipitation method for 
transfection (Luthman and Magnusson, 1983; Hasan et al., 1991; Felgner et al., 1994; Kariko et 
al., 1998). The addition of chloroquine improves transfection efficiency, which is an important 
reaction to control for optimal viral vector titres. Thus cell cytotoxicity mediated by 
chloroquine is well tolerable by 293T cells to enable adequate transfection. In addition, no 
such adverse effect was reported in YB1 knockdown cell lines (Satkunanathan et al., 2014). 
Therefore, the sensitivity of YB1 knockout cells towards chloroquine treatment was surprising, 
and prevented the use of this reagent to supplement Calcium Phosphate-based triple-
transfection for rAAV vector production. In fact, omission of chloroquine from Calcium 
Phosphate transfection methodology still presented with a significant difference in cytotoxicity 
profiles between the two cell lines, even though the overall %cytotoxicity was considered low. 
In order to confidently assess the impact of YB1 knockout on rAAV vector titres a completely 
controlled production system, up to and including the transfection dynamics and cytotoxicity 
profiles between cell lines, was paramount. A difference in cytotoxicity profiles would 
interfere with data interpretation when comparing the effect of YB1 knockout on AAV 
processing. However, examination of alternative transfection reagents revealed that PEI-
mediated transfection, and to a lesser extent Calcium Phosphate (without the 
supplementation of chloroquine), for rAAV vector production remains a suitable alternative. 
Despite this, overall rAAV2 vector genome titres was not enhanced in the current study using 
YB1 knockout cell lines compared against un-edited 293T cells as baseline control, which was 
in contrast to an analogous study that demonstrated that downregulation of YB1 in 293T cells 
correlated with an enhanced rAAV2 and rAAV8 vector genome titres (Satkunanathan et al., 
2014). The possible reasons for which are discussed in detail in Chapter 7 (see sections 7.7, 
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7.9, and 7.11 for further discussions). In the next chapter, we further investigate the impact 
and the role of YB1 and YB1 knockout has on rAAV2 vector production.  
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Chapter 4: The Role of YB1 on Recombinant 
AAV Vector Production 
 
4.1.0 Introduction 
A novel approach to improve rAAV vector systems is the manipulation and regulation of 
endogenous, cell-intrinsic protein expression to influence rAAV vector production and output. 
Recently, host cell factors, including Y-Box protein (YB)1 protein, have been found associated 
with rAAV particles; and targeted knockdown of YB1 protein expression in 293T cells 
correlated with transiently enhanced rAAV vector titres and Rep protein expression 
(Satkunanathan et al., 2014). In Chapter 3 we employed CRISPR/Cas9 genome editing for 
targeted knockout of YB1 expression in 293T cells and explored the feasibility of this approach 
on rAAV vector production. We now expand on the YB1 knockout cel line, and the aim of the 
current study was to further examine the role of YB1 in context of rAAV vector processing. 
Having previously established YB1 knockout cell lines using CRISPR/Cas9 genome editing, we 
aimed to elucidate the capacity at which YB1 expression potentially rescues the cytotoxic 
phenotype associated with selected transfection modalities. Furthermore we were also 
interested in which functional domain of YB1 contributes to rAAV vector production dynamics, 
including rAAV2 vector genome titres, AAV2 protein localisation and expression. Overall, we 
demonstrated that the chloroquine-induced cell cytotoxicity could be rescued in YB1 knockout 
cell lines by the stable expression of full length and select YB1 mutants. Additionally, an 
insignificant effect on rAAV2 vector processing was evident by the YB1 knockout cellls and the 
stable expression of a range of YB1 truncation mutant phenotypes. Despite this, putative YB1 
DNA binding motifs were identified in AAV and Adenovirus sequences, to which specific 
binding to the ITR, rep and E2a DNA sequences was revealed, potentiating in YB1 having an 
effect of these elements in vitro.  
 
4.2.0 Results  
4.2.1 Exogenous YB1 expression by plasmid transfection of 293T and YB1 knockout cell 
lines 
We previously demonstrated that YB1 knockout cells were susceptible to cell cytotoxicity after 
transfection and/or treatment with chloroquine reagent (Chapter 3). We next examined the 
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feasibility in reintroducing exogenous YB1 using pDESTmycYBX1 transfection to both 293T and 
YB1 knockout cells. Therefore, cells were transfected with various amounts of pDESTmycYBX1 
and cultured without antibiotic selection. Cell cytotoxicity or any adverse effect towards 
pDESTmycYBX1 transfection was not observed, and so Western blotting was performed to 
determine the expression levels of endogenous and exogenous YB1 upto 30 days in culture, 
post-transfection (Fig. 4.1).  
 
Given equal loading of protein lysates was well represented by GAPDH across the entire 
timecourse, overall, exogenous YB1 (myc-tagged) was markedly expressed in 293T and YB1 
knockout cells 72h post-transfection (Figs. 4.1A and B, respectively). This was particularly true 
for input quantities of 1μg, 2μg, and 5μg of pDESTmycYBX1 plasmid. Exogenous YB1-myc 
expression was considered easily distinguished from endogenous YB1 – the former resolved to 
approximately 52kDa and endogenous YB1 to approximately 50kDa (Figs. 4.1A and B, compare 
YB1-myc annotation to YB1 annotation). However, the expression of exogenous YB1-myc was 
eventually lost in both 293T and YB1 knockout cells, even when transfected with the highest 
quantities of pDESTmycYBX1 as early as 10 days post-transfection (Figs. 4.1C and D, 
respectively), and at 20 days (Figs. 4.1E and F, respectively), and finally 30 days (Figs. 4.1G and 
H, respectively) post-transfection. Non-transfected 293T and YB1 knockout cells functioned as 
negative controls for pDESTmycYBX1 transfection, and throughout the timecourse did not 
exhibit exogenous YB1-myc expression, especially at the 72h harvest point (Figs. 4.1A-H). On 
the other hand, pDESTmycYBX1-transfected YB1 knockout cells recovered their knockout 
status after the loss of YB1-myc expression after 72h post-transfection (Figs. 4.1D, F, and H). In 
conclusion, exogenously introduced YB1 expression in 293T and YB1 knockout cell lines 
showed no detrimental effects, but stable transformation of either cell line was not achieved 
using pDESTmycYBX1 plasmid transfection, especially without antibiotic selection.  
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Figure 4.1 Western blot analysis of exogenous YB1 expression in 293T and YB1 knockout cell lines 
after pDESTmycYBX1 transfection. Reintroducing and overexpressing YB1 was investigated by 
transfecting 293T and YB1 knockout (A2) cells at different quantities (μg) of pDESTmycYBX1. Western 
blot analysis demonstrated overexpression and reintroduction of YB1 expression (top blots; see YB1-
myc annotated signal compared to endogenous YB1), 72h post-transfection between (A) 293T and (B) 
YB1 knockout cells. However, the expression of exogenous YB1 was considered transient in both 293T 
and YB1 knockout cells, as by (C and D, respectively) 10 days, (E and F, respectively) 20 days, and (G 
and H respectively) 30 days post-transfection, exogenous YB1-myc expression was lost. Baseline YB1 
expression was restored for (C, E, G) 293T. Similarly, (D, F, H) YB1 knockout cells recovered the YB1 
knockout phenotype. Non-transfected 293T and YB1 knockout cells served as negative controls for 
transfection. GAPDH expression (bottom panels) was used to determine equal loading. YB1ko, YB1 
knockout cell line. 
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4.2.2 Infection of YB1 knockout cells with rAAV or lentiviral vectors exhibit comparable 
cytotoxicity profiles to 293T control 
We next explored if the YB1 knockout phenotype exhibited adverse effects to viral vector 
(rAAV2 and lentiviral vectors) infections at various multiplicities of infection (MOI) in 
comparison to 293T as control, using LDH cytotoxicity assays. As positive controls for LDH 
cytotoxicity, 293T and YB1 knockout cells were also triple transfected for rAAV2 vector 
production using Calcium Phosphate precipitation method supplemented with chloroquine in 
parallel. As a result, comparable %cytotoxicity profiles were measured in response to 
rAAV2GFP vector infections at each tested MOI (10, 100, and 1000), throughout the entirety of 
the 72h timecourse (Figs. 4.2A-C; n = 3, P ≥ 0.05). Infections with rAAV2GFP did not exceed the 
%cytotoxicity exhibited by no-treatment controls, which averaged 4.34±1.87% and 4.16±1.76% 
for 293T and YB1 knockout cells, respectively, 72h post-transfection (Fig. 4.2C). On the other 
hand, triple transfection using Calcium Phosphate precipitation method with chloroquine 
resulted in significant cytotoxicity averaging at 21.1±12.31% and 70.57±13.87% for YB1 
knockout cells, compared to 7.71±0.76% and 36.1±5.8% for 293T control, 48h and 72h post-
transfection, respectively (Figs. 4.2B and C; n = 3, P < 0.01 and P < 0.001, respectively). 
Additionally, cytotoxicitiy profiles were considered relatively independent of vector 
transduction rates, as measured by flow cytometry 72h post-infection (Fig. 4.2D). Transduction 
efficiency at a given MOI was incomparable between 293T and YB1 knockout cells; for 
example, using MOI 100, approximately 3.59% and 1.89% of 293T and YB1 knockout cells, 
respectively, were GFP-positive. The disparity was more pronounced at the higher MOI 1000, 
where an appreciable 30.3% and 13.2% of 293T and YB1 knockout cells, respectively, were 
GFP-positive (Fig. 4.2D). The comparable cytotoxicities after rAAV2GFP infection were 
therefore considered independent of vector transduction. Overall, despite exhibiting 
equivalent cytotoxicity profiles to 293T control, the YB1 knockout cells interestingly 
demonstrated a poor transduction capacity for rAAV2 vector compared to 293T. 
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Figure 4.2 LDH cytotoxicity assays for rAAV2GFP transduction of 293T and YB1 knockout cells. 293T 
and YB1 knockout cells were infected with rAAV2GFP vectors at the indicated MOIs, and cytotoxicity in 
response to rAAV2GFP transduction was measured for no-treatment and MOIs 10, 100, and 1000, over 
a 72h timecourse. LDH activity was measured at (A) 24h, (B) 48h, and (C) 72h, post-infection, showing 
overall that YB1 knockout cells exhibited comparable cytotoxicity profiles to 293T control cells at all 
MOIs. Triple transfection for rAAV2GFP production using Calcium Phosphate precipitation method, 
supplemented with chloroquine was used as a positive control for LDH activity, and measured in 
parallel. Error bars reflect ±SD from mean, n = 3; **, P < 0.01; ***, P < 0.001. D) Flow cytometry 
measured the transduction efficiency between 293T and YB1 knockout 72h post-infection with 
rAAV2GFP. No-treatment control served as negative control for flow cytometry. Transduction 
efficiencies are presented within scatter plot. CQ, chloroquine; MOI, multiplicity of infection; NT, no-
treatment control; YB1ko, YB1 knockout cell line. 
 
Similar was observed and calculated for LDH cytotoxicity assays after infections of 293T and 
YB1 knockout cells using lentiviral vector (lentiGFP) at MOIs 1, 5 and 30, over a 72h 
timecourse. Comparable cytotoxicity profiles between 293T and YB1 knockout cell lines were 
observed for each tested MOI of lentiGFP and control treatments (no-treatment control, opti-
MEM™, and opti-MEM™ supplemented with polybrene), across the entirety of the 72h 
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timecourse (Figs. 4.3A-C; n = 3, P ≥ 0.05). C). In fact, %cytotoxicity after lentiGFP infections or 
control treatments also did not exceed %cytotoxicity exhibited by non-treatment controls, 
which averaged 5.14±1.26% and 6.88±1.32% for 293T and YB1 knockout cells, respectively, 
72h post-transfection (Figs. 4.3C). Thus implying that, likewise with rAAV2GFP infections, no 
adverse effects were measurably detected in YB1 knockout cell line in response to opti-
MEM™, polybrene or lentiviral vectors infections at the MOIs tested. Analyses were further 
appreciated given the triple transfection using Calcium Phosphate precipitation method with 
chloroquine resulted in significant cytotoxicity averaging at 40.25±3.87% and 68.82±6.73% for 
YB1 knockout cells, compared to 11.96±1.6% and 32.17±2.73% for 293T control, 48h and 72h 
post-transfection, respectively (Figs. 4.3B and C; n = 3, P < 0.001 for both time-points). 
Transduction efficiencies of lentiGFP infection of 293T and YB1 knockout cell lines were also 
measured using flow cytometry 72h post-infection (Fig. 4.2D). In contrast to the disparity in 
transduction efficiencies measured after rAAV2GFP infections between 293T and YB1 
knockout cells, transduction efficiencies were comparable between the two cell lines for the 
given MOI 72h post-infection. Overall, an equivalent or similar transduction capacity for 
lentiGFP vector between 293T and YB1 knockout cells was concluded. Nonetheless, both viral 
vector systems were considered permissible for transduction of YB1 knockout cells, and 
contributed to no measurable adverse effect, especially when compared to 293T control cell 
line.  
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Figure 4.3 LDH cytotoxicity assays for lentiviral vector (lentiGFP) transduction of 293T and YB1 
knockout cells. 293T and YB1 knockout cells were infected with lentiGFP vector at the indicated MOIs. 
Cell cytotoxicity was measured using LDH cytotoxicity assays, for no-treatment, conditioning with 
optiMEM, optiMEM with polybrene controls, and MOIs 1, 5, and 30 of lentiGFP over a 72h timecourse. 
LDH activity was measured at (A) 24h, (B) 48h, and (C) 72h post-infection, showing overall that YB1 
knockout cells exhibited comparable cytotoxicity profiles to 293T control for all MOIs. Triple 
transfection for rAAV2GFP production using Calcium Phosphate precipitation method supplemented 
with chloroquine was used as a positive control for LDH activity. Error bars reflect ±SD from mean, n = 3; 
***, P < 0.001. D) Flow cytometry demonstrated comparable infection efficiencies for each MOI 
between 293T and YB1 knockout 72h post-infection. No-treatment control cells functioned as negative 
control for flow cytometry. Transduction efficiencies are presented in parentheses. CQ, chloroquine; 
MOI, multiplicity of infection; NT, no treatment control; PB, polybrene; YB1ko, YB1 knockout cell line. 
 
 
4.2.3 Generating stable cell lines expressing YB1 full length and truncation mutants 
In order to dissect the functional domain responsible for the protective phenotype to 
chloroquine-induced cytotoxicity in 293T control cells, YB1 mutants were reintroduced into 
the YB1 knockout cell line. The aforementioned LDH cytotoxicity assays indicated that 
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lentiviral vectors were optimal for gene transfer in YB1 knockout cells. Therefore, full length 
and YB1 mutants were designed for stable expression (Fig. 4.4A). In short, full length YB1 
(YB1FL) functioned to rescue YB1 expression, whereas truncated mutants (YB1Δ1-Δ6) intended 
to examine separate functional domains of the YB1 protein. Cloning fragments that encoded 
the intended YB1 protein forms were PCR amplified from pDESTmycYBX1 template, and the 
approximate sized DNA fragments that were expected after agarose gel electrophoresis were 
identified (Fig. 4.4B). The approximate DNA fragments corresponded to YB1FL (1004bp), 
YB1Δ1 (799bp), YB1Δ2 (682bp), YB1Δ3 (418bp), YB1Δ4 (532bp), YB1Δ5 (617bp), and YB1Δ6 
(853bp). Restriction enzyme digestions of pDUAL.mIL6-puro lentiviral transfer plasmid 
demonstrated mIL6 dropout (approximately 655bp; see red arrow), which was distinct from 
single and uncut controls (Fig. 4.4C; see +BamHI+NotI lane labelled prior and red arrow for 
mIL6 dropout, and compare to controls). Furthermore, the pDUAL vector backbone post-gel 
purification was double restriction digested and demonstrated that a relatively clean pDUAL 
vector backbone was isolated, with no detectable mIL6 dropout (Fig. 4.4C; see lane post and 
compare to lane prior). Unfortunately, two alternative YB1 truncations were not possible to 
clone in the present study due to cloning difficulties. These included constructs reflecting only 
the A/P domain or the A/P plus the CTD (i.e. absent of the CSD). 
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Figure 4.4 Designing full length and mutant YB1 coding sequences for cloning into pDUAL vector 
backbone for lentiviral vector production. A) Schematic of full length YB1 (YB1FL) and YB1 mutants 
(YB1Δ1-Δ6) intended to be stably expressed from YB1 knockout cells. PCR amplifications of full length 
YBX1 (YB1FL) and mutant YB1-encoding sequences (YB1Δ1-Δ6) were (B) confirmed by 1% TAE agarose 
gel electrophoresis. Expectant PCR amplicons of approximate sizes were verified (YB1FL, 1004bp; 
YB1Δ1, 799bp; YB1Δ2, 682bp; YB1Δ3, 418bp; YB1Δ4, 532bp; YB1Δ5, 617bp; YB1Δ6, 853bp). C) The 
quality of pDUAL.mIL6-puro vector backbone prep was also verified by 1% TAE agarose gel 
electrophoresis. Dropout of the mIL6 fragment (approximately 655bp, see red arrow) was distinguished 
from the pDUAL.mIL6-puro vector backbone prior to gel purification (lane prior), and post-purification 
(post). Digestion was compared to single and uncut plasmid controls. aa, amino acid; M1, marker lane, 
100bp DNA Ladder; M2, GeneRuler 1kb DNA Ladder; NTC, non-template control; wt, wildtype. 
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The YB1FL and YB1Δ1-Δ6 DNA fragments were cloned into the pDUAL lentiviral vector 
backbone. Analytical restriction enzyme digestion revealed that the approximate sized DNA 
fragments corresponded to YB1FL (992bp), YB1Δ1 (788bp), YB1Δ2 (671bp), YB1Δ3 (407bp), 
YB1Δ4 (521bp), YB1Δ5 (605bp), and YB1Δ6 (842bp), for most, if not all, selected transformants 
per cloning (Fig. 4.5A). Restricition enzyme digestion of the parental pDAUL.mIL6-puro plasmid 
functioned to differentiate false-positive transformants, and with a mIL6 655bp DNA fragment 
dropout, it was difficult to conclusively differentiate DNA fragments derived from +YB1Δ2 
transformants or +YB1Δ5 transformants. Nonetheless, cloning was further confirmed by 
Sanger sequencing and results are depicted in Figs. 4.5-4.7 (Figs. 4.5B and C, YB1FL and YB1Δ1, 
respectively; Figs. 4.6A-C, YB1Δ2-4, respectively; and Figs. 4.7A and B, YB1Δ5 and YB1Δ6, 
respectively). Cloning junctions at both 5’- and 3’- ends of the YB1FL or YB1Δ1-Δ6 sequences 
were correctly presented. Furthermore, cloning fragments corresponded to the YB1FL, or 
YB1Δ1-Δ6 sequences were all in-frame with their respective ATG start codon (Figs. 4.5-4.7; see 
top sequencing panels – SFFV.F(orward) derived sequencing, green underlined sequence). 
Additionally, TAA stop codons were in-frame with their respective YB1FL or YB1Δ1-Δ6 coding 
sequences (Figs. 4.5-4.7; see bottom sequencing panels – WPRE.R(everse) derived sequencing, 
green underlined sequence). Although, sequencing of the selected +YB1Δ3 transformant using 
the WPRE.R(everse) primer was not determined (Fig. 4.6B; bottom sequencing panel), the 
expected 407bp DNA fragment dropout of approximate size was successfully identified by 
analytical restriction enzyme digestion (Fig. 4.5A). These lentiviral transfer plasmids were 
referred to as pDUAL.YB1FL or pDUAL.YB1Δ1-Δ6, and used to generate lentiviral vectors.  
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Figure 4.5 Cloning of YBX1 full length and mutant YB1 sequences into pDUAL vector backbone for 
lentiviral vector production. YB1FL and YB1Δ1-Δ6 sequences were cloned into pDUAL vector backbone 
and (A) analytical restriction enzyme digest and 1% TAE agarose gel electrophoresis confirmed positive 
transformants with approximate sized DNA fragments (YB1FL, 1004bp; YB1Δ1, 799bp; YB1Δ2, 682bp; 
YB1Δ3, 418bp; YB1Δ4, 532bp; YB1Δ5, 617bp; YB1Δ6, 853bp). Double digested pDUAL.mIL6-puro was 
also run in parallel to help differentiate false-positive screens. B-H) Sequence and sequence 
chromatograms demonstrated successful cloning for selected transformants for (B) YB1FL, and (C) 
YB1Δ1 into the pDUAL lentiviral transfer vector backbone, using SFFV.F(orward) and WPRE.R(everse) 
sequencing primers (top and bottom panels, respectively). Coding sequences were considered in-frame 
with their start codon. SFFV promoter (yellow boxed), BamHI (blue boxed), Kozak sequence (red 
underlined), coding sequence, green underlined, ATG codon, start, TAA reverse complement codon, 
stop, and NotI (grey boxed) sequences are annotated. M1, 100bp DNA Ladder; M2, GeneRuler 1kb DNA 
Ladder. 
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Figure 4.6 Cloning ofYBX1 full length and truncated YB1-encoding CDS into pDUAL vector backbone 
for lentiviral vector production. A-C) Sequence and sequence chromatograms demonstrating successful 
cloning for selected transformants for (A) YB1Δ2, (B) YB1Δ3, and (C) YB1Δ4, into the pDUAL lentiviral 
transfer vector backbone, using SFFV.F(orward) and WPRE.R(everse) sequencing primers (top and 
bottom panels, respectively). Coding sequences were considered in-frame with the start codon. SFFV 
promoter (yellow boxed), BamHI (blue boxed), Kozak sequence (red underlined), coding sequence, 
green underlined, ATG codon, start, TAA reverse complement codon, stop, and NotI (grey boxed) 
sequences are annotated.n.d., not determined. 
 
 
 
 
 
 
 
 
    
200 
    
 
Figure 4.7 Cloning ofYBX1 full length and truncated YB1-encoding CDS into pDUAL vector backbone 
for lentiviral vector production. A-C) Sequence and sequence chromatograms demonstrating successful 
cloning for selected transformants for (A) YB1Δ5 and (B) YB1Δ6, into the pDUAL lentiviral transfer 
vector backbone, using SFFV.F(orward) and WPRE.R(everse) sequencing primers (top and bottom 
panels, respectively). Coding sequences were considered in-frame with the start codon. SFFV promoter 
(yellow boxed), BamHI (blue boxed), Kozak sequence (red underlined), coding sequence, green 
underlined, ATG codon, start, TAA reverse complement codon, stop, and NotI (grey boxed) sequences 
are annotated. 
 
Lentiviral vectors encoding YB1FL and YB1Δ1-Δ6 were stably introduced into YB1 knockout 
cells. These YB1 knockout cell lines carrying an introduced YB1 mutant were herein referred to 
as +YB1FL or +YB1Δ1-Δ6, in accordance to the input vector and encoding transgene. The 
expression and localisation of YB1FL and YB1 mutants were confirmed by ICC and confocal 
microscopy (Fig. 4.8). Here, either αYB1 (ab114999 or PA5-19453) was used to ensure the 
spectrum of YB1 truncations could be detected, given epitope targets were known. Fig. 4.8 
(panels a-i) demonstrated that negligible fluorescent signal or background fluorescence in 
293T cells stained with only the primary αYB1s (panels a-c and d-f for PA5-19453 and 
ab114999, respectively) or secondary antibodies (panels g-i). 293T cells served as positive 
control for endogenous YB1 staining, and indeed demonstrated positive YB1 signal, which was 
predominantly localised in the cytoplasm for either αYB1 antibodies (Fig. 4.8, panels j-l and m-
o). Whereas, in contrast, YB1 knockout cells served as negative controls for YB1 staining; and 
when stained fully with either αYB1 antibodies demonstrated an YB1 knockout phenotype 
with no detectable fluorescent signal, as previously reported (Fig. 4.8, panels p-r and s-u).  
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The +YB1FL cell lines recapitulated the expression and localisation of wildtype YB1 (Fig. 4.8, 
panels v-x, y-aa, and bb-dd). In fact, YB1 retained a strict cytoplasmic localisation even in YB1 
knockout cells re-introduced with higher MOIs of lenti-YB1FL vectors (Fig. 4.8, panels  y-aa, 
and bb-dd). When examining +YB1Δ1-Δ6 cell lines, YB1 truncation mutants – YB1Δ1, YB1Δ3, 
and YB1Δ6 – were characterised as predominantly cytoplasmic in localisation (Fig. 4.8, panels 
ee-gg, nn-pp, and tt-vv, respectively), and thus displayed similar expression and localisation 
profiles to parental 293T and wildtype YB1. On the other hand, when compared to the 
cytoplasmic localisation of 293T control, the YB1Δ2 and YB1Δ4 truncated mutants exhibited 
both cytoplasmic and nuclear localisation (Fig. 4.8, panels hh-jj and nn-pp, respectively). 
Fluorescent signal indicative of YB1Δ2 or YB1Δ4 protein were thus appreciably detected within 
the nuclear compartment in these highlighted cells (Fig. 4.8, panel ii or oo; cells are highlighted 
by white arrows). It was also evident that the YB1Δ2 localisation was absent from the 
nucleolar compartment, as distinguished by high resolution DAPI-staining (Fig. 4.8, panels hh 
and ii), but difficult to discern whether YB1Δ4 protein in +YB1Δ4 cell line showed sub-nuclear 
compartmentalisation. Whereas, YB1Δ5 expression and localisation in +YB1Δ5 cell line was 
identified within the nucleus and relatively absent from the cytoplasm. DAPI-staining of the 
nuclear compartment also helped identify that YB1Δ5 signal was particularly detectable in the 
nucleolar regions of the nuclear compartment (Fig. 4.8, panels qq-ss, see cells highlighted by 
white arrows). With this in mind, and given the fact that YB1Δ5 was a truncation mutant of 
YB1Δ4 and YB1Δ6 (of which were predominantly cytoplasmic in localisation), the CRS1 motif 
was presumably identified as the dominant motif that dictated YB1 localisation to the 
cytoplasm. This observation was also reflected in Table 4.1 which provides a summary of the 
observed subcellular localisations for full length YB1 and truncation mutants identified in the 
present study, and details pertaining to their NLS, CRS, and/or 20S proteasome cleavage site 
are listed in Table 4.1. 
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Figure 4.8 ICC and laser scanning confocal microscopy of 293T, YB1 knockout cells, and YB1 knockout 
cells stably expressing mutant YB1 proteins (YB1FL, YB1Δ1-Δ6). 293T, YB1 knockout, and transduced 
YB1 knockout cells were fixed, blocked and stained for YB1 and mutant YB1 protein. Staining controls 
included 293T cells treated with primary Abs only as indicated (a-c) and (d-f), and secondary Abs only (g-
i). Positive staining controls included 293T stained with the indicated primary Abs and secondary Ab (j-i) 
and (m-o). Negative staining controls included YB1 knockout cells stained with the indicated primary 
Abs and secondary Abs (q-r) and (s-u). Mutant YB1 protein expression was detected in transduced YB1 
knockout cells for YB1FL (v-dd), YB1Δ1 (ee-gg), YB1Δ2 (hh-jj), YB1Δ3 (kk-mm), YB1Δ4 (nn-pp), YB1Δ5 
(qq-ss), and YB1Δ6 (tt-vv). The nuclear compartment was distinguished by DAPI-staining. White arrows 
indicate cells that show mutant YB1 protein localisation in the nucleus, which is in contrast to 293T 
control. PA5-19453 stains N-terminus of YB1; ab114999 stains C-terminus of YB1. Scale bar = 10μm, and 
representative for each panel.  
 
 
    
 
    
 
Table 4.1 List of YB1FL and YB1 mutants and their subcellular localisation and characteristics 
YB1 mutant 
aa 
coverage 
localisation 
CRS1 
(52-
101aa) 
NLS1 
(149-
156aa) 
NLS2 
(185-
193aa) 
NLS3 
(276-
292aa) 
CRS2 
(267-
293aa) 
20S 
cleavage 
site 
YB1 (wildtype) 1-324 C Y Y Y Y Y Y 
YB1FL 1-324 C Y Y Y Y Y Y 
YB1Δ1 1-256 C Y Y Y - - - 
YB1Δ2 1-217 C&N Y Y Y - - - 
YB1Δ3 1-129 C Y - - - - - 
YB1Δ4 52-217 C&N Y Y Y - - - 
YB1Δ5 131-324 N - Y Y Y Y Y 
YB1Δ6 52-324 C Y Y Y Y Y Y 
-, not present; C, cytoplasmic; N, nuclear  Y, present 
 
 
 
 
2
0
3
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Upon further examination of 293T control, +YB1Δ2, +YB1Δ4, and +YB1Δ5 cell lines for YB1 
expression and localisation by post-image analysis, the localisation of YB1 and YB1 mutants 
were further defined by line-profiling analysis. This involved quantifying the grey intensities 
(DAPI and YB1 staining) along the length of individual cells (three cells each were selected) via 
regions of interests (ROIs). Line-profiling through selected cells further confirmed the 
predominant cytoplasmic localisation of YB1 in 293T control cells (see Fig. 4.9A). Staining of 
293T control cells with αYB1 PA5-19453 (Fig. 4.8, panels j-l), or αYB1 ab114999 (Fig. 4.8, 
panels m-o) antibodies demonstrated a similar predominant cytoplasmic location of YB1 
localisation, therefore only the PA5-19453 stained 293T control cells were subjected to line-
profiling analysis. In particular, YB1 fluorescent intensity (green line) was primarily evident 
outside of the nucleus and did not co-localise with DAPI staining (blue line), which 
differentiated the nuclear compartment of stained cells. This was confirmed by examination of 
three separate cells by ROI analysis as representatives of the stained cell population (Fig. 4.9A, 
ROI 1-3).  
 
However, line-profiles of +YB1Δ2 cells defined YB1Δ2 (green line) localisation throughout the 
entire length of stained cells, and included localisation with DAPI-staining (blue line) as a 
differentiating stain for the nuclear compartment (Fig. 4.9B). Given ROI 1-3 were each drawn 
through the length of stained cells and included nucleolar compartments, line-profiling 
indicated that YB1Δ2 fluorescence did not coincide with nucleolar compartments well. This 
was indicated by sharp troughs of YB1Δ2 (green line) and DAPI (blue line) fluorescent 
intensities, at the same points along the length of the ROI 1-3. Stained +YB1Δ4 cells showed 
similar line-profiles for YB1Δ4 to +YB1Δ2 stained cells (Fig. 4.9C). Except, however, line-
profiling of YB1Δ4 signal was picked up throughout the nucleus and not compartmentalised 
strictly in the nucleoplasm as was observed for YB1Δ2. Stained +YB1Δ5 cell line, on the other 
hand, exhibited YB1Δ5 (green line) localisation strictly in the nucleus as per DAPI-staining (blue 
line) (Fig. 4.9D). Furthermore, the highest fluorescent intensities of YB1Δ5 was principally 
detected at the nucleolar compartment by line-profiling, where peak YB1Δ5 fluorescent 
intensities coincided or correlated with troughs in DAPI-fluorescent intensities.  
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Figure 4.9 Mutant YB1 protein (YB1Δ2, YB1Δ4 and YB1Δ5) show nuclear localisation by line-profiling. 
Line graphs represent line-profiling of selected ROIs from 3 separate cells (pictured) of (A) 293T 
(control), or YB1ko cells stably expressing (B) YB1Δ2 and (C) YB1Δ4, and (D) YB1Δ5, using LAS X image 
analysis software. The grey intensities representing YB1 or mutant YB1 (green line) was spatially related 
to the nuclear compartment distinguished by DAPI-staining (blue line). The subcellular distribution of 
YB1Δ2 and YB1Δ5 mutants was therefore distinguished as diffuse throughout the cell (but absent from 
nucleolar regions), and considerably nucleolar localised for YB1Δ2 and YB1Δ5 mutants, respectively.  
Scale = 20μm. ROI, region of interest.  
 
To rule out z-plane discrepancy in the localisation of YB1Δ2, YB1Δ4, and YB1Δ5 truncated 
mutants observed by ICC and line-profiling, orthogonal cross-sections were examined, and 
compared against wildtype YB1 in 293T positive control cell line. Altogether, orthogonal cross-
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sections further confirmed the localisations of YB1, YB1Δ2, YB1Δ4, and YB1Δ5 protein as was 
previously reported (Fig. 4.8) and line-profiling (Fig. 4.9). While 293T control cells displayed 
wildtype YB1 distributed throughout the cell cytoplasm, and relatively absent from the nuclei 
(Fig. 4.10A), YB1Δ2 and YB1Δ4 protein localisation were found throughout the length (x, y 
planes) and depth (z-plane) of +YB1Δ2 (Fig. 4.10B) and +YB1Δ4 (Fig. 4.10C) stained cells. 
Although, YB1Δ2 and YB1Δ4 staining was primarily detected in the cell cytoplasm, notable 
fluorescent signal is also picked up and overlaps with the nuclear compartment throughout 
the x-, y- and z- planes. On the other hand, YB1Δ5 protein was reaffirmed as quite strictly 
nuclear in localisation, but further showed a rather defined compartmentalisation to nucleoli 
regions (Fig. 4.10D), as distinguished by high resolution DAPI-staining. 
 
Figure 4.10 Orthogonal cross-sections further identify YB1Δ2, YB1Δ4, and YB1Δ5 protein localisations. 
Subcellular localisation of wildtype YB1, and truncated YB1Δ2, YB1Δ4, and YB1Δ5 were further defined 
and confirmed by examining orthogonal cross-sections derived from z-stacks of cells stained with αYB1 
(green) and DAPI (blue). Therefore, a strictly cytoplasmic localisation was identified for (A) wildtype YB1 
using 293T positive control; a predominant cytoplasmic with notable nuclear localisation for (B) YB1Δ2 
using +YB1Δ2 and (C) YB1Δ4 using +YB1Δ4 cells. Finally, a nucleoli-defined localisation for (D) YB1Δ5 was 
identified after staining +YB1Δ5 cells.  
 
Finally, the extent of YB1, YB1Δ2, YB1Δ4, and YB1Δ5 staining in the nucleus was quantified by 
calculating average nuclear:cytoplasmic ratios (N/C). In summary, significant localisation of 
YB1Δ2, YB1Δ4 and YB1Δ5 in the nuclear compartment was quantified when compared to 293T 
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control. 293T control cells demonstrated a clear cytoplasmic enrichment of wildtype YB1 when 
staining cells with either αYB1 – PA5-19453 or ab114999, showing N/C ratio of -1.283±0.184 
and -1.392±0.247, respectively after log transformation (Fig. 4.11). Similarly, but to a 
significantly reduced level compared to 293T and wildtype YB1, YB1Δ4 also presented with 
cytoplasmic enrichment with N/C ratio of -0.293±0.271 (Fig. 4.11; n = 30-40 cells analysed, P < 
0.0001). This indicated that YB1Δ4 was predominantly expressed in the cytoplasm, but the 
reduced N/C ratio compared to that quantified in 293T controls suggests that YB1Δ4 was also 
quantified in the nuclear compartment. In contrast to this, YB1Δ2 and YB1Δ5 proteins, 
displayed significant nuclear staining with N/C ratios of 0.443±0.28 and 0.971±0.35 after log 
transformation compared to 293T control with their corresponding αYB1 antibodies (Fig. 4.11; 
n = 30-40 cells each cell analysed, P < 0.0001). Therefore, a particular shift in nuclear staining 
was quantified for YB1Δ4, YB1Δ2, and YB1Δ5, with nuclear predominance quantified for the 
latter two.  
 
 
Figure 4.11 Nuclear/cytoplasmic (N/C) ratios of YB1Δ2, YB1Δ4, and YB1Δ5 compared to 293T control 
cell line. Average N/C ratios (after log10 transfromation) of detected YB1 signal in nucleus and 
cytoplasm were calculated from between 30-40 individual cells, for each cell line that demonstrated 
nuclear localisation of truncated YB1 in YB1Δ2-, YB1Δ4-, and YB1Δ5- expressing cell lines. This was 
compared to the N/C ratio of detected, wildtype YB1 in 293T for the corresponding αYB1 (PA5-19453 or 
ab114999). Error bars reflect ±SD from mean, n = 30-40 cells analysed for each cell line; ***, P < 0.0001.  
 
4.2.4 Expression of YB1 and select truncated mutants rescues the cytotoxicity phenotype 
in YB1 knockout cell lines 
We previously described that the YB1 knockout phenotype was significantly sensitive to 
cytotoxicity after triple transfection using Calcium Phosphate precipitation with chloroquine 
and with chloroquine alone (Section 3.2.11). We then endeavoured to explore whether or not 
    
208 
    
this phenotype could be rescued, and which functional domain of YB1 attributed to this 
undesirable phenotype using LDH cytotoxicity assays. Firstly, all non-treated mutant cell lines 
(+YB1FL and +YB1Δ1-Δ6) demonstrated low %cytotoxicity similar to 293T (8.75±1.38%) and 
YB1 knockout (11.68±1.09%) controls (n = 3 each cell line; P > 0.05) (Figs. 4.12, 4.13-14A).  
 
Significant increase in %cytotoxicity was observed in YB1 knockout cells (62.14±0.23%) 
compared to control 293T (22.97±1.33%) 48h post-treatment with chloroquine (Fig. 4.12). 
However, we observed a rescue in the adverse sensitivity to chloroquine when full length YB1 
or select YB1 mutants were expressed in an YB1 knockout background (Fig. 4.12). Stable 
expression of full length YB1 significantly reduced the %cytotoxicity after addition of 
chloroquine to 33.02±2.27%, 29.6±0.94%, and 32.63±2.67% for +YB1FL, +YB1FL[+], and 
+YB1FL[++], respectively (Fig. 4.12; n = 3 each cell line; P < 0.0001) compared to YB1 knockout 
cells. These %cytotoxicities were appreciably close to that exhibited by 293T control 
(22.97±1.33%), of which difference to 293T control remained statistically significant (n = 3 
each cell line; P < 0.0001, P < 0.05, and P < 0.0001, respectively for and +YB1FL, +YB1FL[+], and 
+YB1FL[++]). This indicated that a complete rescue was not fully achieved by reintroducing YB1 
expression. 
 
Stable expression of particular YB1 mutants also significantly reduced the cell cytotoxicity 48h 
post-chloroquine treatment. The +YB1Δ2, +YB1Δ3, and +YB1Δ4 cells showed the most 
impressive reduction of %cytotoxicity when compared to 293T or YB1 knockout cells after 
chloroquine treatment, exhibiting average %cytotoxicity of 9.68±1.76%, 7.82±1.86%, and 
22.44±3.28%, respectively (Fig. 4.12; compare YB1 knockout to +YB1Δ2 and +YB1Δ3 after 
chloroquine treatment; n = 3 each cell line, P < 0.0001). The +YB1Δ4 cell line also 
demonstrated a significant reduction in %cytotoxicity when compared to YB1 knockout (n = 3 
each cell line; P < 0.0001), and was considered comparable to 293T control, indicating that 
stable YB1Δ4 expression was sufficient to alleviate the cell cytotoxic effects of chloroquine to 
wildtype levels (Fig. 4.12; compare 293T to +YB1Δ4 after chloroquine treatment). Significant 
reduction in cell cytotoxicity was also achieved by +YB1Δ1 (41.74±3.79%) and +YB1Δ5 
(37.5±4.81%) cells lines when compared to YB1 knockout, 48h after the addition of 
chloroquine (Fig. 4.12; n = 3 each cell line, P < 0.0001). The %cytotoxicity in +YB1Δ1 or +YB1Δ5 
cells was still significantly higher than that of control 293T cells (Fig. 4.12; n = 3 each cell line, P 
< 0.0001), indicating a partial rescue by YB1Δ1 or YB1Δ5 expression. Mutant +YB1Δ6 cells 
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exhibited no rescue with elevated %cytotoxicity (71.52±1.12%) when compared to 293T or YB1 
knockout (Fig. 4.12A; n = 3 each cell line, P < 0.0001).  
 
 
Figure 4.12 LDH cytotoxicity measurements from 293T, YB1 knockout, and +YB1Δ1-Δ6 cell lines 48h 
post-treatment with chloroquine. Results presented indicated that YB1 knockout cells were 
significantly susceptible to cell cytotoxicity after chloroquine treatment, but cell cytotoxicity was 
rescued or partially rescued by the stable expression of YB1FL or select YB1 truncated mutants. LDH 
cytotoxicity profiles were calculated for 293T (solid white bars) and YB1 knockout (solid black bars), 
+YB1FL (solid yellow bars), +YB1FL[10] (solid orange bars), +YB1FL[300] (solid red bars), +YB1Δ1 (solid 
off white bars), +YB1Δ2 (solid light grey bars), +YB1Δ3 (solid medium grey bars), +YB1Δ4 (solid dark grey 
bars), +YB1Δ5 (solid light blue bars), and +YB1Δ6 (solid dark blue bars), after treatment with chloroquine 
(final 25μM) 48h post-treatment. LDH activity for each cell line and treatment was calculated as a % of 
max lysis of each respective non-treated control cell line. Error bars reflect ±SD from mean, n = 3; *, P < 
0.05; **, P < 0.01; ***, P < 0.0001. CQ, chloroquine; NT, no treatment; YB1ko, YB1 knockout. 
 
A similar pattern of %cytotoxicity was observed for 293T, YB1 knockout, and +YB1Δ1-Δ6 cell 
lines 48h after triple transfection using the Calcium Phosphate precipitation method 
supplemented with chloroquine (Fig. 4.13A). Averages of 27.45±1.77% and 63.91±1.35% 
cytotoxicity were measured for 293T and YB1 knockout cell lines after triple transfection with 
chloroquine, respectively; and difference considered statistically significant (n = 3 each cell 
line, P < 0.0001). The stable expression of full length YB1 in YB1 knockout cell lines resulted in 
the rescue of the cell cytotoxic phenotype to wildtype levels in +YB1FL cell lines – averages of 
29.56±2.8%, 25.99±1.04%, and 29.9±1.84% cytotoxicity was demonstrated for +YB1FL, 
+YB1FL[+], and +YB1FL[++] cell lines, respectively. These reductions in average %cytotoxicity 
were statistically significant when compared to YB1 knockout cells only (Fig. 4.13A; n = 3 each 
cell line, P < 0.0001), but comparable to 293T control. 
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Similarly, average %cytotoxicity were rescued to 19.08±4.71%, 14.48±0.93%, 12.63±1.87%, 
and 35.43±0.95% for +YB1Δ2, +YB1Δ3, +YB1Δ4 and +YB1Δ5, respectively, after triple 
transfection with chloroquine. These differences of which were considered statistically 
significant when compared to YB1 knockout or 293T control (Fig. 4.13A; n = 3 each cell line, P < 
0.0001 for either comparisons, P < 0.01 between 293T and +YB1Δ5). Therefore, stable YB1Δ5 
expression was identified to partially rescue the cytotoxic effects of triple transfection 
supplemented with chloroquine. Finally, a lack of rescue of the cytotoxic effects of triple 
transfection supplemented with chloroquine was observed for +YB1Δ1 and +YB1Δ6 (Fig. 
4.13A), which correlated with cell cytotoxicity observations 48h post-treatment with 
chloroquine only (Fig. 4.12). More specifically, average %cytotoxicities of 62.67±0.41% and 
70.01±4.66% were calculated for +YB1Δ1 and +YB1Δ6, respectively. When compared to 293T 
control, the elevated %cytotoxicity showed statistical significance (Fig. 4.13A; n = 3 each cell 
line, P < 0.0001). Whereas, comparing to YB1 knockout, %cytotoxicity exhibited by +YB1Δ1 was 
considered comparable, but modestly statistically significance when compared to +YB1Δ6 (Fig. 
4.13A; n = 3 each cell line; P < 0.05). The transfection efficiency of pAAV-hrGFP plasmid was 
also considered, and reported as comparable (>97%) between 293T control, YB1 knockout, 
+YB1FL, and +YB1Δ1-Δ6 cell lines, 48h post-transfection using Calcium Phosphate precipitation 
supplemented with chloroquine (Fig. 4.13B). 
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Figure 4.13 LDH cytotoxicity measurements from 293T, YB1 knockout, and +YB1Δ1-Δ6 cell lines 48h 
post-transfection using Calcium Phosphate precipitation method supplemented with chloroquine. A) 
LDH cytotoxicity profiles were calculated for 293T (solid white bars) and YB1 knockout (solid black bars), 
+YB1FL (solid yellow bars), +YB1FL[+] (solid orange bars), +YB1FL[++] (solid red bars), +YB1Δ1 (solid off 
white bars), +YB1Δ2 (solid light grey bars), +YB1Δ3 (solid medium grey bars), +YB1Δ4 (solid dark grey 
bars), +YB1Δ5 (solid light blue bars), and +YB1Δ6 (solid dark blue bars), 48h post-transfection with 
chloroquine (final 25μM) for rAAV2 vector production. LDH activity for each cell line and treatment was 
calculated as a % of max lysis of each respective non-treated control cell line. Results presented 
indicated that YB1 knockout cells were significantly susceptible to cell cytotoxicity after chloroquine 
treatment, but cell cytotoxicity was rescued or partially rescued by the stable expression of YB1FL or 
select YB1 truncated mutants. Error bars reflect ±SD from mean, n = 3; *, P < 0.05; **, P < 0.01; ***, P < 
0.0001. B) Comparable transfection efficiencies between 293T, YB1 knockout, YB1FL, and YB1Δ1-Δ6 cell 
lines were measured by flow cytometry, 48h post-transfection for rAAV2 vector production. This was 
compared to negligible fluorescence of non-transfected 293T and YB1 knockout cells as negative 
controls. Transfection efficiencies are presented as % in parentheses. CQ, chloroquine; NT, non-treated; 
YB1ko, YB1 knockout. 
 
Cells triple transfected without chloroquine were also examined. The cytotoxicity profiles 
between 293T, YB1 knockout, and +YB1Δ1-Δ6 cell lines, further substantiated that chloroquine 
was the predominant effector that contributed to the adverse cell cytotoxicity in YB1 knockout 
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cells (Fig. 4.14A). Calculated %cytotoxicities after triple transfection without chloroquine were 
considered low and relatively similar to %cytotoxicities exhibited by non-treated 293T, YB1 
knockout, and +YB1Δ1-Δ5 cell lines (Fig. 4.14A). No significant difference in %cytotoxicity was 
measured between control 293T (12.06±0.69%) and remainder cell lines after triple 
transfection without chloroquine. However, +YB1Δ6 exhibited significant cell cytotoxicity 
(43.64±3.48%) when compared against 293T control or YB1 knockout – average of 
13.23±0.31% (Fig. 4.13A; n = 3 each cell line, P < 0.0001 for each comparison). Additionally, a 
significant reduction in %cytotoxicity was also observed for +YB1Δ5 cell line (7.36±1.67%), 
when compared to YB1 knockout cell line – 13.23±0.31% (Fig. 4.13A; n = 3 each cell line, P < 
0.05). These findings were further appreciated by comparable transfection efficiencies (>93%) 
for the pAAV2-hrGFP plasmid of triple transfected cells measured 48h post-transfection, by 
flow cytometry (Fig. 4.14B). 
 
Therefore, from LDH cytotoxicity data, it was generally considered that triple transfection 
using the Calcium Phosphate precipitation methodology without the supplementation of 
chloroquine did not contribute to the cytotoxic phenotype in YB1 knockout or +YB1Δ1-Δ5 cell 
lines. In fact, these data imply that chloroquine reagent remains the predominant contributor 
and effector of cell cytotoxicity in YB1 knockout cells, as previously reported (Chaper 3, 
3.3.11). The cytotoxic effect of chloroquine could be rescued in the present study – fully or 
partially – by restoring the stable expression of full length YB1 and YB1Δ5. Moreover, the 
cytotoxic effect of chloroquine was further reduced to below the baseline reference by the 
stable expression of YB1Δ2-Δ4. It was noted that YB1Δ6 was unable to rescue YB1 knockout 
cells from chloroquine-induced cytotoxicity, which may be a consequence of the complete 
truncation of the A/P domain. Nonetheless, the data thus far indicates a general concensus 
that the CSD of wildtype YB1 protein exerts a dominant protective function, which may be 
negatively regulated in part by the A/P domain, but more-so when the entire CTD of YB1 is 
expressed in tandem with its CSD. Therefore, a complex interplay between YB1’s A/P, CSD and 
CTD domains is rather integral to facilitating resistance to the cytotoxic effects of chloroquine. 
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Figure 4.14 LDH cytotoxicity measurements from 293T, YB1 knockout, and +YB1Δ1-Δ6 cell lines 48h 
post-transfection using Calcium Phosphate precipitation method without chloroquine. A) LDH 
cytotoxicity profiles were calculated for 293T (solid white bars) and YB1 knockout (solid black bars), 
+YB1FL (solid yellow bars), +YB1FL[+] (solid orange bars), +YB1FL[++] (solid red bars), +YB1Δ1 (solid off 
white bars), +YB1Δ2 (solid light grey bars), +YB1Δ3 (solid medium grey bars), +YB1Δ4 (solid dark grey 
bars), +YB1Δ5 (solid light blue bars), and +YB1Δ6 (solid dark blue bars), 48h post-transfection for rAAV2 
vector production. Results presented indicated that generally cell cytotoxicity was comparable between 
+YB1FL, YB1Δ1-Δ5 and control 293T and YB1 knockout cells after triple transfection for rAAV2 vector 
production without chloroquine. However, +YB1Δ6 showed a significant increase in %cytotoxicity after 
triple transfection for rAAV2 vector production. LDH activity for each cell line and treatment was 
calculated as a % of max lysis of each respective non-treated control cell line. Error bars reflect ±SD from 
mean, n = 3; *, P < 0.05; **, P < 0.01; ***, P < 0.0001. B) Comparable transfection efficiencies between 
293T, YB1 knockout, YB1FL, and YB1Δ1-Δ6 cell lines were measured by flow cytometry, 48h post-
transfection for rAAV2 vector production. This was compared to negligible fluorescence of non-
transfected 293T and YB1 knockout cells as negative controls. Transfection efficiencies are presented as 
% in parentheses. NT, no treatmeant. CQ, chloroquine; NT, no treatment; YB1ko, YB1 knockout. 
 
The effect of stable expression of full length YB1 and YB1 truncated mutants (YB1Δ1-Δ6) on 
cell cytotoxicity was also explored 72h post-triple transfection using PEImax. To summarise, 
comparable %cytotoxicities were measured between 293T control, YB1 knockout, and +YB1FL, 
+YB1Δ1, +YB1Δ2, +YB1Δ5 and +YB1Δ6 cell lines, for each respective treatment/transfection 
(Fig. 4.13A). In fact, +YB1FL, +YB1Δ1, +YB1Δ2, +YB1Δ5 and +YB1Δ6 cells did not exhibit 
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%cytotoxicities that exceeded that for 293T (15.89±1.99% and 21.44±2.38%) or YB1 knockout 
(23.87±2.6% and 26.52±1.43%) controls, 72h after no-treatmeant or treatment with PEImax 
only, respectively. Similarly, comparable %cytotoxicities was measured 72h post-triple 
transfection using PEImax for 293T (40.29±2.73%), YB1 knockout (37.94±0.88%), +YB1FL 
(33.65±3.4%), +YB1Δ1 (38.58±1.66%), +YB1Δ2 (39.23±1.78), +YB1Δ5 (37.28±1.78), and +YB1Δ6 
(40.92±2.48%). These findings were further appreciated by comparable transfection 
efficiencies (>94%) was achieved across all cell lines used 72h post-triple transfection using 
PEImax (Fig. 4.13B). Overall, LDH cytotoxicity data indicated that YB1 knockout, and rescue of 
full length YB1 or mutant YB1 expression did not contribute to a cell cytotoxic phenotype after 
exposure to PEImax reagent or triple transfection for rAAV2GFP vector production using 
PEImax. 
 
 
Figure 4.15 LDH cytotoxicity measurements from 293T, YB1 knockout, and +YB1Δ1-Δ6 cell lines 72h 
post-transfection with PEImax. A) LDH cytotoxicity profiles were calculated for 293T (solid white bars) 
and YB1 knockout (solid black bars), +YB1FL (solid yellow bars), +YB1Δ1 (solid light grey bars), +YB1Δ2 
(solid grey bars), +YB1Δ5 (solid light blue bars), and +YB1Δ6 (solid dark blue bars), after no-treatment, 
treatment with PEImax reagent only, or triple transfection for rAAV2 vector production using PEImax, 
72h post-treatment. The %cytotoxicity was considered comparable between all cell lines despite 
transfection with PEImax reagent. LDH activity for each cell line and treatment was calculated as a % of 
max lysis of each respective no-treatment control cell line. Error bars reflect ±SD from mean, n = 3 each 
cell line. B) Flow cytometry analysis for transfection efficiencies for the pAAV2-hrGFP reporter plasmid 
72h post-transfection of 293T, YB1 knockout, +YB1FL, and +YB1Δ1-Δ6 cell lines, against 293T and YB1 
knockout non-treated negative controls. Transfection efficiencies are presented as % in parentheses. 
NT, no-treatmeant. 
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4.2.5 Examination potential interactions between YB1 and AAV during vector production 
In order to accurately visualise the localisation of rAAV2 vector, Rep, Cap or YB1 proteins by 
ICC, the pAAV2-FLuc vector was designed and used to offset the green-fluorescence signal 
produced by GFP expressed from the pAAV2-hrGFP expression vector (Fig. 4.16). Figure 4.16A 
shows the strategy employed to clone a FLuc transgene fragment from pJET1.2-FLuc into the 
pAAV2-MCS expression vector. Complete digestion of the pAAV2-MCS expression vector (Fig. 
4.16B) and the FLuc transgene fragment dropout (approximately 1700bp dropout) from 
pJET1.2-FLuc (Fig. 4.16C-D) were ligated to generate a new vector – pAAV2-FLuc, and 
confirmed by analytical restriction enzyme digestion for the FLuc transgene dropout (Fig. 
4.16E). 
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Figure 4.16 Cloning to generate pAAV2-FLuc plasmid for rAAV2FLuc vector production. A) Schematic 
the cloning strategy used to generate pAAV2-FLuc plasmid, from pAAV2-MCS vector and pJET1.2-FLuc, 
which harbours the FLuc transgene. B) Double restriction enzyme digestion of pAAV2-MCS expression 
vector was distinguished from single and uncut controls by 1% TAE agarose gel electrophoresis. C) 
Double restriction enzyme digestion of pJET1.2-FLuc demonstrated FLuc transgene dropout 
(approximately 1700bp) by 1% agarose gel electrophoresis, especially when compared to single and 
uncut plasmid controls. D) 1% agarose gel electrophoresis of gel purified pAAV2-MCS vector backbone 
(lane annotated 1), which was also subjected to double restriction enzyme digestion (lane annotated 2), 
gel purified FLuc transgene (lane GE). Finally FLuc was pre-ligated with the NotI-HindIII ADPTR molecule 
(lane +ADPTR). Cloning of FLuc into pAAV2-MCS was verified by (E) analytical restriction enzyme 
digestion and 1% TAE agarose gel electrophoresis (approximately 1700bp dropout), compared to uncut 
control. ADPTR, NotI-HindIII adaptor molecule; FLuc, firefly luciferase transgene; GE; gel extracted; M, 
1kb GeneRuler DNA Ladder. 
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In order to identify whether or not the YB1 knockout phenotype influenced the localisation of 
rAAV2 vector particle, AAV2 Cap or Rep proteins, we examined the co-localisation between 
YB1 or YB1Δ1-Δ6, with rAAV2 vector particle (Fig. 4.18), or AAV2 Cap (Fig. 4.19), or AAV2 Rep 
(Fig. 4.20) proteins. Firstly, background fluorescence was determined as absent for triple 
transfected 293T cells stained with primary or secondary antibodies, as shown (Fig. 4.17). The 
influence of selected functional domains of YB1 on the localisation of the aforementioned 
AAV2 proteins was also examined in parallel using the +YB1FL and +YB1Δ1-Δ6 cell lines, that 
stably expressed full length and YB1 mutants.  
 
Figure 4.17 ICC for background fluorescence of triple transfected 293T control cells after staining with 
primary or secondary antibodies. 293T control cells were triple transfected for rAAV2FLuc vector 
production, and 72h post-transfection cells were fixed, blocked and then stained with either primary 
αYB1 (PA5-19543 and ab114999), A20 (AAV2 particle), 10R-A140A (AAV2 Rep), and B1 (AAV2 Cap), or 
secondary Abs (αRabbit Alexa Fluor 488 and αMouse DyLight 633). Control staining showed that only 
background fluorescence or the absence of fluorescent after staining with primary αYB1 (a-d) or 
secondary Abs (e-h), was exhibited in either laser channels. DAPI staining served to differentiate the 
nuclear compartment. Scale bar = 10μm, and representative for all panels. Abs, antibody. 
 
Triple transfected 293T control cells demonstrated a predominant cytoplasmic localisation of 
wildtype YB1 (green fluorescence), with no signal detected in the nuclear compartment when 
using either αYB1 to target YB1’s N- (Figs. 4.18-4.20, panels b and d), or C- terminus (Figs. 4.18-
4.20, panels f and h), confirming early observations shown in Fig. 4.8. The rAAV2 particle in 
triple transfected 293T control cells exhibited a nuclear localisation with notable preference to 
the nucleolar regions (Fig. 4.18, panels c and d), which was in general agreement with previous 
studies (Wistuba et al, 1997; Sonntag et al, 2017). Therefore, no co-localisation between 
wildtype YB1 and rAAV2 particle was inferred from the current study. No fluorescent signal 
corresponding to YB1 protein was detected in triple transfected YB1 knockout cells (Figs. 4.18-
4.20, panels j and l), whereas, rAAV2 particle was detected in YB1 knockout cells with similar 
nuclear localisation (Fig. 4.18, panels k and l) as triple transfected 293T control. The 
localisation of YB1FL protein in +YBFL, +YBFL[+], and +YBFL[++] and mutants YB1Δ1, Δ3, and Δ6 
was predominantly cytoplasmic and as previously described in section 4.3.3. In short, YB1FL 
(Figs. 4.18-4.20, panels j and l, n and o, and r and t), YB1Δ1 (Figs. 4.18-4.20, panels v and x), 
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YB1Δ3 (Figs. 4.18-4.20, panels dd and ff), and YB1Δ6 (Figs. 4.18-4.20, panels hh and jj) 
maintained their predominantly cytoplasmic localisation. YB1Δ2 and YB1Δ4 proteins showed 
diffuse localisation throughout their respective cell lines (Figs. 4.18-4.20, panels z and bb and 
panels hh and jj, respectively), with YB1Δ2 showing some exclusion from nucleolar regions, as 
previously observed. Finally, YB1Δ5 protein consistently demonstrated a predominantly 
nucleolar localisation (Figs. 4.18-4.20, panels ll and nn) as previously identified.  
 
The localisation of rAAV2 particles was within the nuclear compartment, with preferential 
nucleolar localisation in +YB1FL and +YB1Δ1-Δ6 cells (Fig. 4.18, see panels under AAV2 particle 
and respective merged images). This was comparable to that in transfected 293T control cells. 
Therefore, it was considered that rAAV2 particles and YB1Δ2, YB1Δ4, or YB1Δ5 were co-
localised in the nucleus.  
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Figure 4.18 ICC and confocal laser scanning 
microscopy analysis of rAAV2 particle co-
localisation with YB1 and YB1Δ1-Δ6 
truncated mutants. Cells were transfected 
for rAAV2FLuc production. 72h post-
transfection control 293T (a-d and e-h), YB1 
knockout (i-l), YB1FL (m-p, q-t, and u-x), and 
YB1Δ1-Δ6 (y-bb, cc-ff, gg-jj, kk-nn, oo-rr, and 
ss-vv, respectively) cells were fixed, blocked 
and then stained for YB1 (ab114999 or PA5-
19453):AAV2 particle (A20) co-localisation. 
DAPI-staining functioned to differentiate the 
nuclear compartment. Merged images of all 
channels are depicted. Scale bar = 10μm, and 
representative for all panels. Abs, antibody. 
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Using ICC, AAV2 Cap (Vp1-3) was detected throughout the cell, with predominant staining in 
the nuclear compartment, and notable exclusion from the nucleolar regions in 293T, YB1 
knockout or YB1 mutants (Fig. 4.19, panels c and d). Therefore, the localisation of AAV2 Cap 
was considered unchanged or uninfluenced by YB1 knockout, or by the stable expression of 
full length YB1 or YB1 truncated mutants (Fig. 4.19, see panels under AAV2 Cap and respective 
merged images). Although, exceptions to this general observation included the +YB1Δ5 cell 
line and the stable expression of YB1Δ5, which was found to show AAV2 Cap staining within 
the nuclear compartment, which  interestingly also included YB1Δ5 staining present in the 
nucleolar regions (Fig. 4.19, panels mm and nn). Therefore, a potential interaction and 
influence on AAV2 Cap localisation was inferred by the co-localisation between YB1’s CTD and 
AAV2 Cap protein(s). 
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Figure 4.19 ICC and confocal laser scanning 
microscopy analysis of AAV2 Cap co-
localisation with YB1 and YB1Δ1-Δ6.  Cells 
were transfected for rAAV2FLuc production. 
72h post-transfection control 293T (a-d and 
e-h), YB1 knockout (i-l), YB1FL (m-p, q-t, and 
u-x), and YB1Δ1-Δ6 (y-bb, cc-ff, gg-jj, kk-nn, 
oo-rr, and ss-vv, respectively) cells were 
fixed, blocked and then stained for YB1 (PA5-
19453 or ab114999):AAV2 Cap (B1) co-
localisation. DAPI-staining functioned to 
differentiate the nuclear compartment. 
Merged images of all channels are depicted. 
Scale bar = 10μm, and representative for all 
panels. Abs, antibody. 
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AAV2 Rep protein localisation was predominantly nuclear in localisation, and was relatively 
excluded from the nucleolar regions in transfected 293T cells (Fig. 4.20, panels c and d). 
Similar localisation of AAV2 Rep was observed in triple transfected YB1 knockout, +YB1FL and 
+YB1Δ1-Δ6 cell lines (Fig. 4.20, see panels under AAV2 Rep and respective merged images). 
Given that YB1Δ2 and YB1Δ4 proteins were generally found in both the nucleus and cytoplasm 
of +YB1Δ2 and +YB1Δ4 cell lines, respectively, co-localisation between these truncated 
mutants and AAV2 Rep protein in the nucleus of stained cells was acknowledged.  
 
 
In summary, our results suggested that YB1 has no direct influence on the localisation of 
rAAV2 particles, AAV2 Cap and Rep proteins during rAAV2FLuc vector production. Although, a 
possible influence in Cap protein localisation to the nucleolar compartments of transfected 
cells was acknowledged by the stable expression of YB1Δ5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
    
2
2
3
 
 
 
Figure 4. 20 ICC and confocal laser scanning 
microscopy analysis of AAV2 Rep co-
localisation with YB1 and YB1Δ1-Δ6. Cells 
were transfected for rAAV2FLuc production. 
72h post-transfection control 293T (a-d and 
e-h), YB1 knockout (i-l), YB1FL (m-p, q-t, and 
u-x), and YB1Δ1-Δ6 (y-bb, cc-ff, gg-jj, kk-nn, 
oo-rr, and ss-vv, respectively) cells were 
fixed, blocked and then stained for YB1 (PA5-
19453 or ab11499):AAV2 Rep (10R-A140A) 
co-localisation. DAPI-staining functioned to 
differentiate the nuclear compartment. 
Merged images of all channels are depicted. 
Scale bar = 10μm, and representative of all 
panels. Abs, antibody. 
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YB1 is well characterised as a ss and ds DNA binding protein, with preferential binding to 
ssDNA (particularly the 5’-GGGGTT-3’ and 5’-CCTCCT-3’ motifs) and G-rich duplex sequences 
(Zasedateleva et al., 2002; Shi et al., 2013). Therefore, we next considered potential 
interactions of YB1 with AAV- or Adenovirus- associated DNA sequences. Table 4.2 exemplifies 
putative YB1 DNA binding motifs – 5’-GGGGTT-3’ and 5’-CCTCCT-3’, that were identified in 
pAAV2-MCS (ITR sequences), pAAV2/2-RC (rep sequence), and pHelper (E2a sequence) 
plasmids. Regarding the AAV2 ITR sequences screened in pAAV2-MCS, the putative 5’-
GGGGTT-3’ YB1 binding motif was identified in both ITR sequences of the dsDNA plasmid. This 
was further interpreted as present in the rAAV vector genome’s left ITR of the +sense strand 
(122-127nt) and right ITR of the –sense strand (133-138nt from the 5’-end of the right ITR) as 
the ssDNA 5’-GGGGTT-3’ binding motif. The reverse complement of the 5’-GGGGTT-3’ YB1 
binding motif was identified in rAAV vector genome’s right ITR of the +sense strand, which 
potentiates the generation of the dsDNA 5’-GGGGTT-3’ putative YB1 binding motif upon DNA 
replication. Examination of pAAV2/2-RC rep sequence revealed the putative 5’-CCTCCT-3’ YB1 
binding motif early in the rep coding sequence (2bp downstream from the ATG translation 
start codon). Finally, the 5’-GGGGTT-3’ putative YB1 binding motif was identified 78bp 
upstream of the E2a coding sequence in the pHelper plasmid. 
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Table 4.2 YB1 binding motifs identified in AAV and Adenovirus sequences 
target DNA sequence 
AAV2 ITR (left) 5' - GTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT - 3' 
AAV2 ITR (right)* 3’- AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGAG - 5’ 
AAV2 rep  5’- ATGCCGGGGTTTTACGAGATTGTGATTAAGGTCCCCAGCGACCTTGACGAGCATCTGCCCGGCATTTCTG - 3’ 
pHelper E2A 5’- GCGGTTAGGCTGTCCTCCTTCTCGACTGACTCCATGATCTTTTTCTGCCTATAGGAGAAGGAAATGGCCA - 3' 
*, AAV2 right ITR sequence analysed in 3'>5' direction, hence reverse complement of GGGGTT binding sequence identified; bold and 
underlined indicates YB1 binding motif 
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To examine these sequences as potential YB1 binding sites, the putative YB1 binding motifs 
from AAV2’s right ITR, rep, and Adenovirus E2a were PCR amplified centrally as approximately 
500bp capture probes with 5’-desthiobiotin modifications (Fig. 4.21A, see left panel). Control 
capture probes that directly flanked the ITR capture probe’s putative binding motif were also 
amplified as 500bp amplicons with 5’-desthiobiotin modification (Fig. 4.21A, see middle and 
right panels for left and right ITR flanking control capture probes, respectively). As a result, 
capture probes harbouring centrally located 5’-GGGGTT-3’ or 5’-CCTCCT-3’ putative YB1 
binding motifs for ITR, rep, and E2a sequences demonstrated YB1 pulldown in vitro (Figs 
4.21B-D, top panels). More specifically, the ITR capture probe was capable of YB1 pulldown 
from whole cell lysates, whereas, YB1 pulldown was not evident using YB1 knockout cell 
lysates from clone A2 and C5 (Fig. 4.21B, top panel). Reduced pulldown of ‘YB1’ was evident 
using B2 lysate, which was reflective of its partial YB1 knockout phenotype (Fig. Fig. 4.21B). 
Pulldown of YB1 from 293T lysate by the ITR capture probe was further substantiated due to 
the reduced YB1 pulldown when control capture probes (lane R+L flank) were used instead. 
Complete absence of YB1 pulldown when the ITR capture probe was omitted (lane –) was also 
demonstrated.  
 
Similar pulldown of YB1 protein was evident for both the rep and E2a capture probes (Figs. 
4.21C and D, respectively). Although, it was noted that the pulldown of YB1 from 293T lysate 
using the control capture probes was near comparable to the pulldown detected using the rep 
capture probe (see Fig. 4.21B, compare YB1 pulldown from 293T lanes using rep and R+L flank 
and capture probes). Therefore, the specificity of YB1 binding to the 5’-CCTCCT-3’ motif in rep 
was suspect. Regardless, initial YB1 pulldown using PCR amplified capture probes indicated 
that the putative YB1 binding motifs identified in the ITR and E2a sequences may hold merit. 
Lysates were also verified for YB1 expression by 293T control cells or YB1 knockout, including 
partial knockout for clone B2 (Figs. 4.21B-D, middle panel), and normalised loads using GAPDH 
loading control (Fig. 4.21B-D, bottom panel). Further examination of YB1 pulldown revealed 
that, while YB1 pulldown was achieved using ITR, rep, and E2a capture probes, the left flanking 
control capture probe (lane L flank) was relatively unable to pulldown YB1 at the same calibre 
(Fig. 4.21D). This indicated that the associated YB1 pulldown by the left flanking control probe 
potentially represented non-specific binding. However, in contention of this, the right flanking 
capture probe (lane R flank) was capable of YB1 pulldown at comparable level to that of ITR, 
rep or E2a capture probes (Fig. 4.21D), despite no discernable 5’-GGGGTT-3’ or 5’-CCTCCT-3’ 
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motifs present within its sequence. The left flanking control probe, however, possessed single 
5’GGGGTT3’ and 5’CCTCCT3’ motifs, and YB1 pulldown was significantly less by comparison.  
 
 
Figure 4.21 DNA affinity-YB1 pulldown demonstrates potential YB1-specific binding motifs (GGGGTT 
and CCTCCT) in AAV- and Adenovirus- associated DNA sequences. A) 1% TAE agarose gel 
electrophoresis demonstrating the expectant 5’-desthiobiotin labelled PCR amplicons corresponding to 
AAV2 right ITR, rep, Adenovirus E2a capture probes, and the immediate left ITR or right ITR flanking 
sequences control capture probes. PCRs were performed against non-template controls. Potential YB1 
pulldown via streptavidin Dynabeads™ was identified using (B) ITR, (C) p5, or (D) E2a capture probes, 
against the pulldown of YB1 using control capture probes (mixed 1:1), and pulldown of YB1 with capture 
probe(s) omitted (top panel for each). Lysates were also subjected to Western blot analysis to verify YB1 
expression (293T control) and YB1 knockout phenotypes for A2 and C5 clones and partial YB1 knockout 
phenotype in B2 clone (middle panel). Normalised protein loads were determined by GAPDH (bottom 
panel). E) YB1 pulldown from 293T lysates using ITR, rep, E2a, left ITR and right ITR flanking capture 
probes implies some non-specific binding and pulldown was achieved. L flank, left ITR capture probe 
flanking control probe; M, 1kb GeneRuler DNA Ladder; NTC, non-template control; R flank, right ITR 
capture probe flanking control probe; R+L flank, right and left ITR capture probe flanking control probes 
(1:1 mix). 
 
The specificity of YB1 binding to putative YB1 binding motifs was further examined by using 
shorter 3’-biotin labelled capture probes (32bp in length). This was to focus YB1’s binding to 
the putative YB1 binding motif found in the ITRs. Additional control capture probes were 
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introduced, including an irrelevant 32bp sequence from the Luciferase transgene (Luc), and 
the GC-rich sequence previously reported to bind to YB1 with high specificity (Shi et al., 2013). 
Therefore, YB1 pulldown via ITR, GC, and Luc was performed in competition with cold GC-rich 
competitor sequence (Fig. 4.22A). It was evident that the Luc control capture probe was 
capable of YB1 pulldown in the absence of the GC-rich competitor; however, upon the 
addition of the GC-rich competitor, the capacity for Luc capture probe to pulldown YB1 was 
lost. This inferred that the binding to Luc was non-specific, and as much as twice the amount 
of cold GC-rich competitor to capture probe was sufficient to completely out-compete YB1-Luc 
binding. On the other hand, YB1 pulldown was evident by the GC-rich capture probe in the 
absence of the cold GC-rich competitor, but an equivalent level of YB1 pulldown was still 
observed when twice the amount of GC-rich competitor was added. Finally, the dsDNA ITR 
capture probe showed similar YB1 pulldown dynamics to the GC-rich capture probe (Fig. 
4.22A). The pulldown of YB1 was evident even despite the input of GC-rich competitor at all 
indicated ratios. Some degree of YB1 pulldown was lost at 1:¼ and 1:½ ratio of ITR capture 
probe to GC-rich competitor, compared to the complete pulldown of YB1 at higher ratios (1:1 
and 1:2). Therefore, YB1 binding and pulldown by the ITR’s 5’GGGGTT3’ motif was not 
outcompeted using the cold GC-rich competitor.  
 
The potential for YB1 binding to the ssDNA 5’-GGGGTT-3’ motif found in the ITRs was finally 
examined. Firstly, the ssDNA and dsDNA (positive control) ITR capture probes were shown to 
successfully pulldown YB1 from 293T lysate in the absence of the cold GC-rich competitor (Fig. 
4.22B). This binding and pulldown was, however, outcompeted at the excessive 1:10 ratio of 
capture probe to GC-rich competitor, and was further uninfluenced by the titration of input 
293T lysate – 10-200μg (Fig. 4.22B). Next, the specificity of YB1 pulldown using ssDNA ITR 
capture probe was examined, in parallel with ssDNA rep and irrelevant Luc capture probes. 
Here, the ssDNA rep capture probe functioned as an additional control for YB1 specificity as it 
contains an alternative putative YB1 binding motif (5’-CCTCCT-3’). This sequence was only 
relevant in context with the pAAV2/2-RC plasmid (a dsDNA molecule). Therefore, YB1 
pulldown was positively identified for the ssDNA ITR and rep capture probes when no GC-rich 
competitor was added. Interestingly, the Luc capture probe was incapable of YB1 pulldown, 
indicating that the binding to the ssDNA oligo harbouring the putative YB1 binding motifs may 
be highly specific. Furthermore, the degree of YB1 pulldown was more pronounced for the ITR 
capture probe compared to rep when no GC-rich competitor was present. When cold GC-rich 
competitor was added in increasing ratios to the ITR or rep capture probes (1:1, 1:5 and 1:10), 
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the extent of YB1 binding and pulldown was conserved with ssDNA ITR capture probe, 
especially at 1:1 ratio. However, some YB1 pulldown was recognised and detectable at 1:5 and 
1:10 ratios of capture probe to GC-rich competitor. Whereas, the pulldown of YB1 via rep 
capture probe was outcompeted with the addition of the GC-rich competitor (Fig. 4.22C; 1:5 
and 1:10 ratios). Therefore, given YB1 pulldown was not detectable for the irrelevant Luc 
capture probes, the binding to the 5’GGGGTT3’ putative YB1 binding motif found in AAV2 ITRs 
(either ss or ds) was considered specific, inferring that YB1 may bind to the ITR sequences 
during the course of AAV processing. 
 
 
Figure 4.22 Specific binding of YB1 to putative YB1 binding motifs (GGGGTT and CCTCCT) in AAV2 ITR 
and rep sequences. Specific binding of YB1 to AAV2 ITR was determined by pulldown assays using (A) 
short 32nt, dsDNA 3’-biotin-labelled capture probes corresponding to the Luciferase control (Luc), GC-
rich control (GC), and ITR sequences), in the presence of a GC-rich competitor at the indicated ratios. B) 
ssDNA ITR capture probe also demonstrated the capacity for YB1 pulldown from 293T lysate), with GC-
rich cold competitor. The pulldown by dsDNA ITR capture probe functioned as a positive control for YB1 
pulldown. C) YB1 pulldown was demonstrated by ssDNA ITR and rep capture probes, despite the 
addition of GC-rich competitor. The control Luc capture probe failed to pull down YB1. 
 
4.2.6 Impact of YB1 knockout and rAAV2 vector production 
The impact of endogenous YB1, YB1 knockout on rAAV2 protein expression was examined in 
triple transfected cells using PEImax. Given protein loads were normalised using GAPDH as the 
internal loading control, the expression of Rep78, Rep52 proteins, or Vp1-3 proteins was 
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considered comparable between 293T and YB1 knockout cells for all harvest points over the 
72h timecourse (Fig. 4.19A, top and middle panels, respectively). Non-transfected 293T and 
YB1 knockout cell lines as negative controls for transfection exhibited no AAV2 Rep or Vp1-3 
protein expression as expected. It was also appreciated that YB1 expression was consistently 
detected for control 293T lysates but absent for YB1 knockout cell lysates over the 72h 
timecourse (Fig. 14.9A). Additionally, transfection efficiencies for pAAV2-hrGFP plasmid was 
measured as comparable between 293T and YB1 knockout cells (approximately 80% for both 
293T and YB1 knockout) 72h post-transfection by flow cytometry (Fig. 4.19B).  
 
Figure 4.23 Comparable AAV2 
Rep and Vp1-3 expression 
dynamics between 293T and 
YB1 knockout cells. 293T and 
YB1 knockout cells were triple 
transfected for rAAV2GFP 
production and lysates 
examined for AAV2 Rep and 
Vp1-3 expression. A) Western 
blot analysis revealed 
comparable AAV2 Rep and Vp1-
3 protein expression between 
control 293T and YB1 knockout 
cells for each harvest point. This 
was inferred after considering 
GAPDH levels as an internal 
loading control. YB1+ and YB1 
knockout phenotypes were also 
verified between control 293T 
and YB1 knockout cells. B) Flow 
cytometry indicated that 
comparable transfection 
efficiencies (approximately 80%) 
were achieved between 293T 
and YB1 knockout cells 72h 
post-transfection. Transfection 
efficiencies are presented in 
parentheses. h, hours; YB1ko, 
YB1 knockout. 
 
Next, rAAV2 vectors harvested from 293T control, YB1 knockout and +YB1FL, +YB1Δ1-Δ6 cell 
lines were quantified using qPCR and compared to that from control 293T producer cells (Fig. 
4.24). Comparable transfection efficiencies (>97%) was achieved for all cell lines tested 72h 
post-triple transfection for rAAV2GFP production (Fig. 4.24A). Despite this, an insignificant 
difference in relative rAAV2 vector genome titres was calculated for all cell lines when 
compared to 293T as baseline control producer cell line (n = 3 batches per cell line; P > 0.05). 
YB1 knockout cells demonstrated an average 0.85±0.19-fold difference in vector genome titres 
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when compared to 293T control. Similar was measured between 293T and +YB1FL, +YB1Δ1-Δ6 
cell lines, where average fold differences of 1.22±0.15, 0.88±0.15, 0.84±0.46, 0.69±0.22, 
0.86±0.3, 0.75±0.23, 0.58±0.2, 0.73±0.47, and 1.06±0.33 for +YB1FL, +YB1FL[+], +YB1FL[++], 
and YB1Δ1-Δ5, respectively, when compared to 293T (Fig. 4.24B). Some variation in physical 
genome titres, for each cell line when compared to 293T control, was calculated by qPCR for 
each batch (Figs. 4.24C-E, for batches 1-3, respectively). Although, in general titres were 
calculated between a relatively narrow range of 1.2x107-6.5x107 vector genomes/mL across all 
cell lines tested. Ultimately, an insignificant and comparable effect on rAAV2 vector genome 
titres was displayed between all cell lines. This indicated that the YB1 knockout cell line did not 
correlate with an enhanced rAAV vector producer cell line, and that YB1’s functional domains 
(recapitulated as YB1Δ1-Δ6 mutants) also did not contribute significantly to rAAV2 vector 
processing.  
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Figure 4.24 Relative rAAV2 vector genome titres from 293T control, YB1 knockout and YB1Δ1-Δ6 cell 
lines using qPCR. A) Representative flow cytometry analysis indicated that transfection efficiencies of 
pAAV2-hrGFP between 293T, YB1 knockout, +YB1FL and +YB1Δ1-Δ6 were comparable 72h post-
transfection (>97%). This was compared to non-transfected 293T as negative control. Transfection 
efficiencies are displayed in parentheses. B) Recombinant AAV2 vector genome titres produced from 
YB1 knockout, +YB1FL, and +YB1Δ1-Δ6 were quantified by qPCR, and made relative to 293T as control 
producer cell line. A statistically insignificant difference in relative vector genome titres was calculated 
between YB1 knockout, +YB1FL, +YB1Δ1-Δ6 and 293T control (P > 0.05). Error bars reflect ±SD from 
mean, n = 3. Individual physical rAAV2 vector genome titres/mL for each cell line is plotted for (C) batch 
1, (D) batch 2, and (E) batch 3. VG, vector genome; YB1ko, YB1 knockout. 
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4.3.0 Chapter summary 
With an optimal transduction system in play, the transformation of YB1 knockout cell lines 
with lentiviral vectors to stably express full length and truncated mutants of YB1 was 
unchallenged and without complications. In fact, the cohort of cells generated in the current 
study helped to emphasise the importance of YB1 to protect parental 293T cells from the 
induced cytotoxic effects of chloroquine. The rescue of the cytotoxic phenotype, as a result of 
chloroquine treatment of YB1 knockout cells, was mediated by the rescued expression of full 
length YB1. Additional resistance to chloroquine-induced cell death was mediated by YB1 
mutants that commonly shared the CSD. This was particularly reflected by the YB1Δ2 and Δ3 
mutants, which shared a common YB1 domain – the CSD, and were the only truncated forms 
of YB1 that mediated resistance to chloroquine-induced cytotoxicity as opposed to rescue to 
wildtype or near wildtype levels like YB1Δ5. Ultimately, the spectrum of YB1 mutants explored 
suggests that the CSD was likely the principle mediator of this resistance (this was especially 
reflected by YB1Δ2-Δ4), whereas the CTD (as reflected by YB1Δ5) conferred rescue from 
chloroquine-induced cytotoxicity to wildtype levels. Additionally, the results infer that there is 
perhaps a complex relationship that exists between the CSD with the A/P domain and/or CTD, 
which governs YB1’s protective role against chloroquine-induced cytotoxicity, and is discussed 
further in Chapter 7 (see section 7.8 for further discussion).  
 
The transfection of mammalian cell lines is a routine method to generate rAAV vector 
production. PEI-based methods are generally preferred due to its cost-effectiveness compared 
to lipid-based reagents. Additionally, PEI is less sensitive to pH fluctuations as exhibited by 
Calcium Phosphate precipitation (Park et al., 2006; Hildinger et al., 2007; Feng et al., 2008; 
Ling et al., 2016). Scalable generation of rAAV vector production has chiefly been based on 
PEI-meditated transfection of AAV plasmids, also (Grieger et al., 2016). In some contrast, 
transfection of suspension 293 cells by Calcium Phosphate precipitation method was 
associated with poor transfection efficiencies and cell viability (Feng et al., 2007). PEI-based 
transfections were performed in the current study to drive rAAV vector production between 
293T and YB1 knockouts. This was due to the relatively comparable effect on cell cytotoxicity 
of PEI-based transfections between cell lines. Regardless, rAAV2 vector processing was 
considered unaffected by the YB1 knockout phenotype, with equivalent vector genome titres 
to parental 293T and cell lines stably expressing YB1 mutants. The expression dynamics of 
AAV2 Rep78 and Rep52, and Vp1-3 proteins were relatively unchanged also, between 293T 
and YB1 knockout cells over the course of the rAAV2 vector production. However, implied 
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functions of YB1 on rAAV vector processing were identified, including the colocalisation of the 
YB1 CTD with rAAV2 vector particles and AAV2 Cap proteins by ICC and laser scanning confocal 
microscopy. This was implied through colocalisation studies between rAAV2 vector particles or 
AAV2 Cap with YB1Δ5, which showed nucleolar colocalisations. Finally, we showed some 
specific and high affinity binding of YB1 to putative YB1 binding motifs (5’-GGGGTT-3’ or 5’-
CCTCCT-3’) in the ITR, rep and upstream of the E2a DNA sequences. Particular emphasis was 
stressed on the pulldown of YB1 by the ssITR, where YB1 could bind the D-sequence of ITRs 
and potentially interfere with (r)AAV vector processing. 
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Chapter 5: Identification and Molecular 
Cloning of Spodoptera frugiperda Y-Box 
Protein Homologue (SfYB) 
 
5.1.0 Introduction 
The production of rAAV vectors is predominantly mediated using 293T (Xiao et al., 1998; 
Drittanti et al., 2001; Liu et al., 2008), Sf9 (Urabe et al., 2002), or to a lesser extent Ao38 
(Meghrous et al., 2005) producer cells. 293T cells are typically co-transfected with plasmids 
harbouring the AAV2 rep and AAV serotype specific cap genes, AdV-derived helper functions, 
and an AAV2 ITR-flanking transfer vector (Xiao et al., 1998). On the other hand, Sf9 cells are 
derived from the ovarian tissue of S. frugiperda (Vaughn et al., 1977), while the Ao38 cell line 
was established from ovarian tissue of T. ni (Hashimoto et al., 2010; Hashimoto et al., 2012); 
both from the order Lepidoptera. Sf9 and Ao38 cells are well reported for the expression of 
large quantities of heterologous proteins using recombinant baculoviruses (Graber et al., 
1992; Miranda et al., 1997; Usami et al., 2011; Wilde et al., 2014). Sf9 cells were soon after 
successfully exploited for rAAV vector production when co-infected with recombinant 
baculoviruses that include the AAV2 ITR-flanked transfer vector, and vector encoding the 
AAV2 rep and AAV serotype specific cap genes, under the control of baculovirus-derived 
promoters (Urabe et al., 2002; Smith et al., 2009).  
 
Our current knowledge and understanding of the role host cell-derived factors towards AAV 
and rAAV vector biology is quite limited. This is especially the case when concerning insect cell 
lines such as Sf9, where very limited proteomics and genomics data are available. In fact, a 
large subset, if not all, of our knowledge on the impact host cellular factors has of AAV biology 
is modelled by human-derived cell lines (Pegoraro et al., 2006; Holscher et al., 2015; Mano et 
al., 2015; Schreiber et al., 2015; Satkunanathan et al., 2017). Therefore, some elucidation of 
the nature of baculovirus infection of insect cell lines has been achieved (Joshi et al., 2000; 
Popham et al., 2010; Xue et al., 2012; Dong et al., 2017; Wen et al., 2017; Li et al., 2018), but 
remains far from a complete picture. 
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The present study aimed to identify if an Y-Box protein homologue was endogenous to insect 
cell lines based on S. frugiperda and T. ni, given their relevance as producer cell models for 
rAAV vector production (Urabe et al., 2002; Meghrous et al., 2005; Smith et al., 2009). 
Particular emphasis was focused on S. frugiperda and the associated Sf9 cell line, which can be 
considered one of the most clinically relevant models for rAAV(1) vector production 
(Carpentier et al., 2012). Here we systematically identify a set of highly conserved YB1 
homologues in Spodoptera spps. and T. ni in silico, with further experimental evidence by 
cloning suggesting the expression of endogenous Y-Box protein homologue (SfYB) in the Sf9 
cell line. We also show the expression and purification of His-tagged recombinant SfYB in Sf9 
cells using recombinant baculovirus expression vector (rBEV) technology. This facilitated the 
generation of specific antiserum raised against the whole molecule, and in turn will further our 
endeavours to examine the gene regulation and/or genome editing of this factor for rAAV 
vector production.  
 
5.2.0 Results 
5.2.1 Prospective Y-Box or YB1 homologue(s) identified in S. frugiperda and T. ni 
We sought to identify the YB1 or Y-Box protein homologue(s) in alternative cell lines 
(predominantly Sf9) used routinely to generate rAAV vectors (Urabe et al., 2002; Meghrous et 
al., 2005; Smith et al., 2009). Firstly, Western blot analysis of Sf9 lysates (from monolayer or 
suspension cultures) demonstrated that a prospective signal was detected and correlated with 
human YB1 from 293T as positive control, using αYB1 antibodies (Fig. 5.1A). The putative YB1 
homologue was resolved in a 10% SDS-PAGE gel at approximately 50kDa, which was 
comparable to human YB1. The αYB1 were raised against different N- and C- terminus specific 
epitopes of human YB1, and therefore Western blot analysis using three different αYB1 
permitted greater coverage of the prospective Y-Box protein homologue in Sf9 cells, 
depending on the degree of homology shared to human YB1. With this in mind, the human 
YB1 N-terminus specific αYB1 (PA5-19453) performed consistently in detecting the prospective 
YB1 homologue between adherent and suspension cultured Sf9 cells (Fig. 5.1A). Whereas, 
human YB1 C-terminus specific αYB1 (ab114999) performed inconsistently, with signal 
detectable in suspension cell lysates only. This was in spite of the fact that equal loading 
between Sf9 lysates was achieved and determined by Coomassie® Blue gel staining (Fig. 5.1B). 
Furthermore, αYB1’s (ab76149) exact epitope coverage of human YB1 was not disclosed by 
the manufacturers, and was difficult to interpret signals identified with this antibody further, 
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except that a potential Y-Box protein homologue was consistently reported in both adherent 
and suspension Sf9 cells. 
 
 
Figure 5.1 Western blot analysis identifies prospective Y-Box protein homologue in Sf9 cell lines using 
αYB1. A prospective YB1 homologue for S. frugiperda was identified in the (A) Sf9 cell line when 
cultured either as adherent monolayers or cell suspensions, that resolved to approximately 50kDa 
(<52kDa) by Western blotting. This was similar to human YB1 from 293T as a positive control using αYB1 
antibodies. Antibodies including C-terminus specific ab76149 (undisclosed coverage), ab114999 (raised 
against 224-274aa of human YB1), and PA5-19453 (raised against 1-100aa of human YB1). B) Equal 
loading of protein lysates was confirmed by Coomassie® Blue gel staining, especially between adherent 
and suspension Sf9. M, ECL™ Rainbow™ Marker – Full Range.  
 
With a prospective Y-Box protein homologue detected by Western blotting, we screened for 
the homologue sequences (transcribed RNA and aa) in silico. Protein BLAST results for human 
YB1 (NP_004550.2) resulted in no successful hits for candidate Y-Box protein homologues in 
Spodoptera spps or Trichoplusia spps. Similar was reported for the additional reference control 
– a previously characterised YB1 orthologue (Takiya et al., 2004) derived from Bombyx mori 
(silk moth), called B. mori Y-Box protein (BYB; NP_001036897.1). However, in silico BLAST 
analyses using the transcribed mRNA sequences (cDNA) of human YB1 (NM_004559.3) and 
BYB (NM_001043432.1) resulted in positive hits in the TSA database (Fig. 5.2). More 
specifically, input of human YB1 cDNA with organism refinement restricted to Spodoptera spp. 
resulted in positive hits for S. frugiperda (GESP01087352.1). A 116nt sequence match 
corresponded mostly to human YB1’s CSD, and exhibited 97/116nt (84%) homology to S. 
frugiperda’s transcribed RNA sequence (Fig. 5.2A). Furthermore, GESP01087352.1 was 
recognised as an unassembled contig sequence. On the other hand, input of BYB cDNA 
sequence resulted in positive hits for S. frugiperda (GCTM01011706.1), of which 719nt 
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sequence match corresponded to most of BYB’s cDNA, with 619/719nt (86%) homology 
exhibited (Fig. 5.2B). Similar was reported when organism refinement was restricted to T. ni, 
resulting in GBKU01007262.1 transcribed RNA sequence as a positive hit, with 1023nt 
sequence match corresponded to essentially all of BYB’s cDNA, exhibiting 824/1023nt (82%) 
homology (Fig. 5.2C). 
    
   
    
2
3
9
 
 
Figure 5.2 BLAST screening identified Y-
Box protein homologue cDNA sequences 
for S. frugiperda and T. ni.  BLAST analysis 
was performed by input of (A) human YB1 
cDNA sequence (NM_004559.3; as 
Query), and a small stretch of cDNA 
homology was identified (96/116nt; 84%) 
in a contig sequence derived from S. 
frugiperda (Sbjct), that corresponded to 
sequences that encode YB1’s CSD. 
Whereas, input of BYB cDNA sequence 
(NM_001043432.1; Query) identified 
significant sequence homology for most 
of the length of BYB’s cDNA for (B) S. 
frugiperda – 619/719nt (86%) homology, 
and (C) T. ni – 834/1023nt (82%) 
homology. 
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Conceptually translating GESP01087352.1 candidate cDNA for all reading frames revealed a 
274aa ORF – 5’3’ Frame 2 (Fig. 5.3A; see underlined sequence). Using NCBI’s global align tool 
against human YB1 (Fig. 5.3B) or BYB (Fig. 5.3C), the protein sequences exhibited a homology 
of 127/334aa (38%) and 152/334aa (45%) similarity to human YB1, but 232/274aa (85%) 
homology or 242/274aa (88%) similarity to the BYB orthologue. Similar was obtained for 
GBKU01007262.1, of which prospective Y-Box protein homologue for T. ni was pulled out from 
reverse reading frame 1 (3’5’ Frame 1) corresponding to a 272aa long sequence (Fig. 5.4A; see 
underlined sequence), and reverse BLAST against human YB1 (Fig. 5.4B) and BYB (Fig. 5.4C) 
presented with 124/335aa (37%) and a more significant 227/272aa (83%) homology, 
respectively. Therefore, probable Y-Box homologues were identified for S. frugiperda and T. ni, 
and thus, the encoded proteins were referred hereon as SfYB and TnYB, respectively.  
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Figure 5.3 Amino acid sequence determined for S. frugiperda Y-Box protein homologue. S. frugiperda 
Y-Box protein homologue transcribed RNA sequence was conceptually translated, and (A) the forward 
reading frame 2 was selected as a candidate for a putative Y-Box protein homologue. Reverse BLAST of 
the candidate aa sequence (Query) was performed using NCBI global align tool, and in turn 
demonstrated (B) 127/334aa (38%) homology and 152/334aa (45%) similarity to human YB1 
(NP_004550.2; Sbjct); and (C) 232/274aa (85%) homology and 242/274aa (88%) similarity to BYB 
(NP_001036897.1; Sbjct). 
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Figure 5.4 Amino acid sequence determined for T. ni Y-Box homologue. T. ni Y-Box protein homologue 
transcribed RNA sequence was conceptually translated, and (A) the reverse reading frame 1 was 
selected as candidate for a putative Y-Box protein homologue. Reverse BLAST of the candidate aa 
sequence (Query) was performed using NCBI global align tool, and in turn demonstrated (B) 124/335 
residues (37%) homology and 150/335 residues (44%) similarity to human YB1 (NP_004550.2; Sbjct); 
and (C) 227/272 residues (83%) homology and 241/272 residues (88%) similarity to BYB 
(NP_001036897.1; Sbjct).  
 
5.2.2 Prospective Y-Box proteins show evolutionary conservation of their CSD 
Amino acid sequence homology and conservation of Y-Box protein homologues between 
species was further implied through multiple-sequence alignment (MSA) that took into 
consideration additional Y-Box protein homologues of Spodoptera spps. identified in silico. 
These were identified for S. litura, S. littoralis, and S. exigua by methods described above, and 
listed in Table 5.1. As a result, alignment against the entire human YB1 and BYB calculated an 
overall 67% homology shared between human YB1 and selected insect homologues (Fig. 5.5A). 
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Considerable homology and conservation was further reported where sequences that 
corresponded to human YB1’s CSD (residues 51-129aa) and some additional residues flanking 
YB1’s CSD, showed conservation in Y-Box homologues for all selected sequences analysed as 
per heat map (Fig. 5.5A, see boxed aligned sequences: yellow-red highlighted residues were 
considered highly conserved). Aligned residues to YB1’s CSD (residues 51-129aa) showed 
almost 100% conservation, especially between insect homologues, which supports the high 
sequence identity between YB1 or BYB and candidate SfYB or TnYB in initial BLAST 
assessments (Figs. 5.2, 5.3 and 5.4). Finally, the RNP-I and RNP-II binding motifs were also 
mapped (Fig. 5.5A, see green and blue boxed alignments, respectively) and showed almost 
100% homology to human YB1’s RNP-I and RNP-II binding motifs consensus sequences – K/N-
G-F/Y-G-F-I/V and V-F-V-H-F (Landsman, 1992), respectively. On the other hand, conservation 
and homology was considered low at both termini between all Y-Box proteins (blue-green 
highlighted residues were considered showing no-to-low conservation). Furthermore, 
phylogenetic analysis of the selected MSA indicated evolutionary divergence of insect 
homologues from YB1 (Fig. 5.5B). Especially, the insect homologues generally clustered 
together under a single clade, whereas YB1 was considered an out-group, despite the 
significant homology observed in the CSD.  
 
Table 5.1 List of Y-Box protein homologues explored in the present study 
organism 
Y-Box protein 
homologue 
gene 
cDNA (accession 
or GenBank) 
Protein 
(accession) 
H. sapiens YB1 
YBX1; 
NC_000001.11 
NM_004559.3 NP_004550.2 
B. mori 
(Silkworm) 
BYB 
BYB; 
NW_004582015* 
NM_001043432.1 NP_001036897.1 
S. litura 
(Tobacco 
cutworm) 
not defined 
SLYB**; 
LOC111360813 
XM_022977040.1 XP_022832808.1 
S. frugiperda 
(Fall 
armyworm) 
not defined SFYB** GCTM01011706.1 this study*** 
S. exigua 
(Beet 
armyworm) 
not defined SEYB** GAFU01018372.1 this study*** 
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S. littoralis 
(Cotton 
leafworm) 
not defined SLITTOYB** EZ982856.1 this study*** 
T. ni 
(Cabbage 
looper) 
not defined TNYB** GBKU01007262.1 this study*** 
*, whole-genome shotgun assembly derived reference sequence (unannotated); **, putatively 
named as no gene association in the current literature; ***, conceptually translated from 
cDNA (transcribed RNA sequence). 
 
Figure 5.5 Multiple sequence alignment and phylogenetic analyses of human YB1 and Y-Box 
homologues from B. mori, T. ni, and Spodoptera spps. Figure and figure legend continues next page.  
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Figure 5.5 MSA of human YB1 and Y-Box homologues from B. mori, T. ni, and Spodoptera spps. A) 
MSA between human YB1, BYB, and prospective YB1 homologues (S. frugiperda, SfYB; S. litura, SlYB; S. 
exigua, SeYB; S. littoralis, SlittoYB; T. ni, TnYB) was performed using PRALINE MSA tool, and 
demonstrated considerable homology (67% across all species tested) and conversation. This was 
especially the case to sequences that corresponded to human YB1’s CSD (51-129aa; see black boxed) 
and RNP-I and RNP-II binding motifs (see green and blue boxed alignments, respectively). Conservation 
was measured by heat-scale from 1-10 (dark blue [1] – least conserved, to crimson red [10] – complete 
conservation). B) Phylogenetic tree of selected insect Y-Box protein homologues and human YB1 aa 
sequences. The tree was built with MEGA X using the bootstrapped UPGMA method, and inferred 
evolutionary divergence of human YB1 from the insect homologues, and that the insect Y-Box protein 
homologues were highly conserved during the course of evolution. Numbers at nodes correspond to the 
% bootstrap values for 500 replicates and values <50% are collapsed. 
 
Additionally, comparative predictive 3D-modelling of the Y-Box protein homologues was 
performed to reaffirm in silico BLAST analyses that SfYB and TnYB were Y-Box protein 
homologues of YB1 and/or BYB (Fig. 5.6). Firstly, YB1’s N- and C- termini were previously 
reported as highly disordered (Guryanov et al., 2012), and BYB, SfYB, and TnYB aa sequences 
were also identified as intrinsically disordered using the intrinsic disorder prediction algorithm 
based in IntFOLD (Fig. 5.6A). The N- and C- termini of each insect-derived Y-Box protein 
homologue were scored as highly intrinsically disordered (Fig. 5.6A; residue scores ≥0.5 are 
considered disordered). Residues 52-114 of YB1’s CSD had predicted scores <0.5, and thus 
considered structured (Fig. 5.6A, grey shaded region), as similarly reported by Guryanov et al. 
(2012). The equivalent structured regions for BYB (residues 33-100aa), SfYB (residues 37-
104aa), and TnYB (37-104) scored <0.5, also. Next, input of the entire aa sequences of YB1, 
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BYB, SfYB and TnYB into the PSIPRED server was performed to identify intrinsic disorder and 
secondary structure predictions. As a result, N- and C- termini (i.e. aa sequences that flanked 
the Y-Box proteins’ CSD) was predicted to be disordered (Fig. 5.6B), similarly portrayed by 
IntFOLD (Fig. 5.6A). Human YB1 protein demonstrated no identifiable secondary structures 
within the N- or C- termini regions, except for β-sheets within the CSD-encoding domain (Fig. 
5.6B, top panel). On the other hand, despite also displaying disordered N- and C- termini that 
flank a central CSD and β-sheets within the CSD, BYB, SfYB and TnYB also present with 
additional secondary structure predictions (Fig. 5.6B, last four panels). Specifically, BYB was 
predicted to harbour α-helix secondary structures at residues 21-27aa and 69-70aa; SfYB at 
residues 13-18aa, 26-31aa, and 73-74aa; and TnYB at residues 15-19aa, 27-31aa, 73-74aa.  
 
 
Figure 5.6 Y-Box protein homologues demonstrate conserved intrinsic disorder in silico. A) Prediction 
of structured and intrinsically disordered regions of human YB1 (black line), BYB (red line), SfYB (green 
line), and TnYB (blue line) using DISOclust server (part of IntFOLD), is depicted. Residues scoring ≥0.5 
were considered to be disordered. YB1’s CSD is highlighted by grey shading (corresponding to residues 
51-129aa). Regions flanking CSDs of each Y-Box protein is considered intrinsically disordered. Intrinsic 
disorder was further exemplified using (B) PSIPRED and DISOPRED server, which also identified 
disordered regions in the domains that flank the central CSD (red and green boxed residues) for YB1 
(top panel), BYB (second panel), SfYB (second to last panel), and TnYB (bottom panel). Figure legend 
continues next page. 
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Figure 5.6 Y-Box protein homologues demonstrate conserved intrinsic disorder in silico. Additionally, 
secondary structures were also predicted: β-sheets as per yellow highlighted residues and α-helices as 
per pink highlighted residues. Green boxed sequences were predicted to be disordered protein binding 
domains. These were chiefly found in the non-disordered CSDs. See key for annotation of secondary 
structures. 
 
Predictive 3D structures of YB1, BYB, SfYB, and TnYB was then performed using the IntFOLD 
server, to generate template-based 3D models (McGuffin et al., 2015; McGuffin et al., 2018). 
Firstly, multi-template-based  3D modelling of YB1 and Y-Box homologues yielded 3D models 
with the greatest level of accuracy exhibited by the region that represented the CSDs (Fig. 
5.7A-D; models are coloured by a gradient of blue [high accuracy] through white to red [low 
accuracy]). Therefore, the N- and C- termini were difficult to accurately predict based on 
template homology and conservation, which was agreeable with the intrinsic disorder 
exhibited by these sequences (Fig. 5.7). Furthermore, closer examination of the high accuracy 
modelled CSDs reflected that each Y-Box protein homologue generated similar secondary and 
tertiary structures to human YB1 – five β-strands were structurally predicted (Fig. 5.7A-D; see 
inserts and labels β1-5). These were predicted to assemble into a highly conserved β-barrel 
(Fig. 5.7).  
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Figure 5.7 Comparative 3D-structures of YB1 and Y-Box protein homologues’ demonstrate structural 
conservation. 3D-structures of (A) YB1, (B) BYB, (C) SfYB, and (D) TnYB Y-Box protein homologues, were 
modelled using the IntFOLD programme and rendered using Jmol. 3D models were confidently (global 
model quality score >0.34) modelled mainly for the CSD and equivalent regions in the selected 
homologues for predicted 3D-models, using the 5yts, 3trz, 1h95, 1mjc, 2yty, 3trs, and/or 3ulij (PDB) 
templates. N- and C- terminus sequences were modelled with low accuracy, as per colour gradient: 
blue, high accuracy; white, medium accuracy; red, low accuracy. The tertiary structure of YB1 and 
homologues were shown to adopt a relatively conserved β-barrel (see inserts for each). The 3D-models 
depicted in the inserts for each are coloured to reflect separate secondary structures: β-strands (yellow 
arrows; β1-5 annotated), α-helices (pink strands), and loops (blue strands).  
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It was also appreciated that multi-template-based 3D modelling was able to predict tertiary 
structures using RNA binding and cold-shock domain containing proteins, including human 
YB1, as templates (see Table 5.2 for templates used to construct the top model for each Y-box 
protein homologe, their characteristics, and TM-scores). Chiefly, all input Y-Box protein 
homologues were generally templated against PDB’s human YB1’s CSD template (PDB 
template ID: 5yts; UniProt ID: P67809). Superpositions against 5yts as the top template for 3D 
modelling demonstrated structure conservation when concerning the length of the 
superimposed structures, only, i.e. when TM-align and TM-scores was normalised against the 
length of the template(s) used to model as opposed to the entire length of the Y-Box protein 
homologue that was inputted (Fig. 5.8A-D, respectively for YB1 [green model], BYB [blue], SfYB 
[pink], and TnYB [yellow]; see inserts of each for superimpositions against the 5yts template 
[green model] used to construct models, and Table 5.2, highlighted columns). This was 
because the templates used to model the 3D structures corresponded only to the CSDs of each 
Y-Box protein homologue, and N- and C- termini could not be accurantely modelled. 
Nonethesless, use of TM-align generated high TM-scores of 0.974, 0.977, 0.921, and 0.974 for 
YB1, BYB, SfYB, and TnYB, respectively, along the length of the respective template (5yts) aa 
sequence (over 74 residues). TM-scores between 0.5<1.0 are considered to be in about the 
same fold, with 1.0 indicated an exact match. Therefore, with high scores of 0.9>1.0, BYB, SfYB 
and TnYB were considered to share structural conservation with YB1 (Fig. 5.7). Model qualities 
were calculable via the IntFOLD server, and indicated that medium-to-high model qualities 
were achieved (represented by global confidence score >0.3) for the template-based models 
analysed. Specifically, YB1, BYB, SfYB, and TnYB generated global model quality scores of 
0.344, 0.361, 0.361, and, 0.358, respectively with significant confidence in predicted 3D-
structures generated for the top model constructed (P < 0.05 for all). Furthermore, local model 
qualities on a per residue basis (Fig. 5.9A-D for YB1, BYB, SfYB, and TnYB, respectively) 
suggests that modelling of the sequences that correspond to the CSD of each Y-Box protein 
homogue was modelled in best confidence. This was especially made relative to its own N- or 
C- disordered termini given that, on a per residue basis, the predicted residue error (the 
distance between two aligned molecules in Å) greatly exceeded the minimal distance (Å) 
exhibited by matched sequences of the Y-Box protein homologue’s CSD. However, this does 
not come to a surprise given the IntFOLD/PDB templates only matched and modelled against 
the corresponding CSDs and did not include matched sequences for either termini ends. 
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Table 5.2 Y-Box protein model templates and TM-scores using IntFOLD and TM-align 
 
 
Y-Box protein: TnYB 
IntFOLD template 
number: 1 2 3 4 
PDB template ID: 5yts 3ulij 3ts2 2yty 
protein name: YB1* lin28b* lin28a* kia0885* 
host organism: human frog mouse human 
UniProt ID: P67809 B4F6I0 Q8K3Y3 O75534 
TM-score1: 0.270 0.307 0.332 0.210 
TM-score2: 0.974 0.455 0.329 0.339 
*, CSD-containing protein; 1, TM-score using Y-Box protein homologue as normaliser; 2, TM-score using model template (reference) as normaliser. 
Y-Box protein: YB1 
 
BYB 
 
SfYB 
IntFOLD template 
number: 1 2 
 
1 2 3 
 
1 2 3 
PDB template ID: 3trz 5yts 
 
3trz 5yts 1mjc 
 
3trz 5yts 1h95 
protein name: lin28a* YB1* 
 
lin28a* YB1* CspA* 
 
lin28a* YB1* YB1* 
host organism: mouse human 
 
mouse human Escheria coli 
 
mouse human human 
UniProt ID: Q8K3Y3 P67809 
 
Q8K3Y3 P67809 P0A9X9 
 
Q8K3Y3 P67809 P67809 
TM-score1: 0.371 0.227 
 
0.47291 0.284 0.255 
 
0.0439 0.259 0.280 
TM-score2: 0.455 0.974 
 
0.4712 0.977 0.488 
 
0.462 0.921 0.458 
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Figure 5.8 Comparative 3D-structures of YB1 and Y-Box protein homologues’ CSDs demonstrate 
structural homology to PDB templates. JMol rendered 3D-models of YB1, BYB, SfYB, TnYB were 
superimposed against the highest matching PDB template 5yts (green) from IntFOLD as reference using 
TM-align. Models were inputted into TM-align programme to determine CSD structure conservation for 
Y-Box protein homologues: (A) YB1 (yellow; TM-score = 0.974 over 74 residues), (B) BYB (blue; TM-score 
= 0.977 over 74 residues), (C) SfYB (pink; TM-score = 0.921 over 73 residues), and (D) TnYB (yellow; TM-
score = 0.974 over 74 residues). TM-scores for conservation were scored between 0-1, with 1 implying a 
perfect match, and TM-score of 0.5<1 indicating the modelled proteins are in about the same fold.  
 
5.2.3 Recombinant SfYB(His)10 expression by transient transfection of Sf9 cells 
SfYB Y-Box protein homologue was confidently identified in silico. Given Sf9 cells are derived 
from S. frugiperda (Vaughn et al., 1977), and used to generate the previously marketed, 
clinical grade rAAV1 vectors (Glybera) (Carpentier et al., 2012) we aimed to raise antiserum 
specific against SfYB for further characterisation of the endogenous protein. Molecular cloning 
of SfYB was first achieved by codon optimising its coding sequence (SFYBco) for expression in 
S. frugiperda-based cell lines, with respects to codon usage and GC%. The sequence was then 
cloned into an expression vector designed for transfection in insect cell lines (Fig. 5.9A: a 
schematic overview of the cloning procedure used to construct the pIEx-1.His-SFYBco). 
    
252 
    
Agarose gel electrophoresis demonstrated that the pIEx™-1 vector backbone was successfully 
isolated (approximately 3834bp) from a 63bp dropout using BamHI and HindIII. Single 
restriction enzyme digests and uncut pIEx™-1 controls did not exhibit a dropout product (Fig. 
5.9B, see lanes U, +BamHI, and +HindIII, and compare to +BamHI+HindIII). Following which, 
the cloning and ligation of the SFYBco gene string fragment was confirmed by colony PCR and 
agarose gel electrophoresis, identifying clones 6, 7, 13, and 19 generating the expectant PCR 
amplicon of approximately 1111bp (Fig. 5.9C). Agarose gel electrophoresis of analytical 
restriction enzyme digestions further confirmed the SFYBco cloning in selected plasmid clones 
(approximately 832bp dropout expected), which was in contrast to uncut plasmid controls 
(Fig. 5.9D, see lanes pIEx™-1 and pIEx-1.His-SFYBco, under uncut, and compare to selected 
clones +BamHI+HindIII). Therefore, the pIEx-1.His-SFYBco expression vector was constructed 
to express the His-SFYBco transgene, encoding rSfYB(His)10. 
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Figure 5.9 Cloning of SFYBco transgene into pIEx™-1 cloning vector. A) Schematic of cloning strategy 
used to clone SFYBco gene string into the pIEx™-1 cloning vector to construct pIEx-1.His-SFYBco 
expression vector. B) An approximately 62bp fragment dropout and isolation of the pIEx™-1 vector 
backbone was achieved by double restriction enzyme digestion, and compared to single and uncut 
controls by 1% TAE agarose gel electrophoresis. After transformation, positive clones 6, 7, 13, and 19 
were confirmed by (C) colony PCR showing an expected 1111bp (approximate) PCR amplicon by 1% TAE 
agarose gel electrophoresis. D) Selected plasmid clones were further verified to produce the SFYBco 
dropout (approximately 832bp) after analytical restriction enzyme digestion, especially when compared 
to uncut controls. M, Generuler 1kb DNA ladder; NTC, non-template control; U, uncut. 
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Due to the lack of a reporter gene or selection marker in pIEx™-1 plasmid, a positive control 
for transfection was constructed. This encoded the EGFP transgene under control of the IE1 
promoter, which also drives His-SFYBco transcription in the pIEx-1.His-SFYBco construct. A 
schematic overview for sub-cloning the EGFP transgene from pFBGR into pIEx™-1 to generate 
pIEx-1.eGFP is presented (Fig. 5.10A). Agarose gel electrophoresis of pIEx™-1 demonstrated 
that the vector backbone was successfully linearized by NcoI (approximately 3897bp product 
expected), and was distinct from uncut control (Fig. 5.10B, see lanes U and compare to +NcoI). 
The pFBGR plasmid, however, harbours an additional NcoI restriction enzyme site NcoI(3) that 
complicated the isolation of the EGFP transgene as an NcoI fragment. To circumvent this, 
NcoI(3) was removed by AgeI and HindIII restriction enzyme digestion. The vector backbone 
was successfully isolated (approximately 884bp dropout expected harbouring NcoI(3)), which 
was in contrast to uncut and single restriction enzyme digestion controls as presented by 
agarose gel electrophoresis (Fig. 5.10C, see lanes U, +AgeI, and +HindIII, and compare to 
+AgeI+HindIII under pFBGR). The vector backbone was blunted and self-ligated, and plasmid 
clones of the pFBGRΔNcoI(3) intermediate vector was confirmed by analytical restriction 
digests. Several pFBGRΔNcoI(3) clones were encouraging as positive transformants (Fig 5.10C, 
clones 2, 3, 5-10), as no dropout of approximately 884bp was detected. Clone 3 of 
pFBGRΔNcoI(3) demonstrated no dropout of the additional NcoI digestion product of 
approximately 812bp in size, as would have been expected of the parental pFBGR plasmid 
after NcoI treatment (Fig. 5.10D, compare lanes +NcoI of pFBGR and pFBGRΔNcoI(3) clone 3). 
Only the dropout of approximately 922bp product corresponding to the EGFP transgene was 
observed for extraction (Fig. 5.10D, see boxed). Finally, sub-cloning of the EGFP transgene into 
the pIEx™-1 vector backbone was confirmed by colony PCR with several clones (Fig 5.10E, 
clones 3, 5-7, and 15-17) identified as producing the expectant 745bp PCR amplicon. 
Remainder clones presented as concatemeric for the EGFP transgene (Fig. 5.10E, see lanes 
corresponding to clones 1, 2, 4, 8-12, 18, and 19). Therefore, successful sub-cloning of the 
EGFP transgene under promoter control of the IE1 promoter was achieved, to function as a 
positive control for plasmid transfections of Sf9 cells.  
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Figure 5.10 Sub-cloning of EGFP transgene into pIEx™-1 cloning vector. A) Schematic of cloning 
strategy used to clone EGFP transgene from pFBGR into the pIEx™-1 cloning vector to construct pIEx-
1.eGFP expression vector. B) NcoI-mediated linearisation of pIEx™-1 was successfully achieved, 
represented by approximate 3897bp band that was distinct to the uncut control by 1% TAE agarose gel 
electrophoresis. C) The pFBGR demonstrated an approximate 884bp fragment dropout corresponding 
to the surplus NcoI(3) site using AgeI and HindIII, with isolation of the pFBGR vector backbone 
(approximately 6355bp) compared to single and uncut controls. Additionally, pFBGRΔNcoI(3) plasmid 
clones (2,3, 5-10) were identified by analytical restriction enzyme digestion for AgeI and HindIII 
resistance by 1% TAE agarose gel electrophoresis. D) Colony PCR identified plasmid clones 3, 5-7, and 
15-17 as successful pIEx-1.eGFP clones, which produced the expectant 745bp (approximate) PCR 
amplicon by 1% TAE agarose gel electrophoresis. M, Generuler 1kb DNA ladder; U, uncut. 
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Transfection of 8x105 monolayer Sf9 cells with pIEx™-1 (mock) and pIEx-1.His-SFYBco was 
performed to identify rSfYB(His)10 expression. Western blotting analysis revealed that 
transfections with 3μg of pIEx-1.His-SFYBco displayed detectable signal corresponding to His-
tagged protein of approximately 52kDa, 72h post-transfection (Fig. 5.11A, top panel, see 
boxed). The rSfYB(His)10 protein was  also detected using αYB1 (PA5-19453), albeit a very faint 
signal was produced after 3μg plasmid transfection, especially when compared to endogenous 
SfYB expression (Fig. 5.11A, see black boxed for faint rSfYB(His)10), and considering equal 
loading of lysates by Coomassie® Blue gel staining (Fig. 5.11B). Additionally, it was noted that 
non-specific signal was detected in all lysates after α6His-HRP staining, located >52kDa, and 
was present for non-transfected and mock transfected controls (Fig.5.11A, see NT and mock 
lanes, respectively).  
 
Next, with the pIEx-1.eGFP control plasmid, transfection dynamics using different quantities of 
pIEx-1.eGFP and/or pIEx-1.His-SFYBco plasmid (0.5, 3, and 10μg) of 8x105 cells was assessed, 
72h post-transfection. Fow cytometry analysis demonstrated that approximately 49.5% 
transfection efficiency was achieved using pIEx-1.eGFP (0.5μg), especially when compared to 
the 3μg mock transfected negative control (0.36%) (Fig. 5.11C). However, low median 
fluorescent intensity was associated with the 49.5% transfection using pIEx-1.eGFP. 
Additionally, input of higher quantities of pIEx-1.eGFP did not positively correlate with 
improved transfection efficiencies of Sf9 cells – 3μg and 10μg of input plasmid was associated 
with 13.6% and 2.5% transfection efficiencies, respectively (Fig. 5.11C). His-tag staining of 
0.5μg pIEx-1.His-SFYBco-transfected Sf9 cells exhibited 43.1% (Fig. 5.11D); whereas, His-
staining was dramatically reduced despite higher quantities of input plasmid – 3μg and 10μg 
plasmid transfection demonstrated only 13.6% and 2.5% cells His-tag-positive, respectively 
(Fig. 5.11D, see blue and purple lines, respectively). Minimal His-staining of 15.5%, 10%, and 
9.92% resulted after pIEx™-1 mock transfection using 0.5, 3, or 10μg input plasmid, 
respectively (Fig. 5.11D). This was all compared to 0.36%, 0.84%, and 0.65% background 
fluorescence for non-transfected, primary, or secondary stained-only mock transfected 
negative controls, respectively (Fig. 5.11D). Therefore, plasmid transfection of pIEx-1.His-
SFYBco was capable of expressing the rSfYB(His)10, but at rather insufficient quantities by 
transient plasmid transfection using Cellfectin™ II reagent at the indicated quantities. 
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Figure 5.11 Screening for His-tagged rSfYB(His)10 expression after plasmid transfection of Sf9 cells. A) 
Western blot analysis for rSfYB(His)10 expression of non-transfected, mock transfected (pIEx™-1.1, 1μg), 
and pIEx-1.His-SfYBco transfected Sf9 cells using Cellfectin™ II, harvested 72h post-transfection. 
Western blotting was performed using α6His-HRP (top panel) and αYB1 (bottom panel) antibodies, and 
rSfYB(His)10 was detected using αYB1 (boxed) as a  faint signal, especially when compared to native SfYB 
expression. B) Coomassie® Blue gel staining demonstrated equal loading of protein samples. C) Flow 
cytometry analysis of transfection efficiencies of Sf9 cells transfected with 0.5, 3, and 10μg of pIEx-
1.eGFP plasmid, and mock transfected (3μg of pIEx™-1.1). D) Flow cytometry analysis of non-
transfected Sf9 cells and pIEx™-1.1 mock transfected cells as negative staining controls. Mock 
transfected and pIEx.SfYB(His)10 transfected Sf9 cells (0.5, 3, and 10μg each) were therefore completely 
stained for intracellular His-tag (using α6His-HRP) 72h post-transfection. Transfection efficiencies or His-
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staining are presented as % within scatter plots. M, ECL™ Rainbow™ Marker – Full Range; NT, non-
transfected. 
 
Nonetheless, suspension Sf9 cells were transfected with pIEx-1.His-SFYBco to express a 
significant amount of rSfYB(His)10 for subsequent His-tag pulldown assays. Transfected Sf9 cells 
in suspension were first intracellularly stained, and an appreciable 48.4% and 45.3% of the 
transfected Sf9 cell populations were His-tag positive (Fig. 5.12A). This was especially the case 
when compared to non-transfected Sf9 control (0.31%) and pIEx-1.His-SFYBco transfected cells 
stained with only primary (0.3%) or secondary (0.78%) antibodies as negative controls for His-
tag staining (Fig. 5.12A). Following this, transfected Sf9 cells were harvested for rSfYB(His)10 
pulldown in duplicate, and Western blotting of 3μL and 15μL elutes for each revealed 
successful pulldown of His-tagged protein, which resolved to between 49-62kDa for each 
replicate, especially lanes corresponding to 15μL elute loads (Fig. 5.12B, see rSfYB(His)10 
annotation). Additional signals above and below the rSfYB(His)10-annotation were also 
identified that may correspond to degraded rSfYB(His)10, its multimerization, and/or non-
specific protein pulldown (Fig. 5.12B). Furthermore, the quality of pulldown preps was 
assessed by Coomassie® Blue gel staining, which revealed the rSfYB(His)10 protein and 
additional elution products only for loads corresponding to 15μL elute volumes (Fig. 5.12C, see 
rSfYB(His)10 annotation, and red arrows – non-specific pulldown products). 
 
Therefore, transient plasmid transfection of Sf9 cells with pIEx-1.His-SFYBco, either as 
monolayer cells or in suspension, was capable of expressing the desired rSfYB(His)10. 
Furthermore, rSfYB(His)10 was determined to be a soluble protein as per pulldown assays. 
Transient transfection of Sf9 cells, however, only expressed modest levels of rSfYB(His)10, and 
at impractical levels for sufficient purification for the subsequent generation of antiserum. 
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Figure 5.12 Recombinant SfYB(His)10 expression and pulldown after plasmid transfection of Sf9 cells. 
Sf9 cells in suspension were transiently transfected with pIEx-1.His-SFYBco in duplicate, and (A) flow 
cytometry analysis demonstrated 45.3% and 48.4% of His-tag positive cells. Non-transfected and single 
antibody stained transfected cells served as negative controls for gating. Intracellular His-tag staining 
levels are presented as % of cell population of stained cells within scatter plots. Sf9 cells transfected 
with pIEx-1.His-SFYBco were harvested in duplicate for subsequent pulldown of His-tagged recombinant 
protein using Dynabeads™. Elutes of 3 and 15μL loads was subjected to (B) Western blot analysis which 
demonstrated the pulldown of rSfYB(His)10 (see annotation) using α6His-HRP, and (C) Coomassie® Blue 
gel staining. This also showed that the pulldown of non-specific products (see red arrows) compromised 
the prep quality, but rSfYB(His)10  remained distinguishable only in the 15μL elute lanes (see rSfYB(His)10 
annotation). Abs, antibody; M, SeeBlue™ Plus2 Pre-stained Protein Standard. 
 
5.2.4 Scale-up production of rSfYB(His)10 was achieved using recombinant baculoviruses 
To achieve desirable quantities of rSfYB(His)10 protein, we sought to implement rBEV 
technology. This involved the directional cloning by In-Fusion™ of the His-SFYBco transgene 
into a compatible baculovirus cloning vector. Therefore, with the desired homology arms 
incorporated, PCR amplification of the His-SFYBco resulted in the expected sized PCR amplicon 
(approximately 1044bp), confirmed by agarose gel electrophoresis (Fig. 5.13A, see inf_SFYBco 
lane). Subsequent cloning into a pre-linearised pTriEx™-1.1 vector backbone by In-Fusion™ 
resulted in the identification of four main clones 2, 5, 7, and 9 by analytical restriction enzyme 
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digestion (Fig. 5.13B) with approximately 458bp fragment expected. This was in contrast to 
double or single restriction enzyme digested controls of pTriEx™-1.1 (Fig. 5.13B, see lanes 
+EcoRI+NcoI under pTriEx-1.His-SFYBco clones 2, 5,7, and 9, and compare to +EcoRI, +NcoI, 
and +EcoRI+NcoI lanes under pTriEx™-1.1) and single restriction enzyme digested controls of 
the selected pTriEx-1.His-SFYBco clone 2 (Fig. 5.13B, see lanes +EcoRI+NcoI under pTriEx-1.His-
SFYBco clones 2, 5, 7, and 9, and compare to +EcoRI or +NcoI lanes under pTriEx-1.His-SFYBco 
clone 2). Additionally, directional cloning by In-Fusion™ was confirmed by Sanger sequencing 
analysis for clones 2, 5, 7, and 9 (Figs. 5.13C-F, respectively). This revealed that the 5’-cloning 
junction for all selected clones of the pTriEx-1.His-SFYBco plasmid was in-frame to its start ATG 
codon (Figs. 5.13C-F, see start codon annotation in relation to His-SFYBco coding sequence, 
underlined green). 
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Figure 5.13 Cloning by In-Fusion™ of His-SFYBco transgene into pTriEx™-1.1 baculovirus cloning 
vector. A) His-SFYBco transgene sequence with the required homology arms was amplified and 
confirmed by 1% TAE agarose gel electrophoresis (inf_SFYBco; approximately 1044bp amplicon 
expected), relative to non-template control. B) Selected clones of pTriEx-1.His-SFYBco plasmid were 
screened for approximately 458bp fragment dropout after EcoRI and NcoI restriction enzyme digestion, 
and compared to uncut and single cut controls. This indicated all selected plasmid clones were cloned 
correctly. Plasmids were further verified by (C-F) Sanger sequencing using T7.F(orward). The 5’ cloning 
junction was confirmed to be in-frame of the His-tag and SfYB encoded sequences for pTriEx-1.His-
SFYBco plasmid clones (C) 2, (D) 5, (E) 7, and (F) 9. Kozak sequence (underlined red), start ATG codon, 
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10x His-tag coding sequence (blue boxed), and His-SFYBco CDS (underlined green), are annotated. CDS, 
coding sequence; M, Generuler 1kb DNA ladder; NTC, non-template control; U, uncut. 
 
Recombinant BEVs encoding the His-SFYBco transgene and the control rBEV encoding His-GFP 
were then produced by co-transfection of Sf9 cells with flashBAC™ DNA and baculovirus 
cloning vectors. Although accelerated P1 rBEV stocks were harvested from the culture media, 
Sf9 P1 producer cells for each BacSfYB(His)10 vector clone (2, 5, 7, and 9) were harvested after 
7 days post-infection. Both rSfYB(His)10 and rGFP(His)10 proteins were detected using α6His-
HRP by Western blotting (Fig. 5.14A, top panel); rSfYB(His)10 was identified to resolve to 
approximately 50kDa as previously observed using transient transfection methods. This signal 
was absent in non-infected and BacGFP(His)10-infected Sf9 controls. Additionally, the 
rGFP(His)10 protein was identified between 25-37kDa, which was in agreement with previous 
reports concerning poly-His-tagged GFP proteins with approximate molecular weight of 30kDa 
(Mohamadipoor et al., 2009). However, it was noted that non-specific signals were detected 
as previously observed using transient transfection of Sf9 cells (Fig. 5.11A, non-specific signal 
was identified >52kDa) even in non-infected control Sf9 cells. An additional non-specific signal 
was picked up in baculovirus-infected cells at approximately 37kDa, but absent from non-
infected Sf9 control. These did not affect our analysis that the rSfYB(His)10 and rGFP(His)10 was 
detectable after infection with rBEVS, because the rSfYB(His)10 protein expression was 
identified in BacSfYB(His)10-infected Sf9 P1 producer cells only by Western blotting using αYB1, 
and thus was not expressed in non-infected Sf9 and BacGFP(His)10-infected Sf9 control cells 
(Fig. 5.14A, bottom panel). Staining with αYB1 also permitted the detection of the endogenous 
SfYB expression in all control and infected Sf9 cells, which resolved below the rSfYB(His)10 
protein – approximately 50kDa (Fig. 5.14A, bottom panel). Especially, equal loading between 
samples was demonstrated by Coomassie® Blue gel staining (Fig. 5.14B), and infection 
efficiency using BacGFP(His)10 was considered sufficient at 88.2% by flow cytometry analysis 
(Fig. 5.14C). 
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Figure 5.14 Recombinant SfYB(His)10 expression confirmed after BacSFYB(His)10 infections. Sf9 cells 
infected with P0 BacSFYB1(His)10 (P1 producers) were harvested and subjected to (A) Western blotting 
using α6His-HRP and αYB1 (top and bottom panels respectively). The expression of rSfYB(His)10 (see 
annotation) from each BacSfYB(His)10 vector clone-infection of Sf9 cells, and rGFP(His)10 control (see 
annotation), was evident. Equal loading of protein samples was confirmed by (B) Coomassie® Blue gel 
staining. C) Flow cytometry for rBEV-infected Sf9 cells revealed infection efficiency of 88.2% with 
BacGFP(His)10 positive control, and compared to Sf9 infected with BacSfYB(His)10 vector clones 2, 5, 7, 
and 9 (ranging between 0.21-0.36%) and non-infected Sf9 cells served as a negative control for gating. 
Infection efficiencies are presented as % within scatter plots. 7dpi, 7 days post-infection; NI, non-
infected; M, Precision Plus Protein™ Dual Colour Standards. 
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Sf9 cells were further assessed by intracellular His-tag staining and flow cytometry 72h post-
infection with BacGFP(His)10 and selected BacSfYB(His)10 vector clones. Sf9 infected with 
BacSfYB(His)10 vector clone 2 or BacGFP(His)10 stained with either primary or secondary 
antibodies functioned as staining controls, and demonstrated negligible FITC- or APC- positive 
populations (Figs. 5.15A and B, respectively; see black and grey lines for both histograms). The 
single staining controls for BacGFP(His)10-infected Sf9 cells reported fluorescence representing 
infection efficiency of approximately 82% for BacGFP(His)10, similarly to unstained 
BacGFP(His)10-infected Sf9 (Fig. 5.15A, see light grey, dark grey and green lines, respectively). 
Intracellular staining of His-tagged recombinant protein was therefore reported as between 
3.86%-29.6% for BacSfYB(His)10-infected Sf9 cells despite the representative 82% infection 
efficiency (Fig. 5.15A, see red, orange, dark blue and light blue lines, for Sf9 infected with 
BacSfYB(His)10 clones 2, 5, 7, and 9, respectively). BEV clone 9 infections presented with the 
least intracellular His-tag staining (3.86%), and BEV clone 7 presented as the best performer 
(29.6%). Although, interestingly, use of Alexa Fluor-647 secondary for His-tag staining 
presented rather contradictory staining levels - GFP(His)10 was reported at 40.3% (Fig. 5.15B, 
green line), despite 83.2% infection efficiency (Fig. 5.15A, green line). Additionally, the degree 
of His-tag positive cells in BacSfYB(His)10 was dramatically reduced to only 1-4.5% of the 
stained cell populations (Fig. 5.15B, see red, orange, dark blue and light blue lines, for Sf9 
infected with BacSfYB(His)10 clones 2, 5, 7, and 9, respectively). Therefore, intracellular staining 
for rSfYB(His)10 via the His-tag was insufficient or unreliable in correlating expression levels. 
This was perhaps a result of disorder and unpredictable folding that occurs at either N- or C- 
terminus of SfYB protein (Fig. 5.6). However, the BacSfYB(His)10 vector clone 7 infections, at 
the very least, out-performed the remainder and was used in further infection studies.   
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Figure 5.15 Intracellular staining for His-tag protein may not correlate expression levels for target 
rSfYB(His)10. Sf9 cells were infected with BacSfYB(His)10 and BacGFP(His)10 and His-tagged recombinant 
protein expression was analysed by intracellular staining using α6His-HRP primary and (A) Alexa Fluor 
488-conjugated secondary. Intracellular His-staining was deduced to range between 3.86-29.6% for 
BacSfYB(His)10 infected cells, despite a representative 83.2% infection efficiency with BacGFP(His)10. 
Otherwise, cells were stained with (B) Alexa Fluor 647-conjugated secondary, and revealed low 1-4.5% 
(red, orange, dark blue ad light blue lines) of the stained cell population as His-tag positive after 
infections with BacSfYB(His)10. This was especially compared to the 40.3% His-tag staining of 
BacGFP(His)10-infected cells. Single antibody stained cells infected with rBEVs functioned as negative 
controls for gating. Intracellular His-tag staining or infection efficiencies are presented as % of the 
stained cell population within scatter plots.  
 
Therefore, the optimisation of rSfYB(His)10 expression using rBEVs was restricted to Western 
blotting and BacSfYB(His)10 vector clone 7. Monolayer Sf9 and Ao38 insect cell lines were 
infected with BacSfYB(His)10, with Western blot analysis suggesting that the expression of 
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rSfYB(His)10 was relatively equal between infected cell lines (Fig. 5.16A). This was especially the 
case given equal loading of lysates from infected insect cell lines was verified by Coomassie® 
Blue gel staining (Fig. 5.16B). Non-infected Sf9 cells (negative control for rSfYB(His)10 
expression) demonstrated no rSfYB(His)10 expression when harvested in parallel (Fig. 5.16A), 
especially with relatively higher sample load as revealed by Coomassie® Blue gel staining (Fig. 
5.16B). Furthermore, the expression dynamics of rSfYB(His)10 protein was revealed to be 
optimally expressed at four or five days (96h or 120h) post-infection over a six day timecourse 
(Fig. 5.16C), given equal loading of samples by Coomassie® Blue gel staining (Fig. 5.16D). 
Additionally, non-infected Sf9 control cells were harvested in parallel at 1 and 6 days, and 
demonstrated no recombinant His-tag staining by Western blotting (Fig. 5.16C). Therefore, it 
was concluded that the 96h or 120h time points post-infection were the ideal harvest points 
for optimal rSfYB(His)10 expression.  
 
Despite optimising the point at which to harvest infected cells, the level of rSfYB(His)10 
expression in crude lysates was relatively less when compared to the more enhanced 
expression of rGFP(His)10 (Fig. 5.16E). This was despite relatively equal loading between lysates 
as determined by Coomassie® Blue gel staining (Fig. 5.16F). It was also revealed that a 
significant Coomassie® Blue stained signal corresponding to rGFP(His)10 protein was prominent 
compared to rSfYB(His)10 in crude lysates (Fig. 5.16F, see red boxed, and compare with 
+BacSFYB(His)10 lane). Instead, the expression of rSfYB(His)10 in crude lysates derived from 
BacSfYB(His)10-infected Sf9 resembled the protein profile of non-infected control (Fig. 5.16F, 
compare lanes NI and +BacSfYB(His)10). This was further exemplified by Western blotting of 
elutes after His-tagged protein pulldown, and the relative difference in His-tagged 
recombinant protein pulldown was more pronounced (Fig. 5.16G, compare rGFP(His)10 and 
rSfYB(His)10 signals). Further to this, poor prep quality of pulldowns from either BacGFP(His)10- 
or BacSfYB(His)10- infected Sf9 lysates was concluded by Coomassie® Blue gel staining, with 
non-specific pulldown products observed (Fig. 5.16H, distinguish non-specific pulldown 
products from annotated His-tagged proteins).   
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Figure 5.16 Optimisation of rSfYB(His)10 expression for purification. Sf9 and Ao38 cells were infected 
with BacSfYB(His)10, with non-infected Sf9 cells as a negative control, and (A) Western blot analysis 
demonstrated comparable expression of rSfYB(His)10 between Sf9 and Ao38 cells using α6His-HRP. 
Equal loading was demonstrated by (B) Coomassie® Blue gel staining, especially between infected Sf9 
and Ao38 cells. C) Western blotting revealed that the optimal harvest point for rSfYB(His)10 was at day 4 
or 5 post-infection with BacSfYB(His)10 over a 6 day time course. Non-infected Sf9 cells were harvested 
at days 1 and 6 as negative controls. D) Equal loading between negative control lanes or infected Sf9 
lysates at each harvest interval was confirmed by Coomassie® Blue gel staining. E) Western blot analysis 
showed His-tagged recombinant protein expression in crude lysates of Sf9 cells infected with 
BacGFP(His)10 or BacSfYB(His)10 96h post-infection (see annotations for rSfYB(His)10 and rGFP(His)10). 
Non-infected Sf9 cells served as a negative control. Figure legend continues next page.  
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Figure 5.16 Optimisation of rSfYB(His)10 expression for purification. F) Equal loading was demonstrated 
by Coomassie® Blue gel staining, with rGFP(His)10 well distinguishable (see red boxed). G) Western blot 
of eluates of lysates from BacGFP(His)10- or BacSfYB(His)10- infected Sf9 using Dynabeads™ His-Tag 
Isolation and Pulldown, showed suboptimal pulldown of rSfYB(His)10 was achieved relative to the 
pulldown of rGFP(His)10. The prep qualities of pulldowns were considered poor by (H) Coomassie® Blue 
gel staining, with non-specific pulldown products evident. M, Precision Plus Protein™ Dual Colour 
Standards; NI, non-infected control; pi, post-infection. 
 
The expression of rSfYB(His)10 was initially found to be expressed at a more reasonable level 
relative to rGFP(His)10 after infections of Sf9 cells by Western blot analysis (Fig. 5.17A). We 
then reasoned that the lysis protocols used to harvest rSfYB(His)10 was not optimal. Therefore, 
rSfYB(His)10 aa sequence was then assessed in silico and a hydrophobicity plot generated, 
which indicated that the rSfYB(His)10 protein was largely hydrophilic with the given model – 
scorings for <0 was associated with hydrophilicity (Fig. 5.17A). Nonetheless, infected and non-
infected Sf9 cells were fractionated for cytoplasmic and membrane fractions for Western 
blotting. This revealed that the target rSfYB(His)10 was localised to the membrane fraction 
after α6His-HRP staining (Fig. 5.17B). Minimal levels of rSfYB(His)10 was detected in the 
cytoplasmic fraction of infected Sf9 cells. This was in complete contrast to rGFP(His)10 protein, 
which was instead localised in the cytoplasmic fraction and minimally detected in the 
membrane fraction of infected Sf9 cells (Fig. 5.17B). Sample loads were normalised by cell 
numbers, and as a result Coomassie® Blue gel staining revealed that, despite relatively equal 
loading between infected Sf9 fractions, rSfYB(His)10 protein was easily distinguished with 
pronounced Coomassie® Blue staining (Fig. 5.17C, see red boxed). Similarly, rGFP(His)10 was 
prominently stained in the cytoplasmic fraction by Coomassie® Blue staining (Fig. 5.17C, see 
blue boxed). The relevance of these findings was further substantiated by the lack of DNA 
contamination found in the cytoplasmic fractions of non-infected and infected Sf9 cells by 
agarose gel electrophoresis, with only ribosomal RNA species identified (Fig. 5.17D). 
Ultimately, the rSfYB(His)10 protein was confirmed to be expressed in Sf9 cells using rBEVs, 
with optimal expression dynamics for the target His-tagged recombinant protein realised. 
Finally, the target protein was identified to localise with the membrane fraction of infected Sf9 
cells, leading to an adjustment in harvest protocol. 
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Figure 5.17 Recombiant SfYB(His)10 expression localised in the membrane fraction of infected Sf9. A) 
Hydrophobicity plot of rSfYB(His)10 protein was drawn by the ExPASy ProtScale programme using the 
Kyte and Doolittle scoring criteria (Kyte and Doolittle, 1982). This indicated that rSfYB(His)10 is mostly 
hydrophilic with scores <0 along the length of the aa sequence. The y-axis indicates the hydrophobicity 
score for each residue position (x-axis; window size: 9), starting from the N-terminus. Grey shaded 
region corresponds to the His-tag sequence. Cytoplasmic and nuclear fractions were acquired of Sf9 
cells infected with BacSFYB(His)10 or BacGFP(His)10, with non-infected Sf9 serving as negative control. 
Fractions were then analysed for expression and recombinant His-tagged protein localisation by (B) 
Western blotting using α6His-HRP, and revealed the target rSfYB(His)10 was localised predominantly in 
the  membrane fraction. Whereas rGFP(His)10 was found in the cytoplasmic fraction (see annotations for 
both). C) Coomassie® Blue gel staining demonstrated that loadings were well normalised by cell counting 
for cytoplasmic or nuclear fractions between infected and non-infected cells. The recombinant His-
tagged protein was easily distinguished (see red and blue boxed annotations for rSfYB(His)10 and 
rGFP(His)10, respectively). Finally, cytoplasmic fractions were subjected to (D) 1% TAE agarose gel 
electrophoresis in duplicate for each infected and non-infected cells and shows that there was no 
genomic DNA contamination in harvested cytoplasmic fractions. C, cytoplasmic fraction; M, Precision 
Plus Protein™ Dual Colour Standards; Mb, membrane fraction; NI, non-infected control. 
 
5.2.5 Purification of rSfYB(His)10 for the development of antiserum against rSfYB(His)10 
An optimised harvest protocol for rSfYB(His)10 involved sonication of infected Sf9 to disrupt 
DNA and membranes and include this fraction in whole lysates. Therefore, affinity 
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chromatography was implemented to immobilise rSfYB(His)10 via its His-tag. The target 
recombinant protein was eluted in high Imidazole Elution Buffer, resulting in the identification 
of a peak absorbance reading by in-run spectrophotometry between elution fractions 3-11 
(Fig. 5.18A). This likely corresponded to the elution of the target rSfYB(His)10 protein, and was 
further confirmed by Coomassie® Blue gel staining of alternating fractions 5-21 (Fig. 5.18B). 
Initial Coomassie® Blue gel staining of the alternating fractions indicated that a predominant 
protein was eluted from infected Sf9 lysates, which resolved between 48-63kDa and was 
found mainly in early fractions 5-11 (Fig. 5.18A). The elution fraction number 5 showed 
additional non-specific elution products that resolved above the major 43-68kDa protein band, 
but relatively absent in remaining lanes. Therefore, sequential fractions between 6 and 15 
were further assessed, wherein we identified the dominant eluted protein band resolving to 
approximately 50kDa (Fig. 5.18C). Furthermore, the tested elution fractions were considered 
relatively clean preps, given the absence of non-specific elution products (Fig. 5.18C). It was 
also noted that the rSfYB(His)10 protein bound efficiently to the HisTrap Ni-Sepharose resin, as 
the flow-through after binding to the resin demonstrated no discernible signal that 
corresponded to the rSfYB(His)10 protein (approximately 50kDa), whereas the corresponding 
protein band was present in lysates prior to loading the HisTrap column (Fig. 5.18C, compare 
lanes prior and FT). The 50kDa resolving protein likely corresponded to the target rSfYB(His)10, 
but was nonetheless verified in the elution fractions 6-11 by Western blotting using αYB1 
staining, with the dominant protein signal exhibited by fractions 6-8 (Fig. 5.18D). 
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Figure 5.18 Purification of His-tagged rSfYB(His)10 protein. Sf9 cells infected with BacSFYB(His)10 were 
harvested, and lysates subjected to (A) affinity chromatography, which revealed that peak  absorbance 
(A.U) were recorded early for elution fractions 3-11 by in-run spectrophotometry. B) Alternating 
fractions corresponding to 10μL elution fractions 5-21, and (C) 10μL all elution fractions 6-15, 50μL 
lysate before column loading (lane annotated prior) and 50μL flow-through (lane FT) after binding, were 
run on a 10% SDS-PAGE gels and Coomassie® Blue gel staining demonstrated that the rSfYB(His)10 bound 
efficiently to the HisTrap column. This was mainly eluted in fractions 6 and 7 with good prep quality. D) 
Purified rSfYB(His)10 was also detected by Western blotting of elution fractions 6-11 using αYB1 (PA5-
19453), which confirmed the specificity of the eluted product. FT, flow-through; M1, BLUEstain™ 
Protein Ladder; M2, Precision Plus Protein™ Dual Colour Standards; pre, lysate before affinity 
chromatography. 
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Purified rSfYB(His)10 protein concentration was then calculated by densitometry (Fig. 5.19A). A 
sufficient quantity and concentration of rSfYB(His)10 was thus purified – an average of 
148ng/μL of rSfYB(His)10 was calculated. Antiserum raised against the whole rSfYB(His)10 was 
then produced (Covalabs), with antiserum from day 39 post-immunised rabbits (D39) tested 
by dot blot (Fig. 5.19B). Here, we show that the two-fold serial dilution of D39 antiserum from 
1:4000-1:256,000 positively detected blotted rSfYB(His)10 protein in a dose-dependent manner 
(Fig. 5.19B). Additionally, the specificity of the D39 antiserum towards endogenous SfYB 
protein was confirmed by staining 10μg of Sf9 (non-infected with BacSfYB(His)10) and even 
293T and YB1 knockout lysates with D39 antiserum. Antiserum reactivity was observed at 
1:4000 and 1:32,000 dilutions for Sf9 and 293T lysates. The detection of endogenous SfYB 
protein using D39 antiserum was more pronounced using Sf9 lysate compared to 293T lysate 
at 1:32,000 dilution, which was perhaps due to the reduced homology observed between SfYB 
and human YB1. Signal from YB1 knockout lysate was completely absent at the given dilution 
factor also, but staining of YB1 knockout lysate using 1:4000 dilution was capable of producing 
a detectable signal. Given that YB1 knockout has been previously confirmed using αYB1 (see 
Chapter 3), the detected signal at 1:4000 dilution factor was possibly a product of non-specific 
binding given perhaps too low a D39 antiserum dilution was used. The above was further 
substantiated with control staining using only D39 antiserum or HRP-conjugated secondary 
antibodies showing no background signal. Especially, the complete staining of blotted 
rSfYB(His)10 using antiserum derived from pre-immunisation (day 0; D0) at 1:4000 dilution and 
HRP-conjugated secondary antibodies did not yield detectable signal either, implying that the 
pre-immunised rabbits did not harbour a pre-existing pool of antibodies targeting rSfYB(His)10. 
Positive control staining using α6His-HRP primary antibody was capable of detecting blotted 
rSfYB(His)10, but only at 1:4000 and 1:32,000 dilutions.  
 
The specificity of D39 antiserum to endogenous SfYB and rSfYB(His)10 was also demonstrated 
by Western blotting (Fig. 5.19C). Here the approximately 50kDa protein corresponding to 
rSfYB(His)10 or endogenous SfYB could be stained using D39 antiserum at 1:32,000 dilution (Fig. 
5.19C, top panel, see rSfYB(His)10 200ng and Sf9 lanes, respectively). Additionally, staining 
using 6His-HRP only picked up the His-tagged recombinant protein and not endogenous SfYB 
(Fig. 5.19C, bottom panel, compare rSfYB(His)10 200ng lane to Sf9 lane). Protein loads were 
also verified by Coomassie® Blue gel staining, where rSfYB(His)10 and Sf9 lysate was only 
loaded in their corresponding lanes (Fig. 5.19D). Altogether, Western blotting using D39 
antiserum and α6His-HRP differentiated that the D39 antiserum was specific for SfYB.  
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Figure 5.19 Antiserum raised against rSfYB(His)10 shows specificity for SfYB. A) Coomassie® Blue gel 
staining of known quantities of BSA and known volumes of rSfYB(His)10 was used generate of a standard 
curve. An average 148ng/μL for rSfYB(His)10 was calculated by densitometry. B) Dot blot assessment of 
D0 (pre-immunisation) and D39 (post-immunisation) antiserum raised against rSfYB(His)10. Dot blot 
revealed reactivity of D39 antiserum to rSfYB(His)10 and endogenous SfYB protein, but to a lesser extent 
human YB1. Staining of rSfYB(His)10 with only D39 antiserum or secondary, and complete staining with 
D0 antiserum served as negative controls. Complete staining of rSfYB(His)10 protein using α6His-HRP 
served as positive controls. C) D39 antiserum was able to specifically detect rSfYB(His)10 and 
endogenous SfYB in Sf9 lysate by Western blotting (top panel), with α6His-HRP distinguishing 
rSfYB(His)10 from endogenous (bottom panel). D) Protein loads of rSfYB(His)10 and Sf9 lysates were 
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confirmed by Coomassie® Blue gel staining. BSA, bovine serum albumin; D0, day 0 antiserum; D39, day 
39 antiserum; M, Precision Plus Protein™ Dual Colour Standards; YB1ko, YB1 knockout. 
 
5.3.0 Chapter summary  
With the use of a multitude of in silico analyses, we deduced the aa sequences and predicted 
3D-structures (particularly of the CSD) of previously uncharacterised Y-Box proteins of 
Spodoptera spps. (S. frugiperda, S. exigua, S. litura, and S. littoralis) and T. ni. High 
conservation of the whole molecules was identified, especially with respect to the defining 
CSD regions (almost 100%). This was even the case between Y-Box proteins and human YB1. 
Molecular cloning and expression of recombinant His-tagged SfYB in its native host cell line 
(Sf9) was conducive, and perhaps even advantageous compared to expression in T. ni based 
cell lines. And perhaps represents the first attempt to express and purify a recombinant 
protein derived from S. frugiperda or Sf9 using baculovirus technology. This was followed by 
the successful generation of antiserum that was specific for the target endogenous protein 
from Sf9 lysates. 
 
The Sf9 cell line is robustly used for the propagation of rAAV vectors, but the interactions or 
impact of host cell proteins on rAAV vector processing has not been characterised. In having 
identified a Y-Box protein for S. frugiperda, and raised a specific antiserum for endogenous 
SfYB, we can examine the impact of SfYB protein on rAAV vector processing. Therefore, in the 
next chapter, we aim to target SfYB protein expression for gene knockout and explore the 
effects on rAAV vector production.  
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Chapter 6: Generation of SfYB Knockout Cell 
Lines for Recombinant AAV Vector Production 
Using CRISPR/Cas9 Genome Editing 
 
6.1.0 Introduction 
Sf9 cells represents perhaps one of the most clinically relevant models for rAAV(1) vector 
production (Carpentier et al., 2012). In the present study, we utilised the knowledge that an 
existing Y-Box protein homologue (SfYB) is expressed by Sf9 (Chapter 5), and that the 
knockdown of human YB1 in 293T cells correlated with an enhanced rAAV vector producer cell 
line (Satkunanathan et al., 2014). We therefore aimed to modify SfYB protein expression in Sf9 
cells using CRISPR/Cas9 genome editing, and characterised these cells to show that targeted 
disruption of SfYB protein expression was successfully achieved. This was supported by 
analyses of both phenotype and genotype. We also show the significant advantages of 
establishing single cell clones after CRISPR/Cas9 genome editing, and screening for protein 
knockout using specific antibodies that was raised against the target protein of interest. 
However, ultimately, we also show that the disruption of SfYB expression in Sf9 cells did not 
confer an enhanced rAAV vector producer cell line.  
 
6.2.0 Results 
6.2.1 Designing and cloning SFYB-specific gRNAs into CRISPR plasmids 
We previously identified Y-Box protein homologues for Spodoptera spps. including S. 
frugiperda (SfYB; see Chapter 5); from which ovarian tissue established the Sf9 cell line 
(Vaughn et al., 1977). In order to design gRNAs to target the gene encoding SfYB (SFYB) we 
first identified the gene from which the BYB Y-Box protein orthologue was expressed from in 
B. mori, in silico. The BYB gene was annotated for exon and intron sequences based on the 
genomic scaffold (NW_004582015.1) and available transcriptomics data as per 
GCF_000151625.1 (Fig. 6.1A). Initially, the availability of assembled genomic scaffolds for 
Spodoptera spps. was limited to S. litura; for which, an evolutionary conserved Y-Box protein 
homologue was identified in silico (NC_036217.1, LOC111360813) (Cheng et al., 2017b). 
Therefore, the SLYB sequence was mapped for exon and intron sequences based on available 
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transcriptomics data as per LOC11360813 (Fig. 6.1B). Given the significant homology and 
evolutionary conservation between Y-Box protein homologues (section 5.3.2) we reasoned 
that the gene structures would be conserved, also. Using both Y-Box protein homologue gene 
annotations as genomic scaffolds SFYB’s exons (1-5) were mapped for the assembled contig 
accession OEOA01010394.1 (Fig. 6.1C). Following which, gRNAs (gRNAsf1-3) specific for exonic 
sequences were designed manually, which encompassed a 20nt sequence that preceded the 
5’-NGG-3’ PAM sequence (Fig. 6.1C, annotated gRNAsf1-3 designs are depicted relative to 
their target location in exon 1-3, respectively) for cloning into the GeneArt™ linearised, all-in-
one CRISPR nuclease vector.  
 
 
Figure 6.1 Inferring SFYB gene exon and intron sequences using BYB and SLYB genes as genomic 
scaffolds. The Y-Box protein gene homologues endogenous (A) to B. mori (BYB) and (B) S. litura (SLYB) 
were mapped for exon and intron sequences based on the assembled sequences and available 
transcriptomics data. These were mapped to show 5 exons each, and were used as genomic scaffolds to 
map (C) the exon sequences of S. frugiperda’s Y-Box protein gene homologue (SFYB) based on DNA 
sequence homology using the OEOA01010394.1 assembled contig. Designed gRNAs (gRNAsf1-3) are 
annotated to depict their relative target sequences in exon 1-3, respectively.  
 
The strategy employed to clone gRNAsf1-3 DNA oligos into the GeneArt™ linearised, all-in-one 
CRISPR nuclease vector is depicted in Fig. 6.2A. Cloning of each pCRISPR plasmids (pCRISPR-
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SFYBsgRNAsf1-3) was confirmed by Sanger sequencing (Figs. 6.2B-C). Here the DNA sequences 
corresponding to gRNAsf1-3 were correctly identified (Figs. 6.2B-C, see underlined red, blue, 
and green sequences for gRNAsf1-3, respectively), for which flanking sequences corresponding 
to the GeneArt™ all-in-one CRISPR nuclease vector backbone. Therefore, it was deduced that 
all three pCRISPR plasmids encoded the desired gRNA DNA sequences specific for the SFYB 
gene under U6 promoter control. 
 
 
Figure 6.2 Cloning of gRNAsf1-3 oligos into GeneArt™ linear, all-in-one nuclease vector. A) Schematic 
of strategy employed to clone gRNA DNA (gRNAsf1-3) designs into GeneArt™ linear, all-in-one nuclease 
vector for construction of pCRISPR-SFYBsgRNAsf1-3 plasmids, respectively. Cloning was confirmed by 
Sanger sequencing using the U6.F(orward) sequencing oligo for (B) pCRISPR-SFYBsgRNAsf1, (C) pCRISPR-
SFYBsgRNAsf2, and (D) pCRISPR-SFYBsgRNAsf3 plasmids, with gRNA DNA sequences correctly verified 
(see red, blue, and green underlined sequences, respectively for gRNAsf1-3). 
 
6.2.2 Optimising transfections for targeted knockout of SfYB protein expression 
The pCRISPR plasmids encode the SpCas9-2A-OFP ORF under CMV promoter control. 
Therefore, transfection of Sf9 cells with pCRISPR plasmids and the expression of OFP was 
examined 72h post-transfection by fluorescence microscopy and flow cytometry. Transfection 
of Sf9 cells with pCRISPR-SFYBsgRNAsf1-3 resulted in only a few cells per field of view 
expressing OFP (Fig. 6.3A, panels a and b, c and d, and e and f, respectively). This was similar to 
mock transfected Sf9 cells, that exhibited no fluorescent signal indicative of GFP or OFP 
expression (Fig. 6.3A, panels g-h). However, positive transfection control with pIEx-1.eGFP was 
deemed sufficient with notable GFP expression driven by IE1 promoter (Fig. 6.3A, panels j and 
k). The above was further recapitulated by flow cytometry analysis, where transfection of 
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8.5x105 Sf9 cells with 0.5μg or 3μg of pCRISPR plasmids demonstrated no detectable OFP-
positive cell populations 72h post-transfection, and were considered comparable to 0.25% 
exhibited by mock transfected control (Fig. 6.3B). Sf9 cells transfected with pIEx-1.eGFP were 
detectable even with the PE channel (Fig. 6.3B, 48.6% for 0.5μg input). This was due to the 
broad wavelength spectrum emitted by GFP excited from the 488nm laser and is consequently 
picked up in the PE channel, and also because GFP was expressed under the insect-specific IE1 
promoter control. This was in spite of the fact that approximately 59.3% Sf9 cells were GFP-
positive, 72h post-transfection with 0.5μg pIEx-1.eGFP of 8.5x105 cells (Fig. 6.3C, see green 
line). Expectantly, the pCRISPR-transfected cells exhibited negligible GFP fluorescence 
comparable to mock transfection control (FFig. 6.3C). 
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Figure 6.3 Transfection of Sf9 cells with pCRISPR-SFYBsgRNAsf1-3. Figure and Figure legend continues 
next page.  
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Figure 6.3 Transfection of Sf9 cells with pCRISPR-SFYBsgRNAsf1-3. Transfected Sf9 cells were analysed 
by bright field and fluorescence microscopy 72h post-transfection using Cellfectin™ II. A) Low to 
negligible OFP expression was exhibited by Sf9 cells transfected with pCRISPR-SFYBsgRNAsf1-3 (panels a 
and b, c and d, and e and f, respectively). Transfection with pIEx-1.1 served as mock transfection 
control, and demonstrated no fluorescence signal for GFP or OFP (panels g-i), or pIEx-1.eGFP (positive 
transfection control) demonstrated positive GFP expressing populations (panels j and k). Representative 
scale bar = 50μm for all panels. Plasmid pCRISPR transfection efficiency was also examined by flow 
cytometry (B) for OFP expression, of which fluorescence was comparable to mock transfection control 
(black line), despite (C) adequate transfection efficiency demonstrated by 0.5μg pIEx-1.eGFP reporter 
plasmid (59.3%). The % of fluorescent cells is displayed within scatter plots. GFP, green fluorescent 
protein; n.d., not determined; OFP, orange fluorescent protein. 
 
Due to the inefficiency of pCRISPR-SFYBsgRNAsf1-3’s CMV promoter to express SpCas9-2A-OFP 
in Sf9 cells, instead, we opted to transfect Sf9 cells with sgRNA:recombinant Cas9 
ribonucleoprotein (RNP) complexes. However, transfection with RNPs does not include a 
reporter system to track transfection efficiency. Additionally, CRISPRmax™-mediated 
transfection of Sf9 or insect cells was not previously described by the manufacturer. To ensure 
Sf9 cells could be efficiently transfected with nucleic acid using CRISPRmax™ Reagent, pIEx-
1.eGFP reporter plasmid was used to examine transfection capacity of the transfection 
reagent. Additionally, we cross-examined the effect of different serum-free media as diluents 
on transfection efficiency of nucleic acids (Fig. 6.4). We observed a superior transfection 
capacity of Sf9 cells for pIEx-1.eGFP plasmid when transfection mixes were prepared with opti-
MEM™ as diluent (Fig. 6.4A). This was in contrast to mixes prepared with Sf-900™ II SFM or 
Grace’s Insect Medium, across the range of pIEx-1.eGFP input quantities tested (Fig. 6.4B-C). 
The transfection of 4x105 Sf9 cells with 20μg of pIEx-1.eGFP corresponded to the approximate 
amount of input quantity (pmol) of 125ng of sgRNA and 500ng of recombinant Cas9 protein 
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recommended by the GeneArt™ Platinum™ Cas9 Nuclease Kit (Invitrogen). Transfection 
efficiencies of approximately 98-99% was achieved using opti-MEM™ compared to the 29.3% 
or 46.3% transfection efficiencies exhibited by using Sf-900™ II SFM and Grace’s Insect 
Medium for 20μg plasmid quantity, respectively (Fig. 6.4A-C). Mock transfected Sf9 cells 
across all transfection mix preparation methods also demonstrated negligible fluorescence of 
0.27-0.36% (Fig. 6.4A-C). Therefore, it was reasonably deduced that opti-MEM™ functioned as 
the optimum diluent for the transfection of sgRNA:recombinant Cas9 RNP complexes using 
CRISPRmax™ Reagent.  
 
 
Figure 6.4 Optimisation of Sf9 transfections using CRISPRmax™ Reagent and different diluents by flow 
cytometry analysis. Sf9 cells were mock transfected with pIEx-1.1 (negative control) and pIEx-1.eGFP 
plasmid prepared in either Sf-900™ II SFM, Grace’s Insect Medium, or opti-MEM™, and analysed by flow 
cytometry. Flow cytometry revealed that (A) opti-MEM™ functioned as the optimum diluent to prepare 
transfection mixes, and showed almost 100% transfection efficiency for all input plasmid quantities (0.5, 
3, 5, 10, and 20μg) when compared to mock. This was compared to modest transfection efficiencies 
ranging between 29.3-69.3%, which was achieved using (B) Sf-900™ II SFM or (C) Grace’s Insect Medium 
as diluent for input plasmid quantities (0.5, 3, 5, 10, and 20μg). Transfection efficiencies are presented 
as % within scatterplots. 
 
The sgRNAs targeting SFYB gene at the putative SFYB exons 1, 2 and 3, were synthesised by in 
vitro transcription (IVT) (Fig. 6.5). Assembly PCR of each sgRNAsf1-3 DNA template were PCR 
amplified and verified by agarose gel electrophoresis as approximately 125bp PCR amplicons 
    
282 
    
(Fig. 6.5A). Subsequent IVT reactions resulted in the synthesis of the sgRNAsf1-3 recognised as 
approximately 100nt in length, and distinct from input sgRNAsf1-3 DNA templates 
(approximately 125bp), by agarose gel electrophoresis (Fig. 6.5B, compare annotated sgRNA 
bands and DNA template bands). Finally, DNase I treated and purified sgRNAsf1-3 was further 
confirmed by agarose gel electrophoresis as isolated 100nt sgRNA species, with no detectable 
DNA template as contaminants (Fig. 6.5C). 
 
 
Figure 6.5 IVT reactions and purification of sgRNAs for SFYB targeting. A) 2% TBE agarose gel 
electrophoresis of sgRNAsf1-3 DNA template PCR by assembly PCR using the GeneArt™ Precision gRNA 
Synthesis Kit, which demonstrated that approximately 125bp DNA templates for each sgRNA design was 
successfully amplified, especially when compared to assembly PCR of non-template control reaction 
(Tracr fragment plus universal T7 primer mix was ommitted). B) 2% TBE agarose gel electrophoresis of 
IVT reactions for successful synthesis of sgRNAsf1-3 as approximately 100nt ssRNA (bands annotated 
sgRNA), relative to the input 125bp DNA template (annotated) and non-template control reaction (DNA 
template from non-template control was added for IVT reaction). C) 2% TBE agarose gel electrophoresis 
of DNase I-treated and purified sgRNA as isolated 100nt (approximately) ssRNA species corresponding 
to the target sgRNAsf1-3. IVT, in vitro transcription M, 100bp DNA Ladder; NTC, non-template control. 
 
For SFYB gene knockout, Sf9 cells were transfected with sgRNA (sgRNAsf1-3):recombinant 
Cas9 RNP complexes. Single-cell cloning of transfected Sf9 cells was attempted 72h post-
transfection; however, Sf9 cells did not survive at low densities as listed in Tables 6.1 and 6.2. 
Parental Sf9 and transfected Sf9 cells showed no cell growth after one month in culture at 
seeding densities of 0.3, 10, 200, and 500 cells/well in 96-well plates using complete Sf900™ II 
SFM (Table 6.1, red highlighted cells). Variation in media composition, i.e. Sf-900™ II SFM 
with/without 5% FCS, complete Sf-900™ II SFM with/without 5% FCS, or conditioned media, 
did not improve cell growth at very low cell densities (Table 6.2, red highlighted cells).  Higher 
cell densities of 1x104 and 5x103 cells/well of a 96-well plate were required for cell growth 
(Tables 6.1 and 6.2, blue highlighted cells), or confluency by one week in culture at the seeding 
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density of 1x103 cells/well (Tables 6.1 and 6.2, orange highlighted cells). Therefore, 
establishing a cell line from a single cell was not practical. 
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Table 6.1 Observations from single-cell cloning of Sf9 cells 72h post-transfection with sgRNAs and recombinant Cas9 
 
Sf9 non-transfected Sf9+sgRNAsf1:rCas9 RNP Sf9+sgRNAsf2:rCas9 RNP Sf9+sgRNAsf2:rCas9 RNP 
 growth media variant: 
cell seeding 
density/well 
complete Sf-900™ II SFM complete Sf-900™ II SFM complete Sf-900™ II SFM complete Sf-900™ II SFM 
1.00E+04 confluent confluent confluent confluent 
5.00E+03 confluent confluent confluent confluent 
1.00E+03 confluent confluent confluent confluent 
5.00E+02 ng ng ng ng 
2.00E+02 ng ng ng ng 
1.00E+02 ng ng ng ng 
1.00E+01 ng ng ng ng 
3.00E-01 ng ng ng ng 
ng, no growth was detected by 1 month (red highlighted cells) post-seed; blue highlighted cells indicate confluency by 72h or 
by one week (orange highlighted cells); rCas9, recombinant Cas9. 
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Table 6.2 Observations from single-cell cloning of Sf9 cells with various Sf900™ II SFM variations 
 
Sf9 
 growth media variant 
cell seeding 
density/well 
Sf900™ II SFM Sf900™ II SFM + 5% FCS 
complete Sf900™ II 
SFM + 5% FCS 
conditioned media 
1.00E+04 confluent confluent confluent confluent 
5.00E+03 confluent confluent confluent confluent 
1.00E+03 confluent confluent confluent confluent 
5.00E+02 ng ng ng ng 
2.00E+02 ng ng ng ng 
1.00E+02 ng ng ng ng 
1.00E+01 ng ng ng ng 
3.00E-01 ng ng ng ng 
ng, no growth (red highlighted cells) was observed by 1 month post-seed; blue highlighted cells indicate 
confluency by 72h or by one week (orange highlighted cells); rCas9, recombinant Cas9. 
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6.2.3 Characterising Sf9 cells for SfYB knockout 
The strategy to establish SfYB knockout cells is illustrated (Fig. 6.6). This involved multi-runs of 
CRISPR RNP transfection to off-set the potential that only a sub-population of cells were 
transfected with sgRNA(sf1-3):recombinant Cas9 RNP complex at a ratio of 1X and 10X of the 
sgRNA and recombinant Cas9 to CRISPRmax™ Reagent. 
 
 
Figure 6.6 Strategy employed to 
transfect (multi-run transfection) Sf9 
cells with sgRNA and recombinant 
Cas9 complex for targeted disruption 
of SFYB gene. Sf9 cells were 
transfected with 1X or 10X more 
sgRNA(sf1-3) and recombinant Cas9 
relative to CRISPRmax™ Reagent, to 
off-set transfection efficiency 
limitation per transfection cycle. IVT, 
in vitro transcription; rCas9, 
recombinant Cas9. 
 
 
 
 
 
 
 
Initial Western blotting for SfYB protein expression in bulk transfected cells demonstrated 
notable disruption of SfYB expression by sgRNAsf1, which targeted SFYB’s putative exon 1 (Fig. 
6.7). 293T cell lysate also functioned as a positive control for YB1/Y-Box protein homologue 
staining with αYB1, given the unavailability of the antiserum raised against rSfYB(His)10 at the 
time. Western blot analysis of Sf9 cells transfected with sgRNAsf -2 and -3 (targeting putative 
exon 2 and 3, respectively) depicted a minimal or lack of genome editing of the SFYB gene 
(Figs. 6.7B and C, respectively). Coomassie® Blue gel staining was used to demonstrate equal 
loading (Figs. 6.7D-F for SFYB exon 1-3 targeting, respectively).  
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Figure 6.7 Establishing SfYB knockout cell lines. Western blot analysis using αYB1 (PA5-19453) of bulk transfected Sf9 cells with sgRNA and recombinant Cas9 (1:1 ratio 
with CRIPSRmax™) was compared to non-transfected Sf9 and 293T controls for CRISPR/Cas9-mediated disruption of the SFYB gene by targeting (A) exon 1 with sgRNAsf1, 
with SfYB expression seemingly disrupted. Whereas, targeting (B) exon 2 using sgRNAsf2, and (C) exon 3 using sgRNAsf3 both exhibited no disruption in the expression 
levels of SfYB when compared to non-transfected Sf9 controls. Coomassie® gel staining demonstrated relatively equal loads between Sf9 non-transfected control and 
transfected Sf9 cell lysates, for CRISPR/Cas9 targeting of (D) exon 1, (E) exon 2, and (F) exon 3. M, ECL™ Rainbow™ Marker – Full Range; NT, non-transfected control; rCas9, 
recombinant Cas9.  
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Over seven multi-rounds of transfection were performed for sgRNAsf1, with Western blotting 
analysis indicating a progressively increased disruption of the SfYB protein expression since the 
first round (Figs. 6.8A and B). This was especially the case of Sf9 cells consecutively transfected 
with 10:1 ratio of sgRNAsf1 and recombinant Cas9 RNP, where a diminished SfYB protein 
signal was evident compared to non-transfected Sf9 control (Figs. 6.8A and B). Further 
transfections at the 10:1 ratio eventuated in the complete disruption of SfYB expression at the 
sixth and seventh round of transfection, especially when compared to non-transfected Sf9 
control (Fig. 6.8B). Equal protein loads was determined by Coomassie® Blue gel staining (Figs. 
6.8C and D).  
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Figure 6.8 Screening multi-run transfected Sf9 cells with sgRNAsf1 for SFYB disruption. Western blot analysis using αYB1 (PA5-19453) of multi-run transfected Sf9 cells 
with 1:1 or 10:1 ratio of sgRNAsf1+rCas9 to CRISPRmax™ Reagent, for (A) four rounds transfections, demonstrating disruption of SfYB protein expression (partial knockout 
phenotype) by the fourth consecutive transfection of Sf9 cells. This was especially the case at 10:1 ratio of sgRNAsf1+rCas9 to CRISPRmax™ Reagent. And (B) complete 
disruption at the sixth and seventh round of transfections for 10:1 ratio, only. Of which observations were compared to non-transfected Sf9 cells as control for baseline 
expression of SfYB protein. Equal loading of protein samples was demonstrated by (C and D) Coomassie® Blue gel staining for the first four and final three transfection 
rounds, respectively. M, ECL™ Rainbow™ Marker – Full Range; n/a, not applicable; NT, non-transfected control; rCas9, recombinant Cas9.  
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Western blot analysis with antiserum raised against rSfYB(His)10 (described in Chapter 5, 
section 5.3.5) showed a complete knockout of the SfYB protein expression from as early as the 
first round of transfection (1:1 ratio) of the multi-run transfection using sgRNAsf1 (Figs. 6.9A). 
This was with normalised protein loads demonstrated by Coomassie® Blue gel staining (Fig. 
6.9B). However, the knockout phenotype was suggested transient, and the restoration of the 
SfYB phenotype occurred when transfected Sf9 cells were cultured for an extended period – 
by passage 15 and 25 post-transfection (Fig. 6.9A, see lanes p+15 and p+25, respectively).  
 
 
Figure 6.9 Confirmation of partial knockout and knockout phenotypes using SfYB-specific antiserum. 
SFYB gene disruption was confirmed with SfYB-specific antiserum, where (A) Western blotting analysis 
indicated complete knockout of SfYB expression as early as the first round of transfection and passage 3 
post-transfection with sgRNAsf1 and recombinant Cas9 (1:1 ratio to CRISPRmax™ Reagent). 
Additionally, the eventual loss of the knockout phenotype was demonstrated by passage 15 and 25 
post-transfection. Equal loading of protein was depicted by (B) Coomassie® Blue gel staining. M, 
Precision Plus Protein™ Dual Colour Standards; n/a, not applicable; NT, non-transfected control;  p+3, 
passage 3 post-transfection; p+15, passage 15 post-transfection; p+25, passage 25 post-transfection; 
rCas9, recombinant Cas9. 
 
Western blotting for Sf9 cells transfected with sgRNAsf2 initially indicated potential SfYB 
disruption after multi-run transfection for CRISPR/Cas9 genome editing, using αYB1 (Fig. 
6.10A). This was in contrast to Western blott analysis using SfYB-specific antiserum, which 
revealed comparable SfYB protein expression between control Sf9 and transfected Sf9 cells, 
regardless of the increased ratio of sgRNAsf2 plus recombinant Cas9 to CRISPRmax™ (Fig. 
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6.10B), and normalised protein loading demonstrated by Coomassie® Blue gel staining (Fig. 
6.10C). Sf9 transfection with sgRNAsf3 also displayed a similar disparity between αYB1 and 
SfYB-specific antiserum staining of blots for Western blot analysis (Figs. 6.11A-C). Therefore, it 
was concluded that targeted disruption of the SFYB gene was mainly achieved using sgRNAsf1 
and recombinant Cas9 at 10:1 ratio to CRISPRmax™ Reagent. These cells were termed 
Sf9ex1.4-7/10X cells, reflective of the exon target, round of transfection, and transfection 
condition. 
 
 
Figure 6.10 Screening for SfYB knockout cell lines transfected with sgRNAsf2 for SFYB disruption. A) 
Western blot analysis using αYB1 (PA5-19453) of multi-run transfected Sf9 cells (1:1 or 10:1 ratio of 
sgRNAsf2+rCas9 to CRISPRmax™ Reagent), indicating potential disruption of SfYB protein expression, 
especially when compared to non-transfected Sf9 control for baseline expression of SfYB. However, (B) 
staining with SfYB-specific antiserum instead suggests that SfYB disruption was not achieved and 
comparable SfYB protein expression was detected to that of non-transfected Sf9 control. Normalised 
protein loads, especially between transfected Sf9 cells, was determined by (C) Coomassie® Blue gel 
staining. M, ECL™ Rainbow™ Marker – Full Range; n/a, not applicable; NT, non-transfected; rCas9, 
recombinant Cas9. 
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Figure 6.11 Screening for SfYB knockout cell lines transfected with sgRNAsf3 for SFYB disruption. A) 
Western blot analysis using αYB1 (PA5-19453) of multi-run transfected Sf9 cells (1:1 or 10:1 ratio of 
sgRNAsf3+rCas9 to CRISPRmax™ Reagent), indicating some potential disruption of SfYB protein 
expression, especially when compared to non-transfected Sf9 control for baseline expression of SfYB. 
However, (B) Western blot analysis using SfYB-specific antiserum suggested that SfYB disruption was 
not achieved using sgRNAsf3. This was especially the case were comparing relative protein expression to 
that of non-transfected Sf9 control, and (C) normalised loading of protein samples demonstrated by 
Coomassie® Blue gel staining. n/a, not applicable; NT, non-transfected; M, ECL™ Rainbow™ Marker – 
Full Range; rCas9, recombinant Cas9. 
 
Sf9ex1.6/10X and Sf9ex1.7/10X cells were further analysed given their knockout phenotypes 
described by the limits of detection by Western blotting using SfYB-specific antiserum. Scale-
up of the selected SfYB-disrupted Sf9 cell lines were associated with a notable lag in cell 
growth when compared to parental Sf9. This was especially notable when cells were expanded 
in suspension culture. In fact, a significant growth defect was observed by the analysis of 
growth curves and number of live cells/mL between parental Sf9 and selected Sf9ex1.6/10X or 
Sf9ex1.7/10X over a two-week timecourse (Fig. 6.12A, compare black growth curve with blue 
or red growth curves for parental Sf9 and Sf9ex1.6/10X and 1.7/10X, respectively). After two 
days in suspension culture the SfYB-disrupted cell lines exhibited a significant lag in cell growth 
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and delay into log-phase growth compared to Sf9 control, especially Sf9ex1.7/10X cell line (n = 
3 each cell line counted; P < 0.001 compared to Sf9 control for all time points from day three 
onwards in suspension culture). Additionally, peak live cell density of >1x107 cells/mL was not 
achieved by the SfYB-disrupted cell lines. The growth defect was also concluded to be 
independent of an increased rate in cell death as SfYB-disrupted cells showed improved cell 
viability over the two-week growth course compared to Sf9 control (Fig. 6.12B). Both Sf9 
control and SfYB-disrupted cells showed comparable levels of viable cells (%) up to nine days 
in suspension. After which, SfYB-disrupted cell lines, particular Sf9ex1.7/10X, showed 
significantly improved cell viability (n = 3 each cell line counted; P < 0.001). 
 
Figure 6.12 Growth defect of SfYB knockout cell line compared to Sf9. Parental Sf9 and selected Sf9 
knockout cell lines (Sf9ex1.6-7/10X) were cultured in suspension, and cell growth kinetics was measured 
on a daily basis for up to 2 weeks. A) Significant growth defect was measured from day 3 onwards for 
Sf9ex1.6/10X (blue line and open square) or Sf9ex1.7/10X cells (red line and open circle) when 
compared to Sf9 control (black line and solid circle). The observed growth defect was confirmed to not 
be attributed by an increased rate in cell death, as (B) the cell viability (%) was improved for Sf9ex1.6 
(blue solid bars) and 1.7/10X (red solid bars) compared to control Sf9 (grey solid bars), especially from 
day 10-14 in suspension culture. Figure legend continues next page. 
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Figure 6.12 Growth defect of SfYB knockout cell line compared to Sf9. Error bars reflect ±SD from 
mean, n = 3, where averaged cell counts were from cells cultured in triplicate; *, P < 0.05, and ***, P < 
0.001. Coloured * represents the calculated significance that was observed between control Sf9 and 
Sf9ex1.6/10X (blue) or 1.7/10X (red). 
 
Characterisation of SfYB-disruption by CRISPR/Cas9 genome editing was further demonstrated 
by ICC and confocal laser scanning microscopy. Control Sf9 cells exhibited a diffuse cellular 
distribution of SfYB protein by confocal laser scanning microscopy (Fig. 6.13A, panels a-c). On 
the other hand, when examining different fields of view (FOV), SfYB-disruption was portrayed 
by Sf9ex1.7/10X cells stained with αSfYB(His)10 with cells either exhibiting no SfYB protein 
staining (Fig. 6.13A, FOV 1 and 2, panels d-f and g-i, respectively), or significantly reduced SfYB 
expression (Fig. 6.13A, FOV 3, panels j-l, respectively) when compared to Sf9 control cells. 
Partial staining of SfYB expression in Sf9ex1.7/10X cells indicated that a heterozygous SfYB-
disruption phenotype was achieved in transfection of Sf9 cells with sgRNAsf1 and recombinant 
Cas9. Negative staining controls showed background or negligible fluorescence exhibited by 
control Sf9 cells stained with primary antiserum or secondary antibodies only (Fig. 6.13A, 
panels m-o and p-r, respectively). The above findings were also confirmed by orthogonal 
section analysis (Fig. 6.13) to account for the z-plane of stained cells. SfYB predominantly was 
localised throughout the cytoplasm but detectable in the nuclear compartment as well, as per 
DAPI-staining (Fig. 6.13B). However, Sf9ex1.7/10X cells demonstrated no SfYB protein staining 
throughout the cell z-plane by orthogonal section analysis, indicating SfYB knockout (Fig. 
6.13C).  
 
In order to quantify the extent of SfYB-disruption, corrected total cell fluorescence (CTCF) was 
compared between Sf9 control as baseline reference and Sf9ex1.7/10X cells and Sf9 secondary 
antibody only staining control (Fig. 6.13D). Control Sf9 cells exhibited an average of 
4255.37(±1526.56) CTCF, which was significantly different to the average CTCF of 
705.43(±204.3) for Sf9 cells stained with only secondary antibody (Fig. 6.13D, compare black 
solid bar and grey solid bar; P < 0.001). However, the collectively analysed Sf9ex1.7/10X cells 
showed an average 843.28(±690.15) CTCF, which was comparable to Sf9 cells stained with 
secondary antibody only (Fig. 6.13D, compare red solid bar with grey solid bar; P > 0.05). The 
843.28(±690.15) CTCF was also significantly different to the Sf9 baseline reference of 
4255.37(±1526.56) CTCF (Fig. 6.13D, compare black solid bar with red solid bar P < 0.001). 
Therefore, despite the heterozygous SfYB-disrupted phenotype characterised by ICC and 
confocal laser microscopy, a significant reduction in SfYB staining was overall quantified. 
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Figure 6.13 Characterising SfYB knockout cell lines using ICC and confocal laser scanning microscopy. 
The SfYB knockout phenotype was further verified by (A) ICC and confocal laser scanning microscopy of 
Sf9 and Sf9ex1.7/10X. Cells were stained with DAPI to differentiate the nuclei (a, d, g, j, m, and p), and 
SfYB-specific antiserum (b, e, h, k, n, and q). Panels (a-c) refer to control Sf9 cells and panels (d-l) refer 
to three fields of view of Sf9ex1.7/10X cells stained for SfYB, indicating that SfYB disruption was 
achieved. Negative staining controls (Sf9) with either primary αSfYB (m-o) or secondary antibody (p-r) 
exhibited no or background fluorescence. Representative scale bar = 20μm for all microscopy images. 
Orthogonal section analysis of (B) Sf9 and (C) Sf9ex1.7/10X for SfYB expression demonstrated that SfYB 
expression was diffuse throughout the cell when considering x-, y-, and z- planes, but no SfYB protein 
staining was detected in Sf9ex1.7/10X cells. D) Graph presenting CTCF measurements between Sf9 
control, Sf9ex1.7/10X, and Sf9 cells stained with only secondary antibody (negative staining control), 
indicating that Sf9ex1.7/10X exhibited fluorescence similar to the negative staining control. Error bars 
reflect ±SD from mean, n = 30 measured cells for each cell line; except Sf9 stained with secondary 
antibody only control, n = 5; ***, P < 0.001 or P < 0.0001. Abs, antibody; CTCF, corrected total cell 
fluorescence; FOV, field of view. 
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Characterisation of Sf9ex1.7/10X cell line was also performed at the genomic level and 
compared to Sf9 control. Sequence chromatograms of the sgRNAsf1-specific and CRISPR/Cas9 
targeted sequence of Sf9ex1.7/10X identified potential mutations within SFYB’s putatively 
mapped exon 1 (Fig. 6.14A and 6.14B). This was located approximately 21bp downstream of 
the targeted PAM sequence. However, the wildtype sequence was also recognised by Sanger 
sequencing (Fig. 6.14A, compare top sequence read [control Sf9] with bottom sequence read 
[Sf9ex1.7/10X]), and thus confirms the heterozygous SfYB-disrupted phenotype identified by 
ICC and confocal microscopy.  
 
Furthermore, Surveyor mutations screening positively identified that CRISPR/Cas9-mediated 
mutations were present, and likely corresponded to the mutations identified by Sanger 
sequencing (Fig. 6.14C and D). Here, whilst non-template control PCR demonstrated no non-
specific PCR amplification, the expected amplicon of 452bp was produced for Sf9 control and 
for each selected SfYB-disrupted cell line, including the 1:1 mix of genomic template derived 
from control Sf9 and Sf9ex1.7/10X (Fig. 6.14C). Nuclease S treatment of annealed homo- or 
hetero- duplex DNA molecules gave rise to digestion bands of approximately 298bp and 
154bp, along with the initial 452bp band, by agarose gel electrophoresis (Fig. 6.14D). This was 
particularly observed for CRISPR/Cas9 transfected Sf9 cells that demonstrated SfYB-disruption 
by Western blotting, and absent for Sf9 control. In fact, the later established SfYB-disrupted 
cell lines showed more prominent digestion bands, and indicated that the degree of genome 
editing using sgRNAsf1 and recombinant Cas9 improved after each transfection set (Fig. 
6.14D). It was also intepreted that a heterozygous genotype was inferred by Surveyor 
mutation screening assays for each SfYB-disrupted cell line, which did not require the input of 
control Sf9 genomic DNA to simulate a control heterozygous genotype (Fig. 6.14D).  
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Figure 6.14 Genomic profiling of CRISPR/Cas9-mediated genome editing of the SFYB gene. 
Sf9ex1.7/10X CRISPR/Cas9-targeted DNA sequence was amplified and submitted for Sanger sequencing 
in parallel with Sf9 control. A) Chromatograms for Sf9 (top panel) and Sf9ex1.7/10X (bottom panel) 
sequencing results suggest potential mutations and a heterozygous genotype for Sf9ex1/.7/10X 
sequence (red boxed), that is not present in Sf9 control. Green underlined sequence denotes translation 
start codon for SFYB. B) Closer examination of the Sf9ex1.7/10X chromatogram (red box expanded) 
implies some few mutations were recognised compared to Sf9 control, and confers a heterozygous 
genotype. Verification of the genotype was made by Surveyor™ Mutation Screening, where PCR 
amplification of the targeted gene sequence was confirmed as (C) approximately 452bp amplicons by 
2% TBE agarose gel electrophoresis for Sf9 control, select Sf9ex 1.4/10X, 1.5/10X, 1.6/10X, and 1.7/10X 
cell lines, and 1:1 mix of Sf9 and Sf9ex1.7/10X genomic DNA as template (50ng total). PCR reactions 
were then treated with nuclease S and (D) digestion products corresponding to expected fragments 
(given the observed mutation) was detected (approximately 298bp and 154bp) for CRISPR/Cas9 treated 
cell lines, relative to control Sf9, by 2% TBE agarose gel electrophoresis. 1:1, 1:1 mix (50ng total) of 
genomic template from Sf9 control and Sf9ex.17/10X; M, 100bp DNA ladder; NTC, non-template 
control.  
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6.2.4 SfYB Y-Box protein homologue associations with AAV 
The SfYB Y-Box protein homologue harbours the propensity for DNA-binding as was identified 
by electrophoretic mobility shift assays (EMSAs) using dsDNA and different quantities (μg) of 
purified rSfYB(His)10 (Fig. 6.15). Binding to DNA plasmids that correspond to AAV-specific 
plasmids (pAAV2-hrGFP and pFBGR) and non-AAV-specific plasmids (pJET1.2-FLuc and pIEx™-
1) as controls demonstrated non-specific binding, and thus significant shifts in electrophoretic 
mobility by agarose gel electrophoresis, for the selection of plasmids tested (Fig. 6.15A). This 
was despite the quantity of rSfYB(His)10 used, where as low as 0.1μg of rSfYB(His)10 was 
sufficient to entirely shift the mobility of 200ng plasmid migration with accumulation of 
nucleic acid in sample wells (see boxed) when compared to plasmid with no input of 
rSfYB(His)10 as reference (Fig. 6.15A, compare plasmid lanes with input quantities of 
rSfYB(His)10 protein to 0μg input). Similarly, use of DNA probes that corresponded to AAV- (ITR 
and rep) or Adenovirus- (E2A) DNA sequences, and control DNA probes (left or right ITR 
flanking sequences) also exhibited electrophoretic shift in mobility after binding to rSfYB(His)10 
(Fig. 6.15B). Especially, electrophoretic mobility shift was evident using higher inputs of 
rSfYB(His)10 – from 0.1μg input upwards (Fig. 6.15B, see EMS annotation and red boxed). 
Ultimately, the EMSAs performed indicated that SfYB protein is capable of binding to dsDNA 
species; however specificity for AAV- or Adenovirus- associated sequences was not entirely 
observed.  
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Figure 6.15 SfYB binding to DNA demonstrates shift in electrophoretic mobility by agarose gel 
electrophoresis. Recombinant SfYB protein showed DNA-binding propensity, with 200ng of plasmid 
DNA (pJET1.2-FLuc, pIEx™-1, pAAV2-hrGFP, or pFBGR) when mixed with different quantities of 
rSfYB(His)10 in Cutsmart buffer. Plasmids demonstrated (A) shifts in electrophoretic mobility through a 
2% TBE agarose gel for all input quantities of rSfYB(His)10 (see EMS annotation and red boxes). Likewise, 
AAV- or AdV- associated dsDNA probes (50ng each of ITR, rep, E2A, and control left of right ITR flanking 
dsDNA probes) all showed (B) shifts in electrophoretic mobility through a 2% TBE agarose gel for 0.1, 
0.5, and 1μg input of rSfYB(His)10 (see EMS annotated and red boxes). EMS, electrophoretic mobility 
shift; L ITR flank; left ITR flanking control DNA probe; M, GeneRuler 1kb DNA Ladder; R ITR flank; right 
ITR flanking control DNA probe. 
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We also examined co-localisation of SfYB protein with AAV2 Rep, Cap, and particle by ICC and 
confocal laser scanning microscopy (Fig. 6.16). Whilst SfYB protein expression was positively 
detected throughout infected Sf9 control cells (Fig. 6.16, panels a-d, i-l, and q-t), and SfYB-
disruption was reaffirmed by ICC of infected Sf9ex1.7/10X cell lines (Fig. 6.16, panels e-h, m-p, 
and u-x). Additionally, it was noted that SfYB protein expression was not necessarily 
predominantly localised to the cytoplasm of infected Sf9 cells with perhaps some SfYB 
localising to the nuclei (see Fig. 6.13, panels a-d, i-l, and q-t). This was in some contrast to 
previous observations of SfYB locale in non-infected Sf9 cells. Nonetheless, AAV2 Rep protein 
was identified localised to the nuclei for both Sf9 control and Sf9ex1.7/10X, as distinguished by 
DAPI-staining of the nuclear compartment (Fig. 6.16, panels a-d and e-h, respectively). 
Whereas, AAV2 Cap protein staining was found localised to both the cytoplasm and nucleus of 
infected Sf9 control and Sf9ex1.7/10X (Fig. 6.16, panels i-l and m-p, respectively). Finally, 
rAAV2 particle was found localised to the nucleus of either infected Sf9 or Sf9ex1.7/10X cell 
lines (Fig. 6.16, panels q-t and u-x, respectively). It was also acknowledged that single antibody 
staining of infected Sf9 cells for rAAV2 vector production demonstrated no (staining with 
primary antibodies only; Fig. 6.16, panels a-d) or minimal background (staining with secondary 
antibodies only; Fig. 6.16, panels e-h) fluorescence. Ultimately, co-localisation of SfYB protein 
with AAV2 Rep, Cap, or intact particle was positively identified by ICC and confocal laser 
scanning microscopy, which potentially infers possible interactions between SfYB and AAV2 
proteins.  
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Figure 6.16 ICC and confocal laser scanning microscopy of SfYB and AAV2 Rep, Cap, and particle 
localisations. Sf9 and selected Sf9ex1.7/10X were infected for rAAV2GFP vector production, and cells 
were fixed, permeabalised and stained for SfYB and AAV2 proteins. DAPI staining served to distinguish 
the nuclear compartment. Panels (a-d) and (e-h) refer to infected Sf9 and Sf9ex1.7/10X (respectively) 
stained for SfYB and AAV2 Rep. Panels (i-l) and (m-p) refer to Sf9 and Sf9ex1.7/10X cells (respectively) 
stained for SfYB and AAV2 Cap proteins. Finally, panels (q-t) and (u-x) refer to Sf9 and Sf9ex1.7/10X cells 
(respectively) stained for SfYB and AAV2 intact particle. Single antibody staining controls of infected Sf9 
cells with primary (y-bb) or secondary (cc-ff) antibodies demonstrated no to minimal background 
fluorescence. Representative scale bar = 10μm for all panels. 
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6.2.5 The effect of SfYB disruption on rAAV vector production 
We next explored whether or not SfYB expression or disruption affected baculovirus infection 
when compared to Sf9 control. Therefore, the infection efficiency of BacITRGFP was examined 
in context of rAAV -2 or -8 vector production by flow cytometry (Fig. 6.17). We demonstrated 
that comparable BacITRGFP infection efficiencies (>95%) were presented by SfYB-disrupted 
cells and control Sf9 for rAAV -2 or -8 vector production (Fig. 6.17; compare green and blur 
lines, and red and pink lines, respectively). Additionally, it was considered that the infection of 
BacSfYB(His)10 and expression of exogenous SfYB (rSfYB(His)10) did not significantly hinder 
BacITRGFP infection. More specifically, an infection rate of 89.4% was demonstrated for rAAV2 
vector production co-infected with BacSfYB(His)10 compared to 95% for Sf9 cells co-infected 
with control BacMers-M (Fig. 6.17). The above was relative to mock infection control (Sf9 cells 
infected with BacMers-M only; black line), which confidently resulted in no/low proportion of 
cells with detectable fluorescence (0.35%). Therefore, SfYB-disruption or its over expression 
did not affect baculovirus infection.    
 
Figure 6.17 SfYB disruption or exogenous expression does not affect the efficiency of baculovirus 
infection. The infection of Sf9 and Sf9ex1.7/10X cells with MOI 3 baculoviruses and analysed by flow 
cytometry and scatter plots, 72h post-infection. BacMers-M infection of Sf9 functioned as a mock 
infection control for transduction rates. Flow cytometry analysis suggested that BacITRGFP infection 
efficiency was comparable between parental Sf9 and Sf9-disrupted cell lines for rAAV -2 or -8 vector 
production (rates of >95% was recorded). Additionally, the infection rate of 89.4% and 95% was 
considered relatively indifferent with the co-infection of BacSfYB(His)10 or BacMers-M, respectively, 
indicating that exogenous SfYB expression did not compromise the transduction rate of Sf9 cells for 
BacITRGFP. The % of fluorescent cells is displayed within scatter plots.  
 
    
303 
 
Given we previously reported that the YB1 knockout phenotype of 293T compromised the cell 
line’s resistance to chloroquine reagent (see Chapter 3 and 4), we examined whether SfYB 
disruption made the cell line susceptible to cell cytotoxicity by baculovirus infection for rAAV 
vector production. Non-infected Sf9 and Sf9ex1.7/10X cells demonstrated low but comparable 
cytotoxicity profiles, with %cytotoxicity of 1.05±0.05% and 1.12±0.1% for Sf9 (white solid bar) 
and Sf9ex1.7/10X (black solid bar), respectively (Fig. 6.18A, n = 3, P > 0.05). This correlated and 
was in agreement with viable cell counts at day 3 observed previously (Fig. 6.12B). Similarly, 
comparable %cytotoxicity was calculated between Sf9 (13±0.27%, white solid bar) and 
Sf9ex1.7/10X (11.8±0.85%, black solid bar) cells after baculovirus infection for rAAV vector 
production (Fig. 6.18A; n = 3, P > 0.05). It was further appreciated that the infection efficiency 
of BacITRGFP was considered comparable between both cell lines (>93%), as was determined 
by flow cytometry analysis (Fig. 6.18B). This suggested that an incomparable infection rate did 
not confound the cytotoxicity profiles calculated above. Therefore, LDH cytotoxicity assays 
identified that SfYB-disruption did not compromise the cell lines’ susceptibility to cell 
cytotoxicity after baculovirus infection. 
 
Figure 6.18 LDH cytotoxicity assays for baculovirus infection of Sf9 and SfYB knockout cell lines. Figure 
legend continues next page. 
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Figure 6.18 LDH cytotoxicity assays for baculovirus infection of Sf9 and SfYB knockout cell lnes. 
Parental Sf9 and Sf9ex1.7/10X cells were infected with recombinant baculoviruses for rAAV2 vector 
production, and (A) %cytotoxicity measured 72h post-infection using LDH cytotoxicity assays. This 
inferred that comparable %cytotoxicity was measured for infected Sf9 and Sf9ex1.7/10X cell lines. Non-
infected cells functioned as negative controls for baseline cytotoxicity profiles, and were harvested in 
parallel. Error bars reflect ±SD from mean, n = 3; P > 0.05. Infection efficiency of BacITRGFP infection 
was also measured by (B) flow cytometry, with analysis indicating that comparable infections for rAAV2 
vector production was achieved between parental Sf9 and Sf9ex1.7/10X cell lines (>93%), and 
compared to Sf9 mock infected negative control.   
 
An initial indication that rAAV vector production may be influenced by SfYB-disruption was 
inferred by gene transfer assays of 293T with crude rAAVGFP vector lysates (Fig. 6.19). Firstly, 
comparable baculovirus infection efficiencies of approximately 80% between rAAV -2 or -8 
vector productions were determined by flow cytometry analysis (Fig. 6.19A). This was further 
compared against mock infected Sf9 (0.34%) and Sf9 infected with only BacITRGFP and 
BacMers-M (88.6%) as negative and positive controls for baculovirus infection, respectively 
(Fig. 6.19A).  
 
Therefore, the gene transfer rates for rAAV -2 or -8 vector particles encoding GFP transgene, 
derived from control Sf9 (SfAAV vectors) or Sf9ex1.7/10X (Sf1.7AAV vectors) producers, were 
analysed. Firstly, siginificant heat inactivation of baculovirus particles for gene transfer assays 
was indicated by comparing 293T infections with non-heat inactivated and heat inactivated 
crude lysates derived from control Sf9 cells infected with BacITRGFP+BacMers-M only (Fig. 
6.19B and C). A drastic reduction in transduction rates from 62% to 1.16% for non-heat 
inactivated and heat inactivated control lysates, respectively, was confidently observed (Fig. 
6.19B and C). Therefore, with BacITRGFP heat inactivated from sample crude AAV lysates, a 
notable improvement in gene transfer was achieved after 293T infections with Sf1.7AAV 
vector when compared to SfAAV for most dilutions tested (Fig. 6.19A and B, respectively for 
crude AAV2 and AAV8 gene transfers). For instance, infections of 293T with heat-inactivated 
crude Sf1.7AAV2 was able to outperform SfAAV2 infections at the respective dilutions – neat, 
1/5, and 1/25. Infection with neat, heat-inactivated Sf1.7AAV2 resulted in 58% gene transfer 
compared to 33.6% for SfAAV2 at the equivalent dilution (Fig. 6.19B). However, the effect on 
gene transfer was less apparent between rAAV8 vectors derived from parental Sf9 or 
Sfex1.7/10X cell lines (Fig. 6.19C). In fact, only infections with neat Sf1.7AAV8 vector (heat 
inactivated) exhibited improved gene transfer rates (72.2%) compared to SfAAV8 (66.4%) (Fig. 
6.19C). 
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Figure 6.19 Gene transfer assays of 293T with crude rAAV -2 or -8 vectors. Figure legend continues 
next page.  
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Figure 6.19 Gene transfer assays of 293T with crude rAAV -2 or -8 vectors. The infection efficiency of 
BacITRGFP was comparable as determined by (A) flow cytometry and scatter plots of Sf9 and 
Sf9ex1.7/10X cells infected with baculoviruses for rAAV2 and rAAV8 vector production (approximately 
80%). Sf9 cells infected with only BacMers-M functioned as mock infection control (0.34%), and cells 
infected with only BacITRGFP+BacMers-M functioned as positive control for baculovirus infection 
(88.6%). Crude lysates were then harvested by freeze-thaws, heat inactivated, and subsequently applied 
as a titration to 293T cells for gene transfer assays for (B) rAAV2 or (C) rAAV8 vectors. Flow cytometry 
analysis indicated that modestly improved gene transfer with rAAV vector particles derived from 
Sf9ex1.7/10X cells (Sf1.7AAV), particularly Sf1.7AAV2, was observed when compared to rAAV -2 or -8 
vectors from Sf9 (SfAAV -2 or -8, respectively). Crude lysates from mock infected Sf9 served as mock 
crude infection control, and lysates derived from Sf9 cells infected with only BacITRGFP+BacMers-M 
functioned to test the efficiency of BacITRGFP heat inactivation. The baculovirus infection or gene 
transfer rates are displayed as % in scatter plots. HI, heat inactivated; NHI, non-heat inactivated; SfAAV; 
rAAV vector derived from parental Sf9; Sf1.7AAV, rAAV vector derived from Sf9ex1.7/10X. 
 
Having determined that the SfYB-disrupted phenotype in Sf9 did not compromise the cell 
line’s capacity for infection with baculovirus(es), or cell cytotoxicity post-infection, the 
expression levels of AAV2 Rep and AAV Cap (Vp1-3) proteins between cell lines was examined. 
Western blot analysis suggested that AAV2 Rep and AAV2 or AAV8 Vp1-3 protein expression 
was relatively comparable between Sf9ex1.7/10X and Sf9 control (Fig. 6.20A, top and bottom 
panels, respectively). This was despite the fact that Sf9ex1.7/10X cells demonstrated a 
consistent SfYB knockout phenotype (Fig. 6.20A, bottom panel), and equal protein loads were 
demonstrated by Coomassie® Blue gel staining between either baculovirus-infected cell lines 
for rAAV -2 or -8 vector production (Fig. 6.20B). Including, infection efficiencies of 
baculoviruses (BacITRGFP) was considered comparable, recording between 80-82% for control 
Sf9 and Sf9ex1.7/10X cell lines by flow cytometry (Fig. 6.20C). Therefore, it was implied that 
the expression of AAV Rep or Cap proteins was relatively unaffected by the disruption of SfYB 
expression in Sf9 cells.  
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Figure 6.20 SfYB disruption did not influence AAV Rep or Cap (Vp1-3) protein expression. A) Western 
blot analysis revealed that the Rep -78 or -52 protein (top panel) and AAV2 and AAV8 Vp1-3 (middle 
panel) proteins were not influenced by SfYB disruption. Therefore AAV Rep and Cap expression in 
Sf9ex1.7/10X cells remained comparable to that of Sf9 control producer cells. SfYB disruption by 
CRISPR/Cas9 was demonstrated also using SfYB-specific antiserum (bottom panel). B) Equal loading of 
protein lysates was inferred by Coomassie® Blue gel staining, and (C) baculovirus (BacITRGFP) infection 
rates were considered comparable between Sf9 and Sf9ex1.7/10X rAAV vector productions (recording 
between 80-82%, compared to mock infected control at 0.37%). The % of infected cells is displayed in 
parentheses. M, Precision Plus Protein™ Dual Colour Standards. 
 
Lastly, rAAV -2 or -8 vector genome titres from Sf9ex1.7/10X cells was calculated by qPCR, and 
compared relatively to control Sf9 as the baseline producer cell line. We first ensured that the 
efficiency of co-infection with baculoviruses (BacITRGFP) was comparable between producer 
cell lines for rAAV2 (Fig. 6.21A; compare green and red lines) and rAAV8 (Fig. 6.21A; compare 
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blue and pink lines) vector productions. Following which, qPCR analysis of vector genome 
titres indicated that despite SfYB disruption, the relative titres were considered comparable 
and not statistically significant to titres achieved by Sf9 control cells (Figs. 6.21B and C; n = 3 
each, P > 0.05). Relative rAAV2 genome titres showed an average 2.56±1.85-fold more rAAV2 
vector genome titres generated by Sf9ex1.7/10X to that of Sf9 control, but was deemed 
statistically insignificant (Fig. 6.21B; n = 3, P > 0.05). Similarly, an average 1.82±0.64-fold more 
rAAV8 vector genome titres was produced from Sf9ex1.7/10X to that of Sf9 control, and was 
also considered statistically insignificant (Fig. 6.21C; n = 3, P > 0.05). Batch-to-batch variation 
of physical rAAV -2 or -8 vector genome titres was observed, such that as much as 5.45x108 
rAAV2 vector genomes/mL was measured for Sf9 compared to 3.67x108 vector genomes/mL 
for Sf9ex1.7/10X (batch 1), corresponding to 1.48-fold less (Fig. 6.21D). Or as low as 3.2x108 
rAAV2 vector genomes/mL from Sf9 control compared to 8.4x107 vector genomes/mL from 
Sf9ex1.7/10X cells (batch 2), corresponding to 2.62-fold more vector genomes measured from 
the Sf9ex1.7/10X cell line (Fig. 6.21D). Likewise, as much as 1.02x109 rAAV8 vector 
genomes/mL from Sf9 compared to 1.57x109 vector genomes/mL from Sf9ex1.7/10X (batch 3), 
corresponded to 1.54-fold more rAAV8 (Fig. 6.21E). Or as low as 1.82x108 vector genomes/mL 
for Sf9 compared to 4.46x108 vector genome/mL from Sf9ex1.7/10X cells (batch 1), 
corresponding to 2.45-fold more rAAV2 vector genomes measured from the Sf9ex1.7/10X cell 
line (Fig. 6.21D). The above quantification of genome titres was confidently appreciated given 
that the purification quality of rAAV -2 or -8 vector preps from Sf9 and Sf9ex1.7/10X producer 
cells was demonstrated by silver staining, and distinguishable in purified samples compared to 
crude rAAV2 lysate control lane (Fig. 6.21F). 
 
 
    
309 
 
 
Figure 6.21 Comparable rAAV VG titres were detected between parental Sf9 and Sf9ex1.7/10X cell 
lines. The infection efficiency of BacITRGFP was determined by (A) flow cytometry, and considered 
comparable between control Sf9 and Sf9ex1.7/10X cell lines for rAAV -2 or -8 vector production, 
reporting at >94% of cells positively infected compared to mock infection control (0.37%). The % of 
fluorescent cells is displayed in parentheses. Recombinant AAV vectors were then harvested, purified, 
and subsequently quantified by qPCR (B) for relative rAAV2 and (C) rAAV8 VG titres, using Sf9 as the 
baseline control producer cell line. A statistically insignificant difference in relative VG titres for 
Sf9ex1.7/10X cells to that of Sf9 control was calculated by qPCR, indicating that SfYB-disruption did not 
confer an enhanced rAAV vector producer cell line (P > 0.05). Error bars reflect ±SD from mean, n = 3. 
Individual physical (D) rAAV2 and (E) rAAV8 vector genomes/mL, as quantified by qPCR were plotted for 
each batch (1-3), and compared between control Sf9 and Sf9ex1.7/10X producer cells. F) Silver staining 
of purified rAAV -2 or -8 vectors from Sf9 or Sf9ex1.7/10X demonstrated well purified rAAV vector preps 
with capsid proteins positively stained, and compared to crude rAAV2 harvest from Sf9 control. VG, 
vector genome. 
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6.3.0 Chapter summary 
The present study demonstrated that genome editing of the Sf9 cell line was feasible, despite 
the restriction in promoter usage and limited reference genome data available. Regardless of 
this, in silico identification of the Y-Box protein homologue endogenous to S. frugiperda 
permitted the design of gRNAs for subsequent genome editing of the Sf9 cell line by 
CRISPR/Cas9 technology. However, the transient nature of the SfYB disruption seemed to be a 
consequence of the reduced growth kinetics when compared to parental Sf9, and being 
unable to establish single cell clones. In fact, the slower growing genome edited Sf9 cells were 
eventually outgrown by parental Sf9 cells in bulk CRISPR-transfected Sf9 cells for SfYB 
knockout, or reverted back to wildtype, eventuating in SfYB-expression back to wildtype levels. 
The benefit of single cell cloning CRISPR/Cas9 genome-edited cells was demonstrated in 
Chapter 3, and suggested such practice helped isolate homozygous YB1 knockout clones that 
were not in competition of parental 293T cells, or could not revert back to wldtype given the 
homozygous mutation profile(s). Although, this was in spite of the fact that Sf9 cells were 
originally clonal derivatives of the Sf21 cell line (Vaughn et al., 1977). Nonetheless, SfYB 
disruption did not significantly exhibit an enhanced rAAV vector producer cell line quality. 
Recombinant rAAV vector genome titres and AAV Rep and Vp1-3 protein expression were all 
considered comparable to that of parental Sf9 as the control producer cell line.  
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Chapter 7: Discussion and Future Directions 
 
7.1 Introduction 
Recombinant Adeno-associated viral (rAAV) vector technology has grown to become one of 
the most promising tools for gene therapy applications. In fact, the successful implementation 
and licencing of gene therapy products for clinical and therapeutic administration has been 
demonstrated for rAAV. Key examples are rAAV products in the form of Glybera (Carpentier et 
al., 2012) and Luxturna (Bennett et al., 2016) for the treatment of hereditary lipoprotein lipase 
deficiency and Leber’s congenital amaurosis, respectively. However, the demand for sufficient 
quantities of rAAV vector is constrained by current production systems. The importance of 
understanding host-AAV interactions is becoming more prevalent, with the importance of 
particular cell-intrinsic factors to AAV biology and processing slowly being revealed (Mitchell et 
al., 2014; Satkunanathan et al., 2014; Holscher et al., 2015; Schreiber et al., 2015). 
 
The production of rAAV vectors is mediated by transient plasmid transfection of mammalian 
cell lines (293T or HeLa), or recombinant baculovirus infection of insect cell lines (Sf9 or Ao38). 
Plasmids or recombinant BEVs encode the minimally required AAV and/or Adenovirus 
elements to promote rAAV vector assembly, genome replication, and packaging. Ultimately, 
rAAV vector particles are harvested and/or purified for downstream applications. The 
simplicity of rAAV vector genomes (encompassing only the AAV2 ITRs and promoter controlled 
transgene) and nature of minimally required AAV/Adenovirus factors also highlights the 
importance of host-AAV interactions and their impact on rAAV vector production in vitro. The 
inclusion of minimal viral proteins in rAAV vector production systems indicates that an array of 
cell-intrinsic factors need exploiting in order to propagate intact and infective rAAV vectors. A 
potential cell-intrinsic factor, Y-Box protein (YB)1, is thought to negatively regulate rAAV 
vector processing (Satkunanathan et al., 2014). Human YB1 is a cold-shock domain (CSD)-
containing protein, that harbours a significant array of functions: promoting cell survival 
(Lasham et al., 2003; Homer et al., 2005), cell proliferation (Swamynathan et al., 2002; 
Fujiwara-Okada et al., 2013; Wang et al., 2015b), DNA repair (Gaudreault et al., 2004; Das et 
al., 2007; de Souza-Pinto et al., 2009; Kim et al., 2013), gene transcription (Stickeler et al., 
2001; Wei et al., 2012), protein translation (Davydova et al., 1997; Pisarev et al., 2002; 
Nekrasov et al., 2003), and responds to a number of stress responses (Ohga et al., 1998; 
Shibahara et al., 2004; Das et al., 2007; Somasekharan et al., 2015).  
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It was previously identified that human YB1 protein associates with rAAV vector particles and 
negatively regulates rAAV vector production in 293T cells (Satkunanathan et al., 2014). Given 
this, the work presented in this thesis aimed to utilise the CRISPR/Cas9 genome editing system 
to regulate endogenous gene expression of human YB1 or Y-Box protein homologues (SfYB) in 
AAV vector producer cell lines – 293T and Sf9, respectively. We initially and extensively 
characterised knockout cell lines using a wide repertoire of assays to evaluate the genotype 
and phenotype of knockout cell lines. In doing so, we demonstrated a clear advantage of single 
cell cloning of CRISPR/Cas9-transfected 293T. This resulted in clones that were homozygous 
for the knockout mutation. Additionally, we emphasise the importance of using target-specific 
antibodies or CRISPR-validated antibodies in Western blotting for knockout cell lines using 
CRISPR/Cas9 genome editing.  
 
However, YB1 knockout sensitised cell lines to chloroquine-induced cell death, and in turn 
restricted the use of this cell line for rAAV vector production by triple transfection with 
Calcium Phosphate precipitation method supplemented with chloroquine. Upon further 
analysis, rescue and/or resistance to this chloroquine-induced cytotoxic phenotype were 
achieved by the restored expression of YB1 and mutated YB1 encompassing mainly the CSD. A 
complex interplay between YB1’s alanine-proline rich (A/P) domain or C-terminus domain 
(CTD) with the CSD seemed to regulate the rescue/resistance from chloroquine-induced 
cytotoxicity. Here, the general concensus was drawn that the CSD was the key mediator of the 
resistance phenotype to chloroquine-induced cytotoxicity. It was noted that the CTD alone 
(encompassed by YB1Δ5) conferred a rescued phenotype, however; therefore, whether or not 
the CTD, CSD, and/or A/P domain regulate each other in this function remains to be 
characterised. This is difficult to predict given the intrinsically disordered nature of YB1’s 
termini as explored in Chapter 5. However, this is not unreasonable to assume given that YB1 
forms oligomers of itself, especially via its CSD, of which process is modulated by the termini 
sequences (Guryanov et al., 2012). Furthermore, mutation analyses showed that DNA binding 
activity that is exhibited by the CSD is influenced by the CTD (Chen et al., 1995).      
 
Alternative methods of rAAV vector production were unaffected by the YB1/SfYB knockout 
phenotype, and included triple transfection using PEI- or infection with recombinant 
baculovirus- based methodologies. As a result, comparable levels of AAV Rep and Vp1-3 
expression and vector genome titres were calculated between control and knockout cell lines. 
Lastly, direct associations between AAV and human YB1 were inferred using DNA-YB1 affinity 
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pulldown assays and confocal laser scanning microscopy. Potential interactions between 
human YB1 and AAV2 ITR sequence was successfully demonstrated by means of a putatively 
identified YB1 binding motif (5’-GGGGTT-3’).  
 
7.2 CRISPR/Cas9 genome editing efficiently generated stable knockout cell lines 
We demonstrated that YB1 and SfYB knockout cells were established using CRISPR/Cas9 
genome editing technology, targeting YBX1 gene at exons 1, 5 or 7, and intron 6, and SFYB at 
exon 1. The YBX1 gene is located on chromosome 1 (Ch1p34.2), and it so happens 293T cells 
exhibit a pseudotriploid karyotype (Bylund et al., 2004; Kim et al., 2009), and 293T cells likely 
harbour three sets of the YBX1 alleles. Therefore, the efficiency of targeting YBX1 is 
complicated given multiple copies of the YBX1 gene. Despite the pseudotriploid nature of 293T 
cells, potential YB1 knockout cell lines, particularly single cell clones, were successfully 
expanded. Knockout efficiencies were 20% for YBX1sgRNA1 and 60% for YBX1sgRNA3 designs. 
However, when taking into consideration all clones analysed, overall 20% knockout efficiency 
was achieved. This was attributed by the dominant phenotype of a number of clones – partial 
YB1 knockout. However, we found that despite the difficulty expected in targeting multiple 
copies of the YBX1 gene, that CRISPR/Cas9 genome editing benefitted from single-cell cloning. 
This benefit was also emphasised by CRISPR/Cas9 genome editing of Sf9 cells, which could not 
be established as a monoclonal cell population. A consequence of this practical limitation was 
that the knockout phenotype was eventually lost due to the growth defect observed by SfYB-
disrupted Sf9. Also, Sf9 cells exhibit a polyploidal karyotype, with diploid cells demonstrating 
chromosomal instability and propagating as tetraploidy over time in culture (Jarman-Smith et 
al., 2002). The expansion of wildtype SFYB in this manner and the bottleneck generated by 
slower growing SfYB-disrupted cells likely eventuated in the recovery of the parental Sf9 
population. 
 
However, it is appreciated that CRISPR/Cas9-mediated knockout efficiency was reported to be 
insensitive to the copy number of the target gene, but that was determined instead by the 
efficiency at which sgRNAs recognise and bind to its target sequence (Yuen et al., 2017). This 
was of important consideration when targeting sequences within cancer cell lines that exhibit 
considerable cytogenetic abnormalities and genomic instabilities that result in aneuploidy 
(Solomon et al., 2011; Zhao et al., 2014; Frattini et al., 2015). In the present study, the 
transient nature of Cas9 expression, and in turn sgRNA from the pCRISPR-YBX1sgRNA(1-3) 
constructs and sgRNAsf1:rCas9 RNP transfections infer a transient period in which 
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CRISPR/Cas9 mediates DSBs at the targeted sequences. This was in contrast to Yuen et al. 
(2017), whom produced stable Cas9-sgRNA expressing cell lines to determine knockout 
efficiencies of the integrated EGFP transgene. Therefore, the persistent nature of Cas9-sgRNA 
expression off-sets the limitation exhibited by transient expression, and ultimately enhances 
the occurrence of targeted knockouts. 
 
YB1 knockout clones A2 and C5, and to a lesser extent clone B2, exhibited stable YB1 knockout 
phenotype even up to 12 months in culture. This was particularly reflective of sufficiently 
established single cell clones, but also demonstrated a clear benefit of the genome editing tool 
over alternative gene manipulation tools. For example, siRNA can demonstrate targeted 
knockdown for up to 10 days post-transfection (Bartlett and Davis, 2006). Whereas shRNA 
technology, which, despite being able to stably introduce these elements into the target 
genome with lentiviral vectors or generate transgenic mice, can exhibit transient knockdown 
phenotypes (Satkunanathan et al., 2014; Ajiro et al., 2015). Transduction of shRNA-encoding 
lentiviral vectors function to incorporate the DNA intermediate of their vector genome into 
the target genome. Although, the process of integration site selection is rather non-specific, 
but does show preferential integration into active gene loci (Gierman et al., 2007). The 
integration location partly defines the transcriptional activity of the transgene(s) encoded by 
the lentiviral vector, and/or the endogenous genes in which the integration has occurred 
(Hargrove et al., 2008; Moiani et al., 2012). On the other hand, CRISPR/Cas9 genome editing is 
precise and specific, providing the potential for off-target sequences is minimised. There is 
also the consideration that CRISPR/Cas9 genome editing incorporates only indels, or desired 
mutation with a donor template, at the specific target site. Inasmuch, minimum changes to 
the genomic blueprint and DNA composition is made using CRISPR/Cas9 genome editing, 
compared to alternative methods such as shRNA technology. 
 
7.3 Complex spectrum of mutation profiles, alternative splicing motifs, and splicing 
activation are consequences of CRISPR/Cas9 genome editing 
Analysis of sequencing profiles of the CRISPR/Cas9-targeted regions of YB1 knockout clones 
and SfYB-disrupted cells revealed a spectrum of mutations, mainly deletions, as a result of 
CRISPR/Cas9 genome editing. SpCas9 endonuclease generates DSBs at the target sequence, 
precisely 3nt upstream of the adjacent PAM 5’NGG3’ (Gasiunas et al., 2012). After which, 
endogenous NHEJ DNA repair pathway recognises the DSB for error-prone DNA repair and 
mutagenesis (Bibikova et al., 2002). However, NHEJ is typically accompanied by DNA resection 
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at the site of DSB, and can include the loss >25bp (Su et al., 2016b; Shin et al., 2017; Sorenson 
et al., 2017) prior to DNA polymerase-mediated repair. Large resection of DNA at DSBs and 
subsequent error-prone DNA polymerase activity may explain the localisation of the 1bp 
deletion that occurred 104bp upstream of the targeted PAM for the YB1 knockout clone A2. 
This was in contrast to the mutations observed for B2 and C5 clones, which reside well within 
the confines of their respective targeted sequences, and prevents the same locus from being 
re-targeted by CRISPR/Cas9 and YBX1sgRNA-2 or -3, respectively.  
 
Furthermore, given that the selected YB1 knockout clones were derived from single cell clones 
and 293T exhibit a pseudotriploid karyotype (Bylund et al., 2004; Kim et al., 2009), the 
genotypes of the disrupted YBX1 genes were of particular interest. We show evidence of clean 
chromatograms and Surveyor® mutation profiles indicative of homozygous genotypes for 
clones A2 and B2, for their targeted YBX1 gene sequences. This was despite the error-prone 
nature of NHEJ. Additionally, this was in complete contrast to the genotype and mutation 
observed for clone C5 – an A>C substitution followed by an 8bp deletion, but associated with a 
complicated chromatogram indicative of a heterozygous genotype, with mutations in each 
allele. This is further supported by Surveyor® mutation screening and HRM curve analysis. 
Where unilateral targeting of multiple gene copies to produce the same CRISPR/Cas9-
mediated mutation can be difficult, recent reports have described the ability to target multiple 
(up to 62 copies) of the porcine endogenous retrovirus in pigs using CRISPR/Cas9 (Yang et al., 
2015; Niu et al., 2017). Of important note was the ability to distinguish that the heterozygous 
genotype was found to be in context of mutated alleles only, and in the absence of wildtype 
alleles by HRM curve analysis. The importance of distinguishing mutated alleles from wildtype 
alleles was necessary as the presence of wildtype alleles could promote the reversion of 
knockout between the mutation-containing chromatid(s) and wildtype sister chromatid(s), if 
present (Zaboikin et al., 2017). Of course, similar was observed in genome edited Sf9 cells, 
where monoclonal populations could not be established, and a heterozygous genotype with 
intact wildtype SFYB gene eventually recovered. 
 
Furthermore, the mutations that occurred across YBX1’s intron 4:exon 5 splice junction (B2 
clone) potentiated in a disrupted wildtype splicing acceptor motif. Using the HSF v3.0 tool 
(Desmet et al., 2009), predictive assessments for alterations in splicing motifs and alternative 
splicing were calculated, and compared against wildtype scorings as reference. This tool was 
more confidently harnessed when exact mutations were known. C5 clone’s heterozygous 
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genotype and analysis of its Sanger sequencing results did not provide sufficient detail to 
accurately model the mutations for potential splicing alternations. However, clone B2 
demonstrated a homozygous mutation at its intron 4:exon 5 splice junction, despite exhibiting 
a partial YB1 knockout phenotype. In this particular case HSF v3.0 predicted probable changes 
in splicing motifs, with alternative splicing (prediction 2) potentiating in a reading frame that 
was still in-frame with the wildtype stop codon, but encoded a truncated YB1 protein that 
shared 99% sequence homology. The truncation was a result of a 3aa deletion corresponding 
to residues 119-121 (Gly-Ala-Glu) of wildtype YB1. These residues comprise a part of YB1’s CSD 
(YB1 CSD is mapped to between residues 51-129). This would explain the partial YB1 knockout 
phenotype observed as alternative splicing of an in-frame, albeit truncated, YB1 would be still 
be recognised by N- and C- terminus-specific αYB1 used in the study. Although it remains to be 
elucidated whether or not the truncated YB1 protein retains all, if any, wildtype function 
despite the 3aa deletion. The 3aa deletion does not coincide with YB1’s CSD RNP binding 
domains (RNPI and RNPII), which follow the consensus sequences: Asn-Gly-Tyr-Gly-Phe-Ile and 
Val-Phe-Val-His-Phe, respectively (Landsman, 1992; Kljashtorny et al., 2015). However, the 
defining β-barrel secondary structure of the CSD and its ability to bind to nucleic acids 
(Ladomery and Sommerville, 1994; Izumi et al., 2001; Kljashtorny et al., 2015) may be 
compromised. Alternatively, the truncated protein could function in a dominant-negative 
manner, and interfere with data analysis and the interpretation of results, essentially 
confounding downstream investigations (Kapahnke et al., 2016).  
 
The significant homology shared between wildtype YB1 and the 3aa truncated variant led us to 
conclude that the B2 clone may not be a suitable YB1 knockout model. At least not without 
fully characterising the expressed protein, further. This clone also reflects the importance of 
understanding the exact mutation profiles introduced by CRISPR/Cas9 genome editing, and 
the potential impact mutations can have on alterations in splicing motifs and alternative splice 
site activation. Ultimately, A2 and C5 presented as the most promising and confident YB1 
knockout clones generated by CRISPR/Cas9 genome editing of 293T cells. 
 
7.4 Safety profile of YB1 knockout cell lines 
The CRISPR/Cas9 genome editing tool derives mainly from S. pyogenes type II CRISPR-Cas 
system, and more importantly the associated SpCas9 endonuclease, therefore, has a 
prokaryotic origin. S. pyogenes is a common human commensal, typically contributing to the 
skin microbiota. The Gram-positive streptococci are known to be pathogenic and cause 
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pharyngitis, scarlet fever, and necrotising fasciitis (Medina et al., 2003; Terao et al., 2008). 
Much of the human population displays sero-positivity towards S. pyogenes infection, with as 
much as 100% of the adult population displaying protective antibodies and cell-mediated 
immune responses against it (Mortensen et al., 2015). Therefore, the possibility of pre-existing 
immunoreactivity towards Cas9 protein presents a potential hurdle for its utilisation in cellular 
or gene therapy applications. One of the main purposes of establishing an YB1 knockout cell 
line was to engineer a novel cell line for rAAV vector production, principally due to the 
previous observation that YB1 knockdown by shRNA technology correlated with enhanced 
rAAV vector titres (Satkunanathan et al., 2014). This warranted the deep and extensive 
characterisation of the YB1 knockout cell lines generated by CRISPR/Cas9 genome editing; but 
also included investigating the safety profile of using these cells lines by examining for stable 
Cas9 endonuclease expression.  
 
Long-term follow-up (up to 12 months) of YB1 knockout clones in culture demonstrated that 
the pCRISPR-YBX1sgRNA1-3 transfections of 293T exhibited transient transfection dynamics. 
Cas9 was not detected in YB1 knockout clones that were cultured for up to 12 months, 
indicating that Cas9 and sgRNA expression occurred in a transient nature; at least by the limits 
of detection by Western blotting. Therefore, pCRISPR plasmid integration into the target 
genome was not a risk that was observed. This was in spite of the fact that plasmid integration 
into the host genome can occur in vitro and in vivo (Chen and Okayama, 1987; Wang et al., 
2004b; Schiedner et al., 2008); albeit, at near negligible frequencies in vitro without an 
antibiotic selection pressure to promote isolation of transformed cell lines. In fact, the 
pCRISPR constructs possessed no selectable antibiotic marker, and transfection followed by 
single cell cloning was the study design of choice to clonally isolate YB1 knockout cell lines.  
 
Ultimately, Cas9 stable expression was not detected in selected YB1 knockout clones. This 
characterisation potentially increased the safety profile of the engineered 293T cells, 
especially in context with rAAV vector production. We currently understand, and observed, 
that rAAV vectors package or associate with cell-intrinsic constituents. Packaged host cell 
proteins have been identified in association with rAAV vectors, and include a range of host cell 
factors: nucleolin, nucleophosmin, YB1, RuvB, CypA, annexin V (Dong et al., 2014; 
Satkunanathan et al., 2014). The exact relevance of these packaged host cell factors to the 
biology of AAV and AAV processing has not been fully elucidated. In a CRISPR/Cas9 engineered 
rAAV producer cell line, the production process could include the incorporation of Cas9 
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endonuclease into assembling rAAV virions. In turn, the mis-packaged Cas9 could be 
transferred along with the desired transgene into target cells/tissues, and influence immune 
responses. In fact, Adenovirus-CRISPR and AAV-CRISPR systems have been examined in vivo 
for immune responses in mice models (Wang et al., 2015a; Chew et al., 2016). In the latter 
instance, AAV-split-CRISPR involved rAAV9 vectors encoding Cas9 to target the Mstn gene for 
editing in vivo. However, delivery of AAV-split-CRISPR or DNA encoding full length Cas9 elicited 
inflammatory immune reactions, antigen-specific T-cell activation and expansion, and 
generation of Cas9-specific antibodies in a Cas9-dependent, AAV9-independent manner (Chew 
et al., 2016). More recently and more relevantly, pre-existing immune responses to SpCas9 
and SaCas9 was identified from human blood serum. This was in the form of Cas9-specific, 
immunoreactive T-cells (TH1 and cytotoxic CD8+ T-cells) and production of cytokines IFNγ and 
TNFα in response to Cas9-antigen stimulation (Charlesworth et al., 2018). Therefore, careful 
CRISPR/Cas9 designs may have to be considered for genome editing of human cells for gene 
therapy. However, in the present study, the level of Cas9 expression was undetectable by 
Western blotting in YB1 knockout clones. Cas9 protein is unlikely to be packaged and mediate 
Cas9-associated immunoreactivity, for downstream applications, particularly gene therapy 
applications. In turn, the YB1 knockout cell line potentiates a risk-free model for rAAV vector 
production. 
 
7.5 Baculovirus technology for S. frugiperda-native recombinant protein expression 
Insect cell-based systems have proven extremely useful in the production of large quantities of 
recombinant protein. The Sf9 and Ao38 (or High Five™) cell lines are key examples of systems 
that are used for the heterologous expression of recombinant proteins (Lopez-Vidal et al., 
2015; Ge et al., 2016; Mohseni et al., 2016). This also includes the scale-up of rAAV vectors 
(Carpentier et al., 2012). Insect cells are generally infected with baculoviruses, given their high 
and robust efficiency, productive infectivity (Guo et al., 2005), and strong baculovirus-derived 
promoters (Smith et al., 1983b; Martinez-Solis et al., 2016). Whereas, transfection of Sf9 cells 
(and insect cell lines in general) with naked plasmid DNA is typically associated with poor to 
moderate transfection capacities, often ranging between 30-50% (Maeda et al., 2005; Ogay et 
al., 2006). We observed a similar range of transfection efficiency using Cellfectin™ II reagent 
and a GFP reporter plasmid. However, regardless of the gene transfer method applied, a 
discrepancy in intracellular His-tag staining was observed. This was best exemplified by 
baculovirus infections using BacGFP(His)10, in that despite high infection efficiency a lower 
percentage of the cell population stained positively for the His-tag. It was noted that the 
significant disorder in the N- and C- termini in Y-Box proteins (Guryanov et al., 2012), including 
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SfYB may impact on the exposure of the His-tag of rSfYB(His)10. Ultimately it was concluded 
that intracellular His-tag staining was not an accurate correlate for His-tag expression for the 
target recombinant protein, in the current studies.  
 
We also demonstrated a comparable expression profile between infected Sf9 and Ao38 cell 
lines for the rSfYB(His)10 protein expression, as determined by Western blotting. Although, it 
could be argued that some relatively enhanced expression of the rSfYB(His)10 was observed in 
Sf9 cell line. This came as a surprise given multiple records that suggest T. ni-based cell lines 
(High Five™ and Ao38) were considerably better producers of recombinant proteins compared 
to Sf9 or Sf21 (Wickham and Nemerow, 1993; Wilde et al., 2014). This is presumably due to 
the higher demands in metabolism and nutrition during baculovirus infections of T. ni-derived 
cells (Rhiel et al., 1997; Pushparajan et al., 2017). However, we take note that the target 
rSfYB(His)10 was cloned from the endogenous SfYB protein that was derived from S. frugiperda 
(and Sf9 cell line). Therefore, it was recognised that the recombinant protein was expressed 
from its endogenous cell system. It could be reasoned that the expression of recombinant 
protein in their endogenous cell systems is advantageous. Although, it is difficult to define how 
so in the current study, but it can be ruled out that the improved production dynamics in Sf9 
compared to Ao38 was not a result of a transcriptional advantage. This was because 
rSfYB(His)10 expression was under the promoter control of baculovirus-specific p10 promoter, 
and not its native promoter. Therefore, translational regulation of the rSfYB(His)10 was the 
likely process affected.  
 
As per keeping of a eukaryotic cell line, Sf9 cells are capable of post-translational modifications 
of recombinant proteins expressed from baculoviruses (Vrljic et al., 2011). These are usually 
necessary for full functionalities of recombinant proteins derived from heterologous gene 
expression. Post-translational modifications was considered a likely occurrence of rSfYB(His)10 
expression, given the electrophoretic mobility shift from the predicted 29.2kDa to 
approximately 50kDa by SDS-PAGE. The exact post-translational modifications were not 
defined in the present studies for SfYB, but select modifications and their cross-talk are 
capable of regulating protein degradation. For example, protein kinase C (PKC)α is 
phosphorylated to promote its sumoylation and protein stability, which in turn protects 
against ubiquitination and proteasomal degradation (Wang et al., 2015d). Endogenous SUMO 
proteins are components of Sf9 lysates (Langereis et al., 2007), but were not implicated in 
sumoylation of exogenously expressed products (mammalian in origin) from baculoviruses 
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tested (Langereis et al., 2007). Therefore, the advantage of post-translational modifications is 
likely a feature we observe in the present study that permitted improved rSfYB(His)10 
expression in Sf9 cells compared to Ao38. 
 
Nonetheless, antiserum raised against the rSfYB(His)10 was generated and proved a highly 
reactive and specific for SfYB in Sf9 cell lines. This was warranted given the reduced homology 
shared between human YB1 and the newly identified SfYB (predominant homology was 
calculated in the CSD, and extensive variation was reported for the remainder of the whole 
molecule). Additionally, the current pool of αYB1 available commercially were mostly raised 
against human YB1 peptides, but were still capable of cross-reactivity for SfYB in Sf9 lysates. 
Even with C-terminus specific αYB1, where homology and conservation between YB1 and SfYB 
was lowest, was found to cross-react almost comparably to the N-terminus specific αYB1. The 
fact that polyclonal antibodies are raised against several different epitopes of an antigen 
target compared to single, defined epitope derived monoclonal antibodies, proves 
advantageous for cross-reactivity. However, antibodies raised against human specific antigens 
do not always cross-react with protein homologues in different species or isoforms (Werther 
et al., 1996; Rosenbluth et al., 2009). Therefore, with the generation of rSfYB(His)10-specific 
antiserum, we conclusively identified the Y-Box protein (SfYB) in S. frugiperda, Sf9 cell line.  
 
7.6 SfYB is a S. frugiperda Y-Box protein 
Y-Box proteins encompass a large family of CSD-containing proteins that are evolutionarily 
conserved, and essentially found encoded by all domains of life (Karlson and Imai, 2003; 
Nakaminami et al., 2006). The CSD is homologous to prokaryotic cold-shock proteins, which 
function in response to a cold shock. The response functions to regulate transcriptional and 
translational processes to maintain prokaryotic cell viability (Wouters et al., 1999). We 
identified human Y-Box protein homologues that were highly conserved in Spodoptera spps. 
and T. ni. Analyses demonstrated conservation and homology defined to the sequences that 
correspond to the CSD. This comes as no surprise because evolutionary conservation of the 
cold-shock proteins and the homologous CSD has been consistently reported (Mani et al., 
2012; Kljashtorny et al., 2015). In fact, E. coli’s CspA and human YB1’s CSD share approximately 
43% sequence homology (Wang et al., 2000b). The increased homology observed between 
human YB1 and insect homologues (approximately 84%) was likely a matter of evolutionary 
divergence from unicellular cold-shock proteins, of which required a conserved functionality 
for eukaryotic adaptation and development. For instance, it has been reported that 
    
321 
 
mammalian YB1 is indispensable in late embryonic development of mice (Lu et al., 2005; 
Uchiumi et al., 2006). It remains unclear if the highly conserved CSD or evolutionarily acquired 
A/P or CTD domains, or a complex interplay, promotes progressive embryonic development. 
Of course, the expansion of the N- and C- termini of eukaryotic Y-Box proteins are acquired 
features, but showed the most variation between species of insects examined in the current 
study.  
 
It was readily acknowledged that the characterisation of insect Y-Box protein homologues of 
the Lepidoptera order is rather limited (Takiya et al., 2004; Nishita and Takiya, 2005). Human 
YB1 is predicted 36kDa in molecular weight but resolves to approximately 50kDa by SDS-PAGE. 
The SfYB protein revealed a similar electrophoretic mobility (approximately 50kDa) despite 
being predicted 29.2kDa. However, B. mori’s BYB was first reported to resolve to 
approximately 36kDa (Takiya et al., 2004) or approximately 50kDa (Nishita and Takiya, 2005). 
The extent of BYB’s post-translational modifications (if any) has not been elucidated, and may 
likely contribute to shifts in the electrophoretic mobility of the protein (Shirai et al., 2008). This 
was of interest because human YB1’s function has been reported to be regulated by post-
translational modifications. These include: phosphorylation of S102 – implicated in breast 
cancer oncogenesis and chemoresistance (Stratford et al., 2008; Dhillon et al., 2010), S165 or 
S176 – regulating NFκB activation and NFκB-induced genes, and implicated in colon cancer 
(Prabhu et al., 2015; Martin et al., 2017), or ubiquitylation for targeted 20S proteasome-
mediated degradation (Lutz et al., 2006), to name a few. Therefore, given a shift in 
electrophoretic mobility, it is likely SfYB is as extensively regulated in its function(s) similarly to 
human YB1. The context of which these modifications occur does require further elucidation, 
as the aforementioned post-translational modifications of YB1 were mainly characterised in 
context to carcinogenesis. Treatment of rSfYB protein with phosphatases or 
immunoprecipitation with poly-ubiquitin antibody may reveal the exact post-translational 
modifications for further scrutiny. 
  
SfYB also demonstrated structural similarities to human YB1 and to the BYB controls. It was 
deduced that generally the homologues were composed of three main functional domains – a 
short N-terminal domain, the conserved CSD, followed by a CTD. This was similar to BYB 
(Takiya et al., 2004) and Philosamia ricini Y-Box protein (PYB) homologue (Mani et al., 2012). 
Furthermore, secondary structures were recognised by predictive analyses in the conserved 
CSD, including five β-strands assembling into a β-barrel. This was synonymous to human YB1 
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(Kloks et al., 2002; Kljashtorny et al., 2015) and E. coli’s CspA (Newkirk et al., 1994). 
Interestingly, near complete matches in 3D-structure and folding were predicted between 
superimposed BYB, SfYB or TnYB CSDs to human YB1 template model 5yts, as per TM-scores of 
approximately 0.94-97. It is appreciated that tertiary structures of published Y-Box protein 
homologues using, for example – comparative 3D-modelling of YB1 and Bacillus caldolyticus 
CspB (a bacterial cold-shock protein) generated an RMSD value of 0.49Å using molecular 
dynamics simulations (Kljashtorny et al., 2015). However, comparative analysis by RMSD is 
considered a poor measure of protein structure conservation. The RMSD score is largely 
influenced by the overall length of the alignments. Therefore, large protein sequence 
alignments generate a large RMSD value, of which is not scaled for a relative measure of 
structural conservation (Maiorov and Crippen, 1994). The TM-score overcomes this 
dependence on the length of alignment by weighing the distances between superimposed 
residues more strongly compared to those further apart (Zhang and Skolnick, 2004). 
Therefore, the proposed high TM-scores between the 5yts model and Y-Box protein 
homologues indicated that the modelled proteins reflect accurate predictions.  
 
Nonetheless, the CSD is involved in DNA- and RNA- binding activities (Ladomery and 
Sommerville, 1994; Izumi et al., 2001; Kljashtorny et al., 2015), and the RNP-I and RNP-II 
motifs were successfully identified as generally well conserved (Landsman, 1992) in the CSDs 
of BYB (Takiya et al., 2004), SeYB, SlYB, SlittoYB, SfYB and TnYB homologues . In fact, BYB and 
the structurally conserved PYB showed similar preferential affinity or binding to ssDNA and 
ssRNA, and less so to dsDNA species (Nishita and Takiya, 2005; Mani et al., 2012), or enhanced 
DNA binding of mammalian transcription factors for enhanced transcriptional activities (Takiya 
et al., 2004). Despite these functions being mediated mostly by the CSD, the flanking domains 
of BYB or PYB were considered supportive of specific ssDNA binding (Takiya et al., 2004; Mani 
et al., 2012). This also seems to be the case for human YB1 (Izumi et al., 2001; Tanabe et al., 
2015), and is perhaps likely for the newly characterised SfYB. However, experimental evidence 
is required to completely classify these homologues as orthologues.  
 
The disruption of SfYB was also associated with a significant growth defect when compared to 
parental Sf9 cells. Human YB1 is well characterised to have direct associations with cell cycle 
progression and cell proliferation (Fujiwara-Okada et al., 2013; Kotake et al., 2013; Wang et 
al., 2015b; Dey et al., 2016). The knockdown of YB1 protein expression was associated with 
cell cycle defects and slowed cell proliferation, even in selected tumour cell lines (Shiota et al., 
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2008; Wang et al., 2015b). YB1 directly associates and downregulates the tumour suppressor 
gene, p16INK4A locus in order to promote replication (Kotake et al., 2013). The encoded cyclin 
kinase inhibitor regulates cyclin D/cdk4 kinase activity, which would otherwise lead to the 
phosphorylated pRb and accumulation of E2F for entry into S-phase of the cell cycle (Kato et 
al., 1993; Ezhevsky et al., 1997; Narasimha et al., 2014). However, a growth defect was not 
observed in YB1 knockout cell lines established by CRISPR/Cas9 genome editing. The 
immortalisation of 293T cell lines by Adenovirus type 5 E1 ORF (Graham et al., 1977) and SV40 
large T antigen (DuBridge et al., 1987) likely circumvents this growth inhibition. The products 
of the E1 ORF, particularly E1A, promotes host cell entry into active S-phase of the replicative 
cell cycle by up-regulating cyclin E and cdc25A expression and activity (Spitkovsky et al., 1996). 
E1A is also directly implicated in the pRb/E2F-1 pathway, by binding to the pRb family of 
proteins to release key transcription factors that are defined as key regulators of S-phase entry 
from the G1 stage of the cell cycle (Nevins, 1990). 
 
Nonetheless, given the homology shared between SfYB and human YB1, it is likely that certain 
functions may also be shared – including control and regulation of the cell cycle progression 
and proliferation. The inability to establish single-cell clones of the heterozygous SfYB-
disrupted cell line and growth defect, however, may have resulted in a bottleneck for 
population density between SfYB-disrupted cells and parental Sf9 after the establishment of 
the Sf9ex1.7/10X cell line. Meaning the parental Sf9 cells would eventually outgrow the slower 
growing SfYB-disrupted cells. This was eventually observed in the current study, with later 
passaged Sf9ex1.7/10X cell line exhibiting SfYB protein expression restored to wildtype levels. 
Ultimately, the target gene of interest was amenable to genome editing by CRISPR/Cas9 
technology in Sf9 cells; however, the likely role of the SfYB protein in cell cycle progression and 
proliferation meant the gene edited cell line was eventually lost by outcompeted growth. 
 
7.7 Unprecedented consequences to CRISPR/Cas9 genome editing 
Significant and enhanced cell cytotoxicity phenotype was observed for YB1 knockout clones 
treated with chloroquine in any instance. This cell cytotoxicity phenotype was generally 
considered independent of the Calcium Phosphate mix, transfection of plasmid(s), and 
transfection efficiencies for the input pAAV2-hrGFP reporter plasmid. Despite the reported 
cytotoxicity exerted by AAV2 Rep78 protein expression (Yang et al., 1994; Schmidt et al., 2000) 
YB1 knockout cell lines were concluded to be especially sensitive to the effects of chloroquine. 
Lastly, PEI-based transfection or baculovirus infections for rAAV vector production showed 
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comparable cytotoxicity profiles between 293T and YB1 knockout cells, and Sf9 and SfYB-
disrupted cell lines, respectively.  
  
It was noted that rAAV production by Calcium Phosphate precipitation method has shown to 
involve the release of vector into the culture media (Vandenberghe et al., 2010), and PEI-
mediated production processes have also reported rAAV vectors appreciably within the 
culture media (Lock et al., 2010). Some reports describe 293T cells rounding up and detaching 
from the plate after transfection with Calcium Phosphate precipitation or PEI (Lock et al., 
2010; Huijun et al., 2014). With these in mind and given AAV vectors are non-enveloped, some 
level of cytotoxicity may be a direct consequence of rAAV production, resulting in the release 
of particles into the culture media. However, the significant effect from chloroquine treatment 
alone on YB1 knockout cells suggested that chloroquine may be functioning in a more adverse 
and dominant manner to this particular CRISPR/Cas9 genome engineered cell line or clone. 
Perhaps the loss of YB1 has dire consequences that would otherwise be protective to 
chloroquine treatment? 
 
Chloroquine is a quinolone compound and weak base, which has been extensively reported to 
supplement the Calcium Phosphate precipitation method for transfection (Luthman and 
Magnusson, 1983; Hasan et al., 1991; Felgner et al., 1994; Kariko et al., 1998). Chloroquine 
aids transfection in two main ways, i) chloroquine neutralises acidic pH in endocytic vesicles to 
prevent further degradation of input exogenous DNA, and ii) chloroquine also has been shown 
to displace polycations from input DNA to promote nuclear shuttling (Cheng et al., 2006). 
Alternatively, chloroquine is also well recognised as a first-line treatment against malaria due 
to infection with Plasmodium strains (Watt et al., 1988; Levy et al., 1991; Pillai et al., 2001). 
Chloroquine is toxic to Plasmodium strains, and is thought to function by accumulating in the 
digestive vacuoles of P. falciparum infected erythrocytes and interferes with the parasites 
ability to detoxify its digestive vacuole from the haemoglobin proteolysis by-product, 
ferriprotoporphyrin IX (Bray et al., 1999). This leads to significant damage and disruption to 
the Plasmodium membranes (Ginsburg and Demel, 1983; Zhang and Hempelmann, 1987). It 
has also been reported protective against Zika virus infection in vitro (Delvecchio et al., 2016), 
and in vivo using SJL mice models that demonstrated reduced vertical transmission incidences 
(Shiryaev et al., 2017). However, chloroquine-mediated toxicity and cell death of uninfected 
Vero cells was detected, albeit, at high working concentrations of chloroquine (100μM and 
above) than used in the present study. Although a working chloroquine concentration of 25μM 
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was used in the present studies, 293T and CRISPR/Cas9-genome edited derivatives were 
principally examined given their relevance in rAAV vector production, and not Vero cells. 
Therefore, the use of different cell lines may account for the relatively enhanced resistance of 
Vero cells to chloroquine cytotoxicity, compared to 293T and YB1 knocked out-293T 
derivatives.  
 
On the other hand, PEI is a linear, cationic polymer of aziridine monomers, and functions to 
bind to the phosphodiester backbone of DNA or directly to DNA grooves, and condense it into 
positively charged particles that are capable of binding to cell surfaces (Utsuno and Uludag, 
2010). This permits DNA:PEI complexes to become receptive to internalisation by endocytosis, 
and input DNA is further protected by the buffering potential by PEI in acidic endosomes 
(Boussif et al., 1995; Sonawane et al., 2003). This involves binding and retaining of protons 
which influences the influx of Cl-, which perturbs the endolysosomal osmolality to release DNA 
into the cytoplasm for nuclear entry (Pollard et al., 1998; Akinc et al., 2005). Therefore, 
similarly to chloroquine, PEI buffers the endolysosomal pH to protect DNA degradation and 
enhance transfection efficiency. Given PEI operates to buffer the acidic pH of the 
endolysosomal compartment analogous to chloroquine, the present studies could indicate 
that an alternative pathway involving chloroquine that is associated with YB1, but 
independent of PEI, is responsible for an enhanced cytotoxic phenotype in YB1 knockout cells.  
 
The cytotoxic potential of chloroquine has been well defined in a number of tumour cell lines 
(Zaidi et al., 2001; Geng et al., 2010; Kim et al., 2010; Lakhter et al., 2013; Frieboes et al., 2014; 
Vessoni et al., 2016). It has also been identified as a significant sensitising agent of cancer cell 
lines for targeted cell death (Verschooten et al., 2012; Schmukler et al., 2014; Park et al., 
2016). For example, Lakhter et al. (2013) demonstrated that chloroquine prevented the 
degradation of pro-apoptotic p53-upregulated modulator of apoptosis (PUMA) in melanoma 
cell lines in a lysosome-independent manner. This resulted in decreased cell viability and 
increased levels of caspase activity. Also, Kim et al. (2010) demonstrated that chloroquine 
stabilised p53, resulting in transcriptional upregulation of p53-regulated gene targets, 
including apoptotic BAX; although, this was largely dependent on wildtype p53 status. 
Therefore, there is a clear involvement of chloroquine in stimulating the apoptotic cell death 
pathway(s). In contrast to this, YB1 protein has been characterised as a dominant negative 
regulator TP53 gene expression, and of p53 function and p53-mediated apoptosis (Lasham et 
al., 2003; Zhang et al., 2003; Homer et al., 2005; Schittek et al., 2007). The overexpression of 
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YB1 in metastatic melanoma cell lines significantly correlated with chemoresistance, also 
(Schittek et al., 2007). Therefore, taking in to account that chloroquine is capable of inducing 
apoptosis, along with YB1’s role in negatively regulating p53-mediated apoptosis, a possible 
explanation to the heightened sensitivity of YB1 knockout cell line has been proposed. The 
sensitivity observed in response to treatment with chloroquine may be due, in part, to the lack 
of YB1 negatively regulating p53-mediated apoptosis induced by chloroquine. In parental 293T 
cells with intact YB1 expression and function, the adverse effect of chloroquine is most 
probably limited by a functioning relationship between p53 and YB1.  
 
It is, however, noted that 293T cells are transformed 293 cells for the additional, constitutive 
expression of SV40 large T antigen (DuBridge et al., 1987). The purpose of which was for the 
improved performance of replication and/or expression of transfected plasmids harbouring 
the SV40 origin of replication (DuBridge et al., 1987; Heinzel et al., 1988; Mahon, 2011). 
However, more importantly and with relevance to the YB1 knockout cell line sensitivity 
towards chloroquine, SV40 large T antigen has linked to disrupting p53’s tumour-suppressing 
functions, and associated with promoting tumorigenesis (Zhen et al., 1999). The large T 
antigen acts as a potent inhibitor of p53 tumour-suppressor functions. It directly binds to p53 
tumour suppressor (Lilyestrom et al., 2006), and in doing so, encourages the stabilisation of 
p53 levels that are thought to be functionally inactive or dysfunctional (Mietz et al., 1992; 
Bocchetta et al., 2008). This complex influences the biological function of p53 by promoting 
malignant cell growth and extended cell longevity (Lin and Simmons, 1991), possibly by 
activating the insulin-like growth factor-I signalling pathway – at least in primary human 
mesothelial cell (Bocchetta et al., 2008). Additionally, the strong interaction between p53 and 
large T antigen prevents p53’s ability to bind DNA sequences in a site-specific manner 
(Bargonetti et al., 1992), influencing, in turn the cell’s gene expression profile (Chang et al., 
1997; Hermannstadter et al., 2009) in favour of cell transformation.  
 
It is difficult to ascertain the interplay, if any, between SV40 large T antigen and YB1’s anti-
apoptotic functions or even chloroquine from the present studies and the current literature. It 
has been demonstrated that the human Polyomavirus JC virus large T antigen is able to 
interact with YB1 host cellular protein to positively modulate JC virus promoter activities (Chen 
et al., 1995; Safak et al., 1999). It is appreciated that JC virus shows a total 69% homology to 
SV40 (Frisque et al., 1984). Thus, significant structural and functional conservation has been 
demonstrated between their large T antigens (Pipas, 1992; Wang et al., 2004a), including its 
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capacity to bind to p53 (Staib et al., 1996). The functional relationship between JC virus large T 
antigen and YB1 could extend to SV40 large T antigen, and may influence SV40 large T antigen-
p53 tumour suppressor dysfunctional activities. By extension, this could affect the survival of 
293T cells in the presence of chloroquine. This property may be further abrogated and lost in 
the established YB1 knockout cell lines, especially in the presence of certain cytotoxic stresses, 
including chloroquine.  
 
Therefore, CRISPR/Cas9 targeting of host genes potentially introduces a limitation on 
inferences established from data analysis. This is especially of consideration when non-
endogenous, viral factors used to establish immortalised cell lines (such as SV40’s large T 
antigen) potentially show some interplay with the targeted gene and/or encoded protein(s).  
Altogether, this may warrant further investigations to elucidate any interplay between YB1 
and SV40 large T antigen. Or at least encourage alternative transformation or immortalisation 
methodologies that minimally affect the blueprint of the host cell’s genome, as is otherwise 
evident by integrating viral elements or plasmids. Perhaps, CRISPR/Cas9 genome editing could 
be implemented to generate a novel range of immortalised cell lines from primary cell lines. 
This could potentially off-set the limitations in data analysis and interpretations made on 
physiological protein function(s) that may in fact be an artefact due to the exogenous factors 
expressed to establish these immortalised cell lines. 
 
The cytotoxicity associated with the YB1 knockout cell lines presented, may indicate that a 
baseline amount of YB1 is required to maintain select cell function(s) that in turn help with 
AAV production. This was perhaps observed with the knockdown of YB1 in 293T producer cells 
by Satkunanathan et al. (2014). However, YB1 knockout of MEF cell lines was sufficient to 
significantly enhance Dengue virus (DV) viral replication, production, and viral protein 
expression (Paranjape and Harris, 2007) – an alternative RNA virus. It is also noted that YB1 
plays an important role in early development in mice, and YB1 knockout transgenic mice 
developed relatively normally up to embryonic day 13.5 (Lu et al., 2005). After which, the YB1 
knockout phenotype was associated with growth retardation and embryonic lethality (Lu et 
al., 2005; Uchiumi et al., 2006). Whereas, heterozygous mice (YB1+/-) were phenotypically 
indistinguishable from the YB1+/+ counterparts, indicating a non-redundant role of YB1, at least 
in late embryonic development of mice. Given this observed embryonic lethality, the 
enhanced DV viral replication, production and viral protein expression observed by Paranjape 
and Harris (2007), may have been a product of the fact that YB1 knockout MEF lines were 
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generated and immortalised at embryonic day 13.5 (Lu et al., 2005). A point at which the 
redundancy of YB1 on cell functions, which permitted embryonic development and additional 
unknown biological processes, remained intact. The loss of mouse YB1 in these YB1-/- MEF 
lines may have contributed to a conducive cell line that enhanced DV vector processing. It is 
hard to ascertain whether or not YB1 knockout in MEF lines generated post-late stage 
embryonic development would recapitulate the enhanced DV replication and viral protein 
expression. In the current study, YB1 knockout cells were established using CRISPR/Cas9 
genome editing of 293T cells. 293T cells were derived from immortalised 293 cells (Graham et 
al., 1977), of which origin has not been fully established except derived from embryonic 
kidney tissue and thus foetal in origin (please refer to ATCC® CRL-1573™ 
[https://www.lgcstandards-atcc.org/products/all/CRL-1573.aspx?geo_country=gb]). It is not 
fully established whether or not 293 cells were established from tissue late in embryonic 
development – a point in which human YB1 could function non-redundantly, similarly to 
mouse YB1 in MEF lines by Paranjape and Harris (2007). Although, human embryonic kidney 
tissue is a far cry from MEF, it may be argued that the YB1 knockout genotype established in 
293T cells was further unconducive for rAAV vector production, given its non-redundant 
function in as of yet unidentified biological processes. This process(es) was perhaps otherwise 
maintained with a baseline level of YB1 expression in YB1 knockdown cell lines established by 
Satkunanathan et al. (2014) that permitted enhanced rAAV processing, albeit transiently. 
 
Given this cytotoxicity association after CRISPR/Cas9-mediated knockout of human YB1, we 
were concerned that a similar pronounced effect could result after viral vector infections. 
Transductions with rAAV or lentiviral vectors did not significantly alter cell viability at all tested 
MOIs (MOIs: 10-100 for rAAV2GFP, and MOIs: 1-30 for lentiGFP vectors). Additionaly, 
infections of Sf9 and SfYB-disrupted cell lines with baculoviruses (MOI: 3 each baculovirus for 
rAAV vector production) also demonstrated comparable cytotoxicity profiles. Therefore, the 
pronounced sensitivity to select transfection modalities thus far remained an isolated 
consequence of YBX1 gene disruption by CRISPR/Cas9. Viral vector toxicity in YB1 knockout 
cells was a consideration due to the inherent, baseline toxicities that have been previously 
associated with viral vector transductions. For example, several rAAV vectors (serotypes 1, 2, 
5-9) have been examined on primary cortical cultures derived from embryonic rat brain tissue 
and all rAAV serotypes, excluding AAV9, exhibited MOI-dependent cell toxicity (Howard et al., 
2008). Additionally, cell toxicities were found only partly attributed by the expression of the 
GFP reporter. The generation of rAAV serotypes encoding a mutated GFP persisted to exhibit 
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significant cell toxicity after cell infections, demonstrating that rAAV vector was responsible 
for the difference in cytotoxicity. Additionally, gene transfer using lentiviral vectors has been 
previously thought to elicit cell cytotoxicity, mainly due to the envelope protein component – 
VSV-G, which has been implicated in cytopathogenicity and increased caspase-3/7 activity as a 
result of VSV (serotype Indiana) infection of Vero cells (Hoffmann et al., 2010).  
 
The cytotoxicity profiles calculated after treatment with viral vectors was largely considered to 
be independent of transduction or transduction efficiency. The transduction efficiencies using 
lentiviral of baculoviral vectors were generally considered comparable between the 
corresponding cell lines using flow cytometry. Transductions of YB1 knockout cells with rAAV 
vector at MOIs 100 and 1000 were considered incomparable, however – almost 50% less than 
that in parental 293T. It has been previously shown that AAV are compartmentalised into 
Rab7A+ late endosomes and Rab11A+ recycling endosomes (Douar et al., 2001; Ding et al., 
2006; Harbison et al., 2009). AAV, in part, exploits the host cells’ microtubule network to 
traffic itself towards the nucleus (Xiao and Samulski, 2012). YB1 has also been shown to 
interact with microtubules and stimulate their assembly in vitro (Chernov et al., 2008). 
Additionally, YB1 was found to be required for centrosome maturation in metaphase cells 
(Kawaguchi et al., 2015a), where the centrosome is essential for the nucleation and anchoring 
of microtubules. The polymerisation of microtubules occurs by a two-step process involving 
the nucleation of tubulin and then their elongation (Caudron et al., 2002), which was largely 
promoted in the presence of YB1 (Chernov et al., 2008; Kawaguchi et al., 2015a). The 
disruption of endogenous YB1 can negatively affect microtubule assembly, as demonstrated 
by YB1 knockdown HeLa cells using siRNA reduced nucleation of microtubules from 
centrosomes (Kawaguchi et al., 2015a), or complete loss of Rab11A+recycling endosome 
localisation to centrosomes (Kawaguchi et al., 2015b) were observed. In the case of the latter, 
Rab11A+ recycling endosomes are exploited by internalised AAV to traffic to the nucleus for 
efficient transduction or infection. However, it could be reasoned that YB1 knockout 
compromised rAAV transduction due to a potentially inefficiently established microtubule 
network and/or trafficking of Rab11A+ recycling endosomes. We observe only a reduction in 
transduction efficiency in YB1 knockout, and not the complete loss of transduction. This may 
imply that either AAV utilises additional means to traffic infected cells, or YB1 shows some 
redundancy for its role in microtubule assembly and centrosome maturation.  
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7.8 YB1 confers a protective phenotype against chloroquine reagent 
YB1 is predominantly found in the cell’s cytoplasm, with strict conditions that dictate its 
nuclear translocation, such as cell-cycle-dependent cues (Jurchott et al., 2003), genotoxic 
stresses (Zhang et al., 2003), and UV irradiation (Koike et al., 1997). The regulation of YB1’s 
translocation, is mediated in part, by the presence of three nuclear localisation signals (NLS) 
cytoplasmic retention signals (CRS), and the 20S proteasome cleavage site that resides 
between residues 219 and 220, resulting in a truncated N-terminal YB1 fragment and a CTD 
fragment (Kim et al., 2013). 20S proteasome-mediated cleavage of YB1 was generally a 
response to genotoxic stresses (Sorokin et al., 2005; Kim et al., 2013).  
 
It seems that the interplay between NLS1-3 (found between 149-156aa, 185-194aa, and 276-
292aa, respectively) and CRS1 and 2 between 52-101aa and 267-293aa, respectively (van 
Roeyen et al., 2013), dictates the subcellular localisations of YB1 mutants. A list of subcellular 
localisations of full length YB1 and truncation mutants identified in the present study, and 
their characteristics pertaining to NLS, CRS, and the 20S proteasome cleavage site are listed in 
Table 4.1. Therefore, we observed that the presence of either CRS motifs dictated a 
cytoplasmic localisation of YB1 and mutants. These were in general agreement with previous 
reports (Bader and Vogt, 2005; van Roeyen et al., 2013). Although, it was noted that van 
Roeyen et al. (2013) used an outdated annotation of the YB1 sequence (GenBank: J03827.1), 
which sports a shorter YB1 protein sequence (317aa) instead of 324aa (NP_004550.2). YB1Δ2 
and YB1Δ4 were slight exceptions to this rule and instead showed some nuclear shuttling and 
localisation despite the presence of the CRS1 motif. Both YB1Δ2 and YB1Δ4 most closely 
recapitulates the genotoxic stress-induced 20S proteasome cleavage N-terminus fragment 
product, and therefore, it came to no surprise that their localisations was shared with the 20S 
proteasome cleavage product (Sorokin et al., 2005; Kim et al., 2013).  
 
The chloroquine-induced cell death was reverted in YB1 knockout cells stably expressing YB1FL 
and select YB1 mutants. Full length YB1 and YB1Δ5 partially rescued the %cytotoxicity to a 
level similar to that in parental 293T control cells. The cytotoxic phenotype was further 
rescued by the stable expression of YB1Δ2-Δ4, in fact conferring resistance to chloroquine-
induced cell death. However, YB1Δ1 (which showed some disparity between chloroquine 
treatment conditions) and YB1Δ6 were unable to rescue the cytotoxic phenotype at all, with 
%cytotoxicity near comparable to levels exhibited by YB1 knockout cells after chloroquine 
treatment. It was also appreciated that the rescue of cell cytotoxicity was not hugely 
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dependent on the subcellular localisation of YB1 truncated mutants. This was inferred due to 
the fact that rescue of the phenotype was achieved with YB1Δ2, YB1Δ4 (showing cytoplasmic 
and nuclear localisations), YB1Δ3 (cytoplasmic), and YB1Δ5 (nuclear, with nucleolar 
predominance). Therefore, the resistance to chloroquine-induced cytotoxicity could be 
induced by a range of functions relevant to the expression of the respective YB1 domains. 
Resistant phenotypes were particularly established by an intact CSD and minimally CTD 
containing truncation mutants. The CSD demonstrated some particular importance to the 
resistance to chloroquine-induced cell cytotoxicity. This was an interesting observation 
because murine YB1 and MYS4 (murine Y-Box protein 1 paralogue; Ybx2) are essential in 
embryonic development (Lu et al., 2005, 2006; Uchiumi et al., 2006), with significant 
homology shared mainly between their CSD. YB1-/- mice showed embryonic lethality after 
early stage embryonic development (Yalkinoglu et al., 1988; Lu et al., 2005; Uchiumi et al., 
2006), MSY4-/- mice exhibited increased spermatocyte apoptosis, and double YB1-/- and MSY4-/- 
was completely incompatible even in early embryonic development (Lu et al., 2006). 
Therefore, an association between the CSD and developmental viability is certainly 
acknowledged. This conserved function by murine YB1 and MYS4 may extend in vitro to 
alternative cell lines and their orthologues. Essentially, the protection/resistance to 
chloroquine-induced cell cytotoxicity may be a CSD-dependent mechanism that has yet to be 
elucidated in full.  
 
Additionally, overexpression of YB1’s CTD has been associated with suppression of cell 
proliferation and even tumour progression (Shi et al., 2016; Wang et al., 2016c). Wang and 
colleagues (2016c) found that overexpression of the CTD (125-220aa) correlated with 
increased apoptotic Bax and caspase 3 expression, and reduced anti-apoptotic Bcl-2 
expression in EA.hy926 cells. Similarly, YB1’s A/P domain has been previously found associated 
with cell cycle arrest at the G2/M phase and apoptosis (Khandelwal et al., 2009). Cell cycle 
arrest and apoptosis was recorded by expression of as little as the first 77aa of YB1 protein 
(Khandelwal et al., 2009). Particularly, the first 26aa of YB1’s A/P domain was characterised as 
the major death domain by sequestrating cyclin D1 in the cytoplasm (Khandelwal et al., 2009). 
With this in mind, and the fact that truncation mutants YB1Δ1-Δ3 harboured the A/P domain 
and CSD, the protective function of the CSD by the current study was perhaps further 
exemplified. However, given the above and that phenotype rescue was also partially achieved 
by YB1Δ5 (truncated mutant that encoded only the CTD), it could be reasoned that all three 
domains of wildtype YB1 may interplay with one another in a complex manner to confer 
    
332 
 
protection against chloroquine, as seen in parental 293T. For example, the CSD may exert 
particular functions that are either sequestered away or negatively regulated by the A/P 
domain and/or the CTD (concerning the sequences after the 20S proteasome cleavage site). 
This could lead to no rescue or partial rescue of cell cytotoxicity induced by chloroquine, as 
opposed to resistance shown by YB1’s CSD alone. 
 
It is noteworthy that the stable expression of YB1FL, YB1Δ1, YB1Δ2, YB1Δ5, and YB1Δ6 did not 
confer an additional protective phenotype against cytotoxicity exhibited by the PEImax-
mediated transfection. The YB1 knockout cells consistently demonstrated a comparable 
cytotoxicity profile to parental 293T. This further supports that an alternative pathway or 
mechanism involving chloroquine, but independent of PEI, is responsible for an enhanced 
cytotoxic phenotype in YB1 knockout cells to chloroquine reagent. PEI has been previously 
associated with cell cytotoxicity (Boussif et al., 1995), and the mechanism by which this occurs 
has been investigated. Although, most studies explored the impact branched PEI has on cell 
cytotoxicity, linear PEI was used throughout the current study. It is also acknowledged that a 
more significant induction of cell death and cytotoxicity was reported by branched PEI 
compared to linear PEI (Kafil and Omidi, 2011). Nevertheless, branched PEI has been shown to 
induce necrotic cell death and plasma membrane damage (Florea et al., 2002; Moghimi et al., 
2005), and compromise the integrity of mitochondrial membrane potential by facilitating the 
release of cytochrome C (Moghimi et al., 2005), proton leakage and inhibition of the electron 
transport chain (Hall et al., 2013), thus potentiating in cell cytotoxicity and cell death via 
apoptosis. Although, Hall et al. (2013) do not directly correlate the inhibition of the electron 
transport chain and proton leakage with cell cytotoxicity in their studies, Moghimi et al. (2005) 
do correlate the increase in cytochrome C activity with cell cytotoxicity, but at very high 
concentrations of branched PEI. In the present study, approximately 10μg/mL of linear PEI was 
used to transfect cell lines – a concentration at which showed significantly less cytochrome C 
activity after 24h of treatment with free branched PEI (Moghimi et al., 2005). YB1 has also 
been found to negatively regulate mitochondrial oxidative phosphorylation by suppressing the 
translation of associated mRNAs (Matsumoto et al., 2012). Given this and the fact that YB1 
knockout did not correlate with an enhanced cytotoxic response to PEI or PEI-mediated 
transfection compared to parental 293T, it could be surmised that the contribution PEI has on 
the mitochondrial proton leakage and inhibition of the electron transport chain is insignificant 
to the cytotoxic profile presented – at least at the working concentration of PEI used. Also, the 
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proposed mechanism in which PEI mediates cytotoxicity is, to date, independent of p53-
associated signalling.  
 
7.9 Limitations of applying CRISPR/Cas9 genome editing 
The Sf9 cell line has shown promising capacity for heterologous protein expression by 
infection with recombinant baculoviruses (Graber et al., 1992; Miranda et al., 1997; Usami et 
al., 2011; Wilde et al., 2014). This application was then harnessed for scalable rAAV vector 
production by using recombinant baculovirus technology (Urabe et al., 2002; Urabe et al., 
2006). And since has proven as a clinically relevant producer cell model for rAAV vector 
production (Carpentier et al., 2012). CRISPR/Cas9 genome editing was performed on Sf9 cells, 
targeting the putatively identified SFYB gene that encodes the SfYB protein. The approach in 
which we mediated CRISPR/Cas9 genome editing was explored in the present study – plasmid 
transfection or recombinant Cas9 and synthesised sgRNAs. Transfection of Sf9 cells with 
pCRISPR plasmids was complicated by almost negligible OFP expression 72h post-transfection, 
despite having had optimised plasmid transfection in Sf9 cells using the Cellfectin™ II Reagent 
and pIEx-1.eGFP reporter plasmid. The efficiency of transfection does not correlate with 
genome editing; however, SpCas9 is co-expressed with OFP reporter and the poor transfection 
efficiency with pCRISPR plasmids may infer an issue in SpCas9-2A-OFP expression. This was 
problematic because SpCas9 is the main effector molecule that enzymatically induces DSBs 
and promotes gene editing (Gasiunas et al., 2012; Wei et al., 2015b). It was noted that SpCas9-
2A-OFP expression was under CMV promoter contrl, which was in contrast to the IE1 
promoter and hr5 enhancer for pIEx-1.eGFP. The IE1 promoter is a baculovirus immediate-
early gene promoter useful for strong heterologous gene expression in insect cells (Masumoto 
et al., 2012). The CMV promoter is commonly used for the expression of high levels of 
recombinant protein in mammalian cell lines (Wang et al., 2017). Despite this, the CMV 
promoter was previously reported to drive transgene expression in Sf9 cells, either by 
baculovirus infection or plasmid transfection (Li et al., 2014). Albeit, this was less efficient 
compared to the baculovirus-specific polh promoter (Li et al., 2014). Additionally, the CMV-
p10 fusion promoter was also agreeable for protein expression in Sf21 cells, post-infection 
(Mansouri et al., 2016). However, the contribution of the CMV promoter in transgene 
expression was not differentiated from p10 by Mansouri et al. (2016). Alternative reports infer 
that the CMV promoter is weakly active in Sf9 cells, as indicated by near negligible luciferase 
activity (He et al., 2008), and thus in agreement with poor OFP expression frequencies 
reported in the current study. 
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Therefore, the weak expression of the SpCas9-2A-OFP using GeneArt™ CRISPR nuclease 
vectors was considered inadequate for CRISPR/Cas9 genome editing of Sf9 cells. Alternatively, 
transfection of Sf9 cells with sgRNAs generated by IVT and recombinant Cas9 for SFYB 
targeting was instead implemented. This off-sets the need for incompatible promoters to drive 
the expression of the Cas9 nuclease effector in choice cells, without compromising gene 
editing frequencies as previously reported (Liang et al., 2015; Yu et al., 2016; Seki and Rutz, 
2018). It was previously acknowledged that transfection of Sf9 cells (and insect cell lines in 
general) with naked plasmid DNA is typically associated with poor to moderate transfection 
capacities – ranging between 30-50% (Maeda et al., 2005; Ogay et al., 2006). We do find 
further optimised transfection efficiencies using CRISPRmax™ Transfection Reagent and opti-
MEM™ as the diluent in the present study. High and efficient transfection rate of nearly 100% 
was achieved with as little as 0.5μg of plasmid per 4.5x105 Sf9 cells. Therefore, it was inferred 
that highly efficient transfection of IVT sgRNAs and recombinant Cas9 RNP complex could 
similarly be achieved to enhance the genome editing rates of the SFYB gene. 
 
Furthermore, the SfYB protein was identified as a Y-Box protein homologue, and the 
expression of which was consolidated by using SfYB-specific antiserum, raised specifically 
against rSfYB(His)10 protein. Further to this, we were able to BLAST for the gene sequence 
encoding the SfYB protein (SFYB) from the previously assembled contig (OEOA01010394.1), 
and annotated intron/exon sequences based on sequence homology to S. litura’s putatively 
identified SLYB gene sequence (NC_036217.1; LOC111360813). This was an essential 
requirement for designing gRNAs to target the putative SFYB gene for targeted knockout using 
CRISPR/Cas9 technology. CRISPR/Cas9 genome editing requires a gRNA – a crRNA-tracrRNA 
(otherwise synthesised as the sgRNA for in vitro applications) species – that is specific to the 
sequence of interest in order to facilitate Cas9 targeting and targeted nuclease activity (Jinek 
et al., 2012). Additionally, the specificity of gRNAs promotes on-target efficiency and reduces 
off-target effects (Fu et al., 2014; Dang et al., 2015; Xu et al., 2017). The gRNAs designed in the 
present study were restricted to exon-specific sequences given the putative nature of the 
mapped gene sequence. This was also appreciative of the fact that the genomic origin of 
target sites directly dictates the efficiency of sgRNA-Cas9 targeting, with intron-specific 
sgRNAs performing worst (Labuhn et al., 2018).  
 
Initial screens for knockout or partial knockout of SfYB protein expression was performed 
using αYB1 raised against human YB1 peptides. The lack of commercially available αSfYB 
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restricted our screening capabilities by Western blotting to αYB1. This was due to the lack of 
complete and well annotated proteomics data for S. frugiperda, and instead proteins are 
usually identified by aa sequence homology and protein annotations from other insect species. 
Few exceptions of endogenous proteins for S. frugiperda have been successfully cloned and 
characterised (Ahmad et al., 1997; Silva et al., 2013). Quantitative proteomics between control 
and baculovirus infection has also suggested host-baculovirus interactions (Carinhas et al., 
2011; Yu et al., 2015). However, the Y-Box protein homologue for S. frugiperda has not been 
previously described until our current studies.  
 
Given that the homology between YB1 and SfYB is not 100%, we opted to express and purify 
recombinant SfYB protein to raise SfYB-specific antiserum for complete validation of gene 
disruption. Interestingly, initial Western blotting demonstrated a disparity in SfYB-signal and 
expression between using αYB1 and the SfYB-specific antiserum after sgRNAsf1:Cas9 RNP 
transfection. In fact, SfYB knockout, at least by the limits of detection by Western blotting, was 
achieved using the SfYB-specific antiserum. This disparity was likely a result of poor cross-
reactivity of the αYB1 given the reduced aa homology between human YB1 and SfYB; and was 
instead corrected by the more specific nature of αSfYB. We thus demonstrated the importance 
of target-specific primary antibodies for the screening of CRISPR/Cas9 genome edited cell 
lines.  
 
We also emphasise the importance of knowledge of genomic DNA sequences and verified 
annotated coding sequences for CRISPR/Cas9 functionality. This goes without saying given that 
precise Cas9-mediated DNA targeting is sequence- and PAM- dependent (Anders et al., 2014; 
Kleinstiver et al., 2015). Although, advancements in the CRISPR/Cas9 genome editing has 
shown that genomic DNA-specific gRNA-free genome editing has been developed by Zhao and 
colleagues (2017). This was performed in an E. coli system, but was dependent on HR of a 
universal DNA sequence (N20PAM) for Cas9-targeting into the E. coli chromosome. Therefore, 
the process still required precise knowledge of DNA sequences. Initial attempts to identify the 
SFYB gene, and in turn design sequence-specific gRNAs, was very restricted by the limited 
availability of reference genomes for S. frugiperda (Kakumani et al., 2014). This incentivised 
the designing gRNAs based on sequence homology to mapped exons using BYB and SLYB as 
genomic scaffolds. The gRNAs designed in the current study were therefore solely exonic in 
their genomic origin to improve targeting and efficiency of CRISPR/Cas9 genome editing 
    
336 
 
(Labuhn et al., 2018). The complete S. frugiperda reference genome assembly has recently 
been established as of late 2017 (Gouin et al., 2017; Nandakumar et al., 2017).  
 
Identification of off-target cleavage also requires the utilisation of complete reference 
genomes for screening experimentally or in silico (Kim et al., 2015; Tsai et al., 2015). Off-target 
cleavage may potentially confound the interpretations of observations and experimental 
results. This is further complicated in practice with the genetic variation existing in the 
population of a given species (Genomes Project et al., 2012; Genomes Project et al., 2015). 
This includes S. frugiperda, which also exhibits significant genetic variation between its rice- 
and corn- eating sympatric strains (Gouin et al., 2017). This is less an issue in vitro with 
experimental cell lines, which are generally clonally derived and reference genomes are 
typically correlating. However, there remains a probability that genetic variation – in the form 
of polymorphisms and indels – could result in altered on- or off- target sites (Lessard et al., 
2017). Ultimately, and especially concerning human clinical trials and patients, this could 
predispose subjects to undesired and even deleterious effects when using CRISPR/Cas9 
technology. The lack of complete and well annotated genomic DNA data likely limits the use of 
CRISPR/Cas9 genome editing across a number of cell lines. Therefore, the full utilisation of 
CRISPR/Cas9 genome editing is restricted by the extent and depth of available reference 
genome data – both for on- and off- targets. 
 
We previously reported that single cell cloning of pCRISPR-transfected 293T cells was 
beneficial for the establishment of single cell clones. The absolute knockout of YB1 and 
mutations in its encoded YBX1 gene was confirmed; and the approach promoted the 
establishment of YB1 knockout cell lines that were homozygous for the CRISPR/Cas9-mediated 
mutation amongst all YBX1 alleles. However, Sf9 cells – either non-transfected or transfected 
with CRISPR RNP complex, failed to grow as a monoclonal cell population. This was even in 
spite of the fact that Sf9 cells are clonal cell derivatives of the Sf21 cell line (Vaughn et al., 
1977). Monoclonal cell populations failed to grow and expand despite the variations of media 
composition used in the current study, including conditioned media. The addition of 
conditioned media has been shown to stimulate Sf9 cell proliferation in culture (Calles et al., 
2006), although the effect on single cells has not been elucidated. It was noted that Sf9 cells 
showed cell density-dependent growth characteristics, which is a general characterisation of 
both Sf9 and Sf21 cell lines. Therefore, the establishment of single-cell clones by limiting 
dilution was perhaps too difficult to achieve for Sf9 cells. This also prevented the 
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establishment of stable SfYB-disrupted or knockout cell lines using CRISPR/Cas9 genome 
editing. 
 
7.10 YB1 and SfYB knockout cell lines do not enhance rAAV vector titres 
It was previously reported that YB1’s association with rAAV vectors by Satkunanathan et al. 
(2014) may implicate the endogenous host cell protein (YB1) with rAAV processing. This was 
especially promising given that YB1 knockdown using shRNA in 293T cells correlated with an 
enhanced rAAV2 and rAAV8 producer cell line quality, with up to 45-fold more rAAV2 vector 
genome titres calculated compared to control cell lines (Satkunanathan et al., 2014). Although, 
the transient nature of this enhanced producer cell line quality limited the applicability of the 
novel cell line for further research. For example the transient enhanced producer cell line 
quality meant a long-term, stable solution to generate rAAV vector quantities that meet the 
demands of clinical studies had not been achieved.  
 
To supplement this novel approach to enhance rAAV vector production, we endeavoured to 
utilise CRISPR/Cas9 genome editing to manipulate host cellular factors, particularly by 
targeting YB1 expression for knockout. Initial attempts to triple transfect 293T and YB1 
knockout cells for rAAV2 vector production using the Calcium Phosphate precipitation method 
was hindered experimentally by the acute and heightened sensitivity to chloroquine. 
However, despite overcoming the unprecedented complication and limitation of the YB1 
knockout cell lines to the aforementioned selected transfection modality (Calcium Phosphate 
precipitation method supplemented with chloroquine), an enhanced rAAV2 vector producer 
cell line was not identified. In fact, the YB1 knockout cell line generated an equivalent quantity 
of rAAV2 vector genome titres when compared to 293T control. Similarly, rAAV2 vector 
genome titres produced from YB1 knockout and mutant YB1Δ1-Δ6-expressing cells were 
comparable to that from 293T control. The expression dynamics of Rep and Vp1-3 proteins 
was considered overall unaltered by YB1 knockout. And the localisation of AAV2 intact 
particle, Rep and Cap proteins was generally unchanged by YB1 knockout phenotype or the 
stable expression of YB1Δ1-Δ6. Therefore, the YB1 knockout phenotype in 293T did not confer 
an enhanced producer cell line.  
 
It was noted that rAAV2 vector production was mediated by triple transfection using PEImax 
transfection reagent instead of Calcium Phosphate precipitation method, as was used in the 
previous study by Satkunanathan et al. (2014). However, PEI-mediated transfections function 
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rather analogous to Calcium Phosphate transfection mechanism, in that DNA:PEI complexes 
are receptive to internalisation by endocytosis (Utsuno and Uludag, 2010). Furthermore, 
analogous to chloroquine, PEI protects input DNA by buffering the acidic pH of endosomes 
(Boussif et al., 1995; Sonawane et al., 2003). The cytotoxic potential and differences exhibited 
on cultured cell lines by PEI or Calcium Phosphate precipitation methods of transfection were 
screened and thus controlled for by LDH cytotoxicity assays in the current study. However, it 
remains unclear why an overall enhancement in rAAV2 vector genome titres was not a feature 
of YB1 knockout cells. Although, the mass ratio of the three AAV plasmids used to triple 
transfect 293T and YB1 knockout cells in the current studies (1:3:1 mass ratio of pAAV2-hrGFP, 
pHelper, and pAAV2/2-RC) was in some contrast to the mass ratio of plasmids used by 
Satkunanathan et al. (2014)  – 1:1:3 mass ratio of pAAV2-hrGFP, pHelper, and pAAV2/2-RC, 
respectively. It is therefore noted that on a per tissue culture plate basis, a larger quantity of 
each and total plasmid was used by the study performed by Satkunanathan et al. (2014) – 
37.5μg total plasmid using Calcium Phosphate precipitation method compared to 23μg total 
plasmid using PEImax. Although, it is difficult to attribute the lack of enhanced rAAV vector 
titres from YB1 knockout cells by the difference in plasmid quantity and ratio used, mainly 
because different transfection methodologies were used to produce rAAV2 vectors. 
 
Furthermore, YB1 has demonstrated in previous reports to encourage the production 
dynamics of a number of viruses and viral vectors, including HIV1 (Mu et al., 2013), 
recombinant MLV (Li et al., 2012), Influenza A virus (Kawaguchi et al., 2012). But negatively 
regulates DV by functioning in an antiviral manner to repress the translation of viral proteins 
or RNA replication (Paranjape and Harris, 2007). Here, YB1 knockout MEF lines were 
associated with significantly enhanced DV replication, production and viral protein expression 
(Paranjape and Harris, 2007). Associations between YB1 and Adenovirus have also been 
investigated, and Adenovirus viral factors required for rAAV2 vector production by transient 
transfection of 293T cells include helper factors encoded by E1, E2A, E4 and VA genes 
(Matsushita et al., 1998; Xiao et al., 1998). These are supplied either in trans by the pHelper 
plasmid or stably expressed by 293T cells. YB1 has been reported to impact on the splicing 
characteristics of Adenovirus E1A pre-mRNA (Chansky et al., 2001; Raffetseder et al., 2003), 
the gene activity of E2’s late promoter (Holm et al., 2002). The close association between YB1 
and Adenovirus E1B protein and its co-targeting to viral inclusion bodies presumably thought 
to promote Adenovirus replication (Holm et al., 2002). However, when concerning wildtype 
AAV or rAAV vectors, the functions of E1 and E2 gene products are essential for AAV 
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processing, given that these elements are some of a few minimum essential helper factors 
necessary for rAAV vector production (Matsushita et al., 1998; Xiao et al., 1998). The function 
of E1A promotes up-regulation of AAV promoters – p5 and p19 (Tratschin et al., 1984), E1B 
promotes nuclear export of AAV late viral mRNA (Krätzer et al., 2000; Blanchette et al., 2008), 
and E2A functions to promote AAV replication (Ward et al., 1998). Especially, when 
considering the functions that E1A, E1B and E2A have in context with AAV biology, and the 
impact YB1 has on the processing of these proteins, the complete loss of YB1 expression in 
YB1 knockout cell lines generated in the present study may not be completely conducive for 
enhanced rAAV2 vector production. However, the relevance of YB1 to these helper proteins 
has only been identified in context to Adenovirus gene elements or infection, and therefore is 
not strictly AAV-associated. 
 
7.11 The role of YB1/SfYB protein and its association with rAAV vectors 
We demonstrated that AAV Rep and Cap proteins were expressed comparably between 
control 293T or Sf9 and the corresponding CRISPR/Cas9 genome edited cell lines. This was in 
contrast to the improved Rep protein expression and vector genome titres by the YB1 
knockdown cell line, although derived from 293T, using shRNA technology (Satkunanathan et 
al., 2014). It was noted that the expression of AAV Rep and Cap proteins using recombinant 
baculoviruses are not under their wildtype AAV p5, p19 and p40 promoters as we see in AAV 
plasmids (Matsushita et al., 1998; Xiao et al., 1998). Instead, AAV2 rep ORF is under promoter 
control of polh and the serotype-specific cap ORF is under p10 promoter control (Smith et al., 
2009). Therefore, the expressions of these proteins are entirely dictated by the host-cell 
response to baculovirus infection. Whether or not the Y-Box protein homologue, SfYB, is able 
to influence the activity of baculovirus-derived promoters has not been previously identified. 
However, human YB1 is a broadly functioning host-cell factor that is widely implicated in 
regulating exogenous viral promoters. This includes Adenovirus E2 late promoter, of which 
binding promotes the E2 gene expression (Holm et al., 2002). Additional examples include the 
JC virus late gene promoter (Kerr et al., 1994; Chen and Khalili, 1995), and HIV1’s LTR 
promoter (Sawaya et al., 1998), which exhibit enhanced transcriptional activities upon YB1 
binding.  
 
However, the E2 gene helper function is omitted from rAAV vector production using 
baculovirus infection. The helper function is substituted by the productive baculovirus 
infection instead to drive p10 and polh promoter activities. Therefore, the Adenovirus helper 
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genes are absent from rAAV vector processing. This includes the E2 gene, in particular the E2A 
product, which has been recognised to complement AAV viral DNA replication (Ward et al., 
1998) and viral transcription (Chang and Shenk, 1990). E2A was shown to promote elongation 
of replicating AAV genomes (Ward et al., 1998). Vector production in Sf9 is mediated by the 
natural assembly of AAV capsids and replicating AAV ssDNA genomes as per AAV2 Rep 
proteins and host cellular machineries (Ruffing et al., 1992). E2A protein has been shown to 
localise with AAV viral DNA (Pombo et al., 1994), but also associates with Rep78/68 and AAV 
ITRs (Stracker et al., 2003). The purpose of which was suggested to enhance protein binding to 
promote replication and DNA nicking by terminal resolution (Stracker et al., 2003). Although, 
further interplay between YB1 and E2A beyond its binding to the E2 late promoter (Holm et 
al., 2002) has yet to be identified, if any. We have identified relatively specific YB1 binding to 
AAV viral DNA – especially to the ITRs. Therefore YB1, and by extension SfYB, may compete for 
Rep78/68-E2A binding to AAV genomes, ultimately affecting the processivity. The optimal 
processivity or rAAV vectors in Sf9 cell lines or its derivatives may be restricted by the absence 
of Adenovirus E2A protein, and perhaps the SfYB knockout phenotype could not be fully taken 
advantage of.  
 
We also appreciate that human YB1 is implicated in the control of endogenous gene 
expression, mRNA transcription, and protein translation (Didier et al., 1988; Evdokimova et al., 
2001; Skabkin et al., 2001; Stickeler et al., 2001; Hartmuth et al., 2002; Pisarev et al., 2002; 
Higashi et al., 2003; Lasham et al., 2003; Nekrasov et al., 2003; Homer et al., 2005; Deckert et 
al., 2006; Kotake et al., 2013). Interestingly, YB1 generally exhibit functions to inhibit 
translation or stabilise mRNA. YB1 is a major protein component of non-polyribosome-bound 
mRNPs (Kumar and Pederson, 1975; Minich et al., 1993), and regulates the assembly of the 
40S pre-initiation complex to the translation initiation codon of mRNA (Pisarev et al., 2002). 
With low YB1:mRNA ratio, YB1 binds to mRNA as monomer units along the length of mRNA 
using its CSD and CTD, but homo-oligomeric YB1 complexes associate with mRNA instead 
when YB1:mRNA ratio is high (Davydova et al., 1997; Pisarev et al., 2002). Homo-oligomeric 
YB1 complexes to mRNA may impede the association of necessary translation factors because 
mRNA-YB1 complexes may be packaged in such a way that its termini are thought to be 
buried, ultimately preventing the translation machinery from assembling (Skabkin et al., 2004). 
In contrast to this, YB1-depleted lysates were found to be almost completely deficient of 
protein translation of the β-globin mRNA (approximately 90% inhibition with anti-YB1-
mediated YB1 depletion in rabbit reticulocytes) using a cell-free in vitro protein translation 
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system (Evdokimova et al., 1998). Furthermore, YB1-depletion was also associated with the 
accelerated decay of mRNAs, again using rabbit reticulocyte-derived lysates and cell-free in 
vitro systems (Evdokimova et al., 2001). The complete depletion of YB1 or its overexpression 
relative to mRNA levels was found not to be conducive for in vitro protein translation at the 
initiation stage; and low YB1:mRNA ratios was optimal for efficient protein translation. 
Therefore, the YB1/SfYB knockout phenotypes displayed by YB1/SfYB-disrupted cell lines were 
perhaps not conducive for the improved expression of AAV Rep or Cap proteins, in the current 
study. This implies that gene manipulation/knockout by CRISPR/Cas9 genome editing may not 
be wholly appropriate given the probable nature and complexity of human YB1 and SfYB’s 
function in vitro.  
 
It could be reasoned that the lack of enhanced AAV2 rep expression in the current studies was 
a product of compromised protein translation machinery. YB1-depletion using αYB1 
(Evdokimova et al., 1998; Evdokimova et al., 2001), perhaps most closely resembled the 
YB1/SfYB knockout phenotypes generated by CRISPR/Cas9 genome editing system. However, 
the current studies focused on knockout of YB1/SfYB expression in 293T or Sf9 cells, which 
have human or insect origins, respectively. Nonetheless, the cell-free in vitro systems 
identified the inhibitory effect of YB1, but was limited to using β-globin or luciferase mRNA as 
their substrate, only. We previously have shown that the expression of a number of 
endogenous proteins (SOX13, SDF4, PANK4, and GAPDH) was relatively unchanged between 
parental 293T and YB1 knockout cell lines when testing for CRISPR/Cas9 off-targeting. We thus 
simultaneously tested the effect of YB1 knockout phenotype on some endogenous protein 
expressions. The impact YB1 depletion has on mRNA decay and/or translation inhibition 
(Evdokimova et al., 1998; Evdokimova et al., 2001) was rather contested by the YB1 knockout 
cell lines. It is appreciated that the mRNA decay and translation initiation of AAV2 Rep mRNA 
and even for Vp1-3 were not explored in the current study, and may be compromised by the 
YB1 knockout phenotype.  
 
If YB1-depletion is any indicator to the potential impact the YB1 knockout phenotype has on 
rAAV2 Rep and Cap expression (either on mRNA or protein translation), then this could explain 
the comparable rAAV2 vector genome titres between control and genome edited cell lines. 
Whereby, the lack of enhancement of AAV2 rep expression in YB1 knockout cell line would be 
unable to promote rAAV genome replication at an enhanced rate for packaging and ultimately 
enhanced rAAV vector titres. This was perhaps the molecular milieu attained in YB1 
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knockdown cell lines produced by Satkunanathan et al. (2014), which was permissive for 
enhanced AAV2 rep expression, and may have dictated the enhanced vector genome titres 
calculated. This adds another complication of targeting YB1 for CRISPR/Cas9 genome editing 
that may confer a less than conducive cell line for rAAV vector production, after having 
targeted an extremely multifunctional protein. 
  
Regardless of the lack of effect identified in YB1/SfYB knockout cell lines generated in the 
current studies, YB1 has demonstrated a clear role in rAAV vector processing, as determined 
by Satkunanathan et al. (2014). The identification of wildtype YB1 in rAAV vector particles by 
liquid chromatography-mass spectrometry/mass spectrometry (Satkunanathan et al., 2014) 
suggests that it is at the very least a cell-derived impurity that is packaged into rAAV. ICC and 
confocal microscopy was used to trace the localisations of rAAV2 intact particle, AAV2 Rep and 
Cap proteins, relative to wildtype YB1 (including truncated YB1 mutants and YB1 knockout 
phenotype). It was generally considered that the baseline localisations of wildtype YB1 and 
YB1 mutants were unchanged between non-transfected and triple-transfections. Also, the 
localisations of intact rAAV2 vector particle, AAV2 Rep and Cap proteins were unchanged 
between control and knockout cell lines, suggesting that YB1/SfYB does not possess an 
obvious role in trafficking rAAV2 vectors during its production. However, we have identified a 
rather distinct colocalisation between YB1Δ5 (encompassing wildtype YB1’s CTD) and rAAV2 
intact particle and AAV2 Cap within the nucleus. This localisation was more specifically 
localised within the nucleolar compartment. Therefore, there seems to be an association 
between YB1’s CTD and rAAV2 vector during the production process.  
 
AAV assembly of progeny virions or rAAV vectors has been reported to be concentrated in the 
nucleolar regions (Wistuba et al., 1997), a process which is mediated by the AAV2’s AAP 
scaffolding protein (Sonntag et al., 2010; Naumer et al., 2012; Earley et al., 2015). Therefore, 
the assembly of rAAV2 capsids may be one potential point at which wildtype YB1 is packaged 
into rAAV2 vectors as a cell-derived impurity. However, the relevance for YB1’s association 
with rAAV2 assembly within the nucleolus via the CTD is unclear given no significant effect on 
rAAV2 vector genome titres was observed from +YB1Δ5 cell line, relative to 293T control. On 
the other hand, YB1 interaction with AAV ITR sequence was identified in the current study. 
The AAV ITRs are particularly important in the encapsidation and packaging or AAV genomes 
into preformed capsids (Wang et al., 1996; Dubielzig et al., 1999; Bleker et al., 2006).  
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Wildtype YB1 was also found to associate with AAV and Adenovirus DNA sequences by DNA 
affinity-YB1 pulldown studies. YB1 was previously identified to bind to the Y/CCAAT box (also 
known as the Y box) motif – 5’-CTGGATTGG C/T C/T AA-3’ (Didier et al., 1988). However, its 
ability to bind to dsDNA and ssDNA species was not confined to the Y box (Izumi et al., 2001; 
Zasedateleva et al., 2002; Kljashtorny et al., 2015), and preferential binding was observed for 
ss GGGG motifs (Zasedateleva et al., 2002). In the present study we identified putative YB1 
binding motifs in the AAV2 ITRs, within the early coding sequences of AAV2 rep, and upstream 
of Adenovirus E2a gene sequence. Of particular interest was the AAV2 ITR, of which putative 
YB1 binding motif (5’-GGGGTT-3’) was found present in the pAAV2-MCS plasmid (and by 
extension any AAV2 transfer vector used for rAAV vector production), and in the -sense strand 
of the rAAV vector genomes. Importantly, the ITR-containing AAV2 transfer vector is the initial 
copy used as a template for the replication of rAAV vector genomes. 
 
Despite the transient nature of input plasmid during the course of in vitro transfection, 
especially without antibiotic selection, the ds ITR-containing plasmid still functions as target 
for potential binding for YB1. YB1 was captured and pulled down using relatively long 5’-
desthiobiotin-labelled capture probes (dsDNA), with the putative 5’-GGGGTT-3’ YB1 binding 
motif centrally positioned. Similar was demonstrated for the rep and E2a capture probes. 
However, the specificity of these observed binding and pulldowns was questionable given the 
control capture probes (especially the right ITR flanking control probe) also demonstrated YB1 
pulldown. These control probes were initially screened for putative YB1 binding motifs as per 
Zasedateleva et al. (2002), of which only the left ITR flanking capture probe harboured. The 
right ITR flanking control capture probe was still able to significantly bind and pulldown YB1 to 
comparable levels as to the substrates in question. Upon closer examination, the right ITR 
flanking control capture probe harbours a single 5’-GGCGGG-3’ (GC-box) motif, that has been 
reported to show high specific binding to YB1 (Shi et al., 2012; Shi et al., 2013). Although, Shi 
et al. (2013) report using a quadruplet 5’-GGCGGG-3’ oligo in their YB1 pulldown studies, the 
highly specific binding of YB1 to the GC-box found in the right ITR flanking control probe could 
explain the YB1 pulldown that could not be outcompeted by the poly(dI-dC) competitor. It is 
also worth noting that a single copy of the GC-box motif was identified in the ITR (putative 5’-
GGGGTT-3’ containing) and E2a (putative 5’-CCTCCT-3’ containing) capture probes, but absent 
in the rep (putative 5’-GGGGTT-3’ containing) and left ITR flanking control capture probes. 
Therefore the binding and pulldown by the ITR and E2a capture probes may hold merit given 
the rep capture probe, which is without the GC-box, was still able to bind and pulldown YB1 
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similarly. The specificity of the binding was finally verified for the ITR putative YB1 binding 
motif by using shorter ds and ss oligos that were void of the GC-box, and using an irrelevant 
Luciferase transgene sequence as a control capture probe. 
 
It is worth addressing the fact that the rAAV vector genome’s left ITR of the +sense strand 
harbours the putative 5’-GGGGTT-3’ YB1 binding motif, which is in turn positioned 78bp 
upstream of the transgene’s CMV enhancer/promoter sequence. Additionally, the right ITR of 
the +sense strand possesses the ITR-derived 3’-hydroxyl group for unidirectional DNA 
replication, which upon the generation of a dsDNA intermediate, potentiates in the putative 
ds 5’-GGGGTT-3’ YB1 binding motif. Therefore, given YB1 is packaged into rAAV vectors 
(Satkunanathan et al., 2014), and YB1 binding to these sequences is very much probable, with 
the successful YB1 pulldowns achieved by the ssITR capture probes in the present study, it 
could be reasoned that the packaging of YB1 is mediated at this very point of rAAV vector 
processing – rAAV genome packaging into preformed capsids. Alternatively, the interaction 
could suggest a means in which YB1 regulates rAAV genome packaging. The encapsidation 
process of AAV genome occurs in a seemingly polar manner – the 3’-ends are translocated into 
preformed capsids first via Rep40/52’s 3’-5’ helicase/ATPase activity (King et al., 2001). 
Rep78/68 protein complex with the AAV2 ITR sequences is thought to help dock genomes to 
preformed capsids (Dubielzig et al., 1999; Bleker et al., 2006), especially is close association 
with the pores at the five-fold symmetry axes (Bleker et al., 2005). Not only this, the ITR D-
sequences of the AAV2 ITRs, which harbours the 5’-GGGGTT-3’ putative YB1 binding motif, is 
essential for AAV genome encapsidation, as its deletion correlates with inefficient packaging of 
the AAV genome into preformed capsids (Wang et al., 1996). Therefore, with YB1’s relatively 
specific and high affinity binding to ITR sequences demonstrated in the present study, it could 
be reasoned that Rep proteins are in direct competition with YB1 for binding to the ITR. 
Although, AAV2 Rep78 was also found to bind to YB1 by co-immunoprecipitation experiments 
(Nash et al., 2009), the functional relationship between this interaction was not elucidated. 
Regardless, with this competition in binding to the AAV2 ITR comes a potential interplay that 
regulates or dictates the encapsidation of rAAV vector genomes.  
 
7.12 Significance of CRISPR/Cas9 genome editing for AAV gene therapy development 
Utilisation of CRISPR/Cas9 genome editing has begun to revolutionise human gene therapy, 
potentially giving rise to an entirely new class of therapeutics. Harnessing the genome editing 
technology has already shown promising potential as a gene therapy strategy for the 
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treatment of HIV1 (Kaminski et al., 2016). In particular, a number of studies have successfully 
used a combination of AAV and CRISPR/Cas9 genome editing, wherein the vectors’ cell/tissue 
tropism for transduction was exploited. AAV-CRISPR systems developed for targeted 
correction of haemophilia B mice models have shown curative potential for the disease 
phenotype (Guan et al., 2016; Ohmori et al., 2017). Additional in vivo use of CRISPR/Cas9 has 
generally exemplified promising correction of disease phenotypes (Wu et al., 2013; Guan et 
al., 2016; Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016; Huai et al., 2017; 
Ohmori et al., 2017) 
 
Alternatively, harnessing the genome editing tool to improve or enhance a gene and/or 
cellular therapy product is a rather novel research concept. The idea to improve gene or 
cellular therapy products using CRISPR/Cas9 has been demonstrated with the engineering of 
CAR-T cells for endogenous TCR and/or PD-1 knockout. The ultimate goal is to improve the 
efficacy of the engineered T cells to function as tumour-specific T-cells (Blank et al., 2006; van 
Loenen et al., 2010; Wei et al., 2013; Bunse et al., 2014; Wu et al., 2014). Therefore, the 
application of this concept could likely extend to alternative cell or gene therapy products.  
 
A number of cell-intrinsic factors have evolved to function as host restriction factors for viral 
infection and propagation (Laguette et al., 2012; Heusinger et al., 2015). The advantage of 
these is to confer cellular resistance to naturally-occurring viruses in nature. However, such 
restriction factors can be hindrance to in vitro propagation of pseudotyped viral vectors 
(Mitchell et al., 2014; Satkunanathan et al., 2014). This especially includes rAAV vectors, 
which, for the most part are near comparable to their wildtype counterparts – an 
encapsidated ssDNA genome in a capsid shell. This is despite the introduction of ITR-flanked 
AAV transgene and minimal packaging and/or helper factors mediated by plasmid transfection 
or baculovirus infection. The relevance of AAV-host interactions directly or indirectly impacts 
on the ever present limitation of using rAAV vectors for gene therapy/transfer applications i.e. 
the constrained quantities produced by current systems. Therefore, gene regulation of 
characterised or putative restriction factors on rAAV biology with minimal changes in the 
genomic blueprint is an attractive means to establish cell lines for high titre rAAV vector 
output. Targeted and controlled modulation of host cell proteins that otherwise hinder rAAV 
vector processing could lead to optimal rAAV processing and yields. Clear benefits of 
establishing such cell lines could include the generating high doses of rAAV vector that are 
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required to overcome the inefficient transduction efficiencies in vivo (Pajusola et al., 2002), 
and/or pre-existing immunity to AAV (Mingozzi et al., 2013; Katz et al., 2014).  
 
7.13 Future perspectives 
Genome engineering and gene expression manipulation of 293T or Sf9 using CRISPR/Cas9 did 
not confer an enhanced rAAV vector producer cell line. However, the work presented 
represents an alternative application of the technology for gene therapy product 
development. Despite the knockout of YB1 did not correlate with enhanced vector production, 
it may still be advantageous to explore the CRISPR/Cas9 genome editing and knockout of 
alternative cell-intrinsic factors that have been associated as AAV host-restriction factors. In 
turn, examining the effect of knockout of these factors in AAV processing could aid in 
elucidating their function(s) in this context. Of particular interest are cell-intrinsic factors 
which are unlikely to sensitise 293T cells to chloroquine-induced cell cytotoxicity. Examples of 
cell-intrinsic factors could include the promyelocytic leukaemia protein (PML), of which 
overexpression correlated with inhibition of AAV genome replication (Mitchell et al., 2014). Its 
knockdown or knockout may correlate with enhanced AAV genome replication. Perhaps, 
further elucidating the exact role of cell-intrinsic factors may lead to a combination of targeted 
gene regulation and/or editing to promote optimal vector production and output.  
 
Additionally, in order to further explore the utility of Sf9 cell line for rAAV vector production, 
the complete elucidation of host-virus interactions is warranted. Especially, identifying Sf9-
derived cell-intrinsic factors that associate with rAAV vectors and processing is warranted, 
including the direct association between SfYB and AAV using liquid chromatography-mass 
spectrometry/mass spectrometry. Protein expression changes between mock baculovirus 
infection and AAV vector production – synonymous to research on the changes in Sf9 protein 
expression after baculovirus infection (Carinhas et al., 2011; Yu et al., 2015) – could infer 
probable host-virus interactions. Likewise could be performed for the T. ni-derived Ao38 cell 
line for rAAV vector production, which are a recommended cell line for enhanced recombinant 
protein expression compared to Sf9 or Sf21 (Wickham and Nemerow, 1993; Wilde et al., 
2014). The Ao38 cell line also has shown the propensity for rAAV vector production (Meghrous 
et al., 2005), yet remains to become a clinically relevant producer cell line like its Sf9 
counterpart. 
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The examination and elucidation of the complete functions of SfYB in the context of S. 
frugiperda (Sf9) physiology may be justified. Significant homology at the aa sequence level 
does not directly correlate with shared functions. This would require elucidating 
experimentally, but we show that SfYB is at the very least a dsDNA binding protein with little 
sequence specificity. It would also be advantageous to explore whether or not the disruption 
of SfYB may promote the production of recombinant baculovirus(es). This need not be 
exclusively performed using CRISPR/Cas9 genome editing; because of the possible translation 
of human YB1 depletion and its association with deficient protein translation (Evdokimova et 
al., 1998). However, the potential downstream and commercial application of an enhanced 
baculovirus producer cell line or cell line exhibiting enhanced productivity are relevant and 
active research fields (Lai et al., 2012; Gomez-Sebastian et al., 2014; Lopez-Vidal et al., 2015; 
Steele et al., 2017). A key example of the latter is the two-fold improvement in recombinant 
protein expression in stable Sf-caspase-1 knockdown cell lines (Lai et al., 2012). Regardless, 
elucidating the functional nature of YB1/SfYB binding to AAV2 ITR sequences is warranted to 
identify how exactly Y-Box proteins negatively regulate AAV vector production. In vitro 
transcription and translation studies of AAV rep or cap (with wildtype Adenovirus or 
baculovirus specific promoters) in the presence of recombinant YB1 and SfYB protein may 
clarify how these Y-Box proteins impact on these gene expressions.  
 
Alternatively, it is appreciated that secreted YB1 protein is a mediator of the inflammatory 
response (Frye et al., 2009; Hanssen et al., 2013), and implicated in inflammatory diseases 
(van Roeyen et al., 2005). Therefore, the packaging of 293T-derived YB1 (a cell derived 
impurity) into rAAV vector capsids potentiates in the mitogenic stimulation of the subject’s 
immune response by exogenous YB1 post-administration. Therefore, the utility of CRISPR/Cas9 
genome engineering on AAV producer cell lines could be further explored to generate 
potentially safer AAV gene therapy products. This could be achieved by examining the effect of 
rAAV-FLuc vectors derived from YB1 or alternative knockout cell lines on the induction of an 
immune response in vivo, compared to standard rAAV vectors as control. Additionally, the 
transduction capacity of these rAAV-FLuc vectors could be quantitatively assessed in vivo and 
also compared to standard rAAV vectors as control. Ultimately, the case for a standardised 
producer cell line, established by CRISPR/Cas9 genome editing, could be argued in favour for 
clinical grade rAAV vector production.  
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7.14 Final conclusions 
We utilised CRISPR/Cas9 genome editing of 293T and Sf9 cell lines to improve rAAV vector 
production. In the process we identified novel Y-Box protein homologues endogenous to T. ni 
and Spodoptera spps., including S. frugiperda, from which Sf9 cells are derived. We do note 
that CRISPR/Cas9 technologies (especially those that waive rights in their intellectual 
properties for the final CRISPR/Cas9-edited product) designated for insect cells are limited. 
Such CRISPR/Cas9 technologies are predominantly tailored for in vitro use in mammalian cell 
lines. Therefore, use of IVT sgRNA:rCas9 RNP transfection was preferred over pCRISPR 
transfections, especially given the CMV promoter restriction in Sf9 cells, and the risk-free 
genomic integration to give rise to stable Cas9-expressing cell lines. Regardless, we show that 
knockout of YB1 or SfYB was confidently achieved, and that established cell lines exhibited 
homozygosity for the observed knockout mutation(s); however, this was dependent on the 
ability to establish monoclonal cell populations by single cell cloning. We also addressed the 
advantages of using a broad scope of phenotypic and genotypic analysis tools to characterise 
knockout cell lines. This included HRM curve analyses, which differentiated wildtype alleles 
from CRISPR/Cas9-mutated alleles with high sensitivity. We stress the importance of using 
target-specific antibodies for screening knockout cell lines to avoid potential false-positive or 
false-negative data interpretations from Western blotting analyses. We were also able to 
model the disruption of wildtype splicing junctions and that alternative splice sites could be 
generated as consequences of CRISPR/Cas9-mediated mutations. 
  
YB1 knockout cells were significantly sensitised to chloroquine-induced cell cytotoxicity, but 
unaffected by alternative transfection or infection methodologies for vector production. A 
series of YB1 truncation mutants further exemplified the importance of YB1 in protecting 293T 
cells from chloroquine-induced cell death, and that YB1’s CSD was the principle mediator of 
this resistance. Lastly, further implications in YB1-AAV interactions were indicated, particularly 
YB1 interactions with AAV2 ITR 5’-GGGGTT-3’ binding motif and that YB1’s CTD colocalised 
with rAAV2 vector particles and AAV2 Cap protein in vitro. 
  
Ultimately, careful consideration in the choice in endogenous gene target for CRISPR/Cas9 
genome editing is stressed. Targeting endogenous host-cell proteins may potentially have 
unexpected consequences for downstream investigations. This ultimately depends on the 
importance or versatility of the target protein’s function in vitro. Nonetheless, we present the 
first example in which CRISPR/Cas9 genome editing can be utilised to regulate cell-intrinsic 
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factors that may be implicated in rAAV vector production. We also demonstrate the 
capabilities of harnessing the CRISPR/Cas9 technology for potential in gene therapy product 
development. With these in mind, CRISPR/Cas9 technology can further revolutionise human 
gene therapy beyond its current applications and give rise to an entirely new class of 
therapeutics. 
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